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 Abstract 
 
Granulomatosis with Polyangiitis  (GPA)  is a granulomatous inflammatory disease. It is 
generally described as a systemic disorder which can present with a localized presentation 
like the orbit. Orbital GPA can be the initial manifestation of GPA where over time the 
disease may progress and become severe, involving vital organs. This study aimed to look 
for biomarkers in orbital GPA biopsies that could indicate diagnosis and be a predictor for 
the progression of the disease. 
To identify GPA patients, retrospective examination of patients’ medical records, who had 
undergone orbital biopsies for orbital inflammatory disease (OID), over a 21 year period, 
was performed. Long term outcomes of these patients were studied. Further subjective 
and objective histology analyses were  done on haemotoxylin and eosin (H&E) tissue 
preparations. Comparison of  cellular activity  in biopsies  of GPA and other OID were 
performed. Further T cells, B cells and macrophage phenotypes and their cytokines, were 
investigated with immunohistochemistry  (IHC).  IHC cell count  comparisons were 
performed between GPA, sarcoidosis and idiopathic inflammatory orbital diseases (IIOD) 
biopsies. 
Results showed that in  patients who presented with orbital GPA with  no systemic 
manifestations, the disease  remained localised and did not progress to systemic form, 
over time. H&E tissue biopsies examination showed that GPA tissues had a higher cellular 
activity compared to OIDs. Vasculitis and necrosis were found to be independently 
associated with the diagnosis of orbital GPA but  these features were unreliable for 
diagnosis  as  a number of the biopsies did  not exhibit these features. In 
immunohistochemistry staining, T cells, B cells and macrophage subtypes counts were 
comparable between GPA, sarcoidosis and IIOD. Nonetheless cytokines IL-17, IL-23 and 
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 BAFF-receptor (BAFF-R), were found significantly more in GPA compared to sarcoidosis 
and IIOD. This suggests that these cytokines possibly have a role in the pathogenesis of 
GPA and may have diagnostic value. 
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 Summary 
 
Introduction 
 
GPA is a granulomatous inflammatory disease, generally regarded as a systemic disorder 
and  could potentially be life threatening. Although the disease is more commonly 
described in larger major organs (systemic GPA), it is also recognised to occur in less life 
threatening organs such as the eye and nose (localised GPA). Localised GPA is generally 
thought  to represent the earlier stage of the systemic manifestation of the disease. 
Localized GPA is difficult to diagnose, as  early  symptoms are often  similar to other 
inflammatory conditions  and investigations  are usually negative.  Therefore there  is a 
potential for a diagnostic delay to occur where the disease often only becomes apparent 
after the disease has progressed; causing irreversible organ damage or disease spread to 
major organs. The aims of this study were therefore to look for potential biomarkers in the 
orbital biopsies, for the diagnosis of GPA as well as to predict disease progression. The 
study was divided into several parts. 
 
Long term outcome of orbital GPA 
 
In this first section of the study, the main aim was to identify patients who were diagnosed 
with orbital GPA who progressed into the systemic form of the disease. We also observed 
the patient’s demographic pattern, ANCA status, treatment modalities that were advocated 
and general long term outcomes. Our main findings were that, all of our patients 
diagnosed with orbital GPA, who had no associated systemic manifestations  at 
presentation, did not progress to the systemic form of the disease over time. Patients, who 
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 were characterised as systemic GPA, had systemic involvement prior to their orbital 
presentations.  
ANCA was positive in 60% of our patients however only  about  40% had a positive 
serological ANCA investigation at the time of presentation. Patients with negative ANCA 
investigations can  become positive over time thus  repeated  testing should be done  in 
these patients particularly in cases with recurrent and severe attacks. 
 
Histology comparison between GPA and other OIDs 
 
Histology plays an important role in the diagnosis of GPA. Classical pathological features 
seen in GPA  tissue biopsies  stained with H&E  include granulomatous inflammation, 
vasculitis of small to medium size vessels and tissue necrosis. These features are 
however not always apparent in orbital GPA tissues. This study was to compare tissue 
changes and cellular activity in GPA to OIDs to determine if there are factors that could 
differentiate them histologically. 
We were not successful in identifying a biomarker in H&E tissue biopsies that could be 
used as a biomarker for the diagnosis of orbital GPA. Yet we  found that the cellular 
activities in GPA orbital biopsies were higher compared to the combined cellular activities 
of OIDs. This result reflects the more severe clinical course of orbital GPA compared to 
OIDs. In addition, necrosis and vasculitis were independent factors associated with the 
diagnosis of orbital GPA, consistent with the pathological picture of GPA in other organs. 
Nevertheless, these features were not consistently seen in all tissue biopsies of orbital 
GPA in our samples, thus cannot be a reliable feature for the diagnosis of orbital GPA. 
Granuloma was found to be inversely associated with the diagnosis of orbital GPA thus the 
presence of this feature in orbital biopsies suggests that the diagnosis of GPA is unlikely. 
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 T cells in GPA 
 
The involvement of T cells as well as its various subsets in GPA is well documented. CD4 
and CD8 have been demonstrated in GPA affected tissues such as the kidneys and 
CD134 T memory cells has been shown to be present in lungs affected by GPA as well. 
Th17  and its IL-17  cytokine  in particular,  has been the centre of attention in the 
development of many autoimmune inflammatory diseases including GPA. In this section of 
the study we wanted to investigate the presence of T cells and its subsets, as well as 
cytokine  IL-17,  in orbital GPA as well  as compare them to T cell presence in orbital 
sarcoidosis and IIOD. This was done by immunohistochemistry (IHC). 
We found that CD3, CD4, CD8, CD134 and IL-17  were all present in all three orbital 
diseases. CD3, CD4, CD8 and CD134 counts were similar between GPA, sarcoidosis and 
IIOD. There was also no cell type preponderance noted; unlike seen in kidneys affected by 
GPA where CD8 predominates. More important, IL-17 was found to be markedly higher in 
GPA compared to both sarcoidosis and IIOD. Thus despite appearing to be involved in all 
three orbital diseases, the role of IL-17 seems to be more important in orbital GPA rather 
than other OIDs. 
On another note, in our sarcoidosis tissues, the CD4 and CD8 counts were similar where 
the CD4/CD8 ratio was close to one. This did not concur with findings in other organs 
affected with sarcoidosis. Bronchoalveolar lavage fluid investigations in patients with 
pulmonary sarcoidosis showed that a CD4/CD8 ratio of two or more, were indicative the 
disease.  
CD134 previously demonstrated in endonasal biopsies in GPA is a member of the TNFR-
superfamily of receptors. It is suggested that the level of CD134 is associated with GPA 
disease activity. We did not find a significant difference in the presence of CD134 within 
GPA, sarcoidosis and IIOD indicating that this T cell subtype may be significant in 
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 inflammation in general and not specific in GPA development. To our knowledge this is the 
first time CD134 is observed in sarcoidosis and IIOD. 
 
B cells in orbital GPA 
 
B cells are also implicated in the pathogenesis of GPA, particularly after Rituximab; a 
chimeric monoclonal antibody against the protein CD20, has been shown to be effective in 
the treatment of this disease. BAFF is a cytokine that helps maintain and prolong the 
survival of B cells. It binds with the receptor BAFF-R on B cells. The BAFF/BAFF-R 
interaction has been shown to be present in endonasal biopsies of patients with GPA and 
is said to be important in the disease development. In this section, we investigated the 
presence of B cells (CD20) and BAFF cytokines as well as BAFF-R, in orbital GPA by IHC, 
and compared them to B cell presence in orbital sarcoidosis and IIOD.  
We were unsuccessful in staining for BAFF in our sample tissues however were able to 
demonstrate presence of CD20 and BAFF-R in all three orbital diseases. CD20 counts 
were comparable between the three diseases indicating that the role of B cells was similar 
in all three diseases. However BAFF-R expression were significantly higher in GPA 
compared to sarcoidosis and IIOD, signifying a possible significant positive influence of 
BAFF in GPA disease development. Thus while B cells were equally important in all three 
orbital diseases, B cells role in the inflammatory process in GPA may be sustained longer 
due to the prolonged survival time and maintenance of B cells in tissues by BAFF. 
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 Macrophages in GPA 
 
Despite GPA being described as a granulomatous disease (an inflammation predominated 
by macrophages), investigations  on macrophage  and its various  phenotypes,  in the 
disease development, are surprisingly scarce. CD68 has been described to be present in 
tissues affected by GPA such as in the kidneys. Other M2 (alternative activated 
macrophages) have not been identified in GPA. IL-23 cytokine has been shown to have a 
role in the pathogenesis of AAV including GPA but its presence in orbital GPA has not 
been shown. In this part of the study, we performed IHC to look at the presence of 
macrophage subtypes and cytokines, which included CD68, CD204, CD163 in addition to 
cytokines IL-23 and AIF1, in orbital GPA, sarcoidosis, IIOD and compared the presence of 
these immune cells between GPA and IIOD biopsies plus GPA and sarcoidosis biopsies. 
We were unable to get a conclusive stain for CD163, CD204 and AIF1. CD68 and IL-23 
were found to be present in all biopsies from all three orbital diseases. CD68 was found to 
be significantly higher in GPA when compared to IIOD but CD68 counts were comparable 
between orbital GPA and sarcoidosis. The granulomatous nature of GPA explains the 
difference in the presence of these macrophages with IIOD and its similarity to sarcoidosis 
which is also a granulomatous disease. IL-23 in particular was shown to be significantly 
higher in the biopsies of GPA when compared with  both  IIOD and sarcoidosis. This 
cytokine appears to play an important role in the disease development of GPA. The 
function of IL-23 is to promote production of IL-17, a proinflammatory cytokine via Th17. 
As IL-17 was found to be high in orbital GPA too, the IL-23/IL-17 pathway may be the key 
player in the pathogenesis of GPA. 
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 Conclusion 
 
Our study shows that orbital GPA with no systemic presentation may remain solely in the 
orbit and may not have systemic involvement. Cellular activity in orbital GPA is higher 
compared to OIDs. This was seen in both subjective and objective immune cell and tissue 
change counts. This result reflects  the disease severity  compared to OIDs.  Tissue 
necrosis and vasculitis were features independently associated with the diagnosis of GPA 
in the orbits, similar to other organs affected by GPA. However these features were not 
consistently found in all orbital GPA tissues thus may not serve as a good indicator for 
disease diagnosis. The main difference found in the immune cells between orbital GPA, 
sarcoidosis and IIOD were not in the main cell subtypes, but in the cytokines production. 
IL-17, IL-23 and BAFF-R were found significantly more in GPA compared to sarcoidosis 
and IIOD. Therefore it may be suggested that the presence of these cytokines in orbital 
biopsies together with positive clinical correlations may be used as a diagnostic marker for 
the diagnosis of orbital GPA. 
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 1  Chapter 1: Introduction 
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 1.1  Perspective 
 
Orbital granulomatosis with polyangiitis (GPA) is an orbital inflammatory disease that 
poses a diagnostic challenge. Generally, the disease has similar clinical presentation as 
other orbital inflammatory diseases, such as idiopathic inflammatory orbital diseases 
(IIOD) and sarcoidosis. In addition, investigations from serology blood test with anti-
neutrophil cytoplasm antibody (ANCA) which is strongly associated with the disease often 
do not yield a positive result. Localised orbital GPA may progress to involve other major 
organs like the kidneys, where the disease is then termed as systemic GPA, and can be 
potentially life threatening if appropriate and adequate treatment is not advocated early. 
On the other hand, treatment for GPA often involves the use of  strong 
immunosuppressants that carry severe side effects themselves, thus they must be used 
with caution and only when necessary. Therefore, it is indeed important for us to be able to 
make a quick and correct diagnosis. Histology biopsy plays an important role in the 
diagnosis of orbital GPA. However, the evaluation usually involves looking for features 
consistent with GPA that has been described before in other larger organs affected by 
GPA, such as the lungs and kidneys. Again, these features may not always be present in 
orbital samples because tissue biopsies from the orbit are usually small and limited. 
Hence, it would certainly be of benefit if a cellular biomarker could be identified in tissue 
biopsies to diagnose orbital GPA and possibly GPA in general, and potentially also be 
used to predict the disease progression and outcome. In order for us to explore further, it 
would indeed be helpful to first understand GPA in general, particularly the ocular 
manifestations of the disease. 
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 1.2  Introduction 
 
Granulomatosis with polyangiitis (GPA) (previously known as Wegener’s granulomatosis 
(WG)) was initially described by Heintz Klinger, a medical student, in 1931. The disease 
was described to be a variant of another vasculitic disorder; polyarteritis nodosa (PAN). 
However, in 1934 and 1939, Frederick Wegener; a  German pathologist, further defined 
the disease in greater detail  and showed that the disease can be clearly distinguished 
from other inflammatory diseases such as PAN and is actually a distinct inflammatory 
disease(Rasmussen et al., 1990)(Langford, 2001).Since the discovery by Frederick 
Wegener, the disease then later adopted his name as Wegener’s granulomatosis. 
Recently however, The Boards of Directors of the American College of Rheumatology, the 
American Society of Nephrology, and the European League Against Rheumatism(Falk et 
al., 2011)recommended the term granulomatosis with polyangiitis (GPA) as an alternative 
to Wegener’s granulomatosis, to better describe the pathology and to avoid eponyms. 
GPA is pathologically described as a multisystem granulomatous necrotising inflammation 
which is associated with pauci-immune vasculitis of small- to medium-sized blood vessels 
and is presumed to be of autoimmune origin (Holle et al., 2010a). GPA can affect any 
organ system but the disease is seen to have a pre-disposition to affect the upper and 
lower respiratory tract system and the kidneys.  Together with other known vasculitic 
diseases which include Churg Strauss syndrome (CSS), microscopic polyarteritis (MPA) 
and renal limited vasculitis, GPA has been shown to have a strong association with a 
specific antibody called anti-neutrophil cytoplasm antibody (ANCA). Collectively, these 
groups of disorders are known as the ANCA-associated vasculitides (AAV)(Isa et al., 
2012). Despite this strong association with ANCA, a positive ANCA serology is not always 
established in all cases although the absence of ANCA does not preclude diagnosis either.  
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 In the eye, GPA may involve any ocular structure, and ocular manifestations of the disease 
vary.  It has been shown that up to 60% of patients with GPA manifest ocular involvement. 
In addition, ocular signs can be the initial presentation of the disease (Pakrou et al., 2006). 
 
1.3  Epidemiology 
 
The overall incidence of GPA is estimated to be approximately 4 to 8.8 cases per million 
people, although this varies depending on the locality. In the UK, the annual incidence of 
GPA is reported to be towards the higher end at 8.4 cases per million. (Watts et al., 2000) 
GPA is said to occur more commonly among Caucasians(Hoffman et al., 1992). Based on 
epidemiological studies, it is suggested that the prevalence of the disease appears to have 
an apparent latitude dependent predisposition, with a decreasing north-south gradient in 
the northern hemisphere and a reciprocally increasing south-north gradient in the southern 
hemisphere  (Koldingsnes and Nossent, 2000)(O’Donnell et al., 2007)(Gibson et al., 
2006)(Hissaria et al., 2008). The reasons for this remain unclear. One study suggested 
that this distribution may be influenced by ethnicity rather than the geographical location 
(Faurschou et al., 2013). Cases of GPA have been reported throughout other parts of the 
world such as in Japan, India and China(Kobayashi et al., 2010)(Kumar et al., 2001)(Chen 
et al., 2008)(Singer et al., 1990), and in Taiwan, the annual incidence of GPA is said to be 
around 0.37 per million patients per year (Wu et al., 2014). 
The incidence of GPA is seen to peak in the sixth decade of life and there is no apparent 
gender predilection. GPA has generally been considered as a relatively rare disease but 
recent studies have shown otherwise. The prevalence of GPA  has been shown to have 
tripled over a 15 year period(Koldingsnes and Nossent, 2000)(Gibson et al., 2006) with a 
concurrent rise in incidence seen as well(Watts et al., 2000)(Takala et al., 2008). The 
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 disease is also seen to be affecting patients of a younger age (Watts et al., 
2009)(Koldingsnes and Nossent, 2000)(Hissaria et al., 2008)(Takala et al., 2010). 
 
1.4  Systemic (General) versus Localised (Limited) GPA 
 
GPA has a wide range of clinical manifestations and any organ system can be affected 
with varied disease severity. Generally, GPA can be divided into a limited (localised) or a 
general (systemic) form. However, it should be noted that clinically, both terms carry little 
significance; and that the terms are only widely used in clinical trials to classify patients for 
treatment options and in medical literatures. To date, there is no current consensus on the 
characteristics of these two groups, which clearly define them. 
Limited GPA was first described by Carrington and Liebow in 1966 as the identical clinical 
onset and pathologic manifestations to the classic form i.e. the general or systemic form of 
the disease except in the absence of renal involvement (Carrington and Liebow, 1966).  
This term was used by the Wegener's Granulomatosis Etanercept Trial Research (WGET) 
group in their clinical trial for patients fulfilling the American College of Rheumatology 
(ACR) criteria for GPA, but lack features that pose immediate threat to either a critical 
individual organ or to the patient’s life(WGET Research Group, 2002)(Stone, 2003). 
The term “localised GPA” has not been generally accepted worldwide although it has also 
been used in many medical trails and literatures. In the European Vasculitis Study 
Group/The European League Against Rheumatism (EUVAS/EULAR) group, localised GPA 
was defined as individuals with vasculitic features confined only to the upper and/or lower 
respiratory systems, including the orbit (Hellmich et al., 2007)(Jayne and Rasmussen, 
1997). In general, patients with limited or localised GPA are usually considered to have a 
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 milder course of the disease and by and large respond well to less aggressive treatment 
regimens (Tarabishy et al., 2010)(Cassan et al., 1970). 
In contrast, general (systemic) GPA displays a more severe form of the disease with a 
more widespread organ system involvement. Severe GPA in the WGET encompassed 
patients with significant involvement of vital organs that is potentially life 
threatening(WGET Research Group, 2002)(Stone, 2003).The EUVAS/EULAR divided 
patients with general GPA into early systemic, generalised, severe and refractory 
(Hellmich et al., 2007)(Jayne and Rasmussen, 1997). 
The ocular and orbital structures involvement is common in patients with both limited and 
general forms of GPA, and may be the presenting feature in both. A very limited form of 
GPA with localised ophthalmic features only, has also been described (Ahmad et al., 
2000). There appears to be no difference between the spectrum of ocular manifestations 
and incidence of potentially sight threatening complications seen in either the general or 
limited forms of GPA(STAVROU et al., 1993). 
 
1.5  Pathogenesis of GPA 
 
The exact pathogenesis of GPA is still unknown. Pathologically, GPA is described as a 
triad of granulomatous inflammation (inflammation with granuloma formation), vessel wall 
inflammation of small-  to medium sized-  vessel (vasculitis) and tissue necrosis. Many 
factors have been shown to potentially cause these pathological changes seen in GPA 
where some may have a more significant role than others. Indeed, the mechanism of GPA 
development may be a combination of several factors. 
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 1.5.1  Anti-neutrophil cytoplasm antibodies (ANCA) 
 
ANCA have been shown to be strongly associated with AAV including GPA. ANCA are a 
group of Immunoglobulin G (IgG) antibodies directed against the cytoplasm of neutrophils 
granulocytes and monocytes, and their presence in serum can be detected by indirect 
immunofluorescence. In GPA, antigens proteinase 3 (PR3) and myeloperoxidase (MPO) 
are most commonly identified with the disease. ANCA targeting these antigens are 
therefore termed as PR3-ANCA and MPO-ANCA.  
In pattern of staining of ethanol-fixed neutrophils, ANCA is seen to exhibit two main 
patterns namely, c-ANCA (cytoplasmic antineutrophil cytoplasm antibodies) and p-ANCA 
(perinuclear antineutrophil cytoplasm antibodies).c-ANCA are mainly associated with sera 
containing PR3-ANCA and is closely associated with GPA. These neutrophil cells feature 
a diffusely granular cytoplasmic staining pattern. In contrast, p-ANCA, found mainly in sera 
containing MPO-ANCA, is observed to show a neutrophil perinuclear staining pattern and 
is strongly associated with microscopic polyangiitis (MPA). Both these antigens can be 
detected by enzyme-linked immunosorbent assay (ELISA). (Figure 1.1) 
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Figure 1.1: Cytoplasmic staining PR3 (c-ANCA) and perinuclear staining MPO (p-
ANCA) seen via indirect immunofluorescence microscopy 
 
In systemic GPA, c-ANCA are found in about 90% of patients, and in 80-95% of these 
patients the antibody is directed against PR3 (Tarabishy et al., 2010)(Lamprecht and 
Gross, 2007). c-ANCA is reported to have a 91% sensitivity and 99% specificity for active 
GPA (Taylor et al., 2007). 
The exact mechanism in the generation of ANCA is still undetermined. One theory 
suggested that the ANCA production is an autoantibody response to newly exposed 
epitomes of target auto antigen  at the site of initial tissue injuries (Radice and Sinico, 
2005).  Another theory proposed that ANCA generation is initiated in response to 
complimentary peptides that arise from the same gene molecule that encodes PR3 (Bautz 
et al., 2008),although another study failed to find the same association (Tadema 2011). 
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 Despite the established association between GPA and ANCA, the aetiology and exact role 
of ANCA in the pathogenesis of GPA is still uncertain and studies in this area are on-
going. In in vitro studies, ANCA is shown to activate primed neutrophils, promote their 
adherence to and transmigration through tumour necrosis factor (TNF)-stimulated 
endothelium. This antibody also promotes neutrophil degranulation which subsequently 
releases reactive oxygen species and lytic enzymes such as elastase, resulting in vascular 
endothelial cell and tissue damages. This phenomenon is thought to be accountable for 
the extensive damage to vessel walls which are seen in GPA (Seo and Stone, 2004). The 
alternative complement pathway which is an innate component of the immune system’s 
natural defense against pathogens has also been shown to be involved in this process. 
The C3 complement, a protein of the immune system that plays a central role in the 
activation of the complement system, is found deposited in more than half of tissue 
biopsies in patients with AAV (Brons et al., 2001)(Vizjak et al., 2003).In vitro, activation of 
primed neutrophils by ANCA leads to the release of factor B, a component of the 
alternative complement pathway, as well as factor C3. This causes a further activation of 
the alternative complement pathway which releases the split product C5a protein. This 
protein, which acts as a strong chemotactic factor for neutrophils, is also able to prime 
neutrophils for the interaction with ANCA.  Thus, a perpetual cycle for neutrophil 
recruitment and activation is formed, leading to continuing vascular inflammation and 
tissue damage (Kallenberg, 2011a). 
. 
1.5.2  Inflammatory cells associated with GPA 
 
The disease process i.e. inflammation in GPA is also believed to be an interplay of both 
the cellular (mainly T cells) and humoral (mainly B cells) functions of the immune system. 
T and B lymphocytes are both derived from the same hematopoietic stem cells and only 
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 become morphologically distinct upon activation. These leucocytes (white blood cells) are 
the main effector cells in the human adaptive immune system. The adaptive immune 
system is the body’s acquired immune defense system that develops after exposure to 
different antigens during its lifetime. In contrast, the innate immunity is the pre-existing 
immune defense system in the body which is encoded into the human germline. The 
adaptive immune system can be divided into the cell mediated or innate immune 
response, and the humoral or antibody immune response.  
The cellular immune response is also known as the cell mediated immunity. T cells are 
mainly involved in this process, which, as the name reflects, largely involves the activation 
of specific cells such as neutrophils, lymphocytes, phagocytes and the release of various 
inflammatory cell mediators known as cytokines in response to an antigen upon pathogens 
invasion or tissue insult. B cells in contrast are involved in the humoral or antibody immune 
response where substances involved in the immune process are found in bodily fluids or 
“humours”.  The principle function of B cells is in the production of specific antibodies in 
response to specific antigens, hence the term “antibody mediated system”. Apart from this, 
this arm of the immune system also produces larger molecules involved in the immune 
response such as complement factors or proteins. 
Both T and B lymphocytes have been implicated in the development of GPA. The 
granulomatous inflammation seen in different tissues in GPA suggests a strong role of the 
T cell response where various cells are seen to be involved. T cell levels have been shown 
to be increased in patients with active GPA (Lúdvíksson et al., 1998)(Marinaki et al., 
2006). Specific sub-types of T cells such as CD4 and CD8, and their sub-types such as 
CD8+CD57+ and NK-like CD4 cells, have been investigated in the pathogenesis of AAV, 
but their roles have not yet been clearly defined (Iking-Konert et al., 2009)(de Menthon et 
al., 2011).  Recently, both the T-helper 17 (Th1 T cells7) cells and regulatory T (Treg) cells 
are also receiving attention as potential players in disease development in AAV, including 
41 
 GPA (Berden et al., 2009)(Kallenberg).  The role of B lymphocytes and memory plasma 
cells in immune regulation, antibody production and pathogenesis has now been well 
established in various auto-immune diseases(Yoshida et al., 2010)(Dörner et al., 2009). 
Plasma B cells also have been demonstrated to have a role in the production of 
autoantibodies, including ANCA (Jennette et al., 2006)(Fervenza, 2010). In addition, 
activated peripheral B cells have also been linked to disease activity and severity in GPA 
(Popa et al., 1999).Thus, treatment regimens targeting B cells like Rituximab have been 
advocated in the management of AAVs (Khan et al., 2010)(Onal et al., 2008a). 
The granulomatous nature in the pathology of GPA implies a predominant role of 
macrophages in GPA. Active involvements of macrophages have indeed been reported in 
several studies (Mackiewicz et al., 2005) (Park et al., 2012) 
 
1.5.2.1  T cells 
 
T cells can be divided into several subsets where each generally has a distinct function. 
The subsets of T cells include the helper cells, cytotoxic cells, memory cells, regulatory 
cells and natural killer T cells. 
 
1.5.2.1.1  T Helper T cells (Th) 
 
T helper cells express the CD4 glycoprotein on their surface, therefore they are also 
known as CD4+ T cells. However, it is important to note that not all CD4 T cells are T 
helper cells as CD4 can also exhibit cytotoxic and suppressor cell function. CD4 T helper 
cells are activated upon the presentation of antigens by the antigen presenting cells (APC) 
via the major histocompatibility complex (MHC) class II molecules, and are differentiated 
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 into two main subtypes, namely T- helper 1 (Th1 T cells) and T-helper 2 (Th2 T cells), 
distinguished by the cytokines they secrete, as well as other subtypes such as, T-helper 
17 (Th17) and T-helper  αβ.  During  an  immune  response,  CD4  T-cells is directed to 
differentiate into a specific Th subtype via signaling from APCs and, by secreting specific 
cytokines, aid (hence “helper cells”) other immune cells function such as B cell maturation 
and activation of cytotoxic T cells (CD8) and macrophages. In granulomatous inflammation 
such as GPA, CD4 has been shown to have a key role in the inflammatory process as well 
as initiating granuloma formation and maintaining it via production of cytokines interferon- 
γ (IFN-  γ), interleukin-12 (IL-12) and tumour necrosis factor (TNF) (Sneller, 2002)(Hänsch 
et al., 1996). 
 
1.5.2.1.1.1  T Helper 1 T Cells (Th 1 T cells) 
 
Th1 T cells secretes Interleukin (IL) 2, interferon-γ (IFN- γ) and tumour necrosis factor-α 
(TNF-α). It is triggered by IL-12, IL2 and its own cytokine INF-γ. The immune function of 
Th1 T cells is against intracellular bacteria, virus and protozoa by activating macrophages 
and cytotoxic T cells to kill microbes and infected cells. IFN-  γ  can  also  produce  free 
radicals that directly kill intracellular bacteria and protozoa. Apart from this, Th1 T cells 
also stimulate B cells to produce specific IgG antibodies which cover the microbes and 
activate complements. Over-activity of Th1 T cells leads to over stimulation of immune 
cells such as macrophages and lymphocytes, causing chronic inflammation and persistent 
cytokine. This is known as Type 4 (cell mediated) hypersensitivity or delayed type 
hypersensitivity release. Examples of diseases in this group are Type 1 diabetes mellitus, 
multiple sclerosis and tuberculin reaction (Mantoux test) in the diagnosis of tuberculosis. 
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 1.5.2.1.1.2  T Helper 2 T Cells (Th 2 T cells) 
 
Th2 T cells  secreteIL-4, 5, 10 and 13 and acts on extracellular pathogens such as 
multicellular helminths. Its differentiation is triggered by IL-4, IL-5 and IL-13. Th2 T cells 
can also stimulate B cells into producing most antibodies but in particular IgE production 
(Romagnani, 1991). Effector cells stimulated by Th2 T cells are eosinophils, mast cells and 
basophils. In helminths infection, IL-5 activates eosinophils to eradicate the pathogen. IL-4, 
together with IgE can result in the release of histamine, serotonin and leukotriene via mast 
cell stimulation that causes gastric fluid acidification and gastric peristalsis to expel the 
parasite. Over action of Th2 T cells response can lead to Type 1 IgE mediated allergy and 
hypersensitivity such as allergic rhinitis, asthma and atopic dermatitis. 
 
1.5.2.1.1.3  T Helper 17 T Cells (Th 17 T cells) 
 
Th17, a subset of T helper cells, are considered to be a distinct effector lineage from that 
of Th1 T cells and Th2 T cells lineage (Harrington et al., 2005). It is triggered by IL-6 and 
tumour growth factor beta (TGFβ). Th17 produces cytokine Interleukin 17 (IL-17), a pro-
inflammatory cytokine as well as IL-21 and IL-22. It has been postulated that IL-23 may be 
involved in the expansion of Th17 populations and may, but not conclusively proven, to 
produce cytokine IL-17 (Bettelli et al., 2006). IL-17 has an important role in inducing and 
mediating pro-inflammatory responses by enhancing T cell priming, and stimulates  the 
production of other pro-inflammatory molecules such as IL-1, IL-6, and tumour necrosis 
factor TNF.(Figure 1.2) Th17 has been reported to be involved in many auto-immune and 
chronic inflammatory diseases such as rheumatoid arthritis (Choy, 2012), psoriasis 
(Mudigonda et al., 2012)(Tokura, 2012), Crohn’s disease and systemic lupus 
erythematosus (SLE) (Alunno et al., 2012). In the eye, Th17 is shown to play a role in 
ocular inflammation such as uveitis and scleritis (Amadi-Obi et al., 2007), Bechet’s uveitis 
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 (Sugita et al., 2012)(Shimizu et al., 2012) and uveitis associated with Vogt Koyangi Harada 
disease (Chi et al., 2007). In sarcoidosis, bronchus tissue granulomas and in circulating 
memory T cells have been reported to have an increased expression of IL-17A and are 
suggested to be involved in granulomas induction and maintenance (Ten Berge et al., 
2012) 
 
 
 
 
 
 
 
Figure 1.2: The role of IL-17 in inflammation.  The effect of IL-17 on endothelial cells, epithelial 
cells and macrophages leads to production of further proinflammatory cytokines such as IL-1, IL-
6, TNF and GM-CSF resulting in local tissue inflammation. In joints, macrophage, chondrocyte 
and osteoblast activation by IL-17 may results in cartilage damage and bone erosion such as 
seen in rheumatoid arthritis 
 
1.5.2.1.1.4  T Helper αβ T cells (Th αβ T cells) 
 
The  differentiation  of  Thαβ  helper  cells  is  triggered  by  IFN  α/β  or  IL-10. These cells 
function against viruses via their main effector, cytokine IL-10.  ((Hu, 2013)  The main 
effector cells activated by Thαβ helper cells are natural killer (NK) cells, CD8 T cells and 
IgG B cells. Activated NK cells apoptose virus-infected cells and causes viral as well as 
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 host DNA fragmentation. Over-activation of THαβ can cause type 2 antibody-dependent 
cytotoxic hypersensitivity such as diseases like Myasthenia gravis or Graves' disease. 
 
1.5.2.1.2  Cytotoxic T cells 
 
Cytotoxic T cells are generally regarded as CD8 T cells, since these cells express the CD8 
glycoprotein. Nevertheless, the CD8 protein co-receptor can also be found on other 
immune cells such as natural killer cells, cortical thymocytes and dendritic cells. In contrast 
to CD4 cells, these cells recognise antigens via the MHC class I molecules, found on all 
nucleated cell surfaces. These cytotoxic cells, as the name suggests, have the ability to 
destroy foreign cells including tumour cells and infected cells.  
 
1.5.2.1.3  Memory T cells 
 
Memory T cells are antigen specific T cells that persist in circulation even after the 
exposure to the antigen has subsided. Upon re-exposure to the specific antigen, these 
cells provides memory against the antigen, thus expands rapidly and exponentially. Cell 
surface CD45RO is generally considered to be expressed memory cells and can be either 
CD4 or CD8 T cells (Miyara et al., 2011) 
 
1.5.2.1.4  Regulatory T cells (Treg cells) 
 
Regulatory T cells have an important function in controlling the immune process. These 
cells are also known as suppressor cells, where the main role of these cells is to stop T 
cell mediated immunity at the end of an immune response, and suppress auto-reactive T 
cells. There are two main types of Treg cells; naturally occuring, and induced Treg cells. 
Naturally occurring Tregs are produced in the thymus and the induced Tregs generally 
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 develop during an immune response. Naturally occurring Tregs are recognised from other 
T cells by the intracellular molecule FoxP3. Defects or mutation of the FoxP3 gene may 
cause Treg dysfunction that can lead to autoimmune diseases (Miyara et al., 2011). 
1.5.2.1.5  Natural killer cells 
 
Natural killer T cells are distinct from CD4 and CD8 as they do not recognise the MHC 
molecules, but recognise the glycolipid antigen presented by the CD1d molecule. It 
constitutes 0.1% of all T lymphocytes (Terabe and Berzofsky, 2007). These cells also have 
the ability to recognise tumour cells and herpes infected cells and destroying them 
(Novakova et al., 2012). 
 
1.5.2.2 B cells 
 
B cells are a component of the lymphocytic white blood cells which mature in the bone 
marrow, hence the term “B”-cells.  It is the main effector cell in the humoral (or antibody) 
adaptive immune system. B cells can be distinguished from other lymphocyte cells such as 
T cells and natural killer cells by the cell surface B-cell receptor (BCR), which allows them 
to bind to specific antigens. 
BCRs are highly specialised receptor proteins that allow only one specific antigen binding. 
Different types of B cells are continuously produced in the bone marrow where the BCRs 
on cell membrane have the ability to evolve and change over time. The B-lymphocyte 
antigen CD20 is an activated-glycosylated-phosphoprotein. This protein is expressed on 
the surface of all B cells; from immature pro-B cells to mature memory B cells. Its function 
is to facilitate optimum B-cell immune response, specifically against T-independent 
antigens via antibody production.  The CD20 protein complex is generally used as a 
specific B cell marker and is expressed on all B cells, during all stages of development. 
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 B cells and T cells are mainly distinct different by the way they recognise antigens. B cells 
recognise antigens in its naive form i.e. unbound and free in blood and lymph. T cells in 
contrast, recognise antigens in their processed form, where the antigen has been 
“processed” by antigen presenting cells APC’s and then presented to the T cell via the 
MHC molecule. 
 
1.5.2.2.1  B cell Function 
 
The main response of B cells during an immune process is by the production of specific 
antibodies, which are produced in abundance for a specific antigen.  
B cells exist as clones and all B cells are derived or “cloned” from a particular activated B 
cell. These cloned B cells have the ability to recognise the same antigen that activated the 
original B cell they originated from, and will have the same surface protein to bind with this 
specific antigen. The B cells ability to clone itself is the basis of the human immunogenic 
memory, one of the most important functions of the adaptive human immune defense 
system.  
Upon encountering its specific antigen, a single  B cell or a clone of cells with shared 
specificity, exponentially divides to produce numerous B cells. The majority of such B cells 
produced will differentiate into plasma cells for further antibodies production that will help 
in eradicating the pathogen.  The remaining minority becomes memory cells that can 
recognize the exact same epitope of the antigen. In each cycle, the number of memory 
cells proliferates and with each cycle, the B cells’ affinity to the particular antigen matures. 
The increased in number of cells and increased efficiency and specificity is known as the 
“secondary immune response”. Fully differentiated and functioning B cells are called 
effector B cells, and B cells that are not yet activated are termed “naive lymphocytes”. 
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 1.5.2.2.2  The Different Types of B Cells 
 
1.5.2.2.2.1  Plasma B cells (Plasma cells, plasmocytes or effector B cells) 
 
Plasma cells are responsible for the production and secretion of large amounts of 
antibodies upon exposure to an antigen, sometimes referred to as antibody factories. 
These large B cells also play a role in the destruction of microbes by binding with them, 
thus making the pathogen become easier targets for phagocytes. Intracellularly, plasma 
cells contain large amounts of rough endoplasmic reticulum essential for the synthesis the 
antibody. Plasma cells are short-lived cells and undergo apoptosis once the inciting 
pathogen is abolished.  
 
1.5.2.2.2.2  Memory B cells 
 
Memory B cells are derived or cloned from activated B cells. The original activated B cells 
are highly specific to a particular antigen encountered during the primary immune 
response. Memory cells are long lived and have the ability to respond quickly following a 
further exposure to the same antigen (second immune response). 
 
1.5.2.2.2.3  B-1 Cells 
 
These B cells have receptors that show polyspecificity and expresses IgM antibodies more 
than IgG. This polyspecificity receptors means that these cells have low affinities for many 
different antigens. Polyspecific immunoglobulins often have a preference for other 
immunoglobulins, self-antigens, and common bacterial polysaccharides. B-1 cells are 
found predominantly in the peritoneal and pleural cavities, and some in the lymph nodes 
and spleen. 
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 1.5.2.2.2.4  B-2 Cells 
 
B-2 cells are conventional B lymphocytes in the circulation; produced postnatally (unlike 
fetal B-1 cells). 
 
1.5.2.2.2.5  Marginal-zone B Cells 
 
These are non-circulating B cells that are found in the marginal zone of the spleen. They 
can be recruited into the early adaptive immune response, and due to its location, it is 
ideal for defense against blood-bourne antigens. 
 
1.5.2.2.2.6  Follicular B Cells 
 
Follicular B cells exist in the primary and secondary follicles of lymphoid organs such as 
the spleen and lymph nodes. These cells can freely circulate in the body and make up 
95% of B cells in the lymph nodes.  Together with T cells, they assist in promoting the 
primary immune response. 
 
1.5.2.2.2.7  Regulatory B cells (Breg cells) 
 
Bregs are involved in immune regulation. This is done via various mechanisms including 
secretion of IL-10 and TGF β (Yang et al., 2013). Sub-sets of Bregs can be found within 
both the B-1 and B-2 cell population.  
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 1.5.2.2.3  B Cells Activation 
 
B cells ability to produce antibodies can both be dependent or independent of the T cell 
activity. 
 
1.5.2.2.3.1  T Cell Dependent B Cell Activation 
 
The production of antibodies by activated B cells can be under the influence of T cell 
activity. Upon pathogen detection and ingestion by macrophages or dendritic cells, the 
proteins of the ingested pathogen are attached to MHC class II peptide where this complex 
sits on the cell surface. This complex in turn activates T cells resulting in the proliferation 
of T effector and memory cells. In addition, T helper cells activate specific B cells to 
produce antibodies. These antibodies subsequently surround and inhibit the pathogens 
until it is eradicated by phagocytes or the complement system. 
 
1.5.2.2.3.2  T Cell Independent B Cell Activation 
 
Type 1 T cell-independent activation relies upon toll-like receptors e.g. TLR9 for DNA.  The 
activation occurs when B cells that are already bound to antigens, are given a secondary 
activation by these TLR. These activated B cells produced are specific to the TLR-binding 
antigen and are only able to produce IgM antibodies. 
Type 2 T cell-independent activation occurs when B cells are exposed to pathogens with 
an organized and repetitive form, like bacteria. Activation is achieved by the cross-linking 
of the antigen receptors in a multivalent fashion. This leads to IgM synthesis in the 
absence of T cell stimulation. 
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 1.5.2.2.4  B Cell Maintenance 
 
BAFF is a cytokine that belongs to the tumour necrosis factor (TNF) ligand family encoded 
by the TNFSF13B gene that has been shown to have a critical role in B cell survival and 
maintenance(Schneider et al., 1999). It is also known as B Lymphocyte Stimulator (BLyS). 
This cytokine is expressed in B cell lineage cells but is also found on monocytes, dendritic 
cells and bone marrow stromal cells. BAFF is a potent B cell activator with a key role in the 
proliferation and differentiation of B cells(Mackay et al., 2003)(Kalled et al., 2003). In the 
human immune response, it acts potentially as a regulator of B and T cells functions. 
The steady state of BAFF relies on B cells and also on BAFF-binding receptors expression 
(Kreuzaler et al., 2012). BAFF naturally binds with three TNF-receptors, expressed on both 
immature and mature B lymphocytes. These TNF receptors are BAFF-
R (BR3), TACI (transmembrane activator and calcium modulator and cyclophilin ligand 
interactor), and BCMA (B-cell maturation antigen). BAFF has differing affinities to these 
receptors with BAFF-R having the higher affinity to BAFF compared to TACI and BCMA. 
BCMA, which is also expressed on plasma cells, has the worst affinity to BAFF, binding 
better with a protein similar to BAFF called a proliferation-inducing ligand (APRIL). TACI 
has an intermediate binding affinity and interacts with either BAFF or APRIL (Bossen and 
Schneider, 2006). TACI can also be found expressed on sub-sets of T cells. 
BAFF-R in particular, has a role in the positive regulation of B cell development, which is 
critical for B cells’ survival, germinal center maintenance and antibody production 
(Thibault-Espitia et al., 2012)(Kalled, 2006). The BAFF/ BAFF-R interaction activates the 
NF-κB signaling pathways which stimulates B lymphocytes to undergo proliferation and to 
counter apoptosis. Thus, this interaction is crucial for the formation and maintenance of B 
cells and is important for a B-cell survival(Bossen and Schneider, 2006)(Kreuzaler et al., 
2012). 
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 APRIL is another cytokine that belongs to the tumour necrosis factor (TNF) ligand family 
with a high affinity to TACI and BCMA receptors. APRIL, like BAFF, is also found to be 
important for B cell development particularly in the long-term survival of plasma B cells in 
the bone marrow(Bossen and Schneider, 2006). 
 
1.5.2.2.5  BAFF and APRIL T Cells Maintenance 
 
BAFF and APRIL are generally recognised for their function in B cells survival and 
maturation, yet BAFF and APRIL are also expressed by T lymphocytes. BAFF and APRIL 
appear to also promote T cell activation and survival(Leandro and Cambridge, 2013)(Zhao 
et al., 2012)(Ramos-Casals, 2013)(Saussine et al., 2012). In animal studies, BAFF 
expression has been shown to enhance Th1 T cells driven hypersensitivity but inhibits Th2 
T cell mediated pathways. This suggests that interaction of BAFF on T cells may also play 
a role in immunomodulation and inflammation (Mackay et al., 2005). 
 
1.5.2.2.6  Clinical Significance of BAFF 
 
The immunostimulant activity of BAFF appears to be necessary for maintaining normal 
immunity. Inadequate levels of BAFF which leads to failure in B cells activation, reduces 
immunoglobulin production that can result in immunodeficiency. In infections, BAFF is said 
to also have a role in priming or enhancing B and T cell activity to assist in microbial 
eradication (Mackay et al., 2003). On the other hand, excessive levels of BAFF will cause 
abnormally high antibody production, which is the basis of autoimmune diseases such as 
systemic lupus erythematosus and rheumatoid arthritis (Roschke et al., 2002). 
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 1.5.2.3 Macrophages 
 
Macrophages are white blood cells found in tissues and are part of the mononuclear 
phagocyte system. In humans, they are about 21µm in diameter. They are derived from 
differentiation of circulating monocytes and have a role in both the innate (non-specific 
defense  system) and acquired (specific defense  system) immune system. These 
phagocytic cells have the capacity to regenerate and are found in all living tissues. 
Macrophages have the unique ability to either kill or repair. This is done by metabolising 
just a single amino acid molecule, arginine, to either form nitrix oxide (killer molecule) or 
ornithine (repair molecule) (Mills, 2012). Killer macrophages are generally known as M1 
macrophages. They are activated by the lipopolysaccharides (LP), which are molecules 
found on the cell surfaces of gram negative bacteria and IFN-gamma, and secrete mainly 
IL-12 cytokine. They are active in inflammation and produce a small amount of IL-10, an 
anti-inflammatory cytokine. In contrast, M2 macrophages are involved in tissue repair. 
Activation of these molecules is by IL-10 and IL-4, and they in turn produce more IL-10, 
TGF- beta and small amounts of IL-12. Despite somewhat appearing to have a ”protective” 
mechanism in the body, M2 macrophages however have been associated with promoting 
tumour growth (Galdiero et al., 2013). M1 and M2 macrophages are also known as the 
classical (M1) and alternative (M2) activated macrophages.  
However, in general, macrophages are recognised to have three main primary functions 
which are; 1) as scavengers to eradicate pathogens and clear debris, 2) as an antigen 
presenting cell (AP) for other immune cells such as T cells and 3) as one of the effector 
cells during the inflammatory process. Pathogen ingestion by macrophages is termed 
“phagocytosis”. Upon encountering a pathogen, a macrophage will initially ingest it. Once 
within the macrophage, the ingested pathogen becomes trapped in a phagosome. This 
phagosome, along with the trapped pathogen thereafter fuses with lysosome, which is a 
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 spherical vesicle in the cytoplasm of the macrophage containing acid hydrolase. Acid 
hydrolase has the ability to breakdown all kinds of biomolecules, including proteins, lipids, 
carbohydrates, nucleic acids and cellular debris. The trapped pathogen then becomes 
digested by the acid hydrolase and is eradicated. A single macrophage is able to digest 
more than 100 bacteria before finally dying from their own digestive compounds. However, 
not all pathogens are easily removed by this process. Mycobacterium tuberculosis is one 
bacterium known to be resistant to macrophage attacks. 
Upon pathogen invasion, macrophages also stimulate other immune cells such as 
lymphocytes and eosinophils, by releasing various cytokines in response to the pathogen 
attack. In an event where a pathogen is unsuccessfully eradicated and antigens persist, for 
example in the case of mycobacterium tuberculosis, macrophages will accumulate it and 
together with other immune cells, surround the foreign material in an attempt to wall it off. 
The formation of densely packed immune cells form a ball-like structure called granuloma, 
which are typically seen in tuberculosis. As previously described, inflammation with 
granuloma-like features or predominance of mononuclear phagocytic cells,  is generally 
termed “granulomatous inflammation”.  
 
In the acquired immune system,  macrophages also act as an antigen presenting cell 
(APC) to lymphocytes and other immune cells. They can also be activated into effector 
cells, releasing further inflammatory mediators and eradicating pathogens via 
phagocytosis. At some inflammation sites, activated macrophages can morphologically 
transform to resemble epithelial cells, hence termed “epithelioid cells”, seen particularly in 
granulomatous inflammation. These epithelioid cells may fuse to form multinucleated giant 
cells. Epithelioid cells as well as multinucleated giant cells are some of the histological 
features associated with GPA. 
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 There are several cell phenotypes and cytokines identified and associated with the 
macrophage cell lineage (Mosser and Edwards, 2008).  
 
1.5.2.3.1  CD68 Macrophages 
 
CD68 is a glycoprotein which binds to low density lipoprotein, and is particularly useful as 
a marker for the various cells of the macrophage lineage, including monocytes, histiocytes, 
giant cells, Kupffer cells, and osteoclasts. It is generally the most common cell marker 
used to identify M1 macrophage presence in tissues.  
 
1.5.2.3.2  CD163 Macrophages 
 
CD163 has been shown to specifically mark cells of the monocytes/macrophage lineage 
(Lau et al., 2004). CD163 is a scavenger receptor for the haemoglobin-haptoglobin 
complex and is seen upregulated in several inflammatory diseases such as liver cirrhosis, 
type 2 diabetes and rheumatoid arthritis (Andersen et al., 2014)(Jude et al., 
2013)(Fjeldborg et al., 2013).  
 
1.5.2.3.3  CD204 Macrophages 
 
The CD204 (macrophage scavenger receptor) is used as  a marker of the alternative 
activation of macrophages (M2), and influences B cell auto-immunity by regulating soluble 
auto-antigen concentration (Haasken et al., 2013). CD204 together with CD163, have 
been associated in the development of chronic obstructive pulmonary diseases (Kaku et 
al., 2014). However, the roles of these cells have not been established in GPA. 
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 1.5.2.3.4 Allograft inflammatory factor-1 (AIF-1) cytokine  
 
Cytokines produced by macrophages have also been linked to the development of auto-
immune diseases. Allograft inflammatory factor-1 (AIF-1) cytokine, expressed in 
macrophages, as well as neutrophils and also in a subset of CD68 macrophages (Utans et 
al., 1995), AIF-1 is said to have a critical role in the pathogenesis of auto-immune diseases 
such as rheumatoid arthritis, where it has been shown to have a role in vascular 
inflammation (Kimura et al., 2007). Its presence has not been investigated in GPA tissues. 
 
1.5.2.3.5 IL-23 cytokine 
 
Cytokine  IL-23, a heterodimeric cytokine, is made up of two subunits: p40, also a 
component of the IL-12 cytokine, and p19, considered to be the IL-23 alpha sub-unit. IL-23 
is produced by macrophages and dendritic cells, and plays an important role in bridging 
innate and adaptive responses.  In chronic inflammations, IL-23 influences the expansion 
of CD4 T cells to produce IL-17 via Th17, a pro inflammatory cytokine previously described 
in Chapter 3. IL-23  also activates dendritic cells and macrophages to produce further 
proinflammatory cytokines such as IL-1, IL-6, and TNF-α. (Figure 1.3)In contrast to AIF-1, 
IL-23 has been reported to be elevated in patients with AAV, including GPA (Langrish et 
al., 2005). The presence of IL-23 in peripheral inflamed tissues has also not yet been 
demonstrated. 
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Figure 1.3: The IL-23/IL-17 axis in inflammation. IL-23 produced from macrophages and dendritic 
cells promotes the development of Th17 cells which produces IL-17 cytokines. The effect of IL-17 
on endothelial, stroma, epithelial and fibroblast cells  in turns enhances T cell priming and 
produces proinflammatory cytokines such as IL-1, IL-6 and TNF- α leading to an inflammatory 
response. 
 
1.5.3  Infection 
 
Staphylococcus aureus (S. aureus) has been implicated in the pathogenesis of AAV, 
particularly GPA with respiratory involvement, where up to 60-72% of patients were found 
to have nasal carriage of S. aureus(Zycinska et al., 2008)(Laudien et al., 2010).  It is 
postulated that low-grade chronic infection in the upper airway causes release of pro-
inflammatory cytokines that are able to prime neutrophils locally, which are then further 
activated by ANCA(Kallenberg, 2008). One of the mechanisms that have been suggested 
that links infection to GPA development  is molecular mimicry. This is because GPA 
patients who are PR3-ANCA positive possess antibodies reactive with a protein produced 
from PR3-antisense RNA, and these proteins have been shown to have an amino acid 
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 sequence that has homology with proteins from many microbes and viruses(Preston et al., 
2005). In addition, the anti-human lysosomal membrane associated protein (LAMP) 2 
antibodies, have also been shown to target adhesion elements, FimH (fimbriae) on gram 
negative bacteria. Interestingly, anti-LAMP2 antibodies have also been found to be present 
in 100% of AAV patients with active renal involvement and in 93% of a cohort of 84 
patients with GPA, MPA or renal limited vasculitis. This again suggests a connection 
between infection and vasculitis through molecular mimicry  (Kain et al., 2010). 
Nevertheless, there has been no general consensus on this finding and hence further 
confirmatory studies are required. 
Recently, toll like receptors (TLRs) have also been implicated  in the pathogenesis of 
autoimmune diseases such as SLE as well as GPA (Capolunghi et al., 2010). TLRs are 
important receptors on cells of the immune system which function by sensing invading 
pathogens like bacteria and viruses. They  orchestrate  the immune response during a 
pathogen invasion resulting in the release of pro-inflammatory cytokines, lymphocyte 
production and antibody production (Tadema et al., 2011). Expressions of TLR2 and TLR9 
in particular, have been shown to be linked to GPA, as membrane  PR3 expression is 
found to be heightened by TLR2 and TLR9 stimulation. In addition, TLR2 and TLR9 
ligands also act as neutrophil priming agents similar to TNF-alpha, triggering ANCA 
mediated neutrophil activation. This is thought to further explain the role of infections in 
triggering disease activity in GPA (Holle et al., 2013a). 
 
1.5.4  Genetic factors 
 
Genetic associations with GPA have also been studied but results are generally 
inconclusive. The HLA-DPB1-15  allele is reported to have a strong link with the 
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 development of PR3 associated ANCA vasculitis (Lamprecht et al., 2009). Defective allele 
PI*Z on chromosome 14q32.1 has also been associated with disease development in 
ANCA diseases and rheumatoid arthritis (Borgmann et al., 2001). 
 
1.5.5  Drugs 
 
Some drugs have also been seen to be associated with the development of AAV. 
Treatment used  in the treatment of thyroid disease and Graves’  disease such as 
propylthiouracil and benzylthiouracil has indeed been shown to be inducers of this disease 
(Panamonta et al., 2008). However reports were mainly showing associations of these 
drugs with MPO-ANCA and not PR3-ANCA. Other drugs that have also been implicated in 
the induction of ANCA positive vasculitis include sulfasalazine, a drug used in the 
treatment of inflammatory bowel disease. In contrast to propylthiouracil and 
benzylthiouracil, sulfasalazine has been shown to actually induce and exacerbate GPA 
(Denissen et al., 2008). Hydralazine, commonly used in the treatment of hypertension and 
systemic lupus erythromatosus (SLE), has also been shown to cause ANCA positive renal 
vasculitis, resulting in acute nephritis (Keasberry et al., 2013). 
 
1.5.6  Environmental exposures 
 
Exposure to silica has also been shown to have a link in the development of AAV. The 
exact mechanism in which silica causes AAV is still unclear but it is suggested that silica 
particles in the trachea may accelerate the apoptosis of neutrophils by producing free 
radicals. The silica particles also activate alveolar macrophages that then produces 
inflammatory chemokine and cytokines  which may result in immune modulating defect 
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 (Chen and Kallenberg, 2010)(Gómez-Puerta et al., 2013). Vitamin D deficiency is another 
environmental factor that is proposed to cause GPA. Human bodies manufacture vitamin 
D with ultraviolet B rays, thus, it is postulated that, countries in the northern and southern 
hemisphere where GPA is prevalent, Vitamin D deficiencies are high due to the low 
ultraviolet radiation gradient there. Indeed it has been shown that vitamin D may reduce 
cytokines interleukin 6 (IL-6) and tumour necrosis factor –alpha (TNF-alpha) in an 
inflammatory environment (van Hamburg et al., 2012). 
 
1.6  Clinical Presentation in GPA 
 
1.6.1  General GPA 
 
GPA can affect any organ system though the disease tends to affect the upper and lower 
respiratory tract and kidneys more, compared to other structures.  However, the clinical 
presentation varies, and may be non-specific such as symptoms of fever, malaise, 
anorexia, weight loss and arthralgia (Gottschlich et al., 2006). 
 
1.6.2  Upper and Lower Respiratory Manifestations of GPA 
 
GPA has a predilection to affect the upper and lower respiratory tract systems where 
involvement of this system can occur in up to 85% of patients (Manganelli et al., 
2006)(Hoffman et al., 1992). Despite this predilection, symptoms involving the upper 
respiratory are often non-specific. The most frequent initial presentation is chronic sinusitis 
that is unresponsive to treatment seen occurring in approximately 70% of patients with 
GPA. In these patients, recurrent inflammation of the nose could lead to damage to the 
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 nasal mucosal lining resulting in dryness, crusting and epistaxis.  Subsequently, patients 
then become susceptible to infection. As a result of repeated insults from infection and 
inflammation, extensive tissue damage such as nasal septal perforation, can occur. 
Cartilage destruction of the nasal bridge, which gives rise to the ‘saddle nose deformity’, is 
closely associated with GPA, particularly the retro-orbital mass in GPA (Gomes et al., 
2010). (Figure 1.2) 
 
 
Figure 1.4: Saddle nose deformity (arrow) from nasal septum destruction 
 
In the ear, chronic otitis media is a common manifestation of GPA. Perforation or 
thickening of the tympanic membrane, ossicle fusion or damage to the neurosensory 
pathway in the ear resulting in hearing loss, may occur from recurrent ear infections and 
vasculitic inflammation in the middle ear. Oral involvement in GPA include gingivitis and 
ulcer, are seen in 10% of patients. In particular, strawberry gingivitis or hyperplastic 
granular gingivitis is characteristic presentation of GPA although this presentation is rare. 
Subglottic stenosis is a life threatening complication of GPA. GPA patients who present 
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 dyspnoea in the absence of active pulmonary disease should be investigated for this 
condition and managed urgently.  
Lower respiratory or pulmonary involvement can occur in about 45% of GPA patients with 
85% eventually developing lung disease. Respiratory symptoms include dyspnoea, cough, 
chest pain and haemoptysis.  Radiographically, the most common findings on chest X-
Rays are solitary or multiple nodules and masses which mainly represent pulmonary 
granulomas with or without cavitations. Nevertheless, despite these findings, patients may 
still be asymptomatic(Manganelli et al., 2006).  Other chest X-ray findings include fibrosis, 
lung consolidation and signs of secondary chest infection. Lung collapse, severe 
pneumonia; secondary either to the disease or immunosuppressive treatment, alveolar 
haemorrhage and obstruction, are severe pulmonary complications associated with GPA 
and can lead to death.  
 
1.6.3  Renal Manifestations of GPA 
 
Together with secondary infections, renal disease is the main cause of mortality in 
GPA(Singer et al., 1990)(Takala et al., 2008). Renal involvement occurs in 75-80% of 
patients with GPA, yet only 20% of patients, in a non-renal clinic, will have features of 
active glomerulonephritis (Takala et al., 2008).  Clinical signs of renal involvement in GPA 
include proteinuria, microscopic haematuria and, in advanced cases, oliguria (Lamprecht 
and Gross, 2007).  Histopathology from renal biopsies of patients with GPA commonly 
reveals focal and segmental pauci-immune crescentic glomerulonephritis with necrotic 
changes in the glomerular capillary loops seen as one of the earliest histologic 
abnormalities. Once the renal system is involved, the disease may progress rapidly 
although the patient may remain asymptomatic. Prognosis largely relates to serum 
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 creatinine at presentation (Gottschlich et al., 2006). Rapidly progressive glomerulonephritis 
(RPGN) is the most severe renal manifestation of GPA. This condition can lead to the 
need for dialysis or transplantation within weeks if untreated. Another rare but serious 
complication related to ANCA-associated vasculitis, including GPA, is the pulmonary renal 
syndrome. This syndrome is a combination of diffuse alveolar haemorrhage and 
RPGN(Manganelli et al., 2006). 
 
1.6.4  Musculoskeletal Manifestations of GPA 
 
Musculoskeletal symptoms occur in approximately two-thirds of GPA patients, with 
migratory polyarthralgias and myalgias being the most frequent musculoskeletal complaint. 
Although less frequent, symmetrical polyarticular involvement can also resemble 
rheumatoid arthritis (RA). Asymmetric pattern and monoarticular pain are not common in 
GPA and unlike RA;  arthritis in GPA does not cause deformities and is typically non-
destructive. 
 
1.6.5  Cardiovascular Manifestations of GPA 
 
Myocardial infarction associated GPA often results from vasculitis of the coronary vessels 
(Cocco and Gasparyan, 2010). It has been reported in one study that GPA patients appear 
to have an increased morbidity from ischaemic heart disease compared to the rest of the 
population  (Faurschou et al., 2009). In addition, GPA patients with cardiovascular 
manifestations seem to have an increased risk of first GPA relapse after initial remission 
(Pierrot-Deseilligny Despujol et al., 2010). 
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 1.6.6  Gastrointestinal Manifestations of GPA 
 
Gastrointestinal manifestations of GPA are now increasingly recognised as part of this 
disease. Clinically, patients may present with an acute abdominal pain with signs of 
peritonitis (Yildirim et al., 2010). Lesions are normally seen when performing colonoscopy 
or enteroscopy, manifesting as multiple intestinal ulcerations which can involve both the 
large and small bowels (Beppu et al., 2011)(Thanarajasingam et al., 2011). These ulcers 
may subsequently lead to multiple intestinal perforations (Beppu et al., 2011)(Yildirim et 
al., 2010).  Other reported gastrointestinal lesions associated with GPA include vasculitis 
and multiple mesenteric lymphadenopathy (Jeong et al., 2010). 
 
1.6.7  Ocular GPA 
 
Ocular involvement occurs in 50-60% of patients with GPA (Joshi et al., 2009) and any 
ocular structure may be affected; from the eyelid and orbit to the optic nerve. Ocular GPA 
can either manifest de novo, as disease spread from contiguous structures like the 
sinuses, or as part of a more widespread systemic form of the disease. Ophthalmic 
presentations are also variable and can present as an orbital mass (orbital granuloma), 
ocular vasculitis, adnexal inflammation and nasolacrimal duct changes. 
Ocular inflammation can occur with or without systemic manifestations of GPA (Harper et 
al., 2001). Visual loss is seen in up to 8% of patients where severe ocular morbidity can 
occur in both the limited and systemic forms of the disease. In 8-16% of patients, ocular 
manifestations may be the initial presentation of GPA. However, as the signs and 
symptoms are usually non-specific and tend to overlap with those of other orbital 
inflammatory disorders, diagnosis is often difficult (Pakrou et al., 2006)(Fortney  and 
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 Chodosh, 2002). It has been shown that patients with ocular GPA could progress to the 
systemic form in one study  (Choopong et al., 2005).However, others have failed to 
observe the same pattern (Fechner et al., 2002)(Holle et al., 2010a). 
 
1.6.8  Orbital Manifestation of GPA 
 
The orbit is a common ocular structure involved in GPA. In the majority of cases, orbital 
involvement occurs as part of disease spread from adjacent structures such as the nose 
and paranasal sinuses already affected by the disease. Nevertheless, orbital GPA may 
also be the initial manifestation of the GPA, exhibiting either with orbital granuloma 
formation or orbital vasculitis. Common presentations of orbital GPA include proptosis from 
an orbital mass, periorbital swelling, eye redness and pain, reduced vision, diplopia and 
epiphora(Tarabishy et al., 2010)(Pakrou et al., 2006). (Figure 1.3) 
 
 
Figure 1.5: Left eye proptosis (arrow) in orbital GPA 
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 Apart from being the most common ocular presentation of orbital GPA (Tarabishy et al., 
2010)  proptosis  is  also an important sign. Together with respiratory diseases or 
glomerulonephritis, the combination of these symptoms  is  highly  suggestive of the 
diagnosis of GPA(Hoffman et al., 1992). Patients with proptosis and lid destruction are 
susceptible to develop exposure keratopathy. This can further lead to the development of 
corneal ulceration, ocular perforation and blindness (Pakrou et al., 2006). Inflammation of 
the extraocular muscles or vasculitis of the vasa nervorum results in orbital myositis in 
GPA, where patients mainly present symptoms of diplopia and pain on ocular movement 
and show signs of restriction of ocular motility (Salam et al., 2008). 
In orbital GPA, the optic nerve can be affected when there is infiltration of the disease in 
the orbital apex. In such cases, symptoms present in patients may include painless optic 
neuropathy, optic nerve swelling and ensuing atrophy.(Figure 1.4) As the disease further 
infiltrates, patients may develop painful ophthalmoplegia and blindness (Shunmugam et 
al., 2011).Vasculitis involving the cranial nerves supplying the extraocular muscles may 
also cause ophthalmoplegia(Pakrou et al., 2006).The orbital contracture syndrome, 
described as proptosis followed by the development of enophthalmos with radiographic 
evidence of fibrotic changes in the orbit, can also occur as a complication of orbital GPA. 
This complication is thought to be due to the proliferation of fibrous tissue replacing areas 
of acute inflammation and necrosis where ensuing contracture leads to restriction of 
motility and enophthalmos. The optic nerve may also be involved in this, resulting in further 
visual loss.  As with other fibrosing manifestations of GPA, socket contracture responds 
poorly to immunosuppressive therapy (Talar-Williams et al., 2005). 
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Figure 1.6: Left optic disc (arrow) swelling in orbital GPA 
 
 
1.6.9  Sclera and Episcleral Manifestation of GPA 
 
Scleritis involves inflammation of the entire thickness of the sclera and can manifest in two 
forms; necrotising scleritis, which is associated with necrotic features, or non-necrotising 
scleritis, which has no necrotic features.  (Figure  1.5)Necrotising scleritis is one of the 
common ophthalmic presentations of GPA, occurring in 50% of patients (García et al., 
2006)(Biswas et al., 2003) and may be the initial clinical presentation of GPA (Hijikata et 
al., 2009). (Figure 1.6)Typically patients present severe deep boring pain that may radiate 
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 to the jaw and temple with red, tender eyes. The pain associated with scleritis typically 
becomes worse at night, often waking the patient from sleep.  On ocular examination, 
areas of capillary non-perfusion due to severe vasculitis causing capillary closure in the 
deep episcleral vascular bed are seen and are characteristic of this disease. This can 
cause infarction and necrosis of the involved sclera, and exposure of the underlying uvea 
(Galor and Thorne, 2007). Despite scleral thinning, globe perforation is rare. However, 
adjacent ocular structure such as the cornea, trabecular meshwork and ciliary body, may 
also be involved during active inflammation and may result in complications such as 
keratitis, corneal ulceration, uveitis, ocular hypertension or glaucoma(Jabs et al., 2000). 
 
 
Figure 1.7:Left eye scleritis in GPA 
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Figure 1.8: Necrotising scleritis in GPA. Arrow showing the area of sclera thinning 
secondary to tissue necrosis showing the underlying uvea tissue. 
 
Episcleritis, characterised as inflammation of the loose episcleral tissues between the 
conjunctiva and sclera (Pakrou et al., 2006) has also been described in patients with GPA 
(Tojima et al., 1994)  although  not usually associated with systemic diseases. Its 
presentation is usually less severe compared to scleritis. Patients may complain of red eye 
with mild discomfort and epiphora. Ocular examination typically reveals an eye which is 
either diffusely or locally injected.  Episcleritis generally runs a milder course compared to 
scleritis and is frequently self-limiting with few or no ocular complications. In GPA however, 
a short course of topical glucocorticoids for patients with episcleritis is often 
necessary(Tarabishy et al., 2010). 
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 1.6.10 Cornea Manifestation of GPA 
 
Peripheral ulcerative keratitis (PUK) is another frequent ocular manifestation of 
GPA(García et al., 2006) and cases of bilateral eye involvement has been reported in the 
past (Chan et al., 2007). (Figure 1.7) 
 
 
Figure 1.9: Peripheral ulcerative keratitis (arrow) in GPA 
 
Patients presenting with PUK often have concurrent scleritis. In this situation, ocular pain 
may be severe and other symptoms may include photophobia, tearing and poor vision. On 
ocular examination, corneal stromal infiltration and clouding, with invading vessels from 
the limbus are usually seen. The overlying corneal epithelium may breakdown and can 
lead to ulceration and stromal thinning where if left untreated, may result in corneal 
perforation (Pakrou et al., 2006). In GPA, corneal melt has been reported to occur in the 
earlier stages of the disease  and can progress quickly, resulting in visual loss (Galor and 
Thorne, 2007). 
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 1.6.11 Eyelid, Adnexal and Conjunctiva Manifestation of GPA 
 
Eyelid involvement in GPA is rare. Some of the lid manifestations of GPA include ptosis 
and lid granulomas, and in severe cases, lid destruction.  It has been suggested that the 
‘yellow-lid sign’, which is described as resembling florid xanthelasma despite the patient 
having normal lipid metabolism (Dharmasena et al., 2009), when associated with orbital 
inflammation, is an indicator to the clinical diagnosis of GPA (Tullo et al., 1995).(Figure 
1.8)  As for adnexal involvement, dacroadenitis and lacrimal gland enlargements are 
recognised clinical features of GPA which may cause ocular sicca syndrome i.e. dry eyes 
(Khanna and Shrivastava, 2011). 
 
 
Figure 1.10: Left “yellow-lid sign”(arrow) together with proptosis orbital GPA 
together 
 
Nasolacrimal disease and nasolacrimal blockage in GPA may lead to the development of 
dacrocystitis and epiphora. This can occur either as a consequence of inflammatory 
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 spread from the adjacent sinonasal inflammation or a direct consequence of focal GPA 
inflammation (Tarabishy et al., 2010)(Pakrou et al., 2006).Conjunctiva involvement in the 
form of ulcerative and necrotic conjunctivitis can occur in up to 16% of patients with GPA 
(Robinson et al., 2003) and can result in marked cicatricial changes of the conjunctiva 
(Tarabishy et al., 2010). 
 
1.6.12 Uveitis, Retina and Choroid Manifestation of GPA 
 
Uveitis is not a common manifestation of GPA, occurring only in 3% of patients (Bullen et 
al., 1983). More often, uveitis in GPA is observed to occur concurrently with scleritis and is 
termed sclerouveitis. This condition is said to most likely carry a poorer ocular prognosis 
(Pakrou et al., 2006). Retinal and choroid involvement in GPA is also uncommon and can 
present as retinitis, chorioretinitis, macular oedema, exudative retinal detachment or retinal 
necrosis (Pakrou et al., 2006). Retinal vein occlusion has also been reported in patients 
with GPA and is thought to occur due to compression by tissue granulomas to the external 
vascular wall (Wang et al., 2006). Central retinal artery occlusion (CRAO) in GPA can 
occur bilaterally and simultaneously. In these cases, the occlusion is thought to mainly be 
caused by vasculitis. Despite having very poor vision at presentation, prompt treatment of 
the inflammation may improve the visual prognosis in these patients (Morell-Dubois et al., 
2007)(Costello et al., 2005)(Wong et al., 2002). Other reported rare manifestations of GPA 
in the retina and choroid include vitreous haemorrhage from chorioretinal and ciliary body 
granulomas (Kamei et al., 2001), acute multifocal placoid pigment epitheliopathy(Chiquet 
et al., 1999) and sclero-choroidal granulomas mimicking uveal melanoma (Janknecht et 
al., 1995). 
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 1.7  Treatment Options 
 
1.7.1  General Treatment Regimes 
 
GPA, if left untreated, is a fatal disease with a mean survival period of 5 months for only 
50% of patients after diagnosis and 80% would die  within a year, mainly from renal 
disease (Hoffman et al., 1992). Treatment with corticosteroid alone only gives a moderate 
increase in the mean survival period to 12 months. Fortunately, with increased awareness 
of the disease and recent improved treatment regimens, severe morbidity and mortality 
from GPA is becoming less frequent (Holle et al., 2010b).Currently, the combination of 
corticosteroid with either cyclophosphamide, azathioprine or methotrexate, has shown to 
achieve disease remission and improve survival, where survival rates with the combination 
therapy increasing to 95% at 5 year follow up and up to 80% after 10 years. The treatment 
of GPA in general can be divided into two phases; (1) remission induction by the use of 
intensive immunosuppressive therapy, and (2) maintenance therapy with less intensive 
immunosuppressive regimes. 
 
1.7.2  Remission Induction 
 
In 2007, the EUVAS group devised a system of disease sub-groupings for AAVs, based on 
the severity of the presentation, to guide therapy. Currently, the treatment for these 
diseases is based on assessing the patient’s clinical severity and disease extent and 
subdividing the disease into three groups: (1) localised and/or early, (2) generalised 
disease with threatened organ involvement and (3) severe/life threatening disease 
(Lapraik et al., 2007). 
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 Today, the use of cyclophosphamide (CYC) and corticosteroid (CS) (1mg/kg/day) is 
recommended for generalised/systemic GPA.  However, due to its well recognised serious 
adverse effects, such as amenorrhoea, infertility, cystitis, haematuria and transient 
alopecia, the management of GPA is moving away from the use of CYC(Faurschou et al., 
2008)(White and Lynch, 2006)(Fervenza, 2010). New treatment regimens with biologics, 
such as Rituximab (RTX), a monoclonal anti CD20 B cell antibody that depletes B cells, 
are gaining popularity as the first line of treatment in the management of GPA. In fact, RTX 
is now frequently used as an alternative treatment regimen for GPA instead of the 
standard CYC induction protocol recommended by EUVAS.  Moreover, many reports have 
shown RTX to be as effective in the treatment of AAV as CYC(Fervenza, 2010)(Stone et 
al., 2010)(Jones et al., 2010). 
 
1.7.3  Remission induction in limited or early GPA 
 
In limited or early GPA, remission induction has been shown to be successful with the 
combination of methotrexate (MTX) (20-25mg per week) with CS (1mg/kg/day and 
gradually tapered) as CYC and prednisolone, thus avoiding the possible adverse effects of 
CYC in these patients (NORAM study)(De Groot et al., 2005)(Mukhtyar et al., 2009). 
However, in patients with extensive disease and pulmonary involvement, MTX is less 
effective in achieving remission compared to CYC and had a higher relapse rate in this 
group. Nevertheless, for cases of limited GPA, MTX is still widely considered to be the 
drug of choice for such patients. 
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 1.7.4  Remission induction in severe or life threatening GPA 
 
In severe or life threatening GPA (AAV with renal or other vital organ failure and serum 
creatinine>  500micromol/l), treatment recommendation by EUVAS includes the use of 
CYC (IV or pulse) and steroid with adjuvant plasma exchange (plasmapheresis; PE). 
Therapeutic PE involves an extracorporeal blood purification technique that aims to 
remove large molecular weight substances from the plasma such as immune complexes 
and pathogenic autoantibodies which may be involved in disease development. This will 
subsequently reduce tissue damage and promote reversal of the pathological process (Al 
bshabshe et al., 2010). Therapeutic PE has been used to induce disease remission in 
severe renal and pulmonary vasculitic diseases including GPA. In GPA patients  with 
pulmonary renal syndrome, PE together with immunosuppressive treatment has also been 
shown to be successful (Al bshabshe et al., 2010). 
Anti-TNF-α agents such as infliximab and etanercept have also been extensively studied 
for their potential role as remission inducing therapies for vasculitic diseases. Infliximab, a 
chimeric monoclonal antibody directed against TNF alpha was shown to be effective at 
inducing remission in 88% of patients with AAV (Booth et al., 2004). Other studies have 
also reported infliximab to be a potentially useful and safe rescue treatment for patients 
with refractory systemic necrotizing vasculitides(Josselin et al., 2008). Despite the positive 
report outcomes, the safety profile of infliximab is still questionable and further study is 
required.  
In contrast, the Wegener’s Granulomatosis Etanercept Trial (WGET) unexpectedly found 
that etanercept was ineffective for the maintenance of remission in patients with 
Wegener's granulomatosis. In addition, eternecept was also found to be associated with a 
high rate of treatment related complications, including solid organ tumours(Seo et al., 
2005)  where long-term follow up of these patients showed that the incidence of solid 
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 malignancy remained increased during long-term follow-up.  Although etanercept exposure 
during the trial could not solely be attributed to the development of this complication, anti-
TNF therapy with etanercept do appear to further increase the risk of malignancy in 
patients with GPA who are treated with cytotoxic therapy and should be avoided for such 
patients (Silva et al., 2011). 
 
1.7.5  Maintenance Therapy 
 
In AAV patients, maintenance therapy following disease remission is recommended as 
there is a high tendency of occurrence for disease relapse.  MTX and Azathioprine (AZA) 
have both been shown to be as effective as CYC as a maintenance therapy in GPA, thus 
the duration of exposure to CYC may be safely reduced (Jayne et al.). 
In limited GPA, like orbital GPA, it has been shown that the combination of MTX and 
corticosteroid also achieves remission maintenance rates of around 70% (De Groot et al., 
2005). Similarly, mycophenolate mofetil (MMF) has also been demonstrated to achieve 
remission maintenance and moreover, it is a well-tolerated drug. Unexpectedly however, 
MMF was found to be less effective than AZA in maintaining disease remission among 
AAV patients in one study (Hiemstra et al., 2010).  Nevertheless, all three treatments have 
a more favourable adverse effect profile than CYC, thus are a much preferred choice for 
remission maintenance.  
Lefonimide, a pyrimidine synthesis inhibitor that targets T cells by inhibiting the 
mitochondrial enzyme dihydro-orotatedehydrogenase thus limiting pyrimidine synthesis, is 
another treatment option. It has also been reported to be an effective alternative 
immunosuppressive drug for remission maintenance in GPA (Henes et al., 2011)(Metzler 
et al., 2007).However, there are reports of increased frequency of adverse events (Metzler 
77 
 et al., 2007).Relapse rates have also been noted to remain high(Villa-Forte et al., 2007) 
especially in patients who are still ANCA positive at the time of remission. Hence, it is 
recommended that treatment is maintained for up to 12 months post remission where 
continued close follow-up of patients during this period is mandatory. 
It has been postulated that bacterial and viral respiratory tract infections can trigger 
relapses in patients with PR3-positive vasculitis. Reports have shown that treatment with 
co-trimoxazole may be beneficial as this antibiotic would eliminate the offending microbe 
and as a result, halts the initiating stimulus in these patients. In previous studies, treatment 
with co-trimoxazole has been shown to be effective in reducing the incidence of relapses 
in patients with GPA in remission (Zycinska et al., 2009)(Stegeman et al., 1996). In cases 
of persistent endonasal activity of GPA together with S. aureus carriage, treatment with co-
trimoxazole  should also be considered (Kallenberg, 2011b). Co-trimoxazole was also 
recommended by both the EULAR (Mukhtyar et al., 2009)  and the British Society for 
Rheumatology (BSR), and British Health Professionals in Rheumatology(BPHR) 
guidelines (Lapraik et al., 2007) as prophylaxis against pneumocystis jerovicii infection in 
patients with WG/GPA. 
 
1.7.6  Other Treatment Regimes 
 
15-Desoxyspergualin, a synthetic derivative of spergualin, which is a protein from Bacillus 
laterosporus that is capable of preventing T-cell and B-cell maturation, has been used with 
some success in refractory GPA cases (Schmitt et al., 2005).  It may offer a safer 
alternative to CYC for induction therapy, but is not yet supported for routine clinical use. 
Anti-CD52 therapy (alemtuzumab, CAMPATH-1H), a humanized monoclonal antibody to 
CD52, has also been shown to have anti-lymphocyte activity and has been reported to 
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 induce remission in AAV. However, relapses and adverse events are common, thus its use 
in GPA is considered experimental (Walsh et al., 2008). Anti T-cell antibodies such as anti-
thymocyte globulins causes rapid depletion of T lymphocytes and have been investigated 
for use in refractory GPA  (Schmitt et al., 2004). Other upcoming potential treatment 
options for AAV in the future include hematopoietic stem cell transplant, intravenous high 
dose azathioprine, intravenous immunoglobulins and abatacept. 
 
1.8  Management of Ocular Manifestation of GPA 
 
1.8.1  Medical Treatment for Ocular GPA 
 
In general, the treatment of ocular involvement in GPA requires management of the 
underlying systemic disease with corticosteroids and cytotoxic agents. Although the 
disease may be confined to the eye, collaboration between ophthalmologists and 
physicians  for thorough evaluation, investigation, management and future monitoring is 
essential. This is because the ocular presentation may be the initial presentation of GPA 
and could eventually progress to involve other organs over time. In cases where clinical 
evidence of GPA is strong, such as eye symptoms with corresponding sinus or upper 
respiratory characteristics of GPA, necrotizing scleritis particularly with corneal infiltrates or 
concurrent uveitis, or bilateral ocular inflammation, treatment should be advocated even if 
serology testing for ANCA is negative.  
Although ocular GPA usually does not respond to topical agents, topical treatment can be 
considered in milder presentations such as episcleritis or mild anterior uveitis. 
Nevertheless, in rare cases of uveitis, local injection of CS may also be advocated.  Non-
steroidal anti-inflammatory drugs (NSAIDS) can be administered in cases of non-
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 necrotising anterior scleritis. In the more severe form of ocular GPA such as necrotizing 
scleritis, bilateral ocular involvement, orbital and adnexal presentation, posterior scleritis 
and refractory cases, aggressive immunosuppressive treatment with CYC and CS are 
required to ensure adequate control. RTX has been reported to be effective in treating 
various ocular manifestations of GPA such as optic nerve infiltration(Shunmugam et al., 
2011), peripheral ulcerative keratitis (Huerva et al., 2010), optic neuritis (Huchzermeyer et 
al., 2010)  and relapsing necrotizing scleritis(Onal et al., 2008a)(Onal et al., 2008b), 
although remission may take up to seven months to occur (Taylor et al., 2009). 
 
1.8.2  Surgical Intervention for Orbital GPA 
 
Surgical procedures in the management of orbital GPA are mostly performed for 
diagnostic purposes i.e. orbital biopsy. In cases of severe ocular proptosis secondary to 
GPA, conventional medical therapy is often unsuccessful. In these cases where proptosis 
can be associated with pain and optic nerve compression and are refractory to medical 
therapy, surgical orbital decompression should be considered (Hernández-Rodríguez et 
al., 2010). Prompt diagnosis and surgical decompression following acute visual 
deterioration can result in good visual outcome (Fishman et al., 2008). Despite this, related 
ocular symptoms such as diplopia may still be difficult to resolve, even when orbital 
decompression is performed. Dacryocystorhinostomy (DCR) has been shown to be 
effective in restoring nasolacrimal duct NLD function in cases of nasolacrimal obstruction 
secondary to GPA. DCR performed during disease remission and low ANCA titres usually 
result in the best outcomes.  
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 1.9  Problem statement 
 
1.9.1  The Diagnostic Challenges in Orbital GPA 
 
The diagnosis of GPA, particularly the limited form such as orbital GPA, is challenging and 
entails a combination of clinical, serological, radiological and histological features. In 
general, clinicians require a heightened level of clinical suspicion to make judgements, 
particularly as the severity of disease in GPA may range from a non-specific inflammatory 
picture involving only one site or organ, to fulminant multi-organ vasculitis that can lead to 
death (White and Lynch, 2006). 
Classification criteria and definitions for AAV including GPA, for the use of epidemiological 
studies have been proposed by the American College of Rheumatology (ACR) and the 
International Consensus Conference at Chapel Hill (CHCC). However, it has been noted 
that these proposed classifications are rather limited, mainly because they do not include 
the presence of ANCA as a diagnostic criterion (Leavitt et al., 1990).  The European 
League Against Rheumatism/European Vasculitis Study (EULAR/EUVAS) group further 
developed the criteria for the classification of AAV which not only combined the 
recommendations from the ACR and CHCC but also included surrogate biomarkers 
(Hellish et al., 2007).In 2007, a stepwise algorithm was then developed by consensus 
between a group of doctors interested in the epidemiology of vasculitis, for the 
classification of AAV and polyarteritis nodosa (PAN) (Watts et al., 2007). This includes a 
four step algorithm incorporating both the ACR and CHCC systems that has been shown 
to be effective in classifying patients into a single category(Liu et al., 2008)(Kallenberg, 
2008). 
Similarly, in paediatrics, a EULAR/Paediatric Rheumatology European Society 
(EULAR/PReS) working group using a Delphi technique had developed the classification 
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 criteria for childhood vasculitis(Ozen et al., 2006).An agreement was reached to classify 
childhood vasculitis according to vessel size, with small-vessel diseases subdivided into 
granulomatous and non-granulomatous.  The ACR criteria for GPA were modified to 
include two new criteria: (1) the presence of subglottic, tracheal or endobronchial stenosis, 
and (2) the presence of high levels of PR3-ANCA or positive c-ANCA by indirect 
immunofluorescence (Watts and Scott, 2009). 
Nevertheless, it is important to acknowledge that all these classification criteria were 
developed mainly for clinical studies, not for diagnostic purposes and have been shown to 
have their own individual limitations (Rao et al., 1998)(Bruce and Bell, 1997). Therefore, 
these guidelines should not serve as a definitive tool for clinical diagnosis (Watts and 
Scott, 2009). In addition, in the limited form of GPA, like ocular GPA, classical features of 
the disease are often lacking and may not fit any classification or definition.  Moreover, 
ANCA presence and level is a poor indicator for diagnosis and disease activity in the 
limited form of GPA being positive only in up to 65% of patients (Tarabishy et al., 
2010)(Lamprecht and Gross, 2004). As a result, the diagnosis of limited GPA may be 
missed or delayed and only detected once disease progresses to a more severe systemic 
form (Hoffman et al., 1992)(White and Lynch, 2006). 
 
1.9.2  Clinical Presentation 
 
The clinical presentation of orbital GPA, as described previously, often overlaps with the 
clinical presentation of other orbital inflammatory conditions thus poses difficulty in 
establishing a conclusive diagnosis. The manifestation of orbital inflammatory disorders 
(OID) is vast. The differential diagnosis of GPA can be generally divided into autoimmune, 
inflammatory, infectious and neoplastic causes. In particular, sarcoidosis and IIOD are the 
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 main differential diagnosis for GPA. Sarcoidosis shares the same disease process as 
GPA, and IIOD tend to share very similar clinical presentation with GPA as well as 
possibly also presenting a granulomatous inflammatory picture histologically. Other usual 
main differential diagnoses considered with GPA include TED, IgG4 and orbital cellulitis, 
among others. 
 
1.9.2.1 Orbital sarcoidosis 
 
Sarcoidosis is also a multisystem granulomatous disorder. Similar to GPA, it can manifest 
systemically or confined locally like in the eye. Pulmonary involvement is the most 
common manifestation of the disease occurring in 90% of patients, and 15% of these 
patients may exhibit ocular involvement. Uveitis is the most common ocular presentation in 
ocular sarcoidosis, with iridocyclitis being acutely and frequently associated with systemic 
sarcoidosis. Iris nodules and keratic precipitates on corneal endothelium can be seen in 
the anterior segment. In the posterior segment of the eye, vitreous aggregations can be 
seen and nodular granuloma may be present on the optic disc, retina and choroid. Nodular 
granuloma along retina venules, often described to resemble candle-wax dripping, is a 
classic sign of ocular sarcoidosis. Apart from the uvea and retina, any ocular tissues can 
be affected by sarcoidosis, including the orbit and adnexa. Granuloma formation with 
inflammation in the orbits can occur in patients with orbital sarcoidosis where 
presentations such as proptosis, ocular motility dysfunction and ocular pain resemble 
orbital presentations of GPA. Sarcoidosis can also affect the lacrimal gland causing severe 
discomfort as well as upper lid swelling and inflammation,  also  similar  to  GPA. The 
presence of eyelid granuloma and conjunctiva nodules can be useful for tissue biopsy 
purposes in these cases. 
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 1.9.2.2 IIOD 
 
IIOD is a space occupying inflammatory disorder that stimulates other inflammatory 
disorders such as GPA, TED, sarcoidosis as well as neoplasm but has no identifiable 
cause. It is the main differential diagnosis for nearly all OIDs particularly GPA. Clinically, 
patients present with acute pain and redness and can present with diplopia when the 
extraocular muscles are involved. IIOD can also affect the lacrimal glands causing severe 
acute dacryoadenitis. Fibrosis is the predominant feature of the late stage of the disease 
where ocular motility may be affected permanently. IIOD responds promptly with 
corticosteroids. 
 
1.9.2.3 Thyroid eye disease (TED) 
 
TED is the most common cause of systemic related orbital inflammation and may affect 
one eye or both eyes at the same time(Kim et al., 2010). As with GPA, TED may present 
proptosis, poor vision and red eye but other typical features of ocular TED such as lid lag 
and lid retraction together with systemic symptoms of thyroid dysfunction may help in 
distinguishing it from other OIDs. Raised anti thyroid antibodies and an abnormal thyroid 
function test may also assist in the diagnosis of TED, although normal levels do not 
exclude it. 
 
1.9.2.4 IgG4 related disease 
 
IgG4‐related disease is a systemic lymphoproliferative disorder. Affected organs in this 
disease show fibrotic and sclerotic changes with hyper‐IgG4‐gamma‐globulinaemia and 
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 IgG4‐producing plasma cell expansion. In the orbit, it frequently affects the lacrimal gland 
where common presentations of the orbit include bilateral symmetrical lacrimal gland 
swelling and dacryoadenitis. Other ocular symptoms similar to ocular GPA include 
proptosis and eyelid or periocular swelling. The diagnosis of IgG4‐related disease is made 
by performing blood investigations as well as lacrimal gland biopsy. Serologically, patients 
will have high levels of serum IgG4 (>135mg/L) and lacrimal biopsy tissues will show 
marked IgG4 positive plasmacyte infiltration (>40% IgG4‐positive/IgG‐positive cells in five 
high‐power fields) (Masaki et al., 2011)(Plaza et al., 2011). 
 
1.9.2.5 Orbital cellulitis 
 
Infective causes such as orbital cellulitis from bacterial or fungal infections is another 
differential diagnosis of OID. It is particularly important to exclude this diagnosis prior to 
commencement of immunosuppressive treatment, especially when  there is a history of 
trauma to the sinuses or dental infection or intervention (Tarabishy et al., 2010). Patients 
with orbital cellulitis frequently present symptoms of infection such as fever, tachycardia 
and discomfort. Blood investigations typically show leucocytosis and performing blood 
cultures may be useful in identifying the infective agent and excluding the diagnosis of 
other OIDs. 
 
1.9.2.6 Other orbital diseases 
 
Apart from GPA, other systemic inflammatory disorders with orbital presentations include 
Churg‐Strauss syndrome, Tolosa‐Hunt syndrome and Erdheim‐Chester syndrome. 
Rheumatoid arthritis may present episcleritis, scleritis and peripheral ulcerative keratitis. 
85 
 Rhabdomyosarcoma and lymphoma are examples of neoplastic disorders that may 
present proptosis similar to GPA. Orbital tumour metastasis from a remote primary tumour 
should also be considered (Rizvi et al., 2010)(Plaza et al., 2011). 
 
1.9.3  Serology 
 
In current clinical practice, ANCA detection is used as one of the tools for the diagnosis of 
GPA. However, the absence of ANCA does not preclude this diagnosis. In systemic GPA, 
c-ANCA  is found  in about 74-90% of patients, and in 80-95% of these patients the 
antibody is directed against PR3 (Tarabishy et al., 2010)(Lamprecht and Gross, 
2004)(Tsiveriotis et al., 2011)(Wiik, 2002). It is reported that the diagnostic sensitivity is 
91% for c-ANCA and 63% for PR3-ANCA with a specificity of 99% for both for the 
diagnosis of active GPA (27 of 319 patients) (Hagemo et al., 2002)(Taylor et al., 2007) 
 
ANCA titre has also been suggested to act as an indicator of the disease activity, such as 
predicting disease relapses. Nonetheless, ANCA titre is not entirely reliable and should not 
solely be relied upon in the management of GPA patients as it has been shown thatPR3-
ANCA also increases in patients with GPA upon reduction or withdrawal of 
immunosuppression without any relapse (Finkielman et al., 2007)(Rasmussen et al., 
2013). Furthermore, in the limited form of GPA, ANCA is only found to be positive in 50-
65% of patients. Therefore, ANCA presence and level is a poor indicator for diagnosis and 
disease activity (Tarabishy et al., 2010)(Lamprecht and Gross, 2007). 
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 1.9.4  Radiology 
 
Radiographic investigations are used regularly in the investigation of orbital masses. 
Radiological features of orbital and sinus involvement are demonstrable in approximately 
70% of patients with clinical orbital involvement. Imaging with CT and/or MRI is of value in 
the diagnosis of orbital GPA to detect orbital mass lesions, to observe the extent of the 
orbital mass within the orbit and to delineate involvement of adjacent structures (Simmons 
et al., 1987)(Provenzale et al., 1996)(O’Sullivan et al., 1992). 
Orbital mass associated with sinonasal changes and paranasal bony erosions on imaging 
are features highly suggestive of orbital GPA. The presence of bony erosions in GPA is 
reported to be independent of ANCA status and can occur in both systemic and localised 
form of GPA (Tan et al., 2014). 
 
1.9.4.1 Computer Tomography Scan (CT scan) 
 
CT scanning has better ability to assess sinus opacification and bone invasion, which is a 
common finding in GPA (Lohrmann et al., 2006). Classically, appearances on CT are of an 
ill-defined soft tissue mass which may wrap the globe, concealing the optic nerve and 
extraocular muscles, with associated local bony destruction. (Figure 1.9)Orbital lesions on 
unenhanced CT images typically appear homogeneous and isodense relative to the 
extraocular muscles.  On the other hand, the contrast-enhanced CT appearance of orbital 
lesions is that of a moderately heterogenous mass that is isodense or mildly hyperdense 
relative to nasal mucosa. CT scanning with contrast, nevertheless, can show a wide range 
of enhancement characteristics with extreme diversity of enhancement values (Allen and 
Harvey, 2007). Recently, new techniques using 18F-fluorodeoxyglucose positron emission 
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 tomography/computed tomography (FDG PET/CT) has been shown to be a feasible 
modality for evaluating lesion activities, therapeutic monitoring, and follow-up of GPA as 
well as detecting GPA lesions for the purpose of biopsy (Ito et al., 2012). However, to date 
there are no radiological features that can make a specific diagnosis for GPA.   
 
 
Figure 1.11: Axial CT scan of the orbit in GPA showing ill-defined soft tissue mass 
in the right orbit wrapping the globe, concealing the optic nerve and extraocular 
muscles, with associated local bony destruction (arrow). 
 
 
1.9.4.2 Magnetic Resonance Imaging (MRI) (Figure 1.10) 
 
MRI may be useful in characterising orbital lesions in GPA (Figure 1.10). Granulomas on 
T1 and T2 weighted images display low-to-intermediate signals and can be distinguished 
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 from the surrounding orbital fat tissues and extraocular muscles (Muhle et al., 
1997)(Razek et al.). Nevertheless, it is not possible to differentiate between mucosal 
inflammation and granulomatous tissue on MRI during the initial inflammatory process of 
GPA. This is because granulomas can only be distinguished as low-signal-intensity lesions 
on MRI in the later stage of granulomatous development.  On T2 weighted images, a 
marked decrease in signal is said to be characteristic of GPA. However, this is not 
pathognomonic for the disease as similar findings can sometimes be seen with idiopathic 
orbital inflammation, chronic lacrimal gland sarcoidosis and in metastatic melanoma of the 
orbit (Allen and Harvey, 2007)(Courcoutsakis et al., 1997). 
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Figure 1.12: MRI Orbital magnetic resonance imaging in GPA showing heterogenous 
bilateral orbital mass lesions adjacent to the medial walls. The lesions have 
moderate intensity, similar to muscle on axial T 1-weighted (top, red arrows) and 
low intensity on axial T 2-weighted images (below, blue arrows) 
 
Injection of dye contrast during MRI is commonly performed to further highlight lesions in 
the images. In orbital GPA, following injection of dye contrast, varying degrees of image 
enhancement may be seen (Razek et al.).  After gadolinium injection, granulomas may 
portray homogenous (Provenzale et al., 1996) or heterogeneous signal enhancement, or, 
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 in a minority of cases, no enhancement (Muhle et al., 1997). GPA should therefore be 
considered  as one of the differential diagnosis for patients with low to medium-signal-
intensity lesions on T1- and T2-weighted sequences of the nasal cavity, paranasal sinuses 
and orbits. However, it is noted that the unenhanced, non-fat suppressed T1-weighted 
sequence is the preferred method for lesion detection in orbital GPA in one study 
(Courcoutsakis et al., 1997).In addition, bony erosion of the orbit and sinuses mainly seen 
affecting the ethmoid sinuses, nasal septum and medial walls of the orbit, has also been 
demonstrated in GPA (Muhle et al., 1997)(Razek et al.). 
 
1.9.5  Histology 
 
Histology investigations are important in the management of all OIDs. In GPA, classic 
histological features of GPA are described from the histology of larger organs affected by 
the disease such as the lungs and kidneys. The classic pathological features associated 
with GPA include granulomatous inflammation with involvement of multinucleated giant 
cells and epithelioid cells seen to predominate; microabcess or fibrinoid necrosis which 
appear widespread or geographic like, and vasculitis; affecting medium to large size 
vessels. (Figure 1.11) 
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Figure 1.13: Histology of vasculitis (yellow arrow) seen in GPA tissue biopsy. There 
are also presence of surrounding epithelioid cells with eosinophils, neutrophils and 
lymphocytes. 
 
Yet, despite the ongoing active disease, these histological features of GPA are not always 
seen in all biopsy material. This is possibly truer in the case of the limited form of GPA, 
particularly the ocular GPA as tissue biopsy specimens are often too small to capture the 
whole pathologic picture, or the inflammatory process is too mild to mount a typical tissue 
cellular response. In one report, it is stated that classic histological features for GPA are 
only present in 25% of biopsies in known GPA patients (Raynaud et al., 2005). The 
appearance of granulomatous inflammation in tissue biopsies may also represent other 
various OIDs such as sarcoidosis and IIOD. Although it is said that the findings of 
granulomatous inflammation with vasculitis generally points out to the diagnosis of GPA, 
this is probably easier seen in larger tissue samples like the lungs. 
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1.10  Side Effects and Long-term Outcome 
 
Current improved treatment regimens have led to an overall improved survival and 
morbidity rates in patients with GPA. In addition, the toxic profiles of these new drugs also 
seem to be more favourable and are better tolerated by patients compared to earlier 
conventional standard treatment. The 5 year survival probability among GPA patients is 
now reported to be within 65-75% in most studies. Mortality is mainly attributed to 
infection, active vasculitis and renal failure where the risk of death appear to occur highest 
in the first year of disease, especially among patients less than  65 years of age 
(Flossmann et al., 2011). 
In the eye, up to 17% of cases of patients with ocular GPA can end up with significant 
visual problems. Particularly in orbital GPA, orbital masses are found to represent a 
refractory form of GPA; generally unresponsive to immunosuppressants. Patients with 
orbital GPA are thus prone  to develop significant ocular complications with 20-50% of 
patients developing severe visual loss (i.e. 6/60 or less) (Taylor et al., 2007)(Holle et al., 
2013b).Visual loss in GPA is largely caused as a result of corneascleral damage, macular 
oedema, optic nerve compression from orbital mass or vascular occlusion. Due to this, 
prompt disease recognition, management and regular follow up by an ophthalmologist are 
therefore mandatory.  
 
1.11  Area of Research Interest 
 
In general, GPA is a challenging disease to diagnose and manage. This is more so for 
ocular GPA, given its overlapping clinical presentations with other ocular inflammatory 
93 
 disorders, low percentage of ANCA positivity and the lack of classic histological findings in 
biopsies, hence, making it indistinguishable from other orbital inflammatory diseases. Due 
to this, the diagnosis of ocular GPA is often delayed and consequently, appropriate 
treatment is not advocated early. The diagnosis is often only established once severe 
ophthalmic damage, mostly irreversible or permanent vision reduction or loss, has 
occurred.  In some cases, diagnosis may only be clear once renal involvement is apparent 
or other organ damage has developed. 
Further understanding in the immune response involved in vasculitides may help 
distinguish GPA from other AAV and OIDs. Currently, there are no tissue biomarkers 
specific for GPA in ocular, nasal and renal biopsies to enable more accurate diagnosis in 
the early localised stage of the disease and to identify individuals who are at most risk of 
developing severe organ failure. However, recent successful therapeutic agent for GPA 
like RTX, which specifically targets CD20 B cells, brings further light to the pathogenesis of 
GPA. Identifying tissue markers or cellular patterns in tissues biopsies that are specific for 
GPA and that can be easily identified in a regular pathology laboratory would be of great 
value to aid and improve diagnosis. There is also little understanding of how current 
treatment regimens control cellular and humoral factors involved in the pathogenesis and 
progression of GPA.  Identifying a key feature in tissue biopsy; either cellular or tissue 
change, which can predict disease remission and disease extension or relapse would also 
be of great benefit. This key feature could lead to a risk stratification and provide aid in 
formulating a rational treatment approach for GPA, especially in the early stages of the 
disease course. 
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 1.12  Research Hypotheses 
 
1)  There are cells or tissue changes that are found only or more in orbital biopsies of 
GPA compared to the biopsies of OIDs. These specific cell or tissue changes could 
then be used as an indication for the diagnosis of orbital GPA in the absence of 
typical histological features of GPA and serum ANCA. 
2)  There are cells or tissue changes that are found only or more in orbital biopsies of 
GPA patients who progress to generalised GPA compared to orbital GPA that 
remain localised. These specific cell or tissue changes could then be used as a 
predictor for the clinical outcome of orbital GPA. 
 
1.13  Aims of the study 
 
The aims of our study are as follows: 
1.  To identify cell types, markers and tissue changes present in orbital tissue 
biopsies, which are indicative of the diagnosis of orbital GPA despite the absence 
of classical histological features and a negative serum ANCA. 
2.  To identify tissue features in orbital biopsies which correlate with clinical outcome 
and in particular, to determine whether there are tissue biomarkers that could 
predict disease progression or extension. 
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 2  Chapter 2: Long-term Outcome of Ocular GPA 
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 2.1  Overview 
 
The eye and the orbit can be affected by GPA in up to 50-60% of patients (Joshi et al., 
2009)(Pakrou et al., 2006). In 8-16% of patients, the ocular manifestation in GPA is the 
primary presentation of the disease (Pakrou et al., 2006) where in the remaining majority, 
the eye is affected due to disease spread either from adjacent affected structures or as 
part of the overall systemic manifestation of the GPA (Taylor et al., 2007). 
Until recently, GPA is mainly described as an inflammatory disorder with multi-systemic 
organ involvement and can be life threatening when major organs are affected. In patients 
with renal GPA, long term outcome of these patients shows a poor survival rate; 41% 
death within six years follow up, and renal function outcome despite intravenous 
cyclophosphamide treatment (Gottenberg et al., 2007). Survival rates in ANCA positive 
kidney transplant patients however were better. Nevertheless, it is noted that patients with 
concurrent ANCA positivity and GPA faired less better in the long run, as the disease 
relapse rate was higher in this group compared to patients who were ANCA positive but 
with no GPA (Marco et al., 2013). In patients with ANCA positive pulmonary vasculitis, 
patients with GPA i.e. PR3-ANCA positive, were seen to develop severe alveoloar 
haemorrhages, more commonly occurring in nearly 70% of patients with ANCA associated 
vasculitis, compared to MPO-ANCA patients. The development of alveolar haemorrhages 
was also reported to have a strong correlation with concurrent renal vasculitis that can 
lead to renal failure and mortality, particularly in the older age group (Hruskova et al., 
2013). 
In cases of localised GPA, there are currently mixed reviews with regards to the long-term 
outcome of these patients. The localised forms of GPA are usually considered to represent 
an early and milder manifestation of the disease, and are thought to have the potential to 
progress to the aggressive systemic form in due course. Studies in the past have reported 
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 disease progression from localised orbital manifestation of GPA to fulminant systemic 
disease with renal impairment, particularly when patients were not treated adequately at 
the initial stage (Choopong et al., 2005)(Power et al., 1995). In contrast, other larger 
studies which included the monitoring of patients with localised head and neck and 
pulmonary GPA, have shown that localised GPA did not progress to the systemic form 
over time and tend to remain localised (Fechner et al., 2002)(Stone, 2003)(Holle et al., 
2010a).  
GPA with ocular and/or nasal presentation as the first symptom of the disease is easily 
misdiagnosed (Jiang et al., 2013)(Jiang B 2013), and orbital GPA are still considered to be 
a rare manifestation of GPA. However, the presence of orbital GPA has been regarded to 
characterise a refractory course of the disease and is reported to have a high rate of local 
damage that can result in irreversible ocular damage and function (Holle et al., 
2013b)(Holle 2013).  
In general, it would be of great benefit to be able to identify GPA in the early stages of the 
disease or at the stage when the disease may still be confined within non-life threatening 
organs such as the eye. However, as previously described, the diagnosis of orbital GPA is 
very challenging. This further causes dilemma, particularly in the management of orbital 
GPA, as treatment options for GPA often involve drugs with cytotoxic properties and 
undesirable side effects. 
 
Thus, for the purpose of this study, it was first necessary to look at the clinical features of 
orbital GPA, to examine the effect of the disease on patients and the outcome after 
receiving treatment. More importantly, we wanted to identify patients with localised GPA 
who progressed to the systemic form of the disease in order to better understand the 
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 pattern of the disease progression and in particular, to examine their histology to try and 
identify potential markers for GPA, within the tissues. 
 
2.2  Aims 
 
The aim of this section of the study was to observe the clinical presentation, disease 
progression and the long-term clinical outcome of patients with orbital GPA in our centre. 
We wanted to determine: 
1)  The clinical features and long-term outcome of ocular GPA in terms of its clinical 
presentation, patients’ past medical histories, ANCA status, course of management 
and outcome (i.e. a minimum of two years of follow up), which have not been 
previously reported before.  
2)  The rate of progression of localised GPA to systemic GPA, and to compare the 
patients’ clinical background with patients who remained as orbital or localised 
GPA. 
 
2.3  Method 
 
2.3.1  Ethical Approval 
 
Ethical approval for the study was obtained from the Moorfields & Whittington Research 
Ethics Committee (REC ref. no. 09/H0721/75, LIGS 1023). 
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 2.3.2  Study Centre and Patients 
 
This was a retrospective study of all patients who had undergone orbital or adnexal biopsy 
for orbital inflammatory disease at Moorfields Eye Hospital a period of over 21 years.  
All patients who had undergone an orbital or adnexal biopsy between 1988 and 2009 were 
identified from the UCL/Institute of Ophthalmology Pathology Database. Patient details 
were entered into an electronic database and each patient was allocated a study number. 
Patient details were anonymised and the primary key (i.e. patient details with matched 
study number) was kept in a locked filing cabinet. Patients’ case notes were then recalled 
from the Moorfields Eye Hospital medical record library. A comprehensive review of the 
clinical notes available was then performed. 
 
2.3.3  Inclusion Criteria 
 
The diagnosis of orbital GPA is based on several factors and is generally from a 
combination of either typical ocular presentation of orbital GPA, previous history of GPA in 
other organs (particularly adjacent organs such as the nose, radiological investigations), 
positive serum ANCA or histological features in orbital biopsies.  
In our study, it was paramount that we avoid confounding factors for the next stages of the 
study i.e. during histology analysis of orbital biopsies. Therefore, our patient selections (or 
inclusion criteria) were very specific. We included patients into the study strictly only if their 
diagnosis and the clinical management for their orbital disease were not influenced by 
histology investigations. This means that patients were included only if their orbital 
diagnosis were established from two or more combinations of the following: (1) the clinical 
history (e.g.  previous diagnosis of GPA affecting other organs); (2) typical disease 
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 presentation and manifestations of the disease (e.g. lid lag in thyroid eye disease (TED), 
necrotising scleritis in GPA); (3) blood investigations (e.g. ANCA positivity for GPA, raised 
angiotensin converting enzyme (ACE) in sarcoidosis) or (4) radiological tests (nasal bony 
erosions in GPA, muscle belly enlargement in TED).  
In addition, only patients with a minimum follow up period of two years were included in the 
study.  
 
2.3.4  Exclusion Criteria 
 
Patients were strictly excluded from the study if the diagnosis and management of their 
orbital problem had been influenced or had only been made based on the histological 
appearance of their orbital biopsy or had a minimum follow up period of less than two 
years.  
 
2.3.5  Clinical Data 
 
A comprehensive review of clinical notes available was performed to obtain information on 
patient demographics and clinical diagnosis. In the GPA group, we further looked at the 
orbital and ocular presentation, orbital structure involved for tissue biopsy, ANCA status, 
other organ involvement (otolaryngology, cardiac, respiratory, renal and central nervous 
systems), treatments (medical and surgical), duration of follow up and long-term outcome. 
We also sent out letters and contacted the general practitioners of the patients to obtain 
further clarification and information with regards to patients’ medical progression and 
status.  
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 2.4  Definition of Terms 
 
2.4.1  Localised GPA 
 
We defined localised GPA as features of GPA confined to the ocular, upper and/or lower 
respiratory tract disease without any other systemic involvement, non-ocular organ 
threatening or life threatening disease. 
 
2.4.2  Systemic GPA 
 
GPA patients who did not fulfil our criteria for localised GPA were classified as general 
GPA. 
 
2.4.3  Progression of GPA 
 
We defined disease progression as individuals with localised GPA that further developed 
general GPA from the period of their orbital manifestation.  
 
2.4.4  Newly Diagnosed GPA 
 
This is defined as patients who were never previously diagnosed with GPA (in any organ 
system) before the orbital biopsy. The diagnosis of GPA was made at the ophthalmology 
presentation. 
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 2.4.5  Known GPA 
 
This is defined as patients who are known cases of GPA where the diagnosis of GPA was 
established prior to the ocular presentation. 
 
2.5  Results 
 
2.5.1  Patient Characteristics 
 
A total of 470 patients had been identified via the Moorfields Eye Hospital database and 
biopsy specimen records, to have undergone orbital biopsy for orbital inflammatory 
disorders between the years 1980 to 2009. 234 patients fulfilled our inclusion criteria and 
were therefore included in the study. The majority of patients excluded from the study were 
those with their orbital diagnosis mainly based on or influenced by the histological 
appearance of their biopsies. Others were excluded due to incomplete clinical data, lost 
files or a follow up period of less than two years.  
 
The mean follow up time for the whole group were 47.26 SE 5.051 months (i.e. 3.9 years), 
ranging from a minimum period of 23.9 months to 12.1 years. The mean age of the whole 
sample population was 50.5 SE 1.11 (i.e. 12-97) years old. Patients’ characteristics in the 
GPA and non GPA patients are listed in Table 2.1. There was a female preponderance 
seen in the sample (female = 147, male = 87) with a female to male ratio of 3:2. (Figure 
2.1)Both GPA and non GPA groups were similar in age and gender. (Table 2.1) 
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 Table 2.1: Patient characteristics in GPA and non GPA group 
  GPA (n=36)  Non GPA (n=198) 
Age (mean (range))  50.7 (14-87)  50.4 (12-97) 
Gender     
       Female (n(%))  21 (58.4%)  127 (64.2%) 
       Male (n(%))  15 (41.6%)  71 (35.8%) 
       Female : Male  3:2  3:2 
 
 
 
Figure 2.1: Gender distribution of whole sample population  
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Gender (Total 234) 
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 Of the 234 patients, 36 (15.4%) patients fulfilled our criteria for the diagnosis of GPA and 
198 were classified as non GPA. The distribution of diseases in the non GPA group 
included 67 chronic idiopathic inflammation of the orbit (IIOD) (28.6%), 16 lymphoid 
hyperplasia (6.8%), 14 sarcoidosis (5.6%), three myositis (1.3%), 33 dacroadenitis 
(14.1%), 12 thyroid eye disease (5.1%) and 54 miscellaneous diseases e.g. eosinophilic 
angiocentric fibrosis, Churg-Strauss disease, foreign body etc. (23.1%). (Figure 2.2) 
 
 
Figure 2.2: Distribution of ocular diseases in sample population 
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 The majority of biopsies in the whole study population were from orbital masses (45.3%). 
37% of patients had biopsies taken from the lacrimal gland. The remaining 17.7% of the 
biopsies were taken from other orbital structures such as nasolacrimal duct/sac, 
extraocular muscle, sclera and eyelid. (Table 2.2) 
 
Table 2.2: Organ involvement in GPA patients 
Number of 
organs affected 
by GPA 
               Organs involved  Total 
patients 
1 organ 
 
Limited to orbit only  6 
2 organs 
 
Orbit + sinonasal 
 
20 
3 organs 
 
Total 
orbit + sinonasal + lungs 
orbit + sinonasal + kidney 
orbit + sinonasal + central nervous 
system 
 
7 
5 
1 
1 
4 organs  Total 
orbit + sinonasal + lungs + kidneys 
orbit +sinonasal + lungs + 
cardiovascular 
3 
1 
2 
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 2.5.2  GPA Group 
 
The patient characteristics and clinical overview in the GPA group are summarised in 
Figure 2.3,Table 2.2 and Table 2.3. 
 
Figure 2.3: Gender distribution in the GPA group. 
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107 
 Table 2.3: Summary of patient characteristics within the GPA group; comparing 
between newly diagnosed GPA (initial presentation of GPA) and known GPA 
(recurrent or orbital extension of the disease) 
Patient characteristics  Known GPA 
(n=19) 
Total (% in sub-
group) 
 
Newly diagnosed 
GPA (n=17)  
Total(% in sub-
group) 
Total (n=36) 
(% of total) 
 
 
Gender:  Male  8 (42.1%)  7 (41.1%)  15 (41.7%) 
 
  Female  11 (57.9%)  10 (58.8%)  21 (58.3%) 
 
Mean follow 
up time 
(months +/-SEM) 
  28 +/- 3.1   27 +/- 2.2   
 
Laterality:  Unilateral  18 (94.7%)  16 (94.1%)  34 (94.4%) 
 
  Bilateral  1 (5.3%)  1 (5.9%)  2 (5.6%) 
 
Clinical 
presentation: 
Proptosis  7 (36.8%)  10 (58.8%)  17 (47.2%) 
  Lacrimal gland enlargement  3 (15.8%)  8 (47%)  11 (30.5%) 
 
  Lid swelling  7 (36.8%)  7 (41.1%)  14 (38.9%) 
 
  Decrease vision  0  9 (52.9%)  9 (25%) 
 
  Orbital pain  5 (26.3%)  9 (52.9%)  14 (38.9%) 
 
  Red eye  4 (21%)  3 (17.6%)  7 (19.4%) 
 
  Diplopia  7 (36.8%)  7 (41.1%)  14 (38.9%) 
 
  Reduced ocular motility  5 (26.3%)  7 (41.1%)  12 (33.3%) 
 
  Globe displacement  2 (10.5%)  7 (41.1%)  9 (25%) 
 
  Nasolacrimal/sinonasal 
(epiphora/dacryocystitis) 
14 (73.7%)  2 (11.8%)  16 (44.4%) 
 
  Facial numbness/pain  7 (36.8%)  0  7 (19.4%) 
 
PR3-ANCA:  Positive  12 (63.1%)  9 (52.9%)  21 (58.3%) 
 
  Positive on presentation  7 (36.8%)  6 (35.3%)  13 (36.1%) 
 
Structure 
biopsied: 
Orbital mass  6 (31.6%)  15 (88.2%)  21 (58.3%) 
  Lacrimal gland  8 (42.1%)  3 (17.6%)  11 (30.5%) 
 
  Nasolarimal duct  11 (57.9%)  2 (11.8%)  13 (36.1%) 
 
  Muscle/eyelid/conj  3 (15.8%)  1 (5.9%)  4 (11.1%) 
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 2.5.3  Patient characteristics 
 
There were 15 (41.7%) males and 21 (58.3%) females in the GPA group (Figure 2.3) with 
an average age of 50.35 SE 2.87 (i.e. 14-87 years old). Of the 36 patients managed as 
orbital GPA, 19 (52.8%) had a previous diagnosis of GPA (known GPA) from other organ 
manifestations of the disease and had received or were still on treatment (prednisolone 
with or without second line treatment).  (Table 2.3)  Ocular presentation was the initial 
symptom of GPA in the remaining 17 (47.2%) patients. (Figure 2.4) 
 
 
 
Figure 2.4: Distribution of patients according to newly diagnosed or known (recurrent) GPA. 
 
 
   
17 
19 
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 2.5.4  GPA Classification and Organ Involvement 
 
Based on our definition, 34 patients fulfilled our criteria for localised GPA and two patients 
were classified to have systemic GPA as they had been previously diagnosed as renal 
GPA (Figure 2.5)(Table 2.3). The majority of cases (n=30, 83.3%) had some degree of 
sinonasal involvement together with their orbital disease. Only 6 (16%) out of the 36 
patients had the disease confined to the orbit only. (Table 2.2) 
 
 
Figure 2.5: Distribution of patients according to type (form) of GPA. 
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 2.5.5  Ocular Presentation 
 
Ocular presentation was observed to be more severe in the newly diagnosed GPA group. 
The most common ocular presentation in orbital GPA patients were proptosis (n=17, 
47.2%), lid swelling (n=14, 38.9%), diplopia (n=14, 38.9%) and reduced ocular motility 
(n=12, 33.3%). These were seen particularly in the newly diagnosed GPA patients (n=10, 
58.8%).Symptoms from the nasolacrimal duct system also predominates (n=16; 44.4%) 
but in contrast, it is mainly contributed from known GPA patients (n=14, 73.7%). In up to 
half the patients (n=9, 52%) in the newly diagnosed group presented with concurrent 
reduced vision where in the known GPA group, none of these patients complained of 
reduced vision on presentation.(Figure 2.6) 
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Figure 2.6: Ocular presentations in GPA group. 
 
In known GPA patients, epiphora secondary to nasolacrimal duct obstruction was the main 
clinical presentation, occurring in 14 (73.7%) of the 19 patients. Five of these patients also 
presented with dacryocystitis and two with mucocele. Interestingly, facial symptoms such 
as facial pain or facial numbness only occurred among patients in the known GPA (n=7, 
37%) and not in newly diagnosed GPA patients. Proptosis, diplopia and lid swelling 
occurred in seven patients in the known GPA group (six localised GPA and one 
generalised GPA). Five of these patients had associated ocular pain and two had lacrimal 
gland enlargement. (Figure 2.6) 
Lacrimal gland involvement occurred in nearly a third of the patients (n= 11, 30.5%). In two 
out of the 11 patients, lacrimal gland enlargement was the initial manifestation of orbital 
GPA. Epiphora due to nasolacrimal duct inflammation and block was the initial 
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 presentation of GPA in one patient, with no other signs of orbital or sinus involvement. In 
this patient, the diagnosis of GPA was based on the CT appearance of the paranasal 
sinuses where extensive bony destruction was seen despite not previously having any 
nasal surgery. In addition, ANCA titres were also found to be elevated.  
 
2.5.6  Orbital Structure Involved 
 
In most cases tissues for biopsies were taken from a combination of orbital structures. 
However, biopsies were mainly obtained from orbital masses (n=21, 58.3%) and the 
nasolacrimal duct (n=13, 36.1%). Eleven (30.5%) out of the 36 GPA patients had lacrimal 
gland enlargement clinically where biopsy tissue from this structure was taken. (Table 2.2) 
 
2.5.7  ANCA status 
 
Only 21 (58.3%) patients were documented to be ANCA positive at some point of the 
course of their disease, where GPA was localised in the orbit and sinonasal in 10 (27.8%) 
patients. Only 13 (36.1%) of the 36 patients investigated during their first ocular 
presentation were ANCA positive; seven from patients with pre-existing GPA and six from 
the newly diagnosed group. Five patients with pre-existing GPA who were previously 
ANCA positive were not ANCA positive during their orbital presentation, and three patients 
in the newly diagnosed GPA further became ANCA positive during the course of their 
disease. 
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 2.5.8  Treatment and Follow Up 
 
In addition to ophthalmology review, patients were also evaluated and managed, where 
necessary, by physicians with special interest in vasculitis and GPA.  
All patients received corticosteroid as the mainstay of treatment. Interestingly, seven 
patients (all in the newly diagnosed group) were successfully stabilised with only systemic 
corticosteroids where six were successfully tapered off treatment. The remaining one 
patient was maintained on low dose oral corticosteroid. 
The majority of patients had second line immunosuppressants which included 
azathioprine, methotrexate or mycophenolate mofetil for remission induction and remission 
maintenance therapy. Tacrolimus was used for remission maintenance in one patient. A 
total of 14 patients received cyclophosphamide during the course of their disease and four 
of these patients received an additional treatment with Rituximab due to disease 
recurrence. Eight patients in total had received Rituximab where RTX was the initial 
treatment of choice in four patients, instead of cyclophosphamide, to achieve disease 
remission. Only one patient was given an additional treatment of cyclophosphamide after a 
previous course of Rituximab due to disease recurrence. A total of seven patients 
underwent orbital mass debulking. 
14 patients had dacryocystorhinostomy (DCR) for nasolacrimal duct block and all patients 
received post-operative steroid treatment. Repeat DCRs were performed in three patients 
where additional second line immunosuppressant was given during the subsequent 
procedures to better control the post-operative inflammation. In the majority of these 
patients, additional or increasing second-line immunosuppressive treatment was not 
necessary.  
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 2.5.9  Outcome 
   
The main aim for this section of the study was to identify patients with orbital GPA who 
progressed into the systemic form of the disease i.e. from orbital GPA progressing to 
involve major organs and becoming life threatening, such as the kidneys, overtime. In this 
study however, retrospective case note reviews of all the 36 patients  with orbital 
GPA,together with information gathered from general practitioners  and other medical 
specialities from other hospitals,  revealed that to date, patients  who presented with 
localised orbital GPA with no pre-existing systemic involvement, did not progress to the 
systemic form overtime. Therefore, in this sample group, in patients with localised GPA, 
the disease remained localised within the orbit and did not spread to involve other organs. 
In contrast, patients with systemic disease  however,  may  further develop orbital 
manifestations as seen in our 2 patients in the known GPA group. 
At the two year follow up mark, we found that nine out of the 36 patients (25%) had further 
deterioration of vision throughout their follow up; six were due to cataract formation, two 
due to recurrent orbital inflammation and one patient developed a refractory painful red 
blind eye, which was eventually enucleated. The three patients with worsening vision due 
to recurrence and refractory blind eye were patients in the known GPA group. All other 
patients had their pre-inflammation vision restored. 30 patients remained on maintenance 
immunosuppression. In six patients, it was possible to halt treatment. All patients who 
underwent DCR had good post-operative outcome with resolution of their problem 
although three patients had to undergo repeat procedures.  
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 2.6  Discussion 
 
Our hospital is a tertiary referral centre where we receive referrals for orbital inflammation 
disorders and ocular manifestation of GPA. Our retrospective study goes back to a period 
of 21 years where we reviewed 36 patients who were diagnosed and managed as orbital 
GPA with a minimum follow up of two years from their orbital presentation. Our aim was to 
look at their clinical presentations, course of management and clinical outcomes. In 
particular, the main aim for this section of the study is to identify patients with orbital GPA 
who progressed to the life threatening systemic form over time, and compare their clinical 
presentations with those who remained with localised disease.   
 
2.6.1  Clinical presentation 
 
It is known that orbital GPA occurs either;(1) solitary as ocular vasculitis or orbital mass 
(granuloma) formation or (2) as disease extension from adjacent affected structures, such 
as paranasal sinuses (contiguous spread), or (3) as part of an overall manifestation of the 
systemic disease (Pakrou et al., 2006). In this study, our group of patients could also be 
divided into two main groups; (1) patients newly diagnosed with localised GPA from their 
orbital presentation i.e. de novo,  and (2) patients with GPA presenting with an orbital 
extension/manifestation of the disease i.e. from disease spread from adjacent structures or 
systemic form of the disease.  
Orbital and adnexal manifestations of GPA are variable, and typical presentations include 
orbital mass or proptosis (69%), nasolacrimal duct obstruction (52%), limited ocular 
rotations (52%), lid erythema and oedema (31%), bony destruction (21%), and reduced 
visual acuity (17%) (Woo et al., 2001)(Tarabishy et al., 2010). In our group of patients, the 
orbital clinical symptoms and signs are  more severe if the orbit was the initial 
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 manifestation of GPA (newly diagnosed GPA) compared to recurrent cases or disease 
spread from other structures (known GPA). These include proptosis, pain, globe 
displacement, limitations in ocular motility and reduced vision. Proptosis due to a 
retrobulbar orbital mass was the most common clinical finding in newly diagnosed GPA 
patients. Despite this, surprisingly, there were no permanent visual impairments in the 
majority of these patients.  
Nearly a third of the patients (i.e. 11 out of 36) in our study group presented with lacrimal 
gland involvement as an initial manifestation of orbital GPA. Although there have been few 
reports of similar findings in GPA patients in the past, the number of cases were generally 
small (Soheilian et al., 2002)(Perry et al., 1997)(Leavitt and Butrus, 1991). It is interesting 
that in one patient, recurrent nasolacrimal duct block with no other orbital, ocular or sinus 
involvement was an initial presentation of GPA. It has been reported that NLD obstruction 
is not always due to contiguous spread from the sinuses, but it may be a direct effect of 
focal GPA vasculitis in the lacrimal drainage system (Ghanem et al., 2004). 
Patients with a previous history of GPA (known GPA) in our study group, generally had 
milder orbital symptoms, mainly affecting the nasolacrimal drainage system; NLD block. 
These patients were usually referred for the management of epiphora where five patients 
had associated dacryocystitis and two with mucocele.  Contiguous spread from affected 
sinuses can cause nasolacrimal duct inflammation and blockage leading to symptoms of 
epiphora and dacryocystitis. This problem is reported to be typically a late manifestation of 
GPA and affects approximately 7% of patients (Eloy et al., 2009). Dacryocystorhinostomy 
(DCR) has been shown to be a safe and successful procedure for this problem (Kwan and 
Rose, 2000). However, DCR is not recommended in GPA if the disease is still active due 
to the risk of recurrence and disease extension to the orbit and skin (Eloy et al., 2009). All 
our patients were successfully treated with DCR and in nearly all patients, additional or 
increasing second-line immunosuppressive treatment was not necessary. This may be due 
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 to the fact that these patients had previously received treatment for the GPA and thus 
disease manifestations were milder.  
However, it is important to point out  that some patients with pre-existing GPA (known 
GPA) with localised GPA and was  already on treatment, presented severe orbital 
symptoms such as proptosis, diplopia and ocular pain. This suggests that localised 
disease manifestation can still extend to involve adjacent structures despite being on 
treatment, hence indicating local inflammatory activity is still uncontrolled and on-going. 
Furthermore, it has been reported that in patients with known GPA, signs of ocular 
inflammation may indicate an active disease in other organs although there were no 
systemic symptoms observed. Therefore, although the ocular symptoms may be mild, 
further investigation to determine the extent of the disease systemically is important 
(Tarabishy et al., 2010). 
 
2.6.2  ANCA status 
 
GPA has been established to have a strong association with c-ANCA (Rao et al., 1995). In 
our sample population, more than half of the patients (n=21, 58.3%) were ANCA positive 
at presentation where nine were from the newly diagnosed group and 12 from the known 
GPA group. This is aligned with other earlier reports where it is stated that in limited GPA 
about 50-65% of patients will demonstrate ANCA positivity (Tarabishy et al., 
2010)(Lamprecht and Gross, 2007). However, only a third of our patients were found to be 
ANCA positive at the time of presentation.Patients who are ANCA negative at presentation 
can become positive over time. Conversely, patients with GPA who were ANCA positive in 
previous serology tests  may  show  a negative ANCA  result on  repeat  testing,  despite 
clinically presenting an active orbital GPA. This demonstrates that although ANCA titers 
are useful in the diagnosis of GPA, in localised GPA they can be unpredictable and 
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 therefore unreliable for diagnosis and disease management.  Alternatively, this also 
suggests that serology testing for ANCA should be done periodically in patients with orbital 
inflammatory diseases particularly those with recurrent attacks as it may manifest later in 
the disease course. 
 
2.6.3  Treatment regimes 
 
In most patients, second line immunosuppressant was given and showed good control of 
the disease. Interestingly, seven patients were successfully stabilised with only 
corticosteroid. In  2010 Watkins et al, reported that the majority of their patients with ANCA 
positive ocular diseases were treated with systemic corticosteroids, and over three-
quarters of the group were prescribed systemic immunosuppressive medications, 
indicating a quarter of the patients did not receive other immunosuppressive treatment 
other than corticosteroid (Watkins et al.). In another study however, only one out of 10 
patients with orbital GPA achieved good control with remission, with corticosteroid therapy 
alone and the majority had to receive a combination of a systemic immunosuppressive 
medication and corticosteroid (Perry et al., 1997). These findings suggest that the 
treatment for orbital GPA varies between individuals and needs to be judged and adjusted 
based on the clinical presentations. 
 
2.6.4  Long term outcome 
 
Nine of the 36 patients developed deterioration in vision due to various  complications 
secondary to GPA. Although poor vision was not the main presenting symptom in the 
known GPA group, patients who developed poor vision overtime were mainly from this 
group, particularly in those with recurrent orbital inflammation. Orbital mass in GPA in 
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 particular, have been described before as a refractory form of GPA which can cause 
severe visual loss (Holle et al., 2013b). Therefore in orbital GPA, it appears that prompt 
diagnosis and treatment is crucial during the initial presentation phase or within the earlier 
stage of the disease, as even though  symptoms may be severe but early aggressive 
treatment can be organ and sight saving in the long run. Episodes of recurrent orbital 
inflammation that could occur due to diagnostic delay and inadequate treatment may result 
in permanent organ damage and visual loss overtime. This further highlights the need for 
early disease detection and intervention with the appropriate treatment.  
 
More importantly we discovered that in our two year follow up; all patients with localised 
GPA did not show progression to the generalised or severe form. This echoed 2 previous 
published studies by Fechner, 2002 and Holle, 2010. Fechner et al reported that their 
patients with only orbital involvement of GPA did not develop systemic progression of 
Wegener's granulomatosis throughout their follow up (Fechner et al., 2002). However this 
study was fairly small compared to our study, where only 15 GPA patients were involved; 
12 with orbital GPA. Similarly, Holle et al in 2010, in their large study, found that none of 
their patients with localised GPA progressed to the severe generalised disease stage 
(creatinine > 500 micromole/l)(Holle et al., 2010a). Nonetheless, it should be noted that 
unlike our study which is only limited to the orbit, in their study, the criteria for localised 
GPA were a combination of the head and neck, orbit and the respiratory tract. 
In general, it is therefore possible that orbital GPA does remain localised and does not 
progress to systemic GPA over time. It also appears that patients with systemic GPA had 
the systemic manifestations of the disease prior to orbital symptoms. The lack of 
progression of the disease from the orbit to other organs could be a result of prompt 
disease recognition and management, or newer and better treatment regimens. 
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 2.7  Conclusion and Further Plan 
 
Our initial findings show that the presentations of orbital GPA vary. The course of 
management for these patients generally requires clinical judgement based on individual 
presentations and is catered according to individual requirements.  
Our main finding in our patient population was that no patients showed progression of the 
disease. Localised form of GPA remained localised and do not progress to systemic GPA. 
On the other hand, we also found that extension of pre-existing GPA from other organs to 
the orbit is not uncommon despite patient receiving treatment. We also discovered that 
newly diagnosed orbital GPAs have more severe ocular presentations compared to known 
GPA but yet have good visual outcomes, suggesting that early and appropriate treatment 
results in positive clinical results. In contrast, patients with poor visual outcomes were 
within the known GPA group i.e. patients with recurrent GPA, who have received or are on 
treatment. 
It is difficult to conclude whether early intervention or treatment prevents disease 
progression in cases of localised GPA or whether localised manifestation of GPA is 
actually a separate entity from the generalised systemic form. Nevertheless, early 
diagnosis, prompt management and intervention during the orbital stage are still important 
as it appears that the long-term outcomes in most of these patients are generally 
encouraging. This will also reduce the need for long-term maintenance therapy. As a 
result, this would lessen patients’ exposure to cytotoxic drugs and therefore reduces side 
effects. In addition, it would be more cost effective if long-term maintenance therapy can 
be reduced. 
Our primary aim in this study was to look for any cell or tissue changes that could act as a 
biomarker for disease progression in orbital GPA. However, since the disease remained 
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 localised in all of our patients, it was therefore no longer possible to investigate and 
determine these histological features. Nevertheless, our initial findings did raise further 
questions with regards to orbital GPA, which include: (1) is orbital GPA a true distinct 
disease entity or could it be a severe form of idiopathic orbital inflammatory disease? (2) 
Are there actual cellular and histological differences between orbital GPA and other OIDs? 
(3) If there are, what particular features may be different and could they be used clinically 
as a disease biomarker for the diagnosis of orbital GPA, thus helping in early diagnosis? 
(4) Are there any histological difference between known GPA and newly diagnosed GPA?  
We therefore proceeded to explore these questions by comparing the histology of orbital 
GPA with other OIDs. 
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 3  Chapter 3: Histology of Ocular GPA Compared to other 
OIDs 
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 3.1  Overview and Objective 
 
Histology investigations regularly play an important role in clinical practice. Histology 
analysis from tissue biopsy could help in establishing the diagnosis, confirming a clinical 
suspicion, detecting disease progression and in monitoring treatment response. Therefore, 
understanding the histological features and recognising the pattern of tissue responses 
that characterises a particular disease is vital. In the management of OIDs, tissue biopsy is 
always performed whenever possible. 
It is first useful to understand the cells involved during an inflammatory process, which is 
the focal feature in these orbital diseases. Generally, inflammation is a body response by 
vascular tissues to harmful stimuli, such as pathogens, damaged cells, or irritants. The 
inflammatory response is a multifaceted biological process involving interactions between 
a vast amount of various cellular, protein and biochemical substances. The human 
inflammatory process can be broadly divided into two; acute inflammation and chronic 
inflammation. GPA, IOID and sarcoidosis are chronic inflammatory diseases. 
 
3.2  The Acute Inflammatory Process 
 
The acute inflammation is an immediate response to injury or attack by invading micro-
organisms. It constitutes several components that include tissue damage, vascular 
changes, activation and adhesion of leucocytes to the vascular endothelial wall, and 
leucocyte emigration to the site of injury.  
The initial immune cells involved in the early stage of this process are cells from the innate 
immune systems, namely, the local macrophages, histiocytes, dendritic cells and Kupffer 
cells. These cells possess certain receptors that recognise foreign antigens and become 
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 activated upon invasion or tissue damage. Together with the damaged tissue and also 
bacterial products, these cells release various inflammatory mediators such as bradykinin, 
histamine, free radicals, prostaglandins, etc. This then results in local tissue changes 
which include vascular dilatation leading to increased blood flow resulting in redness 
(rubor) and increased local heat (calor), increased vascular permeability causing 
extravasation of plasma fluid along with inflammatory cells leading to tissue swelling 
(tumor). There is increased sensitivity to pain (dolor) and local tissue functional loss may 
occur (funtio).   These features represent the classical features of acute inflammation and 
are usually the clinical presentation manifested by patients. 
Neutrophils are the main cellular components during acute inflammation. During active 
inflammation, neutrophils in the blood vessels adhere to the vascular endothelium wall and 
migrate through the permeable vascular wall towards the site of injury. Together with 
macrophages, neutrophils neutralise the offending body and remove injured tissue. Apart 
from neutrophils, other effector cells involved in the acute inflammatory phase include 
lymphocytes, mast cells and basophils.  
In addition to cellular activity, the inflammatory process is also aided by a series of 
biochemical cascades by non-cellular proteins in the plasma such as the complement 
system and fibrinolysis systems, to initiate and propagate the response. The acute 
inflammatory response ceases once the stimulus has been removed as it requires 
constant stimulation to be sustained. 
 
3.3  The Chronic Inflammatory Process 
 
The term “chronic inflammation” is used when the acute inflammatory process does not 
cease and the inflammatory process persists. The prolonged inflammatory process leads 
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 to a progressive shift in the type of cells present at the site of inflammation, and 
simultaneous destruction and healing of the tissue from the inflammatory process is 
characteristic of chronic inflammation. 
The main effector cells in chronic inflammation are macrophages. When a pathogen is not 
successfully removed, macrophages together with lymphocytes and other inflammatory 
cells surround the organism. These inflammatory cells form a wall around the pathogen to 
limit its activity or damage, creating a ball-like structure known as “granuloma”. 
Macrophages then remove the engulfed pathogen  via digestion. In other instances, 
macrophages tend to group together to form one large cell known as giant cells. 
Macrophages tend to also alter their shape during an inflammatory process, and could 
resemble other cells such as the epithelial cells termed epithelioid cells, and Langerhan 
cells. The formations of granuloma are also seen in other auto-immune diseases which are 
not related to pathogen invasions such as sarcoidosis. Usually, where inflammation is 
related to macrophage dominance via giant cells or granuloma formation, this is termed as 
“granulomatous inflammation”.  GPA is described as a granulomatous inflammatory 
disease. 
 
3.4  The Various Morphologic Patterns in Inflammation 
 
3.4.1  Granulomatous inflammation 
 
Granulomatous inflammation is a distinct type of chronic inflammation where activity of 
cells from the mononuclear phagocyte cell lineage predominates. The inflammation is 
characterised by collection of macrophages, multinucleated giant cells and epithelioid 
cells. Granulomas, as described above, are present. Nevertheless, more diffused pattern 
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 of cell aggregation is not uncommonly seen in granulomatous inflammation. Granulomata 
can frequently have a  necrotic centre surrounded by macrophages with a cuff of 
lymphocytes surrounding it. This Inflammatory reaction is influenced by cytokines such IFN 
gamma, lymphotoxins, IL-3, GM-CSF and IL-12. In response toIL-12 drive, the immune 
response shifts towards T- helper 1 T cell (Th1 T cells) mediated immune response rather 
than T-helper 2 (Th2 T cells) reaction. TNF also play a role in granuloma formation, where 
in the absence of TNF secreting macrophages, granulomas are seen not to form.   
Granulomatous inflammation is  often seen as a Type 4 Hypersensitivity reaction and 
manifests in a variety of conditions such as allergy, infection with tuberculosis, leprosy and 
syphilis, and autoimmune disorders such as GPA and sarcoidosis.  Granulomatous 
inflammation is also known to occur in auto-immune and neoplastic diseases as well as 
conditions of unknown causes (William 1983).  
 
3.4.2  Fibrinous inflammation 
 
Fibrinous inflammation can be an acute inflammation but most often is a chronic response. 
It is characterised as inflammation with fibrin deposits. This often results from severe injury 
to blood vessels where significant increase in vascular permeability allows fibrin to pass 
through the blood vessels. This type of inflammation is commonly seen serous cavities 
such as in the pericardial cavity, causing restrictive fibrosis, pleural space and peritoneal 
cavity resulting in adhesions.   
 
3.4.3  Purulent inflammation 
 
Inflammation associated with pus formation is known as purulent inflammation. At the site 
of inflammation, collection of large amounts of neutrophils with necrotic tissues and fluid 
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 are seen. Abscesses are described as pus enclosed by surrounding tissues. Purulent 
inflammations are usually associated with pyogenic bacterial infections such as 
staphylococci. It has been described that in GPA, foci of microabscesses, where a 
collection of neutrophils are seen within necrotic tissues, together with surrounding 
granulomatous inflammation. 
 
3.4.4  Serous inflammation 
 
Serous inflammation is characterised by the large outpouring of non-viscous serous fluid 
derived from blood plasma. The fluids are commonly secretions from mesothelial  cells 
of peritoneal, pleural or pericardial linings. Viral infection resulting in skin blisters are an 
example of this inflammation.  
 
3.4.5  Ulcerative inflammation 
 
Ulcerative inflammation occurs mainly near an epithelial surface. The inflammatory 
process can lead to tissue necrosis causing exposure of lower layers. Ulcers are 
epithelium excavation resulting from the inflammation. 
 
 
3.5  Potential Outcomes of Inflammation 
 
The end result or sequalae from an inflammatory reaction relies largely on the tissue type 
that is injured as well as the mechanism or agent that incite the inflammatory process. In 
general, the outcome of inflammation can either be complete resolution and restoration of 
128 
 normal tissue function, fibrosis, abscess  formation or persistent chronic inflammation. 
These changes can be seen to occur even during an ongoing active inflammatory state, 
particularly in severe and/or chronic inflammation. 
 
3.5.1  Resolution 
Complete resolution usually occurs in mild and short lived inflammatory conditions. 
Resolution is said to occur when the inflamed tissue is restored to its normal status and 
changes that are associated with inflammation such as vasodilatation and cellular and 
biochemical infiltration, cease. Tissue damage is removed and cells regenerate, restoring 
normal structure as well as tissue function. 
 
3.5.2  Fibrosis 
Fibrosis usually occurs when there is large amount of tissue damage. In this situation, 
tissues generally are unable to regenerate leading to fibrous scarring made up of collagen. 
Scarring is devoid of specialised structures thus tissue function at that site is lost. 
 
3.5.3  Abscess Formation 
Pus collection in a cavity or tissue is called an abscess. It is usually associated with 
infection. The pus is seen to be made of dead neutrophils together with bacteria and 
debris of destroyed tissues. 
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 3.5.4  Chronic inflammation 
 
As previously mentioned, chronic inflammation occurs when the inciting agent causing the 
inflammation  persists and is not removed during the acute inflammatory phase. This 
process could continue over days, months and even years leading to continuous local 
tissue damage. Macrophages are the predominant cells seen in chronic inflammation. 
These cells have the ability to produce toxins, used to defend against the pathogen. 
However, these toxins may also cause normal surrounding tissue damage and as a 
consequence localised tissue destruction such as necrosis can occur 
 
3.6  Inflammatory Cells and Tissue Changes seen in GPA Biopsies 
 
The histopathology of GPA was first described by Frederick Wegener in the 1930s based 
on post mortem lung examination of patients with systemic GPA. The histology of GPA 
was seen to consist of a variable mixture of granulomatous lesions with microabcesses or 
fibrinoid necrosis, tissue necrosis and vasculitis of small to medium sized vessels. 
Interestingly, it is reported that granuloma formations are seen to occur early in the 
disease process with vasculitis developing in the later stages (Wegener 1990).  
 
3.6.1  Lung histology in GPA 
 
In the lungs, the histology of GPA is reported to be divided into major and minor pathologic 
manifestations. Major manifestations are described to be the classical appearance of GPA 
histology and were of use diagnostically. In contrast, minor manifestations were histologic 
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 changes observed in association with classical GPA lesions, but were inconspicuous and 
deemed unuseful for diagnostic purposes. 
The major pathologic features in GPA include (1) parenchymal necrosis, (2) vasculitis, and 
(3) granulomatous inflammation accompanied by an inflammatory infiltrate composed of a 
mixture of neutrophils, lymphocytes, plasma cells, histiocytes, and eosinophils. The 
majority of patients (85%) were described to have parenchymal necrosis either seen as 
microabscesses or as geographical necrosis. The necrotizing granulomatous lesions 
consisted of poorly formed granuloma and scattered giant cells.  
Minor pathologic  changes included interstitial fibrosis, alveolar hemorrhage, tissue 
eosinophils, organizing intraluminal fibrosis, endogenous lipoid pneumonia, lymphoid 
aggregates, and a variety of bronchial/bronchiolar lesions (including acute and chronic 
bronchiolitis), follicular bronchiolitis, and bronchiolitis obliterans. Interestingly, eosinophils 
were found to be present in 100% of these cases although classified as a minor 
manifestation (Travis 1991). 
 
3.6.2  Renal histology in GPA 
 
Kidneys affected by GPA are typically described as segmental pauci-immune crescentic 
necrotizing glomerulonephritis. In the early stages of the disease, thrombotic changes in 
the glomerular capillary loops may be seen.  Thereafter, segmental fibrinoid necrosis with 
nuclear  debris  and disruption of the glomerular basement membrane occurs. In due 
course, cellular crescent is seen formed, collapsing the remaining glomerular tuft and 
tissue necrosis ensue. Granulomatous inflammation is generally not typical in renal GPA 
and cellular infiltrates seen are predominantly mononuclear leucocytes with moderate 
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 infiltration of neutrophils. The presence of vasculitis however, is not typically observed in 
renal biopsy specimens affected by GPA. 
 
3.6.3  Ocular histology in GPA 
 
In the limited form of GPA like in the orbit and nasal cavity, classical histological features 
of GPA are not always apparent in the majority of cases and have been reported to only 
occur in 16-25% of patients with upper respiratory GPA (Raynaud et al., 2005) and 54% in 
orbital GPA (Kalina et al., 1992). Despite this, clinically, orbital GPA could still present 
severe ocular symptoms and signs such as pain and proptosis that could result in 
permanent ocular morbidity like diplopia, reduced vision and even blindness. Indeed, 
orbital GPA has been described to represent a refractory form of GPA which could result in 
grave ocular consequences (Holle et al., 2013b). 
The pathologic features of biopsies from patients with ophthalmic GPA have been 
previously described. The histology of ophthalmic GPA is associated with granulomatous 
foci, collagen necrosis, neutrophil/nuclear dust, plasma cells and infiltrating eosinophils 
(Ahmed et al., 2008).  The presence of granular degeneration of the interstitial collagen, 
mummification of the collagen with the disappearance of fibroblastic nuclei, and a 
polymorphous infiltrate exhibiting plasma cells, lymphocytes, neutrophils and eosinophils 
within the epithelioid granulomas, are thought to be particularly indicative of the diagnosis 
of GPA (Ahmed et al., 2008). 
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 3.7  Ocular Histology in Sarcoidosis 
 
The histology of sarcoidosis typically shows a non caseating granulomatous inflammation 
with presence of foreign giant cells. Infiltrating immune cells in tissue biopsies are similar 
to that of GPA but in sarcoidosis, well formed granulomatous nodules (granuloma) are 
typically seen and are approximately the same size. Features of necrosis can also be 
observed. The presence of asteroid bodies which are star shaped acidophilic bodies within 
the tissues can be seen although their presence is not pathognomonic with the diagnosis 
of sarcoidosis. 
 
3.8  Ocular Histology in IIOD 
 
The histology of IIOD is non-specific and diverse (Yuen and Rubin, 2003). Tissues are 
seen to have a varied polymorphous immune cellular infiltration (neutrophils, plasma cells 
and macrophages). It can also portray a typical granulomatous inflammation like pattern, 
display tissue eosinophils, as well as infiltrative sclerosis (Fujii et al., 1985). 
 
3.9  Ocular Histology in TED 
 
Orbital tissues in TED are characterised to portray lymphocytic infiltration, focal 
aggregation of B cells, plasma cells and mast cells. In the orbit, accumulation of 
glycosaminoglycan can also be observed as well as an increased in adipocyte 
differentiation.  
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 3.10  Objective 
 
The histological features of ocular GPA previously described are not truly pathognomonic 
for orbital GPA as other orbital inflammatory diseases, such as sarcoidosis and idiopathic 
inflammatory orbital diseases, may also display similar features. We therefore wanted to 
investigate the histological features that are associated with the clinical diagnosis of orbital 
GPA; using both histopathology reports and the tissue biopsies, and compare them to the 
histology of other OIDs. In addition, we wanted to also identify any features in the histology 
of orbital GPA that may not be present in the biopsies of OIDs or those which may have 
greater presence in orbital GPA biopsies. 
 
The main aims in this part of the study were to: 
1)  Examine subjectively if there is a difference in the cellular occurrences and tissue 
changes between GPA and non-GPA orbital biopsies based on histopathology 
reports. 
2)  Objectively identify and quantify the different cell types and tissue changes present 
in orbital biopsies of patients diagnosed with orbital inflammatory disease. 
3)  Compare the amount (by count) of the different cell types and tissue changes, 
between patients diagnosed with GPA with OIDs.  
4)  Compare the amount (by count) of the different cell types and tissue changes, 
within the GPA group.  
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 3.11  Method 
 
3.11.1 Patient selection 
 
All previously identified patients were included in the study. Patients were allocated the 
same study numbers to maintain anonymity and we followed the same definition of terms 
as before. 
 
3.11.2 Subjective Comparisons with Histopathology Reports 
 
Histopathology reports were obtained from the medical case notes and each report were 
allocated a study number corresponding to the patients study number. The diagnosis for 
each report was also masked. The biopsy reports were then reviewed. The cell types and 
tissue responses were documented qualitatively as present (+ve) when described in the 
report, or absent (-ve) when not described in the report. Cell types that were noted in the 
histopathology reports  included neutrophils, eosinophils, lymphocytes, macrophages, 
plasma cells, giant cells and mast cells. The tissue responses noted include nuclear 
debris, granulomas, vasculitis, necrosis and fibrosis. (Appendix A) 
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 3.11.3 Objective Comparisons with Orbital Tissue Biopsies 
 
3.11.3.1  Tissue Selection 
 
Tissue biopsies, in paraffin block preparation from patients included in the study, were 
obtained from the Pathology Department, Institute of Ophthalmology, University College of 
London (UCL) archive storage. The blocks were anonymised  by  using the pathology 
numbers which matched an allocated patients’ study numbers. This also masked the 
diagnosis for each block. 
 
3.11.3.2  Slide Preparations and Haematoxylin and Eosin (H&E) 
Stainings 
 
Haematoxylin and eosin (H&E) staining was performed on all blocks for general cellular 
and tissue morphological definition and analysis. A sledge microtome was used for tissue 
sectioning and blocks were cut at a thickness of 5 micrometers and then placed on 
Superfrost plus object glass slides. Slides were only labelled by the patients’ pathology 
numbers to maintain anonymity and masked the pathology. The object slides were then 
left on a hot plate for 60 minutes at 40°C to encourage good tissue adherence to the slide 
and were then further incubated overnight at 37°C before use. H&E staining was 
performed for all slides on the same day and under the same laboratory conditions as per 
laboratory protocol via the automated H&E staining machine. Slides were then mounted 
with DPX mounting medium and cover slips and allowed to dry overnight. 
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 3.11.3.3  Imaging and Objective Cell and Tissue Counts 
 
The images of the whole slide from every biopsy were taken with the Hamamatsu 
Nanozoomer Digital Pathology Scanner and captured images were saved using pathology 
numbers to maintain patients’ anonymity and the diagnosis masked. Cell and tissue counts 
were done masked to the patient’s identity as well as disease diagnosis. Inflammatory 
cells and tissue changes observed on the slide images were then counted using the 
ImageScope image analyser and ADCIS® Stereology Toolkit. Cell count was performed 
for lymphocytes, plasma cells, eosinophils, neutrophils, mast cells, macrophages and giant 
cells. Tissue changes were characterised as nuclear debris,  granulomas,  vasculitis, 
fibrosis and necrosis. (Appendix A) 
Cell counting was performed using the ADCIS® Stereology Toolkit frame count 
programme. The region of interest was first identified manually from the image of the 
tissue section. This was done by drawing around the border of the whole tissue section. 
The software was then programmed to generate 20 random counting frames within the 
region of interest. Figure 3.1 Each counting frame measured 1mm x 1mm and consisted of 
two inclusion lines (right and top borders) and two exclusion lines (left and bottom borders) 
resulting in a total area of 20mm
2 analysed for every slide. This was then repeated in all 
slide images to ensure that the total area analysed were standardised on all images. Cells 
lying within the frame or on the inclusion line and not touching the exclusion line were 
included in the count. Each different cell types identified were appointed different colour 
codings and marked by hand (e.g. red for neutrophils, green for lymphocytes, etc.)(Figure 
3.2). This was performed in all 20 frames. At the end of the 20 frames, the software then 
generated the total number of cells marked for each different cell type to produce the total 
count of each cell type in that slide image. 
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 For quantifying tissue changes, the ADCIS® Stereology Toolkit point count programme 
was also used. As previously described, the region of interest was identified from the slide 
image manually. 20 random points were programmed to be generated by the software 
within the region of interest. Figure 3.3 Different tissue changes were assigned to different 
colour codings. The points were then marked with the different colour code if it ‘hits’ (or 
marks) on a particular tissue change. This was performed on all 20 points. The computer 
then generated the number of ‘hits’ for the different tissue changes. Figure 3.4 
 
3.11.4  Image analysis 
 
 
Figure 3.1: Image analysis for objective cell count using a H&E GPA tissue at 20x 
magnification. A total of 20 random counting frames (blue frames), each 1mmx1mm 
(1mm
2), generated by the ADCIS® Stereology Toolkit within the region of interest 
(marked red). 
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Figure 3.2: Example of frame counting for cell count on a H&E GPA tissue at 400x 
magnification.  Each counting frame measures 1mm x 1mm and consists of two 
inclusion lines (right and top borders) and two exclusion lines (left and bottom 
borders). Each different cell types are identified by hand and marked using different 
colour codings. Only cells within the frame and not touching the exclusion lines 
were included in the count 
 
Figure 3.3: Example of tissue count with point counting on a H&E GPA tissue A: 
Image analysis for tissue changes at 20x magnification. A total of 20 random point 
counts (blue x) within the region of interest (marked in red) B: Enlarged section (40x 
magnification) demonstrating generated “blue x”. 
 
A  B 
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Figure 3.4: Point counting for tissue changes (image at 100x magnification). Different color 
codings  are assigned to different tissue changes. The points are then marked with a 
different colour code if it ‘hits’ (or marks) on a particular tissue change. Above is an example 
of a ‘zero score’, where none of the points are marking a tissue change. 
 
3.11.5 Validation process for cell and tissue counts 
 
Identification of cells and tissue changes were counter checked and validated by a senior 
pathologist (secondary supervisor) who was also masked from patients’  identities  and 
diagnoses. A portion of the slides were also re-counted to ensure total counts were 
reproducible. 
 
3.12  Data Analysis 
 
3.12.1 Subjective Histopathology Analysis 
 
Comparison of the total number of reports with positive presence of the cell types and 
tissue changes were then compared between the GPA and  non GPA i.e. other orbital 
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 inflammatory diseases (OID),  via the Mann Whitney test with SPSS17. Further sub-
analysis within the GPA group was also conducted with the Mann Whitney test SPSS17. 
 
3.12.2 Objective Tissue Biopsy Analysis 
 
Cell counts were entered into an excel data sheet where anonymised pathology numbers 
were then matched to the corresponding study number for each patient. Patients were 
then divided into two groups – clinically diagnosed orbital GPA and OIDs and cell and 
tissue counts were compared.  
Further sub-analysis within the orbital GPA group was also performed. 
 
3.12.3 Statistical Analysis 
 
Student’s t-test and Fisher’s exact test were performed with GraphPad Prism 5 and 
SPSS17 for comparison between groups during the subjective analysis with 
histopathology reports. The Mann Whitney test was performed with GraphPad Prism 5 for 
comparison  of the cell and tissue count on tissue biopsies between the groups. 
Multivariate analysis was performed with SPSS17 to look for any independent association 
of a cellular profile or tissue response with the diagnosis of GPA for both subjective and 
objective analysis. 
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 3.13  Results 
 
3.14  Histopathology Report (subjective analysis) 
 
3.14.1 GPA versus OID 
 
234 histopathology reports from all patients previously identified and included in the study 
were reviewed. In general, the histopathology reports showed a mixed pattern of acute 
and chronic inflammation. 
In the histopathology reports of GPA patients, the several inflammatory cells and tissue 
changes were cited more frequently more compared to the combined histopathology 
reports from OIDs. This indicated a more active and distinctive presence of inflammatory 
cells in GPA biopsies. (Table 3.1) (Figure 3.5) 
Granulomatous inflammation was the predominant feature described for orbital GPA, as 
seen reported in all GPA biopsies. Comparisons of the cellular and tissue change 
occurrences reported as present in the histopathology report, between the GPA and non-
GPA patients are summarised in Table 3.1. Neutrophil (p= <0.001), eosinophils (p=0.02), 
macrophages (p=0.04), vasculitis (p=<0.001), and necrosis (p=<0.001) were reported 
present significantly more in the GPA group compared to the OID group. Further 
multivariate analysis showed that the presence of neutrophils and vasculitis were 
independently  associated with the clinical diagnosis of GPA with an odd ratio of 3.9 
(p=0.01) and 4.8 (p=0.006) respectively (Table 3.1). 
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 Table 3.1: Subjective comparison of the cellular and tissue change profile reported 
present in histopathology reports between GPA and OID (non-GPA) patients. 
 
Cell type/tissue 
change 
GPA 
(n=36)Tota
l (%) 
OID 
(n=198) 
Total (%) 
Unadjusted  Adjusted 
      OR  p  OR  P 
 
 
Neutrophils 
 
19 (53%) 
 
30.9 (15%) 
 
5.9 (2.7-12.6) 
 
<0.001* 
 
3.9 (1.4-11.2) 
 
0.01* 
 
Eosinophils  19 (53%)  62 (31%)  2.5 (1.2-5.0)  0.02*  0.7 (0.24-1.8)  0.42 
 
Lymphocytes  19 (53%)  113 (57%)  0.8 (0.4-1.7)  0.86     
 
Macrophages  16 (44%)  55 (28%)  2.1 (1.0-4.3)  0.04*  2.0 (0.9-4.5)  0.11 
 
Plasma cells  18 (50%)  85 (43%)  1.3 (0.7-2.7)  0.47     
 
Giant cells  2 (6%)  23 (12%)  0.4 (0.1-2.0)  0.39     
 
Nuclear debris  2 (6%)  6 (3%)  1.9 (0.4-9.7)  0.36 
 
 
   
 
Granuloma  12 (33%)  45 (23%)  1.7 (0.8-3.7)  0.21     
 
Vasculitis  19 (53%)  11 (6%)  19.0 (7.8-46.4)  <0.001*  4.8 (1.6-14.7)  0.10 
 
Necrosis  22 (61%)  21 (11%)  5.4 (2.4-12.0)  <0.001*  2.4 (0.9-4.5)  0.006* 
Fibrosis  4 (11%)  111 (56%)  1.2 (0.6-2.6)  0.72     
 
 
   
OR = odds ratio; CI = confidence interval, % = percentage of patients with positive occurrence of 
cell type or tissue response reported in biopsy within each group, * = significantly different 
statistically (p<0.05). 
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PMN=neutrophil, Eos= eosinophils, Lymp=Lymphocytes, Mac=Macrophages, PC=plasma cells, GC=Giant 
cells, ND=Nuclear debris, Gran=granuloma; Vasc= vasculitis, Nec=Necrosis, Fib=Fibrosis, * = significantly 
different statistically (p<0.05). 
Figure 3.5: Subjective comparison (via histopathology reports) of immune cells and 
inflammatory tissue changes between GPA and non GPA 
 
3.14.2 Subanalysis within the GPA Group 
 
3.14.2.1  ANCA positive versus ANCA negative 
 
Eosinophils and lymphocytes were more frequently observed in the ANCA positive group 
compared to the ANCA negative group. However these differences were found to be only 
borderline significant, with p values of 0.08 and 0.09, respectively. 
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 3.14.2.2  Newly Diagnosed GPA versus Previously Known GPA 
 
There were no significant differences in cellular occurrences between the newly diagnosed 
GPA and the known GPA patients. Nevertheless, there were more cellular activities 
observed in the newly diagnosed GPA group compared to the known GPA group. (Figure 
3.6) Interestingly, nuclear debris and giant cells were not found in any of the biopsy of 
patients who are known GPA. Both entities were only found in the biopsies of those who 
were newly diagnosed with GPA. 
 
PMN=neutrophil, Eos= eosinophils, Vasc= vasculitis, Nec=Necrosis, Lymp=Lymphocytes, Fib=Fibrosis, 
Mac=Macrophages, PC=plasma cells, GC=Giant cells, Histio=Histiocytes, ND=Nuclear debris, 
Gran=granuloma; * significantly different statistically (p<0.05) 
Figure  3.6: Graph of cellular and tissue occurrence in biopsies between newly 
diagnosed GPA and those with orbital extension of pre-established GPA (known 
GPA). Newly diagnosed GPA shows more cellular activity compared to known GPA 
and nuclear dusts, and giant cells were reportedly seen only in newly diagnosed 
group. 
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 3.15  Orbital Tissue Analysis (objective analysis) 
 
3.15.1 GPA versus OID 
 
A total of 239 tissue blocks from 234 patients were retrieved from thePathology 
Department, Institute of Ophthalmology, University College of London (UCL) archive 
storage. Out of these, 39 blocks were from patients diagnosed and clinically managed with 
GPA, and 200 blocks were from other orbital inflammatory diseases (OID) which included 
65 IOID, 35 dacryoadenitis, 14 sarcoidosis, 12 thyroid eye diseases, four myositis, 23 
lymphoid hyperplasia and 47 other OIDs such as dermoid, dacryosistitis, mucocele, orbital 
xanthogranuloma, Churgg Strauss syndrome and post-surgical granulomas. 
The orbital biopsies showed a mixed picture of acute and chronic inflammation. Orbital 
biopsies from GPA patients were found to be heavily infiltrated with inflammatory cells 
resulting in an intense (darker) stained picture compared to other OIDs. (Figure 3.7) 
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Figure 3.7: H&E stained tissue biopsies. All tissues were stained in parallel i.e. at 
the same time and with the same technique and laboratory condition. A, C and E are 
at 40X magnification and B,D and F are at 100X magnification.(A&B) represent H&E 
stained tissue biopsy of GPA showing a more infiltrated, densly packed and heavily 
stained picture compared to tissue biopsy from IIOD (C&D) and orbital sarcoidosis 
(E&F) 
 
 
 
 
 
 
 
A  B 
C  D 
E  F 
147 
 Objective count comparisons for each cell types and tissue changes are summarised in 
Table  3.2. Further multivariate analysis showed that necrosis and vasculitis were 
independently associated with the clinical diagnosis of GPA with an odd ratio of 2.40 
(p<0.001) and 1.33 (p<0.001) respectively. However, not all slides from this GPA group 
had features of necrosis and vasculitis. 12 out of 39 orbital GPA biopsies (31%) did not 
have necrosis and five (13%) from these did not have both vasculitis and necrosis. 
Interestingly,  granuloma was shown to be significantly less in orbital GPA biopsies 
compared to OIDs, and in addition, it was found to be inversely associated with the clinical 
diagnosis of orbital GPA (odds ratio = 0.12, p=0.02). (Table 3.2) 
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 Table  3.2: Quantitative (objective count on H&E slides) Cell/Tissue Comparison 
between GPA and other OIDs. Cell count were performed in 20x1mm
2 (20mm
2) field 
in each case  and tissue change were determined and counted from 20 random 
points generated 
 
Cell & tissue 
changes 
GPA (n=39) 
Mean +/- SE 
Other OIDs (n=200) 
Mean +/- SE 
Unadjusted  Adjusted 
      p  OR  p 
Neutrophils  37.2 +/- 10.4  11.1 +/- 2.4  <0.001 *  0.99 (0.97 - 1.01)  0.26 
Eosinophil  50.0 +/- 19.4  12.4 +/- 2.4  0.002 *  1.00 (0.99 - 1.01)  0.50 
Lymphocyte  3292.3 +/- 141.2  3671.5 +/-187.6  0.582     
Macrophage  290.5 +/- 19.7  188.89 +/- 8.8  <0.001 *  1.00 (0.99 - 1.01)  0.34 
Plasma cells  81.82 +/- 16.5  66.30 +/- 6.4  0.146     
Giant cells  0.26 +/- 0.9  0.32 +/- 0.1  0.066     
Mast cells  0.33 +/- 0.2  0.12 +/- 0.03  0.096     
Nuclear 
debris 
3.7 +/- 1.5  0.96 +/- 0.3  0.011 *  1.08 (0.96 - 1.22)  0.19 
Granuloma  0.5 +/- 0.4  0.55 +/- 0.1  0.046 *  0.12 (0.21 - 0.71)  0.02* 
Vasculitis  7.13 +/- 0.8  2.95 +/- 0.2  <0.001 *  1.33 (1.15 - 1.54)  <0.001
* 
Necrosis  3.0 +/- 0.4  0.35 +/- 0.75  <0.001 *  2.39 (1.73 - 3.3)  <0.001
* 
Fibrosis  6.59 +/- 0.5  7.63 +/- 0.5  0.906     
 
OR = odds ratio; CI = confidence interval, * = significantly different statistically (p<0.05) 
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 3.15.2 Subanalysis within the Orbital GPA Group 
 
3.15.2.1  Newly Diagnosed GPA versus Known GPA 
 
18 out of 39 blocks from the GPA group were newly diagnosed GPA while the remaining 
21 were previously diagnosed with and treated for GPA from other clinical manifestations 
before their orbital presentation i.e. known GPA. Comparison between these groups 
showed that eosinophils (p=0.045) and macrophages (p=0.06) were found marginally 
more in the known GPA group compared to the newly diagnosed GPA group.  (Figure 3.6) 
     
3.15.2.2  Other Comparisons in the GPA Group 
 
There were no differences in any of the cell and tissue counts with regards to ANCA status 
(positive versus negative) (p=0.1), disease extension (generalised versus localised GPA) 
(p=0.3) and treatment regime (single or multiple therapies) (p=0.1). 
 
3.16  Discussion 
 
In this part of the study, our main aim was to see if there is a difference between the 
histology of orbital GPA and OIDs, by comparing the cell types and tissue changes 
subjectively (via histopathology reports) and objectively (via immune  cell and tissue 
change counts). 
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 We found that even based on only histopathological reports; there were differences in the 
cellular activity between orbital GPA and other OIDs where GPA portraying a more active 
cellular pattern in their biopsies. The same findings were also true when we performed 
objective cellular and tissue change comparison on H&E stained tissue analysis. Tissue 
biopsies of GPA patients were found to have increased immune cell activity compared to 
the other OIDs combined. This is reflects that ocular GPA can have a more aggressive 
clinical course compared to other OIDs, and can cause severe ocular morbidity.  The 
appearance of the H&E stained tissues of orbital GPA displayed a busier, deeply stained 
and mixed cellular composition compared to other OIDs. This appearance is consistent 
with the histology of lung tissues affected with GPA; described by one article asareas with 
a deep basophilic, “dirty” appearance which is suggested to be due to the high presence of 
neutrophils and nuclear debris (Lagstein and Myers, 2009)(Mukhopadhyay and Gal, 2010). 
 
Vasculitis and necrosis were features independently associated with the diagnosis of 
orbital GPA in this study. These two features are in keeping with the classic triad of the 
pathological features of GPA which are granulomatous inflammation, vasculitis and 
extensive tissue necrosis. Vasculitis in particular, is said to be an important feature in the 
histology of GPA where one study suggested that, granulomatous inflammation without 
vasculitis is more characteristic of other orbital inflammatory diseases rather than GPA 
(Bijlsma et al. 2011). In the lungs, necrotizing vasculitis is said to be the single most 
important feature in the histological diagnosis of GPA (Mukhopadhyay and Gal, 2010). 
Similarly, in the kidney, the main histological feature seen in patients with active renal GPA 
is segmental glomerular necrosis (Aasarød et al., 2001a)(Aasarød et al., 2001a). Together 
with the higher inflammatory activity observed, it is likely that the presence of necrosis and 
vasculitis seen clinically, reflect the more severe and destructive nature of orbital GPA, 
compared to other OIDs. Nevertheless, it is important to point out that in a number of the 
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 orbital GPA tissues in our study, features of necrosis and vasculitis were absent despite 
being at the point of active inflammation. This may largely be attributed to the small tissue 
sample. 
 
GPA and sarcoidosis are both described as granulomatous inflammatory diseases. 
However, the histology of sarcoidosis differs slightly compared to GPA where in 
sarcoidosis, features of discrete, well-formed, interstitial non-necrotizing granulomas are 
mainly seen (Mukhopadhyay and Gal, 2010). In GPA, the term “granulomatous 
inflammation” described mainly made up of loose collections of histiocytes, multinucleated 
giant cells and other inflammatory cells, is said to be poorly defined (Holle et al., 
2010a)(Holle et al., 2010a).  Even in the lungs, compact, ‘sarcoid-like’,  non-necrotizing 
granulomas are said to be exceptional in GPA (Travis et al., 1991). Granulomas in the 
lungs with GPA are suppurative or neutrophil filled in nature, with a dirty appearance due 
to the high presence of neutrophil and nuclear debris. They are also described to have an 
irregular contour, unlike granulomas seen in sarcoid or infection (Mukhopadhyay and Gal, 
2010). The histology of our orbital GPA biopsies also showed an inflammatory picture with 
abundance of macrophages where distinct granuloma formations were very much less. 
 
We also observed a high count in neutrophils and nuclear debris in orbital GPA biopsies. 
Neutrophil in particular, when analysed based on histopathology reports, were found to be 
independently associated with the diagnosis of orbital GPA. In addition, nuclear debris, 
which is thought to originate from fragmented neutrophils, have been repeatedly described 
in pathological reports in GPA (Ahmed et al., 2008)(Lamprecht and Gross, 2007)(Ahmed 
et al., 2008), but does not seem to be observed in the biopsies of any other ocular 
inflammatory conditions. Nuclear debris is an entity that has only recently become a 
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 subject of interest in GPA. In our study, the occurrence of nuclear debris  reported in 
histopathology reports in the whole sample, were most likely to be under-represented as 
pathologists may not have specifically reported this phenomenon in the past. 
Nevertheless, despite this, the presence of nuclear debris was still reported more in the 
GPA group compared to other OIDs. This finding was also consistent in the H&E tissue 
analysis.  
 
 ANCA has been demonstrated to play a considerable role in the pathogenesis of 
vasculitides. The presence of ANCA causes increased neutrophil migration, and adhesion 
to vascular endothelium and subsequent neutrophil degranulation leading to vascular 
inflammation or vasculitis. This may explain the presence of nuclear debris in biopsies of 
GPA in this study but not in the biopsies of other orbital inflammatory diseases which are 
not associated with ANCA. The exact aetiology of ANCA production and why it is involved 
in AAV still remains unclear. One theory suggests that the production of ANCA may be 
related to ineffective neutrophil apoptosis (programmed cell death) or ineffective removal 
of the apoptotic cell fragments of neutrophils. Therefore, alternatively, the presence of 
these nuclear debris,  that are thought to originate from neutrophils  may be triggering 
stimuli for the production of ANCA instead. This may also explain how ANCA, which 
targets neutrophil intracellular antigens, may be raised in these diseases. In addition, on 
examining the histopathology reports, GPA subgroup analysis showed that nuclear debris 
were only reported in the newly diagnosed patients which strongly suggests the active role 
of neutrophils in the acute and initial stage of the disease.  
 
The role of eosinophils in the pathogenesis of GPA is not clear although its presence in 
orbital GPA biopsies has been documented in several  publications  (Ahmed et al., 
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 2008)(Choopong et al., 2005). In this study, eosinophils were found to be significantly 
higher in orbital GPA compared to other OIDs although this was lost when other 
confounding factors were controlled for. This suggests that tissue eosinophils in OIDs 
might be associated with disease severity, rather than being associated with GPA in 
particular. In addition, based on our H&E analysis, eosinophils were observed to be 
marginally more in patients with known GPA compared to newly diagnosed GPA. This may 
indicate two important possibilities: (1) that recruitment of eosinophils are higher during the 
recurrence of GPA, or (2) that eosinophils are unaffected by treatment and are retained in 
the affected peripheral tissues. Thus, apart from being associated with disease severity in 
OIDs, the role of eosinophils in orbital GPA may also be associated with disease 
recurrence or chronicity.  
 
Lymphocyte  count was overall  markedly  higher compared  to other immune cells. 
Lymphocytes are one of the major effector cells in the inflammatory response and play a 
role in both the acute and chronic inflammatory processes. Lymphocytes can generally be 
T cells, B cells or natural killer cells (NK T cells), where each subtypes have specific 
important roles in the immune system. T cells and B cells in particular are responsible for 
the cellular and adaptive immune responses respectively; both critical human defense 
systems. In the active state, lymphocytes also help recruit other immune cells and 
biochemical entities to the target site further perpetuating the immune response. Over 
activity of these immune cells as well as other cells in the inflammatory process is the 
basis of chronic inflammation. Lymphocytes subtypes have been linked to the 
pathogenesis of GPA however in H&E tissues, it is not possible to distinguish these 
subtypes apart. This could only be done with immunohistochemistry staining. 
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 We also performed subgroup histology comparison between biopsies of newly diagnosed 
GPA and known GPA patients. Although there were no significant differences seen in the 
occurrence of cells and tissue changes, newly diagnosed GPA appeared to have more 
cellular activity compared to known GPA.  Also, as previously mentioned, nuclear debris 
as well as giant cells were found only in patients who were newly diagnosed with GPA.  
This observation may explain the findings in the first part of our study where we noted that 
newly diagnosed patients tend to present more severe clinical symptoms compared to 
known GPA. This outcome is also comparable to a previous study by Stone JH in 2003 
who reported that in patients with GPA, the disease was more severe in the newly 
diagnosed GPA compared to relapse cases (Stone, 2003). Therefore, these results appear 
to suggest that in orbital GPA, (1) cellular activity is more intense in the first episode of the 
disease, (2) the cellular activities change as inflammation in GPA becomes  chronic or 
when the disease relapses, and (3) treatment may alter the cellular profile or activity in 
GPA. 
 
3.17  Conclusion and Further Plans 
 
There were no distinctive features found in the biopsies of orbital GPA that could act as a 
marker for early diagnosis. We found that there are significant differences observed in the 
levels of cellular activity between GPA orbital biopsies and OIDs where orbital GPA had 
significantly higher inflammatory activities compared to OIDs. This mirrors the more severe 
clinical presentation of orbital GPA. The cause of this increased activity is still unknown 
and factors that enhance the recruitment of these inflammatory cells are also unclear. 
It is interesting to note that there were also differences found in the cellular activities 
between orbital biopsies of newly diagnosed GPA patients compared to orbital biopsies of 
155 
 known GPA patients. This may suggest that in GPA, cellular activities in the peripheral 
tissues may be influenced by disease chronicity and treatment.  
The main difference in the histology of orbital GPA, as already been well established by 
previous studies, are the prominent presence of necrosis and vasculitis i.e. the key 
histological features in the diagnosis of GPA. However, these features were not always 
present in tissue biopsies of patients with GPA, as discovered in this study. It is also 
important to note that there were also significant differences found in the presence of 
certain cells such as neutrophils and macrophages. In addition, it was also interesting to 
discover that granuloma formation was inversely associated in the biopsies of orbital GPA 
despite the disease being described as a granulomatous inflammatory disease. This is a 
marked contrast from orbital sarcoidosis which is also described as a granulomatous 
inflammatory disease where granuloma formations in tissues are the key feature. Thus 
from these findings, there may be a possibility of specific sub-types of the inflammatory 
cells present in orbital GPA that differ from other OIDs, that could account for the 
difference in the clinical manifestation in orbital GPA compared to other OIDs. 
We therefore proceeded to further investigate this with immunohistochemical staining and 
looked for specific cell sub-types, cell receptors and cytokines from the different infiltrating 
cells such as T lymphocytes, B lymphocytes, macrophages and neutrophils in orbital GPA 
biopsies.  
We chose to compare the presence of these cells specifically with two other OIDs which 
are orbital sarcoidosis and IIOD. The purpose for this is because IIOD shares very similar 
disease presentation and progression with orbital GPA and is often very difficult to discern 
from orbital GPA clinically, and orbital sarcoidosis has the same inflammatory process as 
orbital GPA i.e. granulomatous inflammation although it does not usually share similar 
clinical progression and outcomes with orbital GPA.   
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 4  Chapter 4: T lymphocytes 
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 4.1  T cells in GPA 
 
The involvement of T lymphocytes (T cells) in the pathogenesis of GPA has been well 
documented (Hua et al., 2009)(Lamprecht and Kabelitz, 2011)(Popa et al., 1999). In tissue 
biopsies of GPA, T cells and macrophages are seen to predominate. However, total blood 
lymphocyte numbers, and absolute and relative numbers of CD4 T helper cells were 
observed to be relatively low in GPA patients compared with control samples. It is 
postulated that this lymphopenic effect in GPA may occur due to extensive migration of 
blood T cells to tissues, and also as a result of treatment effects (Berden et al., 2009). T 
cells are seen in abundance in kidneys of patients with crescentic glomerulonephritis and 
correlate negatively with renal function (Aasarød et al., 2001b)(Aasarod K 2001).  
 
4.2  CD4 T cells in GPA 
 
CD4 T cells and its various subsets have been shown to have a significant role in the 
development of the disease in GPA (Lamprecht and Kabelitz, 2011)(Abdulahad et al., 
2006)(de Menthon et al., 2011) (Abdulahad et al 2006). Patients with GPA appear to have 
an increased CD4+ effector memory T cells compared to naïve CD4 cell population during 
remission. However, during disease activity, serum effector memory T cells are found to 
decrease, indicating recruitment of these cells into affected tissues  (Abdulahad et al., 
2006). Indeed, CD4+ effector memory cells have been found in urine of patients with 
active glomerulonephritis secondary to GPA (Abdulahad et al., 2009). Tregs have also 
been shown to be defective in GPA that may be responsible for the relapsing and remitting 
behaviour of the disease  (Abdulahad et al., 2007).  Nonetheless, the cause of the 
dysfunction in these cells in GPA is still unclear. Other effector CD4 cells such as 
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 CD4+CD28- cytotoxic T cell, have also been seen to be expanded in GPA and to do so 
even during disease remission (Abdulahad et al., 2006). 
 
4.3  Th1 T cells and Th2 T cells in GPA 
 
Both Th1 T cells and Th2 T cells have been implicated in the disease development in 
GPA. A study by Csernok E in 1999 showed biopsy of nasal granuloma in GPA expressed 
IFN- γ with no IL-4, indicating a strong Th1 T cells link (Csernok et al., 1999). However, a 
similar study, also with GPA nasal biopsies by Balding et al in 2001, revealed that nasal 
tissue from patients with GPA showed an increased expression of IL-4, down-regulation of 
IL-2 and no detectable IFN-gamma, thus implicating a Th2 T cells response (Balding et al., 
2001). It has been suggested that Th1 T cells may play a role in localised GPA and as the 
disease progresses to become systemic, a shift to a Th2 T cells response may occur. This 
however has yet to be confirmed (Berden et al., 2009). 
 
4.4  Th17 in GPA 
 
The role of T-helper 17 (Th17) cells have recently been investigated as potential players in 
disease development in AAV, including GPA (Berden et al., 2009). Th17 has also been 
reported to be instrumental in the pathogenesis of these diseases (Kallenberg, 2011a). In 
particular, levels of IL-17 were found to be high in patients with GPA compared to healthy 
individuals, and in ANCA positive GPA patients, Th17 was found to be skewed upon 
stimulation of PR3 (Abdulahad et al., 2008). Th17 is also seen to be expanded in both 
active and quiescent GPA (Wilde et al., 2012). 
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 4.5  CD8 in GPA 
 
CD8 as well as CD4 have been shown to be activated in GPA (Schlesier M 1995). CD8 T 
cell sub-types such as CD8+CD57+ (Iking-Konert et al., 2009) have been implicated in the 
pathogenesis of the disease and is said that it could have a direct contribution to vascular 
endothelium damage seen in the disease (Schlesier et al., 1995).  CD8 has also been 
found in tissues of organs affected by GPA. In kidneys affected with GPA, CD8 (cytotoxic) 
T cells were found to be present in the intraglomerular tissues where these cells made up 
two-thirds of the total T cells in the tissue. In particular, not only CD8 T cells together with 
macrophages were found to be the predominant cellular infiltrates in these tissue biopsies, 
it is suggested that CD8 also carries a prognostic value where the presence of these cells 
in renal tissues indicate a poorer renal prognosis (Aasarød et al., 2001a)(Aasarød et al., 
2001a). 
 
4.6  Other T cell subtypes in GPA 
 
Other T cell sub-types reported include the presence of CD134 in various organ tissue 
biopsies affected by GPA. CD134 has been demonstrated to be present in renal, lungs 
and nasal tissues affected by GPA (Wilde et al., 2009). CD134, also known as OX40, is a 
member of the tumour necrosis factor receptor (TNFR)-superfamily and a co-stimulatory 
molecule.  The expression of CD134 is dependent on full activation of T cells, thus are not 
expressed on naïve T cells. It plays a critical role in maintaining an immune response by 
preventing activated T cell death. In GPA, CD134 is not only postulated to have a role in 
the disease development, but is also said to be responsible for the relapsing disease 
course where circulating CD134 subsets is thought to be the starting point for organ and 
tissue inflammation (Wilde et al., 2009). 
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 4.7  T cells in sarcoidosis 
 
CD4 T cells play an important role in the pathogenesis of sarcoidosis. In target organ sites, 
granuloma formation; classically seen in the histology of sarcoidosis, is driven by the CD4, 
Th1 T cells, macrophage and INF-γ production immunologic response (Grunewald and 
Eklund, 2007)(Grunewald et al., 2006). Indeed, lymphopenia involving CD4, CD8 and 
CD19 has been observed in patients with sarcoidosis, indicating recruitment into active 
target organs. The degree of lymphopenia was also seen to correlate with the degree of 
disease activity (Sweiss et al., 2010). The use of bronchoalveolar lavage fluid (BALF), 
looking at CD4/CD8 ratios in the lungs, is currently widely used in the diagnosis of 
sarcoidosis. It is said that the ratio of CD4/CD8 of 2 and more indicate a strong positive 
diagnosis for sarcoidosis (Winterbauer et al., 1993). In the eye, CD4/CD8 ratios in vitreous 
samples were also shown to have similar findings with BALF in patients with sarcoidosis, 
implying a high diagnostic value in the diagnosis of ocular sarcoidosis (Kojima et al., 
2012). Apart from this, Th17 has also been proposed to have a role in the pathogenesis of 
sarcoidosis.  An imbalance in Th17 and Tregs in peripheral blood and BALF has been 
associated with the diagnosis of sarcoidosis (Huang et al., 2013). 
 
4.7.1  T cells in IIOD 
 
There have not been many reports or investigations performed to look into the role of T 
cells in the pathogenesis of IIOD. However, it has been shown that in the histology of IIOD, 
a predominance of T cells were seen when compared to lymphoid hyperplasia which had a 
mixed T and B lymphocytes, and lymphoma which had predominant B cell involvement 
(Lowen et al., 2005). The treatment of refractory IIOD does include medication with T cell 
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 and B cells immunosuppressor activity such as mycophenolate mofetil, thus indicating the 
active role of these cells in this disease (Patel et al., 2011). 
 
4.8  Objective 
 
We wanted to demonstrate whether the T cells sub-types seen in serum and other organs 
affected by GPA were also present in GPA orbital tissues. In particular, we wanted to 
compare the presence of these cells to IIOD and orbital sarcoidosis to discover the 
significant role of these cells in the disease process of orbital GPA. The main objectives for 
this part of the study are: 
 
1.  To demonstrate the presence of CD3, CD4, CD8, CD134 and cytokine IL-17 in 
orbital tissue biopsies of GPA, 
2.  To compare the presence of CD3, CD4, CD8, CD134 and cytokine IL-17 between 
orbital tissue biopsies of GPA and IIOD, and 
3.  To compare the presence of CD3, CD4, CD8, CD134 and cytokine IL-17 between 
orbital tissue biopsies of GPA and orbital sarcoidosis 
 
   
162 
 4.9  Method 
 
4.9.1  Subject and Tissue selection 
 
Paraffin blocks of 25 patients from the orbital GPA group and 25 patients from the IIOD 
group were randomly selected from the pool of patients already included for the previous 
section of the study. Due to insufficient tissue in one case, only 13 paraffin blocks from the 
14 patients clinically diagnosed with orbital sarcoidosis were used for the IHC study.  
 
4.9.2  Antibodies 
 
IHC was performed for cell markers CD3 (A0452, DAKO, Cambridgeshire, UK) protein 
complex, CD4 (Clone 4B12; M7310, DAKO, Cambridgeshire, UK), CD8 (Clone C8/144B; 
M7103, DAKO, Cambridgeshire, UK); CD134 (Clone ACT35; 555836, BD Pharmingen™, 
Becton, Dickinson and Company, Oxford, UK) and IL-17A (IL-17A; AHP455G AbDSerotec, 
Kidlington, UK). 
 
4.9.3  Slide preparation 
 
Slide preparations and stainings for each antibody were performed on the same day and 
under the same laboratory conditions for all cases. Tissue sections from the blocks were 
cut using a sledge microtome at a thickness of 5 micrometer and mounted on Superfrost-
plus object glass slides. The slides were left on a hot plate at 40°C for 60 minutes and then 
incubated overnight at 37°C before use.   
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 4.9.4  Immunohistochemistry staining of fixed paraffin tissues (Table 4.1) 
 
Slide preparations and stainings for each antibody were performed on the same day and 
under the same laboratory conditions for all cases. Tissue sections were de-waxed in two 
changes of xylene (each 5 to 10 minutes) with agitation at regular intervals, then twice with 
100% ethanol (10 to 20 seconds) and then hydrated in 90%, 70%, and 50% ethanol, each 
for 10 to 20 seconds, followed by two washes in water. Sections were then incubated in 
the appropriate antigen retrieval solution where Tris/EDTA pH 9.0 (H-3301, Vector Labs, 
UK) was used for CD3, CD4, CD8, and sodium citrate pH 6.0 (H-3300, Vector Labs, UK) 
was used for CD134 and IL-17A. Heat induced epitope retrieval was performed using 
pressure cooker at 95°C. Slides were then cooled under running water and left immersed 
in Tris-buffer solution (9L distilled water + 1L DAKO Wash Buffer 10X, Code S3006; DAKO 
UK) for 5 minutes.  
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 Table 4.1: Immunohistochemistry protocol for T cells investigations 
 
Cell 
type 
Antigen 
retrieval 
Epitope retrieval  Mode of 
staining 
Antibody 
concentration 
Incubation 
time 
(temperature) 
Result 
CD3  Tris/EDTA  
pH 9.0 
95
oHeat 
(pressure cooker) 
 
Autostainer  1:400  _  Positive 
 
CD4  Tris/EDTA  
pH 9.0 
95
oHeat 
(pressure cooker) 
 
Autostainer  1:50  _  Positive 
 
CD8  Tris/EDTA  
pH 9.0 
95
oHeat 
(pressure cooker) 
 
Autostainer  1:50  _  Positive 
 
CD134  sodium citrate  
pH 6.0 
95
oHeat 
(pressure cooker) 
Manual  1:200  24 hours 
(4
oC) 
Positive 
 
 
IL-17A  sodium citrate  
pH 6.0 
95
oHeat 
(pressure cooker) 
Manual  1:800  24 hours 
(4
oC) 
Positive 
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 4.9.5  Automated staining for CD3, CD4 and CD8 
 
CD3, CD4 and CD8 stainings were then performed by the DAKO Autostainer Plus on all 
slides  at concentrations of 1:400,  1:50  and  1:50  respectively as per manufacturer 
recommendation. Positive and negative controls with inflamed  tonsil tissue were also 
performed. 
 
4.9.6  Manual staining for CD134 and IL-17A 
 
Tissue staining for CD134 and IL-17A  were stained manually; concentrations for both 
primary antibodies used were titrated using inflamed tonsil tissues until an optimal tissue 
stain were achieved.  
After de-waxing and antigen retrieval as previously described above, slides were placed in 
a moist chamber and tissues were kept hydrated with Tris-buffer solution. A ring was then 
made around the tissues for all slides using a hydrophobic barrier pen (ImmEdgePen H-
4000). Primary antibodies; CD134 (1:200) and IL-17A (1:800), diluted in blocking solution 
were added and left to incubate overnight at 4°C. Washing with Tris-buffer was performed 
after each incubation step. The LSAB+ and Dako REAL™ Detection Systems kit K5005 
AP/RED, Rabbit/Mouse; DAKO, UK was used forCD134 and IL-17A visualization. Finally, 
the slides were counter-stained with haematoxylin, then mounted with DPX mounting 
medium and cover slips, and allowed to dry overnight before imaging. Positive and 
negative controls with inflamed appendix tissue for each antibody were also performed. 
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 4.10  Imaging and image analysis 
 
4.10.1 IHC 
 
ADCIS ® Stereology Toolkit frame count programme was used as before. Patient’s identity 
and the diagnosis for each slide were masked during the counting process. For IHC, a 
total of 50 count frames (instead of 20) were randomly generated by the software for all 
slide images making up a total area of 50 mm
2 analysed for every slide. As previously 
done, only stained cells within the frame and not touching the exclusion lines were 
included in the count, and the software then generated the total number of marked cells to 
generate the total count. 
 
4.10.2 Validation process for cell and tissue counts 
 
Identification of cells and tissue changes were counter checked and validated by a senior 
pathologist (secondary supervisor) who was also masked from patients’ identities and 
diagnoses. A portion of the slides were also re-counted to ensure total counts were 
reproducible. 
 
4.10.3 Data analysis 
 
Cell counts were entered into an Excel spreadsheet. The Mann Whitney test was 
performed with SPSS17 for quantitative comparisons of the individual stained cells 
between GPA and IIOD, and GPA and orbital sarcoidosis. Odds ratio was calculated via 
the 2x2 frequency table. 
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 4.11  Results 
 
4.11.1 T cell identification in orbital GPA, IIOD and sarcoidosis 
 
CD3, CD4, CD8, CD134 and IL-17A positive stained cells were found present in orbital 
GPA tissue biopsies as well as in tissue biopsies of sarcoidosis and IIOD. 
 
4.11.2 Cell count comparison between GPA and IOID 
 
Count comparison for each T cell sub-types between GPA and IIOD are summarised in 
Table 4.2 and Figure 4.1– Figure 4.5. T cells (CD3) (p=0.01, OR=1.57) and CD8 (p=0.04, 
OR=1.56) were found significantly more in orbital GPA when compared with IOID. Other T 
cell sub-sets such as CD4 and CD134 were found to be comparable between the two 
diseases. In particular,  IL-17A cytokine expression in orbital GPA was found to be 
considerably higher in GPA compared to IOID (p<0.001) and further odds ratio calculation 
revealed that a high IL-17A count in an orbital biopsy was likely to be from GPA tissues 
and not from IIOD (OR=  ). 
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 Table 4.2 Quantitative T-Lymphocyte, T- Lymphocyte Subsets and Cytokines cell 
counts and comparisons between orbital GPA and IIOD (cell count performed in 
50x1mm
2 (50mm
2) field in each case) 
Cells      Orbital GPA 
(mean +/-SEM) 
 
IOID 
(mean+/-SEM) 
 
p  OR  CI 
 
CD3 
 
5221+/-449 (130532)  3633+/-560 (90827)  0.01*  1.57  0.24 -10.30 
 
 
CD4 
 
1157+/-145 (28914)  864+/-162 (21606)  0.07     
 
 
CD8 
 
1041+/-140 (26021)  764.5+/-15.1 (19113)  0.04*  1.56  0.24 -10.30 
 
 
CD134  
 
94.6+/-18 (2365)  59+/-11 (1475)  0.09     
 
 
IL-17A 
 
 
270+/-39 (6758)  88+/-9 (2212)  <0.001*  *   
 
* = significant odds ratio 
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 4.11.3 Cell count comparison between GPA and sarcoidosis 
 
Count comparison for each T cell sub-types between GPA and sarcoidosis are 
summarised in Table 4.3 and Figure 4.1 - Figure 4.5. CD3, CD4, CD8 and CD134 counts 
were found to be comparable between these two diseases. However, marked IL-17A 
expressions were observed in orbital GPA compared to sarcoidosis (p=<0.001). Further 
odds ratio calculations revealed that a high IL-17A count in an orbital biopsy was more 
likely to be from GPA tissues, and not from orbital sarcoidosis (OR=  ). 
 
Table 4.3 Quantitative T-Lymphocyte, T- Lymphocyte Subsets and Cytokines cell 
counts and comparisons between orbital GPA and orbital sarcoidosis (cell count 
performed in 50x1mm
2 (50mm
2) field in each case) 
Cells  Orbital GPA 
(mean+/-SEM) 
 
Orbital sarcoidosis 
(mean+/-SEM) 
 
p  OR  CI 
CD3 
 
 
5221+/-449  4951+/-851 (64369)  0.5     
CD4  
 
 
1157+/-145 (28914)  955+/-198 (12422)  0.5     
CD8  
 
1041+/-140 (26021)  1015+/-267 (13200)  0.3     
CD134  
 
 
94.6+/-18 (2365)  150+/-37 (1955)  0.7     
IL-17A 
 
 
270+/-39 (6758)  71 +/-16 (924)  <0.001*  *   
 
* = significant odds ratio 
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Figure 4.1: CD3 tissue stainings. A: Negative CD3 staining on an inflammed tonsil (primary antibody 
not added, x100), B: CD3 staining on a GPA orbital tissue (HRP/DAB+, Rabbit/Mouse; x100), C: CD3 
staining on an IIOD (HRP/DAB+, Rabbit/Mouse; x100), D: CD3 staining on an orbital sarcoidosis tissue. 
(HRP/DAB+, Rabbit/Mouse; x100), E: Scatter plot of CD3 showing range of counts and standard error of 
mean  bar  for each of the three orbital diseases  with ANOVA test showing significant difference 
between them (p<0.03). Dunn’s multiple comparison revealing the main difference in CD3 cell counts 
between and GPA and IOID. 
p= 0.03 
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Figure 4.2: CD4 Tissue stainings A: Negative CD4 staining on an inflammed tonsil (primary antibody 
not added, x100), B: CD4 staining on a GPA orbital tissue . (HRP/DAB+, Rabbit/Mouse; x40), C: CD4 
staining on an IIOD tissue (HRP/DAB+, Rabbit/Mouse; x40), D: CD4 staining on an orbital sarcoidosis 
tissue (HRP/DAB+, Rabbit/Mouse; x40), E: Scatter plot of CD4 showing range of counts and standard 
error of mean  bar  for each of the three orbital diseases with ANOVA test showing no significant 
difference between them (p<0.21). 
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Figure  4.3:  CD8 tissue stainings with HRP/DAB+ A:  Negative CD8 staining on an inflammed tonsil 
(primary antibody not added, x100), B: CD8 staining on a GPA orbital tissue,  (HRP/DAB+, 
Rabbit/Mouse; x40), C: CD8 staining on an IIOD tissue (HRP/DAB+, Rabbit/Mouse; x40), D: CD8 staining 
on an orbital sarcoidosis tissue (HRP/DAB+, Rabbit/Mouse; x40), E: Scatter plot of CD8 showing range 
of counts and standard  error of mean  bar  for each of the three orbital diseases  with ANOVA test 
showing no significant difference between them (p<0.12). 
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Figure 4.4: CD134 tissue stainnigs with AP/RED A: Negative CD134 staining on an inflammed tonsil 
(primary antibody not added, x100), B: CD134 staining on a GPA orbital tissue. (AP/RED, 
Rabbit/Mouse; x40), C: CD134 staining on an IIOD tissue (AP/RED, Rabbit/Mouse; x40), D: CD134 
staining on an  orbital sarcoidosis tissue (AP/RED, Rabbit/Mouse; x40), E: :  Scatter plot  of CD134 
showing range of counts and standard error of mean bar for each of the three orbital diseases with 
ANOVA test showing no significant difference between them (p<0.16). 
p= 0.16 
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Figure 4.5: IL-17A tissue stainings with AP/RED A: Negative IL-17A staining on an inflammed tonsil 
(primary antibody not added, x100), B: IL-17 staining on a GPA orbital tissue (AP/RED, Rabbit/Mouse; 
x100), C: IL-17A staining on an IIOD (AP/RED, Rabbit/Mouse; x100), D: IL-17A staining on an orbital 
sarcoidosis tissue. (AP/RED, Rabbit/Mouse; x100), E: Scatter plot of IL-17A showing range of counts 
and  standard  error of mean  bar  for each of the three orbital diseases with ANOVA test showing 
significant difference between them  (p<0.001). Dunn’s multiple comparison revealing IL-17A 
significantly more in GPA compared to both IOID and orbital sarcoidosis. 
p <0.001 
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 4.12  Discussion 
 
In this section of the study, we were able to demonstrate the presence of CD3, CD4, CD8, 
CD134 and IL-17A in orbital GPA, sarcoidosis and IIOD tissues.  
The presence of T cells in general, found in all GPA, IIOD and sarcoidosis biopsies were 
consistent with previous reported studies demonstrating an important role of this cell in 
each of these orbital diseases. In this study, we further showed that the presence of CD3, 
CD4, and CD8 were comparable between GPA, IIOD and sarcoidosis implying that these 
immune cells have equal importance in the pathogenesis of these diseases.  
 
The IL-17A cytokine findings in our orbital GPA were particularly significant. IL-17A is now 
shown to be present in the disease process in orbital GPA like other autoimmune 
inflammatory diseases, such as rheumatoid arthritis and SLE. More importantly, the level 
of IL-17A in our orbital biopsies was markedly more in the orbital GPA compared to IOID 
and sarcoidosis, suggesting a significant role of IL-17A in orbital GPA compared to IIOD 
and orbital sarcoidosis. Thus, the presence of IL-17A is not only skewed in the serum of 
GPA patients (Abdulahad et al., 2008), but is largely expressed in orbital tissue as well. IL-
17A is a pro-inflammatory cytokine produced by Th17, a distinct sub-set of T helper cells 
of Th1 T cells and Th2 T cells(Harrington et al., 2005).Therefore, this may indirectly imply 
an active role of Th17 in the inflammatory process in peripheral tissues of GPA, instead of 
Th1 T cells and Th2 T cells, which have shown conflicting findings in the past (Balding et 
al., 2001)(Csernok, 2003).During inflammation, IL-17Ainduces release  of other 
inflammatory cytokines such as IL-6, GM-CSF, TGF-  beta and TGF-  alpha; attracting 
further immune cells such as neutrophils and lymphocytes to the target site. 
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 IL-17A  has also been suggested to have a role in the initiation and maintenance of 
granuloma formation. Indeed in sarcoidosis, expressions of IL-17A  are reported to be 
increased in circulating memory T cells and in bronchus tissue granulomas (Ten Berge et 
al., 2012). In this study however, the involvement of IL-17A in granulomas induction and 
maintenance was not mirrored  in our orbital GPA biopsies which had a higher IL-17A 
expression but with very few granuloma formations. Furthermore, the level of IL-17A was 
not significantly higher in our sarcoidosis sample. Hence, it appears that IL-17A may have 
a different mechanism in the pathogenesis of GPA compared to sarcoidosis. This may also 
account for the difference in the clinical presentation of the two diseases. 
 
In our study there were no significant difference seen in the role of CD3, CD4, CD8 and 
CD134 in orbital GPA when compared to IIOD and orbital sarcoidosis. Although we did 
find that the level of CD3 and CD8 were higher in orbital GPA compared to IIOD, the odds 
ratio did not show any marked significance in the presence of these cells, unlike in the 
kidneys affected by GPA where CD8 cells were seen more than CD4 in affected 
tissues(Aasarød et al., 2001a).In addition, it was also interesting to observe that the 
CD4/CD8 ratio within the groups were all close to one and did not show any type pre-
dominance.  This seemed to imply that both CD4 and CD8 have equal roles in the 
inflammatory process in orbital GPA, IIOD and sarcoidosis. This is unexpected, especially 
with sarcoidosis, as CD4 T lymphocytes have been documented to be dominant in this 
disease (De Jager et al., 2008)where the CD4/CD8 ratio is usually more than 2.   
 
CD134 in the orbital tissues in our study did not show a significant difference between the 
GPA and IOID, or GPA and sarcoidosis. CD134 was to be present in tissues affected by 
the GPA and is shown to be directly associated with disease activity.  (Wilde et al., 
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 2009)Unfortunately, we did not investigate this association in GPA patients. Nonetheless, 
interestingly we were unable to find any reports linking CD134 with sarcoidosis or IIOD in 
previous studies, thus to our knowledge, this study may be the first to show such 
association. 
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 5  Chapter 5: B Lymphocytes 
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 5.1  B Cells in GPA 
 
The role of B lymphocytes and memory plasma cells in immune regulation, antibody 
production and pathogenesis has been established in other auto-immune diseases such 
as systemic lupus erythematosus (Yoshida et al., 2010)(Dörner et al., 2009). Plasma B 
cells have been shown to be actively producing autoimmune antibodies in AAV, including 
ANCA (McQueen, 2012)(Jennette and Falk, 2008)(Fervenza, 2010).  
Since the success of Rituximab i.e. a chimeric monoclonal antibody against the protein 
CD20 B cells, for the treatment of GPA, B cells have become implicated in the 
pathogenesis of GPA (Ferraro AJ 2008). Indeed, the presence of B cells in GPA tissue 
biopsies have been established, where aggregates of B cells in endonasal tissue affected 
with GPA were seen present in the vicinity of PR3+ cells (J Voswinkel, 2008). In addition, 
activated peripheral B cell levels have been linked to disease activity and severity in GPA 
(Popa et al., 1999). 
In the lungs, granulomata obtained from the lower and upper respiratory tract affected by 
GPA is seen to contain follicle-like B cell clusters. It is then suggested that these 
granulomata could be the place of auto-antigen presentation, and formation of high-affinity 
ANCA could occur within these neo-formed ectopic or tertiary lymphoid-like tissue areas 
(Krämer et al., 2007). 
In the kidneys, patients with refractory renal GPA were found to respond very well with 
Rituximab, again implying the role of B cells in the disease development in this organ 
(Selamet et al., 2007).However, in one study looking at renal tissues affected by GPA, 
glomeruli were noted to have an abundance of CD8 T cells and macrophages 
Nevertheless, surprisingly no B cells were detected in the tissues (Aasarød et al., 2001a). 
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 Serum BAFF levels have also been reported to be elevated in patients with GPA and in 
nasal biopsies of patients affected with GPA, where BAFF has been shown to be present 
in these tissues (Zhao et al., 2012). Interestingly, BAFF and ANCA appear to function 
independently as shown in one study. BAFF levels were shown to be inversely correlated 
with ANCA titre indicating that BAFF does not drive ANCA production in GPA (Bader et al., 
2010). 
 
5.2  B cells in Sarcoidosis 
 
B cells have been shown to play a part in the disease development of sarcoidosis as well. 
Large B-cells infiltrate the granulomatous tissue and increased molecular signs of antibody 
maturation were said to be indicative of direct involvement of B cells in local inflammatory 
processes in patients with sarcoidosis(Kamphuis et al., 2013).  However, patients with 
severe chronic sarcoidosis were reported to have absolute B-cell lymphopenia and 
exhibited significantly decreased frequencies and total numbers of serum memory B cells. 
This is said to suggest that there is disturbed homeostasis, intrinsic signaling defects, and 
anergy within the peripheral B-cell compartments in severe chronic sarcoidosis (Lee et al., 
2011). 
Serum BAFF levels were also found to be significantly elevated in sarcoidosis patients 
when compared with healthy control patients, suggesting BAFF’s role in the pathogenesis 
of this disease (Ueda-Hayakawa et al., 2013). Patients with active disease also had a 
higher BAFF level compared to inactive sarcoidosis patients. In addition, BAFF was shown 
to be strongly correlated to the serological markers for the disease, such as serum 
hypergammaglobulinemia and angiotensin converting enzyme levels (Saussine et al., 
2012).  
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 5.3  B Cells in IIOD 
 
Reported investigations in the involvement of B cells in IIOD are scarce. In one study 
however, presence of B cells were mentioned in the histology of IIOD (McCarthy et al., 
1993). Nevertheless, the effectiveness of Rituximab in the treatment of refractory IIOD 
have been shown, thus suggesting a positive influence of B cells in the pathogenesis of 
IIOD (Shao et al., 2013). 
 
5.4  Objective 
 
Rituximab appear to be very effective in the treatment of orbital GPA, sarcoidosis, as well 
as IIOD, indicating a role of B cells in all three diseases. However, the extent of 
involvement of this cell in each disease is unclear. We wanted to discover if there exist a 
difference in the B cell presence between orbital biopsies of GPA, sarcoidosis and IIOD, 
which may aid in differentiating them apart, histologically. In addition, we also wanted to 
look at the involvement of BAFF and APRIL in these tissues.  
 
Our specific objectives in this part of the study are: 
1.  to demonstrate the occurrence of CD20, BAFF, APRIL, BAFF-R, TACI and BCMA 
in orbital tissue biopsies of GPA, sarcoidosis and IIOD, 
2.  to compare the occurrences of CD20, BAFF, APRIL, BAFF-R, TACI and BCMA 
between orbital tissue biopsies of GPA and IIOD, and 
3.  to compare the occurrences of CD20, BAFF, APRIL, BAFF-R, TACI and BCMA 
between orbital tissue biopsies of GPA and orbital sarcoidosis. 
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 5.5  Method 
 
5.5.1  Patient and Tissue Selection 
 
The same paraffin blocks from the previously selected 25 orbital GPA blocks, 25 IIOD 
blocks and 13 orbital sarcoidosis blocks were used. 
 
5.5.2  Antibodies 
 
IHC was performed for cell markers CD20cy (Clone L26; M0755, DAKO, Cambridgeshire, 
UK), cytokine BAFF (TNFSF13B Antibody, NBP1-86933, Novus Biologicals, Cambridge, 
UK)  and BAFF-R (11C1; ab16232Abcam, Cambridge, UK), IL-17 (IL-17A; AHP455G 
AbDSerotec, Kidlington, UK). 
 
We were unable to obtain a suitable APRIL, TACI and BCMA antibody within the time 
frame of this study. 
 
5.5.3  Slide Preparations 
 
Slide preparations and stainings for each antibody were performed on the same day and 
under the same laboratory conditions for all cases. Tissue sections from the blocks were 
cut using a sledge microtome at a thickness of 5 micrometer and mounted on Superfrost-
plus object glass slides. The slides were left on a hot plate at 40°C for 60 minutes and then 
incubated overnight at 37°C before use.   
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 5.5.4  Immunohistochemistry Staining of Fixed Paraffin Tissues (Table 
5.1) 
 
Tissue sections were de-waxed in two changes of xylene (each 5 to 10 minutes) with 
agitation at regular intervals, then twice with 100% ethanol (10 to 20 seconds) and then 
hydrated in 90%, 70%, and 50% ethanol, each for 10 to 20 seconds, followed by two 
washes in water. Sections were then incubated in the appropriate antigen retrieval solution 
where Tris/EDTA pH 9.0 (H-3301, Vector Labs, UK) was used for CD20, and sodium 
citrate pH 6.0 (H-3300, Vector Labs, UK) for BAFF and BAFF-R as recommended by the 
supplier. Heat induced epitope retrieval was performed using pressure cooker at 95°C. 
Slides were then cooled under running water and left immersed in Tris-buffer solution (9L 
distilled water + 1L DAKO Wash Buffer 10X, Code S3006; DAKO UK) for 5 minutes.  
 
5.5.5  Automated Staining for CD20 
 
CD20cy using concentration of 1:200; as per manufacturer recommendations,  were 
performed by the DAKO Autostainer Plus. The LSAB+ and Dako REAL™ Detection 
Systems kit (K5001 HRP/DAB+, Rabbit/Mouse) were used for visualization. Positive and 
negative controls with tonsil tissue were also performed. (Table 0.1) 
 
5.5.6  Manual Staining for BAFF and BAFF-R 
 
5.5.6.1 Manual Staining for BAFF 
 
For BAFF, after de-waxing and antigen retrieval as previously described above,  slides 
were removed from the staining rack, placed in a moist chamber and tissues were kept 
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 hydrated with Tris-buffer solution. A ring was then made around the tissues for all slides 
using a hydrophobic barrier pen (ImmEdge Pen H-4000). BAFF primary antibody, diluted 
in blocking solution at concentrations of 1:10, 1:20, 1:50, 1:100, 1:200 and 1:400, was 
added, and left to incubate overnight at 4°C.  Washing with Tris-buffer was performed after 
each incubation step. The LSAB+ and Dako REAL™ Detection Systems kit (K5001 
HRP/DAB+, Rabbit/Mouse) were used for visualization. Finally, the slides were 
counterstained with haematoxylin, then mounted with DPX mounting medium and cover 
slips and allowed to dry overnight before imaging.  
 
5.5.6.2 Manual Staining for BAFF-R 
 
Primary antibody for BAFF-R were titrated using inflamed tonsil tissues until an optimal 
tissue stain were achieved.  
After de-waxing and antigen retrieval as previously described above, slides were removed 
from the staining rack, placed in a moist chamber and tissues were kept hydrated with 
Tris-buffer solution. A ring was then made around the tissues for all slides using a 
hydrophobic barrier pen (ImmEdge Pen H-4000).  BAFF-Rprimary  antibodies at  a 
concentration of 1:50, as per supplier recommendation, diluted in blocking solution were 
added and left to incubate overnight at 4°C. Washing with Tris-buffer was performed after 
each incubation step. The LSAB+ and Dako REAL™ Detection Systems kit K5001 
HRP/DAB+, Rabbit/Mouse; DAKO, UK were used for visualization. Finally, the slides were 
counter-stained with haematoxylin, then mounted with DPX mounting medium and cover 
slips, and allowed to dry overnight before imaging. Positive and negative slides with tonsil 
tissue for each antibody were also performed. 
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 5.6  Imaging and Image Analysis 
 
5.6.1  IHC 
 
ADCIS ® Stereology Toolkit frame count programme was used as before. Patient’s identity 
and the diagnosis for each slide were masked during the counting process. For IHC, a 
total of 50 count frames (instead of 20) were randomly generated by the software for all 
slide images making up a total area of 50 mm
2 analysed for every slide. As previously 
done, only stained cells within the frame and not touching the exclusion lines were 
included in the count, and the software then generated the total number of marked cells to 
generate the total count. 
 
5.6.2  Validation process for cell and tissue counts 
 
Identification of positive stained cells were counter checked and validated by a senior 
pathologist (secondary supervisor) who was also masked from patients’ identities and 
diagnoses. A portion of the slides were also re-counted to ensure total counts were 
reproducible. 
 
5.7  Data analysis 
 
Cell counts were entered into an Excel spreadsheet. The Mann Whitney test was 
performed with SPSS17 for quantitative comparisons of the individual stained cells 
between GPA and IIOD, and GPA and orbital sarcoidosis. Odds ratio was calculated via 
the 2x2 frequency table. 
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5.8  Results 
 
 
5.8.1  T Cell Identification in Orbital GPA, IIOD and Sarcoidosis 
 
CD20 and BAFF-R were all present in orbital GPA tissue biopsies as well as in tissue 
biopsies of sarcoidosis and IIOD. 
We were unsuccessful in getting a convincing stain for BAFF in our control samples 
despite using various antibody concentrations. (Table 5.1) Attempts on staining BAFF on 
diseased tissue i.e. GPA, also did not successfully produce clear and convincing results. 
(Figure 5.3) 
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 Table 5.1: Immunohistochemistry protocol for B cells investigation 
 
Cell 
type 
 
Antigen 
retrieval 
 
Epitope 
retrieval 
 
Mode of 
staining 
 
Antibody 
concentration 
 
Incubation 
time 
(temperature) 
 
Result 
 
 
CD20  Tries/EDT
A 
 pH 9.0 
95
oHeat 
 (pressure cooker) 
Autotime
r 
1:400  _  Positive 
 
 
 
BAFF-R  sodium 
citrate  
pH 6.0 
95
oHeat 
(pressure cooker) 
Manual  1:50  24 hours 
(4
oC) 
Positive 
 
 
 
BAFF  sodium 
citrate 
pH 6.0 
95
oHeat 
(pressure cooker) 
Manual  1:10  24 hours 
(4
oC) 
Unsuccessful 
 
 
 
  sodium 
citrate  
pH 6.0 
95
oHeat 
(pressure cooker) 
Manual  1:50  24 hours 
(4
oC) 
Unsuccessful 
 
 
 
  sodium 
citrate 
pH 6.0 
95
oHeat 
(pressure cooker) 
Manual  1:100  24 hours 
(4
oC) 
Unsuccessful 
 
 
 
  sodium 
citrate  
pH 6.0 
95
oHeat 
(pressure cooker) 
Manual  1:200  24 hours 
(4
oC) 
Unsuccessful 
 
 
 
  sodium 
citrate  
pH 6.0 
95
oHeat 
(pressure cooker) 
Manual  1:400  24 hours 
(4
oC) 
Unsuccessful 
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 5.8.2  Cell Count Comparison between GPA and IOID 
 
Count comparison for CD20 and BAFF-R between GPA and IIOD are summarised in 
Table  5.2. CD20 counts were found to be similar between GPA and IIOD (p=0.2). 
However, BAFF-R levels were found to be significantly higher in orbital GPA compared to 
IIOD (p=0.01). Further odds ratio calculation showed that a high counts of BAFF-R found 
in an orbital biopsy was 7 times more likely to be from GPA tissues than from IIOD (OR= 
6.6). (Table 5.2) (Figure 5.1&Figure 5.2) 
 
 
Table 5.2: Quantitative CD20 and BAFF-R comparisons between orbital GPA and 
IIOD (cell count performed in 50x1mm
2 (50mm
2) field in each case) 
 
 
Cells 
 
Orbital GPA 
 
IOID 
 
p 
 
OR 
 
CI 
 
 
CD20  
(mean+/-SEM) 
 
 
1025+/-232  
 
1026+/-363 
 
0.2 
 
 
 
   
BAFF-R  
(mean+/-SEM) 
 
486+103 (12635)  203+/-34  0.01*  6.6*  0.64 – 55.66 
 
* = significant odds ratio 
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 5.8.3  Cell Count Comparison between GPA and Sarcoidosis 
 
Count comparison for CD20 and BAFF-R between GPA and sarcoidosis are summarised 
in Table 0.3. CD20 counts were found to be similar between GPA and orbital sarcoidosis 
(p=0.2). However, BAFF-R expressions were found to be significantly higher in orbital GPA 
compared to orbital sarcoidosis (p=0.02). Further odds ratio calculation showed that a high 
BAFF-R count in an orbital biopsy was 6 times more likely to be from GPA tissues than 
from orbital sarcoidosis (OR= 6). (Table 5.3) (Figure 5.1&Figure 5.2) 
 
 
Table 5.3: Quantitative CD20 and BAFF-R counts and comparisons between orbital 
GPA and orbital sarcoidosis (cell count performed in 50x1mm
2 (50mm
2) field in each 
case) 
 
 
Cells 
 
Orbital GPA 
 
Orbital 
sarcoidosis 
 
p 
 
OR 
 
CI 
 
 
 
CD20 
(mean+/-SEM) 
 
 
1025+/-232  
 
932+/-213  
 
0.4 
 
 
 
   
BAFF-R  
(mean+/-SEM) 
 
486+103   238+/-135   0.02*  6*  0.65 – 55.66 
 
* = significant odds ratio 
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Figure 5.1: CD20 tissue stainings with HRP/DAB+. A: Negative CD20 staining on an inflammed tonsil (primary antibody 
not added, x100), B: CD20 staining on a GPA orbital tissue. (HRP/DAB+, Rabbit/Mouse; x40), C: CD20 staining on an 
IIOD  tissue (HRP/DAB+, Rabbit/Mouse; x40), D: CD20 staining on a or orbital sarcoidosis tissue (HRP/DAB+, 
Rabbit/Mouse; x40), E: Scatter plot of CD20 showing range of counts and standard error of mean bar for each of the 
three orbital diseases with ANOVA test showing no significant difference between them (p<0.41). 
p <0.41 
A  B 
C  D 
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Figure 5.2: BAFF_R tissue stainings with HRP/DAB+. A: Negative BAFF-R staining on an inflammed tonsil (primary 
antibody not added, x100), B: BAFF-R staining on a GPA orbital tissue (HRP/DAB+, Rabbit/Mouse; x100), C: BAFF-R 
staining on an IIOD (HRP/DAB+, Rabbit/Mouse; x100), D: BAFF-R staining on an orbital sarcoidosis tissue. (HRP/DAB+, 
Rabbit/Mouse; x100), E: Scatter plot of BAFF-R showing range of counts and standard error of mean bar for each of 
the three orbital diseases with ANOVA test showing significant difference between them (p<0.001). Dunn’s multiple 
comparisons revealing BAFF-R significantly more in GPA compared to both IOID and orbital sarcoidosis. 
p <0.008 
A  B 
C  D 
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 5.9  Discussion 
 
In this section of the study, we were able to demonstrate the presence of CD20 and BAFF-
R in orbital GPA, sarcoidosis and IIOD tissues.  
 
The presence of B cells in our study corresponds with other studies that show the 
involvement of B cells in GPA. B cells not only have been documented to have a role in 
the pathogenesis of GPA, but have also been reported to have an influence in disease 
activity and severity in GPA (Popa et al., 1999)(Eriksson et al., 2010). In addition, 
Rituximab, a monoclonal anti-B cell CD20 antibody, has recently been found to be very 
effective in treating refractory AAV (Jones et al., 2010)(Khan et al., 2010)(Onal et al., 
2008a), including refractory ophthalmic GPA (Joshi et al., 2011)(Hinze and Colbert, 2008). 
Thus this further confirms the association of this immune cell in the disease process of 
GPA.  
 
We did not find a significant difference in the presence of CD20 in GPA when compared to 
IIOD and orbital sarcoidosis. This indicates that B cells may have equal significance in the 
disease process in all three orbital inflammatory diseases. We were unfortunately unable 
to establish the presence of B cell activating factor (BAFF) in our tissue biopsies despite 
following tested published protocols and varying the antibody concentrations. The failure in 
staining BAFF in our sample tissues could be due to two possibilities: (1) our tissue 
samples were archived tissues and not fresh tissues, hence it may be possible that the 
cytokine may have not been preserved thus preventing good staining, 2) the paraffin 
preparation may have degraded the fragile BAFF cytokines in our sample tissues.   
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 We were however successful in staining BAFF-R in all of our sample tissues. In one study, 
it is reported that the critical functions of BAFF in B and T cell biology are highly influenced 
by the expression of BAFF receptors on immune cells (Ng et al., 2004). BAFF-R 
specifically interacts with BAFF (Thompson et al., 2001), and has a higher affinity to this 
cytokine compared to TACI and BCMA. Thus, the positive presence of BAFF-R in these 
sample tissues indirectly suggests a positive BAFF activity in orbital GPA compared to 
IIOD and sarcoidosis. 
 
Although CD20 counts were found similar in all three diseases, our orbital GPA tissues 
were found to exhibit more BAFF-R compared to the other two diseases. Indirectly, this 
may also imply that the activity of BAFF may be higher in orbital GPA as well, compared to 
sarcoidosis. B cells indeed have been shown to be involved in the pathogenesis of auto-
immune diseases, including GPA. In addition, plasma B cells have also been reported to 
produce auto-immune antibodies including ANCA, which is linked to the pathogenesis of 
GPA. Thus, although the number of B cells may be similar in all three diseases, the 
significantly higher levels of BAFF-R found in orbital GPA suggests that the activity of B 
cells in this disease differs to that of sarcoidosis and IIOD. 
 
The marked expressions of BAFF-R seen in orbital GPA indicate a potentially higher BAFF 
level in this disease. Therefore, in GPA, although the number of B cells present in 
peripheral tissues may be similar to sarcoidosis and IIOD, these active B cells may survive 
longer and may have a more prolonged and sustained activity under the influence of 
BAFF. This may explain the difference in the manifestations and severity of orbital GPA 
compared to IIOD and orbital sarcoidosis.  
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 The presence of B cells in orbital GPA as well as sarcoidosis and IIOD also affirms the 
potential effectiveness of Rituximab treatment, which targets these cells in these diseases. 
   
195 
 5.10  B- cell staining trials 
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 5.10.1 Trails of BAFF staining at different primary antibody 
concentrations 
 
 
Figure 5.3: Unsuccessful BAFF staining on an inflamed tonsil tissues at different concentrations with 
HIER sodium citrate pH6 epitome retrieval and HRP/BAD+.  A: Unsuccessful BAFF staining (1:10 
concentration) (HRP/DAB+, Rabbit/Mouse; x40), B: Unsuccessful BAFF staining (1:50 concentration). 
(HRP/DAB+, Rabbit/Mouse; x40), C: Unsuccessful BAFF staining (1:100 concentrations). (HRP/DAB+, 
Rabbit/Mouse; x40), D: Unsuccessful BAFF staining (1:200 concentration). (HRP/DAB+, Rabbit/Mouse; 
x40) 
 
 
 
   
A  B 
C  D 
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 6  Chapter 6: Macrophages 
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 6.1  Macrophages in GPA 
 
The presence of CD68 has been demonstrated in GPA tissues (Rasmussen et al., 1990). 
Macrophages in GPA tissue biopsies have been observed to be loaded with tissue 
debris(Mackiewicz et al., 2005), and in the lungs, multinucleated giant cells are shown to 
express osteoclastic-like enzymes, said to possibly cause tissue destruction(Park et al., 
2012). In the kidneys affected by GPA, significant correlation was found for the glomerular 
infiltration of CD68-positive macrophages with the presence of glomerular necrosis, as well 
as with the number of glomeruli with crescents. In addition, a significant correlation was 
also found for the interstitial, as well as for the glomerular infiltration of CD68-positive 
macrophages with serum creatinine concentration at the time of biopsy (Weidner et al., 
2004). 
 
6.2  Macrophages in Sarcoidosis and IIOD 
 
As with GPA, macrophage phenotypes in sarcoidosis and IIOD have also not been 
extensively reported. There are almost no reports describing the involvement of different 
macrophage subtypes in the pathogenesis of IIOD. In sarcoidosis however, presence of 
CD68 in sarcoidosis have been reported and is shown to be able to help in histological 
diagnosis of sarcoidosis on small transbronchial biopsies (Menestrina et al., 
1992)(Jaskiewicz et al., 2006). In one study, CD163 was demonstrated to be expressed in 
inflammed lungs in sarcoidosis despite regarded as an M2 macrophage marker (Abdullah 
et al., 2012).  IL-23 polymorphism has also have been associated with sarcoidosis (Judson 
et al., 2012)especially in sarcoid uveitis(Kim et al., 2011).The defect in the TLR9 pathway 
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 is said to be responsible in the production of cytokine IL-23 in sarcoidosis(Veltkamp et al., 
2010). 
6.3  Objective 
 
Macrophages are the predominant cellular component in granulomatous inflammation 
which is one the main feature in the histology and pathology of GPA as well as 
sarcoidosis. However, very little data on macrophage phenotypes, either during the course 
of disease or in different organs in these diseases, exist. We therefore wanted to further 
investigate the role of macrophages in orbital GPA. 
 
The main of objective for this part of the study is: 
1.  To demonstrate the occurrence of CD68, CD163, CD204, macrophages and 
cytokine AIF1 and IL-23 in orbital tissue biopsies of GPA, sarcoidosis and IIOD 
2.  To compare the occurrences of CD68, CD163, CD204 macrophages and cytokine 
AIF1 and IL-23 between orbital tissue biopsies of GPA and IIOD 
3.  To compare the occurrences of CD68, CD163, CD204 macrophages and cytokine 
AIF1 and IL-23 between orbital tissue biopsies of GPA and orbital sarcoidosis 
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 6.4  Method 
 
6.4.1  Tissue selection 
 
The same paraffin blocks from the previous selection of 25 patients from the orbital GPA 
group, 25 patients from the IIOD group and 13 paraffin of orbital sarcoidosis were used. 
 
6.4.2  Antibodies 
 
IHC was performed for cell markers CD68 (Clone PG-M1; M0876, DAKO, Cambridgeshire, 
UK), CD163 (5C6-FAT, BM4041, Novus Biologicals, Cambridge, UK) CD204 (Macrophage 
Scavenger Receptor Antibody, NBP1-88125, Novus Biologicals, Cambridge, UK), AIF 1 
(NB100-94240, Novus Biologicals, Cambridge, UK) and IL-23 (H-113; sc-50303, Santa 
Cruz Biotechnology, Inc, Santa Cruz, CA, USA). 
 
6.4.3  Slide preparation 
 
Slide preparations and stainings for each antibody were performed on the same day and 
under the same laboratory conditions for all cases. Tissue sections from the blocks were 
cut using a sledge microtome at a thickness of 5 micrometers and mounted on Superfrost-
plus object glass slides. The slides were left on a hot plate at 40°C for 60 minutes and then 
incubated overnight at 37°C before use.   
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 6.4.4  Immunohistochemistry staining of fixed paraffin tissues (Table 6.1, 
Table 6.2,Table 6.3) 
 
Tissue sections were de-waxed in two changes of xylene (each 5 to 10 minutes) with 
agitation at regular intervals, then twice with 100% ethanol (10 to 20 seconds) and then 
hydrated in 90%, 70%, and 50% ethanol, each for 10 to 20 seconds, followed by two 
washes in water. Sections were then incubated in the appropriate antigen retrieval solution 
and primary antibodies. Staining protocols that were attempted for each antibody are 
described below. 
 
6.4.5  Automated staining for CD68 (Table 6.1) 
 
For CD68, Tris/EDTA pH 9.0 (H-3301, Vector Labs, UK) was used for antigen retrieval. 
Thereafter, heat induced epitope retrieval was performed using pressure cooker at 95°C. 
Slides were then cooled under running water and left immersed in Tris-buffer solution (9L 
distilled water + 1L DAKO Wash Buffer 10X, Code S3006; DAKO UK) for 5 minutes. IHC 
staining for CD68 (1:400) was then performed by the DAKO Autostainer Plus. Washing 
with Tris-buffer was performed after each incubation step. The LSAB+ and Dako REAL™ 
Detection Systems kit (K5001 HRP/DAB+, DAKO, UK) were used for visualization. Finally, 
the slides were counterstained with haematoxylin, then mounted with DPX mounting 
medium and cover slips and allowed to dry overnight before imaging. Positive and 
negative slides with tonsil tissue for each antibody were also performed. 
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 6.4.6  Manual staining for IL-23 staining (Table 6.1) 
 
After de-waxing, sodium citrate pH 6.0 (H-3300, Vector Labs, UK) was used for antigen 
retrieval. Heat induced epitope retrieval was performed using pressure cooker at 95°C. 
Slides were then cooled under running water and left immersed in Tris-buffer solution (9L 
distilled water + 1L DAKO Wash Buffer 10X, Code S3006; DAKO UK) for 5 minutes. Slides 
were then removed from the staining rack, placed in a moist chamber and tissues were 
kept hydrated with Tris-buffer solution. A ring was then made around the tissues for all 
slides using a hydrophobic barrier pen (ImmEdge Pen H-4000). IL-23 (1:800), diluted in 
blocking solution was added, and left to incubate overnight at 4°C. Washing with Tris-
buffer was performed after each incubation step. The LSAB+ and Dako REAL™ Detection 
Systems kit K5001 HRP/DAB+, DAKO, UK were used for visualization. Finally, the slides 
were counterstained with haematoxylin, then mounted with DPX mounting medium and 
cover slips and allowed to dry overnight before imaging. Positive and negative slides with 
tonsil tissue for each antibody were also performed. 
 
6.4.7  Manual staining forCD163 on tonsil (control tissue) (Table 6.1) 
 
6.4.7.1 Trial with variation in Protein K Antigen Retrieval timing 
 
After de-waxing, slides were removed from the staining rack, placed in a moist chamber 
and tissues were kept hydrated with Tris-buffer solution. A ring was then made around the 
tissue using a hydrophobic barrier pen (ImmEdge Pen H-4000). Proteinase K was used for 
antigen retrieval; placed on top of the tissue (within the barrier ring) and was left for 
various timings (3 minutes (recommended time by manufacturer), 5 minutes and 10 
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 minutes), to obtain the best staining. CD163 primary antibody, diluted in blocking solution 
at 1:50 concentration, as recommended by supplier, was added, and left to incubate 
overnight at 4°C. Washing with Tris-buffer was performed after each incubation step. The 
LSAB+ and Dako REAL™ Detection Systems kit K5001 HRP/DAB+, Rabbit/Mouse were 
used for visualization. Finally, the slides were counterstained with haematoxylin, then 
mounted with DPX mounting medium and cover slips and allowed to dry overnight before 
imaging. 
 
6.4.7.2 Trial variation with differing antibody concentrations (antigen 
retrieval with Protein K for 3 minutes applied) 
 
After de-waxing, slides were removed from the staining rack, placed in a moist chamber 
and tissues were kept hydrated with Tris-buffer solution. A ring was then made around the 
tissue using a hydrophobic barrier pen (ImmEdge Pen H-4000). Proteinase K was used for 
antigen retrieval; placed on top of the tissue (within the barrier ring) and was left for 3 
minutes (as per-supplier protocol). CD163 primary antibody, diluted in blocking solution at 
concentrations of 1:10, 1:20, 1:50, 1:100, 1:200 and 1:400, was added, and left to incubate 
overnight at 4°C. Washing with Tris-buffer was performed after each incubation step. The 
LSAB+ and Dako REAL™ Detection Systems kit (K5001 HRP/DAB+, Rabbit/Mouse) were 
used for visualization. Finally, the slides were counterstained with haematoxylin, then 
mounted with DPX mounting medium and cover slips and allowed to dry overnight before 
imaging. 
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 6.4.8  Manual staining for AIF1 on tonsil (control tissue) (Table 6.2) 
 
6.4.8.1 Trial with Sodium citrate pH 6.0 antigen retrieval and variation of 
primary antibody concentration 
 
After de-waxing, sodium citrate pH 6.0 (H-3300, Vector Labs, UK) was used for antigen 
retrieval. Heat induced epitope retrieval was performed using pressure cooker at 95°C. 
Slides were then cooled under running water and left immersed in Tris-buffer solution (9L 
distilled water + 1L DAKO Wash Buffer 10X, Code S3006; DAKO UK) for 5 minutes. Slides 
were then removed from the staining rack, placed in a moist chamber and tissues were 
kept hydrated with Tris-buffer solution. A ring was then made around the tissues for all 
slides using a hydrophobic barrier pen (ImmEdge Pen H-4000). AIF1 primary antibody, 
diluted in blocking solution at concentrations of 1:10, 1:20, 1:50, 1:100, 1:200 and 1:400, 
was added, and left to incubate overnight at 4°C. Washing with Tris-buffer was performed 
after each incubation step. The LSAB+ and Dako REAL™ Detection Systems kit (K5001 
HRP/DAB+, DAKO, UK) were used for visualization. Finally, the slides were 
counterstained with haematoxylin, then mounted with DPX mounting medium and cover 
slips and allowed to dry overnight before imaging. Positive and negative slides with tonsil 
tissue for each antibody were also performed. 
 
6.4.8.2 Trial with Tris/EDTA pH9.0 antigen retrieval and variation of 
primary antibody concentration 
 
After de-waxing, Tris/EDTA pH9.0 (H-3301, Vector Labs, UK) was used for antigen 
retrieval. Heat induced epitope retrieval was performed using pressure cooker at 95°C. 
Slides were then cooled under running water and left immersed in Tris-buffer solution (9L 
distilled water + 1L DAKO Wash Buffer 10X, Code S3006; DAKO UK) for 5 minutes. Slides 
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 were then removed from the staining rack, placed in a moist chamber and tissues were 
kept hydrated with Tris-buffer solution. A ring was then made around the tissues for all 
slides using a hydrophobic barrier pen (ImmEdge Pen H-4000). CD204 primary antibody, 
diluted in blocking solution at concentrations of 1:10, 1:20, 1:50, 1:100, 1:200 and 1:400, 
was added, and left to incubate overnight at 4°C.  Washing with Tris-buffer was performed 
after each incubation step. The LSAB+ and Dako REAL™ Detection Systems kit (K5001 
HRP/DAB+, Rabbit/Mouse) were used for visualization. Finally, the slides were 
counterstained with haematoxylin, then mounted with DPX mounting medium and cover 
slips and allowed to dry overnight before imaging.  
 
6.4.8.3 Trial with Proteinase K antigen retrieval 
 
After de-waxing, slides were removed from the staining rack, placed in a moist chamber 
and tissues were kept hydrated with Tris-buffer solution. A ring was then made around the 
tissue using a hydrophobic barrier pen (ImmEdge Pen H-4000). Proteinase K was used for 
antigen retrieval; placed on top of the tissue (within the barrier ring) and was left for 
various timings (3 minutes (recommended time by manufacturer), 5 minutes and 10 
minutes), to obtain the best staining. CD163 primary antibody, diluted in blocking solution 
at 1:50 concentration (as recommended by supplier), was added and left to incubate 
overnight at 4°C. Washing with Tris-buffer was performed after each incubation step. The 
LSAB+ and Dako REAL™ Detection Systems kit (K5001 HRP/DAB+, Rabbit/Mouse) were 
used for visualization. Finally, the slides were counterstained with haematoxylin, then 
mounted with DPX mounting medium and cover slips and allowed to dry overnight before 
imaging. 
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 6.4.9  Manual CD204 staining on tonsil (control tissue) (Table 6.3) 
 
After de-waxing, sodium citrate pH 6.0 (H-3300, Vector Labs, UK) was used for antigen 
retrieval. Heat induced epitope retrieval was performed using pressure cooker at 95°C. 
Slides were then cooled under running water and left immersed in Tris-buffer solution (9L 
distilled water + 1L DAKO Wash Buffer 10X, Code S3006; DAKO UK) for 5 minutes. Slides 
were then removed from the staining rack, placed in a moist chamber and tissues were 
kept hydrated with Tris-buffer solution. A ring was then made around the tissues for all 
slides using a hydrophobic barrier pen (ImmEdge Pen H-4000). CD204 primary antibody, 
diluted in blocking solution at concentrations of 1:10, 1:20, 1:50, 1:100, 1:200 and 1:400, 
was added, and left to incubate overnight at 4°C.  Washing with Tris-buffer was performed 
after each incubation step. The LSAB+ and Dako REAL™ Detection Systems kit (K5001 
HRP/DAB+, Rabbit/Mouse) were used for visualization. Finally, the slides were 
counterstained with haematoxylin, then mounted with DPX mounting medium and cover 
slips and allowed to dry overnight before imaging.  
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 Table 6.1: Immunohistochemistry protocol for macrophages investigation (CD68, IL-
23 and CD163) 
Cell 
type 
Antigen retrieval  Epitope retrieval  Mode of 
staining 
Antibody 
conc. 
Incubation 
time 
Result 
CD68  Tris/EDTA  
pH 9.0 
95
oHeat (pressure 
cooker) 
Autostaine
r 
1:400  _  Positive 
 
 
 
IL-23  sodium citrate 
pH 6.0 
95
oHeat (pressure 
cooker) 
Manual  1:800  24hours 
(4
oC) 
Positive 
 
 
 
CD163  Proteinase K  
(3 min) 
95
oHeat (pressure 
cooker) 
Manual  1:50  24 hours 
(4
oC) 
Unsuccessful 
 
 
 
  Proteinase K 
(5 min) 
95
oHeat (pressure 
cooker) 
Manual  1:50  24 hours 
(4
oC) 
Unsuccessful 
 
 
 
  ProteinaseK 
(10 min) 
95
oHeat (pressure 
cooker) 
Manual  1:50  24 hours 
(4
oC) 
Unsuccessful 
 
 
 
  Proteinase K 
(3 min) 
95
oHeat (pressure 
cooker) 
Manual  1:10  24 hours 
(4
oC) 
Unsuccessful 
 
 
 
  Proteinase K 
(3 min) 
95
oHeat (pressure 
cooker) 
Manual  1:20 
 
24 hours 
(4
oC) 
Unsuccessful 
 
 
 
  Proteinase K  
(3 min) 
95
oHeat (pressure 
cooker) 
Manual  1:50 
 
24 hours 
(4
oC) 
Unsuccessful 
 
 
 
  Proteinase K  
(3 min) 
95
oHeat (pressure 
cooker) 
Manual  1:100 
 
24 hours 
(4
oC) 
Unsuccessful 
 
 
 
  Proteinase K  
(3 min) 
95
oHeat (pressure 
cooker) 
Manual  1:200 
 
24 hours 
(4
oC) 
Unsuccessful 
 
 
 
  Proteinase K  
(3 min) 
95
oHeat (pressure 
cooker) 
Manual  1:400 
 
24 hours 
(4
oC) 
Unsuccessful 
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 Table 6.2: Immunohistochemistry protocol for macrophages investigation (AIF1) 
Cell 
type 
Antigen retrieval  Epitope retrieval  Mode of 
staining 
Antibody 
concentration 
Incubation 
time 
Result 
 
AIF1  sodium citrate pH 
6.0 
95
oHeat 
pressure cooker) 
Manual  1:10  24 hours(4
oC)  Unsuccessful 
 
 
 
  sodium citrate pH 
6.0 
95
oHeat 
(pressure cooker) 
Manual  1:20 
 
24 hours(4
oC)  Unsuccessful 
 
 
 
  sodium citrate pH 
6.0 
95
oHeat 
(pressure cooker) 
Manual  1:50 
 
24 hours(4
oC)  Unsuccessful 
 
 
 
  sodium citrate pH 
6.0 
95
oHeat 
(pressure cooker) 
Manual  1:100 
 
24 hours(4
oC)  Unsuccessful 
 
 
 
  sodium citrate pH 
6.0 
95
oHeat 
(pressure cooker) 
Manual  1:200 
 
24 hours(4
oC)  Unsuccessful 
 
 
 
  sodium citrate pH 
6.0 
95
oHeat 
(pressure cooker) 
Manual  1:400 
 
24 hours(4
oC)  Unsuccessful 
 
 
 
  Tris/EDTA pH 9.0 
 
95
oHeat 
(pressure cooker) 
Manual  1:10  24 hours(4
oC)  Unsuccessful 
 
 
 
  Tris/EDTA pH 9.0  95
oHeat 
(pressure cooker) 
Manual  1:20 
 
24 hours(4
oC)  Unsuccessful 
 
 
 
  Tris/EDTA pH 9.0  95
oHeat 
(pressure cooker) 
Manual  1:50 
 
24 hours(4
oC)  Unsuccessful 
 
 
 
  Tris/EDTA pH 9.0  95
oHeat 
(pressure cooker) 
Manual  1:100 
 
24 hours(4
oC)  Unsuccessful 
 
 
 
  Tris/EDTA pH 9.0  95
oHeat 
(pressure cooker) 
Manual  1:200 
 
24 hours(4
oC)  Unsuccessful 
 
 
 
  Tris/EDTA pH 9.0  95
oHeat  
(pressure cooker) 
Manual  1:400 
 
24 hours(4
oC)  Unsuccessful 
 
 
 
  Proteinase K (3 
min) 
95
oHeat  
(pressure cooker) 
Manual  1:50  24 hours(4
oC)  Unsuccessful 
 
 
 
  Proteinase K (5 
min) 
95
oHeat  
(pressure cooker) 
Manual  1:50  24 hours(4
oC) 
 
Unsuccessful 
 
 
 
 
  ProteinaseK(10 
min) 
95
oHeat  
(pressure cooker) 
Manual  1:50  24 hours(4
oC) 
 
Unsuccessful 
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 Table 6.3: Immunohistochemistry protocol for macrophages investigation (CD204) 
 
Cell 
type 
Antigen 
retrieval 
Epitope 
retrieval 
Mode 
of 
staining 
Antibody 
concentration 
Incubation 
time 
Result 
 
CD204  sodium 
citrate pH 
6.0 
95
oHeat 
(pressure 
cooker) 
Manual  1:10  24 
hours(4
oC) 
 
Unsuccessful 
 
 
 
 
  sodium 
citrate pH 
6.0 
95
oHeat 
(pressure 
cooker) 
Manual  1:20 
 
24 
hours(4
oC) 
 
Unsuccessful 
 
 
 
 
  sodium 
citrate pH 
6.0 
95
oHeat 
(pressure 
cooker) 
Manual  1:50 
 
24 
hours(4
oC) 
 
Unsuccessful 
 
 
 
 
  sodium 
citrate pH 
6.0 
95
oHeat 
(pressure 
cooker) 
Manual  1:100 
 
24 
hours(4
oC) 
 
Unsuccessful 
 
 
 
 
  sodium 
citrate pH 
6.0 
95
oHeat 
(pressure 
cooker) 
Manual  1:200 
 
24 
hours(4
oC) 
 
Unsuccessful 
 
 
 
 
  sodium 
citrate pH 
6.0 
95
oHeat 
(pressure 
cooker) 
Manual  1:400 
 
24 
hours(4
oC) 
 
Unsuccessful 
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 6.5  Imaging and image analysis 
 
6.5.1  IHC 
 
ADCIS ® Stereology Toolkit frame count programme was used as before. Patient’s identity 
and the diagnosis for each slide were masked during the counting process. For IHC, a 
total of 50 count frames (instead of 20) were randomly generated by the software for all 
slide images making up a total area of 50mm
2 analysed for every slide. As previously 
described, only stained cells within the frame and not touching the exclusion lines were 
included in the count, and the software then generated the total number of marked cells to 
generate the total count. 
 
6.5.2  Validation process for cell and tissue counts 
 
Identification of positive stained cells were counter checked and validated by a senior 
pathologist (secondary supervisor) who was also masked from patients’ identities and 
diagnoses. A portion of the slides were also re-counted to ensure total counts were 
reproducible. 
 
6.5.3  Data analysis 
 
Cell counts were entered into an Excel spreadsheet. The Mann Whitney test was 
performed with SPSS17 for quantitative comparisons of the individual stained cells 
between GPA and IIOD, and GPA and orbital sarcoidosis. Odds ratio was calculated via 
the 2x2 frequency table. 
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 6.6  Results 
 
6.6.1  Macrophage identification in orbital GPA, IIOD and sarcoidosis 
 
CD68 and IL-23 postive stained cells were found present in all orbital GPA tissue biopsies 
as well as in tissue biopsies of sarcoidosis and IIOD. 
We were unsuccessful in getting convincing stains for CD163, CD204 and cytokine AIF1 in 
our control samples despite using various antibody concentrations (Figure 6.7 - Figure 
6.12). 
 
6.6.2  Macrophage comparison between GPA and IOID 
 
 
Count comparison for CD68 and IL-23 between GPA and IIOD are summarised in Table 
6.4. CD68 counts as well as IL-23 were markedly higher in GPA compared to IIOD where 
p values were <0.001 for both diseases. Further odds ratio calculation showed that high 
levels of CD68 in tissue biopsy were more likely to be from GPA and not for IIOD. As for 
IL-23, odds ratio calculations showed that high levels of IL-23 in tissue biopsy were nine 
time more likely to be from GPA than IIOD in an orbital biopsy were 7 times more likely to 
be from GPA tissues than from IIOD (OR= 9.3). (Table 6.4) (Figure 6.1&Figure 6.2) 
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 Table 6.4: Quantitative CD68 macrophage and IL-23 cytokines cell counts and 
comparisons between orbital GPA and IIOD (cell count performed in 50x1mm
2 
(50mm
2) field in each case) 
 
Cells 
 
Orbital GPA 
 
IOID 
 
p 
 
OR 
 
CI 
 
CD68 
(mean+/-SEM) 
 
2202+/-216 
 
1152+/-152 
 
<0.001* 
 
* 
 
 
 
IL-23  
(mean+/-SEM) 
 
3186+/-338 
 
1461+/-208 
 
<0.001* 
 
9.3* 
 
1.05 – 82.78 
 
* = significant odds ratio (p<0.05) 
 
6.6.3  Macrophage comparison between GPA and sarcoidosis 
 
 
The count comparison for CD68 and IL-23  between GPA and orbital sarcoidosis is 
summarised in Table 6.5. CD68 counts were similar between GPA and orbital sarcoidosis 
(p=0.1). Nevertheless, IL-23 was found to be significantly higher in orbital GPA compared 
to orbital sarcoidosis (p=0.02)(Figure 5.3). Further odds ratio calculation showed that high 
levels of IL-23 in an orbital biopsy were more likely to be from GPA tissues and not from 
orbital sarcoidosis. (Table 6.5)(Figure 6.1&Figure 6.2) 
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 Table 6.5: Quantitative CD68 macrophage and IL-23 cytokines cell counts and 
comparisons between orbital GPA and sarcoidosis (cell count performed in 
50x1mm
2 (50mm
2) field in each case) 
 
 
Cells 
 
Orbital GPA 
 
Orbital 
sarcoidosis 
 
p 
 
OR 
 
CI 
 
CD68  
(mean+/-SEM) 
 
 
2202+/-216  
 
1561+/-300 
 
0.1 
   
IL-23  
(mean+/-SEM) 
 
3186+/-338   1461+/-326  0.02*  *   
 
* = significant odds ratio (p < 0.05) 
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Figure  6.1:  CD68 tissue stainings with HIER Tris/EDTA pH9 antigen retrieval and HRP/DAB+. A: 
Negative  control slide  on an inflammed tonsil (CD68  primary antibody not added, x100), B: CD68 
staining on a GPA orbital tissue (HRP/DAB+, Rabbit/Mouse; x100), C: CD68 staining on an IIOD 
(HRP/DAB+, Rabbit/Mouse; x100), D: CD68 staining on orbital tissues from patients with idiopathic 
orbital inflammatory disease. (HRP/DAB+, Rabbit/Mouse; x100), E: Scatter plot of CD68 showing range of 
counts and standard  error of mean bar for each of the three orbital diseases, with ANOVA test showing 
significant difference between them (p<0.03). Dunn’s multiple comparison revealing main difference 
between and GPA and IOID. 
p <0.002 
D 
B  A 
C 
215 
  
 
 
 
IL-23
GPA IOID Sarcoidosis
0
1000
2000
3000
4000
5000
Orbital inflammatory diseases
C
E
L
L
 
C
O
U
N
T
 
 
Figure 6.2: IL-23 tissue stainings with HIER with sodium citrate pH6 antigen retrieval and HRP/DB+. A: 
Negative control slide  on an inflammed tonsil (IL-23  primary antibody not added, x100), B: IL-23 
staining on a GPA orbital tissue (HRP/DAB+, Rabbit/Mouse; x100), C: IL-23 staining on an IIOD 
(HRP/DAB+, Rabbit/Mouse; x100), D: IL-23 staining on an  orbital sarcoidosis tissue. (HRP/DAB+, 
Rabbit/Mouse; x100), E: Scatter plot of IL-23 showing range of counts and standard error of mean bar for each of 
the three orbital diseases with ANOVA test showing significant difference between them (p<0.001). 
Dunn’s multiple comparisons revealing IL-23 significantly more in GPA compared to both IOID and 
orbital sarcoidosis. 
p <0.0001 
A  B 
C  D 
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 6.6.4  IL-17A and IL-23 correlation 
 
 
Based on our IL-17A  and IL-23 results, we further analysed the possible correlation 
between IL-17A and IL-23. All 3 groups failed to show any significant correlation between 
the 2 entities (orbital GPA p=0.9; IOID p=0.5; orbital sarcoidosis p=0.2. (Figure 6.3 - Figure 
6.5) However, in the orbital GPA group, we observed 2 outliers in our data. Upon removal 
of these data, there appear to be a possible positive significant correlation (Pearson r = 
0.43, p=0.02) between IL-17A and  IL-23, and linear regression revealed that for every 
increase of IL-23 by 8 counts there is a 100 count increase of IL-17A (p=0.04). (Figure 6.6) 
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Figure  6.3: Scatter plot for correlation analysis between IL-17  and  IL-23  in GPA. Results show no 
correlation between IL-17 and IL-23 in GPA 
 
 
Figure 6.4: Scatter plot for correlation analysis between IL-17A and IL-23 in IIOD. Results show no 
correlation between IL-17A and IL-23 in IIOD. 
 
 
Figure 6.5: Scatter plot for correlation analysis between IL-17A and IL-23 in sarcoidosis. Results show 
no correlation between IL-17A and IL-23 in sarcoidosis. 
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Figure 6.6: Scatter plot (with and without outliers) for correlation betweenIL-17A and IL-23 in GPA. 
Graph A: In GPA, two outliers (values more than 2 sd) were noted in the data (within blue circle) Graph 
B: Upon removal of these outliers (i.e. data in blue circle in graph A), there appear to be a possible 
significant positive correlation (Pearson r = 0.43, p=0.02) between IL-17A and IL-23 in GPA, and linear 
regression revealed that for every increase of IL-23 by 8 counts there is a 100 count increase of IL-17A 
(p=0.04) 
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 6.7  Discussion 
 
In this section of the study, we were able to demonstrate the presence of CD68 and IL-23 
in orbital GPA, sarcoidosis and IIOD tissues.  
 
GPA, sarcoidosis and IIOD are chronic inflammatory diseases, thus the presence of CD68 
in such tissues was expected. However, CD68 was found to be markedly elevated in GPA 
compared to IIOD. This suggests that, with the presence of more M1 macrophages i.e. 
active in inflammation, the inflammatory activity in GPA is more intense compared to IIOD.  
This may explain the more severe clinical presentation and outcome of GPA compared to 
IIOD. Macrophages also promote other immune cells to the target site during inflammation; 
hence, this may explain the more cellular presence seen in the histology of GPA compared 
to OIDs as previously seen in the early part of our study. It was also noted that the CD68 
count was comparable between GPA and sarcoidosis. This again was unsurprising as 
sarcoidosis is also a chronic granulomatous disease like GPA where macrophage activity 
and presence predominate.   
 
We were unable to get conclusive staining for CD163, CD204 and AIF1. This again could 
be due to the quality of the sample tissues that we had obtained or the possibility of protein 
degradation during paraffin tissue preparation. Furthermore, one should not discount that it 
is possible that these proteins are not present in these tissues.  
 
The significant increase in IL-23 in GPA compared to both IOID and sarcoidosis is 
particularly interesting. IL-23 is produced by macrophages and dendritic cells and its role 
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 in inflammation is primarily established as a crucial factor in the development of Th17 and 
IL-17 cytokine production (Boniface et al., 2008). Nevertheless, IL-23 alone has been 
shown to induce disease pathology. In one animal study, IL-23 was shown to be critical in 
inducing arthritis and osteoclast formation, independent of IL-17A, resulting in bone 
destruction (Adamopoulos et al., 2011). This mechanism may offer an explanation to the 
feature of bony destruction seen in orbital GPA which is not commonly seen in orbital 
sarcoidosis or IOID. Nonetheless, this would require verification by further studies. IL-23 
has also been linked to disease severity. In AAV, including GPA, patients with elevated 
levels of IL-23 had more active disease compared to those with low IL-23 (Nogueira et al., 
2010). 
In autoimmune diseases, IL-23 has been shown to drive pathogenic T cells that induce 
autoimmune inflammation by expanding self-reacting IL-17A, TNFα and IL-6 producing T 
cells  (Langrish et al., 2005). Indeed the IL-23/IL-17 pathway has been shown to be 
involved in several autoimmune diseases such as Crohn’s disease (McGovern et al., 
2009) and Vogt Koyanagi Harada disease (Chi et al., 2007). Serum IL-17 and IL-23 levels 
have been shown to be significantly more compared to healthy individuals in AAV and 
remained elevated in a proportion of convalescent patients (Nogueira et al., 2010). To the 
best of our knowledge, this is the first report to show the presence of IL-17A and IL-23 in 
inflammatory orbital tissues. In this study we not only demonstrated that IL-23 is present in 
inflammatory orbital tissues, but that IL-23 is also found to be significantly more in orbital 
GPA. There is also a probable indication of a positive correlation between IL-23 and IL-
17A in our GPA group although clarification with further studies will be required. 
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 6.8  Macrophages staining trials 
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 6.8.1  CD163staining 
 
6.8.1.1 Trial with variations in length of exposure with Protein K ( antigen 
retrieval) 
 
     
 
Figure  6.7: Unsuccessful CD163 staining on inflamed tonsil tissues with variations in length of 
exposure with Protein K as an antigen retrieval. A: Unsuccessful CD163 staining using Protein K for 3 
minutes and antibody concentration of 1:50. (HRP/DAB+, Rabbit/Mouse; x40), B: Unsuccessful CD163 
staining using Protein K for 5 minutes and antibody concentration of 1:50. (HRP/DAB+, Rabbit/Mouse; 
x40), c: Unsuccessful CD163 staining using Protein K for 10 minutes and antibody concentration of 
1:50. (HRP/DAB+, Rabbit/Mouse; x40) 
 
 
 
 
 
   
A  B 
C 
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 6.8.1.2 Trial with variations with antibody concentration (using antigen 
retrieval with protein K for 3 min) 
 
 
Figure 6.8: Unsuccessful CD163 staining on inflamed tonsil tissues with variations in antibody 
concentrations A: CD163 staining with antibody concentration of 1:10 using Protein K for 3 minutes for 
antigen retrieval. (HRP/DAB+, Rabbit/Mouse; x40), B: CD163 staining with antibody concentration of 
1:20 using Protein K for 3 minutes for antigen retrieval. (HRP/DAB+, Rabbit/Mouse; x40), C: CD163 
staining with antibody concentration of 1:50 using Protein K for 3 minutes for antigen retrieval. 
(HRP/DAB+, Rabbit/Mouse; x40), C: CD163 staining with antibody concentration of 1:100 using Protein 
K for 3 minutes for antigen retrieval. (HRP/DAB+, Rabbit/Mouse; x40), D: CD163 staining with antibody 
concentration of 1:200 using Protein K for 3 minutes for antigen retrieval. (HRP/DAB+, Rabbit/Mouse; 
x40), E: CD163 staining with antibody concentration of 1:400 using Protein K for 3 minutes for antigen 
retrieval. (HRP/DAB+, Rabbit/Mouse. 
   
A  B 
C  D 
E  F 
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 6.8.2  CD204 
 
6.8.2.1 Variation of antibody concentration with sodium citrate pH6 
epitome retrieval 
 
 
 
 
Figure 6.9: Unsuccessful CD204 staining on inflamed tonsil tissues with sodium citrate pH 6.0 and 
variations in antibody concentrations  A: CD204 staining with antibody concentration of 1:10 using 
sodium citrate pH 6.0 for antigen retrieval. (HRP/DAB+, Rabbit/Mouse; x40), B: CD204 staining with 
antibody concentration of 1:20 using sodium citrate pH 6.0 for antigen retrieval. (HRP/DAB+, 
Rabbit/Mouse; x40), C: CD204 staining with antibody concentration of 1:50 using sodium citrate pH 6.0 
for antigen retrieval. (HRP/DAB+, Rabbit/Mouse; x40), D: CD204 staining with antibody concentration of 
1:100 using sodium citrate pH 6.0 for antigen retrieval. (HRP/DAB+, Rabbit/Mouse; x40), E: CD204 
staining with antibody concentration of 1:200 using sodium citrate pH 6.0 for antigen retrieval. 
(HRP/DAB+, Rabbit/Mouse; x40), F: CD204 staining with antibody concentration of 1:400 using sodium 
citrate pH 6.0 for antigen retrieval. (HRP/DAB+, Rabbit/Mouse; x40) 
 
A  B 
C  D 
E  F 
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 6.8.3  AIF 
 
6.8.3.1 Variation with concentration using sodium citrate pH 6.0 for 
antigen retrieval 
 
 
 
 
Figure 6.10: Unsuccessful AIF staining on inflamed tonsil tissues with sodium citrate pH 6.0 and 
variations in antibody concentrations A: AIF-1 staining with antibody concentration of 1:10 using 
sodium citrate pH 6.0 for antigen retrieval. (HRP/DAB+, Rabbit/Mouse; x40), B: AIF-1 staining with 
antibody concentration of 1:20 using sodium citrate pH 6.0 for antigen retrieval. (HRP/DAB+, 
Rabbit/Mouse; x40), C: AIF-1 staining with antibody concentration of 1:50 using sodium citrate pH 6.0 
for antigen retrieval. (HRP/DAB+, Rabbit/Mouse; x40), D: AIF-1 staining with antibody concentration of 
1:100 using sodium citrate pH 6.0 for antigen retrieval. (HRP/DAB+, Rabbit/Mouse; x40), E: AIF-1 
staining with antibody concentration of 1:200 using sodium citrate pH 6.0 for antigen retrieval. 
(HRP/DAB+, Rabbit/Mouse; x40), F: AIF-1 staining with antibody concentration of 1:400 using sodium 
citrate pH 6.0 for antigen retrieval. (HRP/DAB+, Rabbit/Mouse; x40) 
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 6.8.4  Variation with concentration using Tris/EDTA pH 9.0 for antigen retrieval 
 
 
 
 
Figure 6.11: Unsuccessful AIF staining on inflamed tonsil tissues with Tris/EDTA pH 9.0 and variations 
in antibody concentrations. A: AIF-1 staining with antibody concentration of 1:10 using Tris/EDTA pH 
9.0 for antigen retrieval. (HRP/DAB+, Rabbit/Mouse; x40), B: AIF-1 staining with antibody concentration 
of 1:20 using Tris/EDTA pH 9.0 for antigen retrieval. (HRP/DAB+, Rabbit/Mouse; x40), C: AIF-1 staining 
with antibody concentration of 1:50 using Tris/EDTA pH 9.0 for antigen retrieval. (HRP/DAB+, 
Rabbit/Mouse; x40), D: AIF-1 staining with antibody concentration of 1:100 using Tris/EDTA pH 9.0 for 
antigen retrieval. (HRP/DAB+, Rabbit/Mouse; x40), E: AIF-1 staining with antibody concentration of 1:20 
0 using Tris/EDTA pH 9.0 for antigen retrieval. (HRP/DAB+, Rabbit/Mouse; x40), F: AIF-1 staining with 
antibody concentration of 1:400 using Tris/EDTA pH 9.0 for antigen retrieval. (HRP/DAB+, 
Rabbit/Mouse; x40) 
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 6.8.4.1 Variations in length of exposure with Protein K (in antigen 
retrieval) 
 
 
 
Figure 6.12: Unsuccessful AIF staining on inflamed tonsil tissues with and variations in length of 
exposure with protein K antibody. A: AIF-1 staining using Protein K for 3 minutes for antigen retrieval 
and antibody concentration of 1:50. (HRP/DAB+, Rabbit/Mouse; x40), B: AIF-1 staining using Protein K 
for 5 minutes for antigen retrieval and antibody concentration of 1:50. (HRP/DAB+, Rabbit/Mouse; x40), 
C: AIF-1 staining using Protein K for 10 minutes for antigen retrieval and antibody concentration of 
1:50. (HRP/DAB+, Rabbit/Mouse; x40) 
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 7  Chapter 7: General discussion, Limitation of Study and 
Future Direction 
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 7.1  General Discussion 
 
7.1.1  Overview 
 
GPA is generally regarded as a rare disease although recent findings have shown an 
increase  in incidence (Watts et al., 2000)(Takala et al., 2008)as well as 
prevalence(Koldingsnes and Nossent, 2000)(Gibson et al., 2006)  of the disease. The 
disease is also now seen to affect patients at a younger age (Watts et al., 2009). In 
addition, despite being more common in Caucasians, the disease is now being discovered 
more and more among other races (Kobayashi et al., 2010)(Kumar et al., 2001)(Chen and 
Kallenberg, 2010)(Singer et al., 1990)(Wu et al., 2014). GPA can affect any organ system 
in the body. In ocular GPA, the disease can affect any structure in the eye. The diagnosis 
of GPA in general, is challenging. This is because the disease manifestation mimics other 
inflammatory diseases and typically only becomes distinguishable when the disease 
advances, often in the life threatening stage, or in the case of localised GPA, at the stage 
when irreversible structural damage or disease progression to the life threatening systemic 
form, has occurred. Thus, early detection of the disease is crucial. Current advances in the 
treatments of GPA with immunomodulatory agents and biologics have improved survival 
rates in GPA dramatically, and structural and organ damage can be limited. This further 
underscores the need of early diagnosis of the disease. 
The diagnosis of GPA relies heavily on a combination of clinical presentations together 
with investigations such as serological ANCA detection, radiology appearance and 
histology evaluation. Positive investigation results are often (although not always) more 
associated with the systemic form of GPA. However, in localised GPA such as orbital 
GPA, investigations are typically negative. Nevertheless, it is important to note that 
negative investigations do not preclude the diagnosis of GPA.  
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 When possible, histology plays an important role in the diagnosis of GPA. A combination 
of granulomatous inflammation associated with geographical necrosis and vasculitis of 
small to medium size vessels in tissue biopsies, are typically associated with the diagnosis 
of GPA. Yet, in the absence of these features, particularly in small sample tissues from the 
nose or orbit, diagnosis becomes inconclusive leading to difficulty in deciding disease 
management options. Indeed, typical histology appearance are only said to be present in 
about 30% of cases (Isa et al., 2012). Thus, having a specific biomarker in the histology for 
GPA to aid early diagnosis would be advantageous. In particular, it would also be of great 
benefit to find a biomarker in localised GPA that could predict disease outcome (i.e. to 
progress to remain localised). 
Indeed, various cells have been implicated in the pathogenesis of GPA, particularly T and 
B cells. Nonetheless, many studies are directed towards serum investigations. Very little is 
done in organ tissue samples and even less in orbital tissues. 
 
7.1.2  Results in Long-term Outcome of Patients with Orbital GPA 
 
 
In the first part of the study, we looked into the long-term outcome (minimum 2 years follow 
up) of our patients with orbital GPA.  The main aim was to identify individuals who 
progressed from orbital GPA to systemic GPA over time. We discovered that patients with 
no systemic involvement at the time of presentation, i.e. patients with localised GPA, 
remained localised and did not progress to the systemic form. The two patients identified 
as systemic GPA had systemic involvement prior to the orbital presentation. This finding 
supported the notion that orbital GPA is a separate disease entity and is not necessarily a 
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 part of a widespread systemic spectrum of GPA. In contrast, patients with systemic GPA 
could progress to cause disease involvement in the orbits as seen in our 2 patients. 
We found that patients with orbital symptoms as the initial presentation of GPA (newly 
diagnosed GPA) had severe clinical symptoms and signs compared to those presented 
with a recurrence of the disease. Proptosis was the main manifestation of orbital GPA 
occurring in nearly half the patients (47.2%). This was largely due to the presence of a 
retrobulbar orbital mass pushing the eye forwards. Lacrimal gland involvement in GPA has 
not been frequently reported. However, in our study, about 30% of patients had lacrimal 
gland involvement as the first presentation of the disease. 
In general, patients with recurrent orbital GPA came with milder ocular symptoms and 
signs commonly associated with nasolacrimal  duct obstruction (77.7%). Nevertheless, 
patients with severe visual outcome were among this group of patients as well. Severe 
visual outcome was associated with patients with severe recurrence of their localised 
GPA, presenting orbital symptoms such as diplopia and proptosis. Therefore, it appears 
that, even though orbital symptoms are more severe in cases where the orbit is the initial 
presentation of GPA, but the long-term visual outcome appears to be good compared to 
cases of recurrent orbital GPA inflammation. This emphasise the need for early diagnosis 
and prompt advocation of appropriate  treatment in the initial stages of the disease 
development, to prevent permanent organ damage and functional loss.  Interestingly, 
symptoms of facial pain may be an initial clue for disease recurrence of the orbit in GPA, 
seen occurring only in the known GPA group in this study. 
A small proportion of patients i.e. seven out of 36 of patients (20%), were successfully 
stabilised with only corticosteroids, however the majority still required second line 
immunosuppressants along with corticosteroids for disease control.  ANCA was only 
positive in 60% of patients in this study, which is consistent with other reported studies 
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 (Tarabishy et al., 2010). This highlights the poor reliability of this test for the diagnosis of 
orbital GPA and the need for a more distinctive marker for the disease.  
 
7.1.3  Histology of Orbital GPA Compared to Other OIDs 
 
 
As none of our patients with localised GPA progressed to the systemic form  of the 
disease, we were unable to look for possible prognostic biomarkers in the histology of 
orbital GPA. However, we proceeded to look for the histological differences between 
orbital GPA and OIDs. 
We found  that general cellular activities in orbital GPA were markedly elevated when 
compared to OIDs. This was seen true when  subjective comparison was done with 
histopathology reports, as well as with objective cellular counts. It is particularly important 
to note that this comparison was made between the cells in orbital GPA alone with the 
combined cellular counts from all other OIDs. This highlights the intensity of inflammation 
that occurs in orbital GPA, reflecting the more severe clinical presentation of the disease 
compared to OIDs.  
Typical histology changes associated with GPA, such as granulomatous inflammation, 
necrosis and vasculitis, were also features seen in most of our GPA biopsies. However in 
a number of our GPA tissue samples, some of these characteristic histologic features of 
GPA  were  not seen. Despite vasculitis and necrosis being shown to be independently 
associated with the diagnosis of orbital GPA in this study, necrosis was not observed in 
the histology of about 31% of our GPA patients (n= 12), and 5 of these patients (13% of 
total GPA patients) did not have both the features of necrosis and vasculitis in their tissue 
biopsies. This shows that necrosis and vasculitis are not consistent attributes found in 
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 GPA orbital biopsies thus are unreliable features  for diagnosis. In addition, distinct 
granuloma formation was shown to be inversely associated with the diagnosis of orbital 
GPA in this study. Therefore, it can be postulated that, orbital biopsies from an orbital 
inflammatory disease that portrays presence of granuloma in the histology; associated with 
absent or minimal vasculitic and necrotic features, are indicative of a diagnosis of other 
OIDs and not orbital GPA. 
From this point we wanted to further see if specific immune cell subtypes differ in orbital 
GPA that could account for the disease development. In particular, we wanted to compare 
these cell sub-type activities with sarcoidosis and IIOD. These two diseases were chosen 
on the basis that sarcoidosis share a similar disease process as GPA, which is 
granulomatous inflammation, and is always the reference point for typical granulomatous 
diseases. IIOD on the other hand, has similar disease presentations as GPA, both often 
very difficult to clinically distinguish apart. 
 
7.1.4  T Cells in GPA 
 
The role of T cells in the pathogenesis of GPA is well investigated and reported. CD4 has 
particularly been implicated in the disease development of GPA largely due to the 
granulomatous nature of the disease. CD8 also has been shown to predominate in kidneys 
affected by GPA, as well as having a prognostic value. Kidneys with CD8 presence are 
said to have a worse renal prognosis in GPA compared to kidneys without CD8 presence. 
However, in our study sample, all main T cell sub-types (Cd4 and CD8) were comparable 
in all three diseases.  
The main element that was found to be significantly elevated in orbital GPA when 
compared to sarcoidosis and IIOD was cytokine IL-17 (p<0.001). In addition, a high IL-17 
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 in tissue biopsies were more likely to be from orbital GPA and unlikely from sarcoidosis 
and IIOD. IL-17 has indeed recently become the center of attention as the key player for 
many other auto-immune diseases as well as systemic GPA(Kallenberg, 2011a)(Berden et 
al., 2009). Our findings were consistent with these results suggesting that IL-17 has a 
significant role in the pathogenesis of orbital GPA as well. To our knowledge this is the first 
study to show the presence of IL-17 in orbital inflammatory disease tissues. 
We also looked into the presence of CD134, a member of the TNFR superfamily, shown to 
be present in nasal biopsies affected by GPA. We succeeded in establishing the presence 
of CD134 in orbital biopsies of GPA, sarcoidosis and IIOD in our study, again, possibly the 
first study to do so. However, we did not see a significant difference in this cell’s presence 
between the three diseases, indicating that the influence of CD134 in the inflammatory 
process of these orbital diseases is similar. 
Although our study is not focused on the orbital sarcoidosis, we did discover an interesting 
finding. From the orbital sarcoidosis samples in our study, we did not observe an elevated 
CD4/CD8 ratio that is usually associated with the diagnosis of the disease using BALF. 
Furthermore,  IL-17  is mainly associated with granuloma formation (Ten Berge et al., 
2012), but this was not reflected in our study. IL-17 was markedly more in GPA that is 
inversely associated with granuloma, and sarcoidosis did not portray an elevated IL-17 
despite being associated with granuloma formation. This may indicate that the involvement 
of T cells in orbital sarcoidosis may somewhat differ, although further investigations would 
be required to confirm this. 
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 7.1.5  B Cells in GPA 
 
B cells were found in all sample tissues from all three diseases. This affirms the 
effectiveness of  Rituximab  as a treatment option for these diseases. We were 
unfortunately unable to properly investigate the presence and extent of BAFF in these 
orbital diseases. However, the presence of BAFF-R was markedly higher in orbital GPA 
than sarcoidosis and IIOD. BAFF activity is indeed dependent on the presence of B cells 
as well as BAFF receptors. BAFF-R is one of the TNF receptors with a high affinity for 
BAFF. Due to this, it could be concluded that the high BAFF-R level in GPA could 
indirectly suggest a high BAFF activity as well. The function of BAFF is to prolong the 
survival of B cells as well as maintain its activity. Increased activities of B cells have been 
associated with auto-immune diseases presumably from the over-production of auto-
immune antibodies, including ANCA. Therefore, although CD20 B cells are similar in all 
three orbital inflammation, it is possible that in GPA, the more severe presentation of the 
disease is due to the higher inflammatory activity as a result of longer surviving B cells with 
a more sustained inflammatory activity, influenced by BAFF. 
 
7.1.6  Macrophages in GPA 
 
CD68 and IL-23 was seen present in all three orbital diseases. However, CD68 were only 
significantly higher in GPA when compared to IIOD. The presence of CD68 was 
comparable between GPA and sarcoidosis. Indeed, both GPA and sarcoidosis are 
described as granulomatous diseases and not typically a characteristic of IIOD, although 
some granulomatous changes can be observed in this disease. Thus, the low CD68 count 
in orbital IIOD compared to GPA was not unexpected. We were unfortunately unable to 
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 successfully determine the role of M2 macrophages (CD163 and CD204) as well as 
cytokine AIF1 in GPA, sarcoidosis or IIOD. 
The main finding in this section of the study was the presence of IL-23.To the best of our 
knowledge; this is the first evidence of IL-23 presence in orbital tissues. More importantly, 
IL-23 was found to be significantly more in orbital GPA compared to IIOD and sarcoidosis. 
In addition, we calculated that the high IL-23 count in tissue biopsies was 9 times more 
likely to be from orbital GPA compared to IIOD, and not likely from sarcoidosis. IL-23 
indeed has been established in disease development in auto-immune diseases like GPA 
(Nogueira et al., 2010).  IL-23  is  one of the key factors in IL-17  production via Th17 
(Boniface et al., 2008), thus indirectly influences an inflammatory reaction. It has been 
shown to be elevated in serum AAVs including GPA. Although there is a suggestion of a 
possible correlation between IL-17 and IL-23 in our study, we were not able to conclusively 
prove it. 
Apart from its association with IL-17, IL-23 itself has also been independently linked to 
disease development i.e. inducing arthritis and bone destruction (Adamopoulos et al., 
2011). This may explain the bony destruction seen in orbital imaging and cartilage 
destruction in the nose (saddle nose deformity) seen in GPA but not in IIOD or sarcoidosis. 
Indeed, in orbital imaging, nasal symptoms, radiological evidence of orbital and paranasal 
bony destruction is strongly associated with the diagnosis of orbital GPA.  
 
7.1.7  Overall Conclusion 
 
 
The main aim of this study was to attempt to identify a biomarker that could be used to 
predict  disease outcome in orbital GPA  by comparing the  histology of patients whose 
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 localised disease  progressed  to the systemic form of GPA;  to those whose disease 
remained localised  in the orbit. We found that in  our sample population,  patients  who 
presented with localised orbital GPA with no systemic disease and did not progress to 
involve other organ systems. Thus orbital GPA might be regarded as a distinct disease 
entity associated with the systemic disease. Early recognition of this disease and prompt 
appropriate treatment is key in the prevention of permanent ocular damage and functional 
loss. ANCA serology is an unreliable diagnostic tool for the diagnosis of orbital GPA. 
 
Histology examination none the less showed a difference between orbital GPA biopsy and 
biopsies of OIDs. GPA biopsies portrayed  a  more increased  and  intense inflammatory 
activity compared to OIDs evidenced by higher immune cell counts and tissue changes 
seen. Necrosis and vasculitis in particular were associated with the diagnosis of orbital 
GPA in H&E tissue staining but it is important to note that a proportion of the GPA tissue 
samples did not displayed these changes, making them an unreliable disease indicator. 
Immunohistochemical staining showed that the main differences found in immune cells 
activity, between GPA, IIOD and sarcoidosis biopsies, were not among the main immune 
cell subtypes,  such as  T and B cell subtypes  (e.g.  CD3, CD4, CD20 etc.).    Instead, 
significant differences were seen within the cytokine activities. IL-17, BAFF-R (most likely 
reflecting BAFF activity) and IL-23 cytokines were found significantly more in orbital GPA 
tissues compared to sarcoidosis and IIOD. The IL-23/IL-17 axis may play a role in the 
disease development of GPA although a positive correlation between these two cytokines 
was notable to be established in our sample population. Also, B cells survival and activity 
appear to be prolonged in GPA, via the influence of BAFF, which may explain the clinical 
severity of the disease compared to IIOD and sarcoidosis. The significant levels of these 
cytokines present in GPA compared to IIOD and sarcoidosis  suggests  that, to  some 
extent, cytokines IL-17, IL-23 and BAFF in orbital biopsies may have a diagnostic value for 
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 the diagnosis of orbital GPA. Therefore, in an orbital biopsy, the presence of these 
cytokines  within  the tissues, together with  positive clinical correlations,  may indicate a 
higher possibility for the diagnosis of orbital GPA rather than IIOD and sarcoidosis. 
 
7.2  Limitation of Our Study 
 
Our study has some limitations. Firstly, all specimens used were archived tissue biopsies. 
This may impact the quality of the tissue staining that was done, although we succeeded 
to produce positive staining and obtain results for most of the target cells and proteins we 
aimed for. Secondly, our study only demonstrates the presence of these cells and 
cytokines in these tissues but do not demonstrate the active role or mechanism of action of 
these entities in the disease development.  In addition, performing double staining, 
fluorescence staining or in situ hybridisation would be helpful to properly identify the cell 
origin of these  proteins tested.  Correlation between the cytokine count and clinical 
outcome would also have been of benefit to provide more information on the influence of 
these entities in the disease process in orbital GPA. 
 
7.3  Future Directions 
 
In the process of this study we discovered that orbital GPA is a distinct disease entity and 
may not have systemic involvement, suggesting a favourable survival outcome for patients 
with orbital GPA. Early diagnosis and prompt treatment can prevent permanent  organ 
damage and visual  loss.  Histology shows that the immune activities in orbital GPA 
biopsies are more marked compared to other OIDs, and together with the typical clinical 
course of the disease, this suggests a distinct mechanism of action in its diseases 
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 development. Therefore continuous studies looking into the pathogenesis of this disease 
are necessary and important.  
 
We were successful in showing that there is a difference in the activity of immune cells and 
cytokines between GPA and IIOD as well as with sarcoidosis. We noted that the significant 
differences were observed not among the main inflammatory cells subtypes; such as CD4, 
CD8 and CD20, but in other biological factors that influence inflammation such as cytokine 
IL-17, IL-23 and indirectly BAFF; by the presence of BAFF-R. Thus it is hoped that further 
studies could follow on from this where, future investigations should be directed towards 
looking into the function of proteins such as IL-17 and IL-23 in the pathogenesis of GPA. A 
prospective study of a similar nature i.e. comparing between GPA and OIDs, using fresh 
tissues biopsies, taken at or nearing the time of disease presentation, while inflammation 
is still active  would be the best way forward. Ideally, biopsy should be done prior to 
advocating immunosuppressants to display the true picture and activity of the inflammatory 
cells. In addition, staining for cells with IL-17 receptors and IL-23 receptors instead of the 
IL-17 and IL-23 cytokines would more likely yield better stainings and results. Following 
from that, hopefully, better understanding of the disease process in orbital GPA and GPA 
in general, will be achieved. 
 
This study hopefully, may also assist physicians in the future management decisions for 
patients with orbital GPA. The significant role of BAFF and B cells in GPA biopsies affirms 
the effectiveness of medications that target B cells lymphocytes such as Rituximab. The 
use of this treatment in GPA could be considered earlier in disease development, and not 
just for refractory cases, particularly in cases where GPA is affecting life threatening 
organs. 
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Lastly,  this study may hopefully lead to  the development of better targeted treatment 
options for GPA in the future. Drugs targeting the IL-17 pathway or theIL-23/IL-17 axis; 
that possibly have a significant role in the disease process could be an effective mode of 
treatment  for this disease. This not only will provide another treatment option in the 
management of GPA, but may also potentially be lifesaving. 
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 9.1  Appendix A 
 
9.1.1  Cells and tissue change examples and descriptions on H&E stained 
tissues 
 
 
9.1.1.1 Lymphocytes 
 
 
Figure 9.1: Lymphocytes (arrows) 
 
Lymphocytes are white blood cells. They make up about 20-50% of total white blood cells 
in the human body. They originate from the bone marrow.  
Lymphocytes are made up of 3 main cells (agranulocytes) type namely T cells, B cells and 
natural killer cells. Microscopically and on H&E staining, a normal lymphocyte is distinct 
from other white blood cells by having a large, dark-staining nucleus with little to no 
eosinophilic cytoplasm. This coarse, dense lymphocyte nucleus is approximately 7μm in 
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 diameter, about the size of a red blood cell. Occasionally a clear halo-like perinuclear zone 
around the nucleus is seen in some lymphocytes or could portray a small clear zone to 
one side of the nucleus. It is not possible to distinguish between T cells and B cells in H&E 
stain. Lymphocyte phenotypes can be determined via their specific cell surface protein 
such as cluster of differentiation (CD) markers like CD4 T cells and CD20 B cells, or by the 
production of particular proteins like cytokines.  
Lymphocytes play an integral part of the immune system where their main function is to 
defend the body against pathogens such as bacteria, parasites and viruses; cancer cells 
as well as foreign materials. Apart from circulating in the blood and lymph fluid, 
lymphocytes can also be found in organs such as the spleen, thymus, tonsils, liver, bone 
marrow and lymph nodes. The immunity against antigens by lymphocytes is achieved by 2 
main immune responses which are the cell mediated immunity; mainly by T cells function, 
and humoral  (antibody-driven) adaptive immunity, mainly by B cells. In general cells, 
mediated immunity focuses on the active destruction of infected or cancerous cells, while 
the humoral immunity focuses on identifying antigens prior to cell infection and antibody 
production. 
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 9.1.1.2  Plasma cells 
 
 
Figure 9.2: Plasma cells (arrows) 
 
Plasma cells are also known as plasma B cells, plasmocytes, and effector B cells. They 
are differentiated mature B cells that are specialised for the production of large volumes of 
antibody (immunoglobulins). Plasma cells originate from the bone marrow and move freely 
in connective tissues. In the peripheral blood plasma cells constitute about 0.1-3% 
leucocyte count in bone marrow. Plasma cells have distinctive microscopic features which 
are easily identified on H&E tissue staining. Morphologically, they are typically large 
lymphocytes which are oval in shape measuring 10-20μm.  They  have  a  considerable 
nucleus-to-cytoplasm ratio, where the cytoplasm is deeply basophilic, reflecting the 
ribosomal content of the cell, and an eccentric nucleus. The nucleus contains within it 
heterochromatin that alternates with light areas giving rise to a cartwheel or clock face 
feature which is characteristic of the cell. Plasma cells produce antibodies that are 
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 released locally in tissues or in the blood circulation and are essential for defence against 
infections. 
 
9.1.1.3  Eosinophils 
 
 
Figure 9.3: EosInophils (arrows) 
 
Eosinophils are granulocytic white blood cells. Originating from the bone marrow, they 
form about 2-6% of the human white blood cells. They are about 12-17 μm in size based 
on microscopic examination. They are acid loving, hence the term “eosinophilic”, a 
property that is responsible for the brick red appearance of the cell on staining with eosin. 
Eosin staining on these cells is also mainly concentrated in the small granules within the 
eosinophil cytoplasm; thus making the cell appear granulated microscopically. These 
granules contain histamines and cytotoxic proteins and play a role in pathogen eradication 
and inflammation. Apart from these features, eosinophils are also characterised as having 
lobed nucleus, either two or four lobes. In the circulation, they persist for about 8-12 hours 
but in tissues they can survive for up to12 days even without active stimulation. 
Eosinophils can be found in the thymus, lower gastrointestinal tract, uterus, ovary, spleen 
and lymph node. Their presence in other organs is usually associated with disease. 
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 Development and maturation of eosinophils is in response to cytokines IL-3,  IL-5  and 
granulocyte macrophage colony stimulating factor (GM-CSF). One of the main functions of 
eosinophils is during parasitic infection. During invasion, these cells can degranulate 
releasing the cytotoxic proteins and together with IgE antibody, eradicate the pathogen. 
Other functions include destruction of tumour cells, regulating other immune cells functions 
such T and B lymphocytes via becoming an antigen presenting cell, and also promote 
damage tissue repair. Together with mast cells, they are also play a part in allergic 
reactions. 
 
9.1.1.4  Neutrophils and nuclear debris 
 
 
Figure 9.4: A: Neutrophils (yellow arrows) and B:Nuclear debris (red arrows) 
 
Neutrophil granulocytes; also known as neutrophils are formed from stem cells in the bone 
marrow. They make up the majority of the phagocytes in humans, constituting 40% to 75% 
of total white blood cells. Together with eosinophils and basophils, they form the 
polymorphonuclear cells characterised by their multilobulated nucleuses. Generally, 
neutrophils have an average diameter of 8-15 µm and contain a nucleus divided into 2–5 
lobes. The separated lobes are connected to one another by chromatin. The name 
A  B 
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 neutrophil derives from staining characteristics on haematoxylin and eosin (H&E) 
histological or cytological preparations. In contrast to eosinophils which stain bright red 
and basophils that stains dark blue, neutrophils stain with a neutral pink hue. Neutrophils 
are short-lived and highly motile. In the initial phase of inflammation i.e. acute 
inflammation, either due to infection, trauma or cancer; neutrophils are seen as the first 
and main responders migrating from blood vessels to the site of attack or injury. The 
migration of neutrophils through interstitial tissues is influenced by chemical signals such 
as IL8, C5a and leukotriene B4, where this process is termed as chemotaxis. Neutrophils 
recruitment to the site of injury occurs within minutes, and these cells are the hallmark of 
acute inflammation. Nuclear debris is believed to be fragments of neutrophils left after 
degradation during an inflammatory process. This however this remains uncertain. In pus, 
neutrophils are the predominant cells seen, accounting for its whitish/yellowish 
appearance. 
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 9.1.1.5  Mast cells 
 
 
Figure 9.5: Mast cells (arrow) 
   
Mast cell is a granulocytic cell found in mast tissues and mainly found surrounding blood 
vessels and nerves. They appear mostly in tissue layers with close contact to the external 
environment such as the skin, intestinal lining, lung mucosa, mouth, nose and also 
conjunctiva. Mast cells have similar properties to basophils from the white blood cell family 
in that both contain granulated cells within them containing histamine and heparin. Mast 
cells are generally known for their role in allergies and anaphylaxis reaction via interaction 
with immunoglobulin E (IgE) resulting in histamine release. Apart from this, they also have 
a protective role particularly against intestinal worn infestations. 
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 9.1.1.6  Macrophages and giant cells 
 
 
Figure 9.6: Macrophages in the form of epithelioid cells forming a multinucleated 
giant cell 
   
Macrophages are large specialised cells of the immune system. It has the ability to 
recognise, engulf and ingest pathogens and target cells. Macrophages are differentiated 
circulating monocytes that change into macrophages upon migration and entry into 
affected tissues or organs. Thus macrophages provide the first line of defence from 
infection  in  tissues.  Macrophages  are  about  21μm  in  size  and  can  survive  for  several 
months. Activated macrophages can transform in shape resembling epithelial cells known 
as  epithelioid  cells. These cells appear elongated with pale granular eosinophilic 
cytoplasm with an ovoid nucleus. The shape and contour of epithelioid cells are non-
distinct  but these cells  often aggregate into one another forming giant cells. Further 
organisation of these cells is the basis of granuloma formation.  
 
271 
 9.1.1.7  Granuloma 
 
 
Figure 9.7: Granuloma (arrows) 
   
Granulomas are an organised collection of immune cells, predominantly constituting 
macrophages. It is an immune response to attempt to wall off foreign materials in the body 
which were not or cannot be eliminated. These foreign materials include bacteria, fungi or 
foreign materials such as suture fragments. All granulomas, regardless of cause, could 
contain a number of other immune cells and matrix. These other immune cells include 
neutrophils, lymphocytes, eosinophils, giant cells, fibroblasts and may also have fibrosis 
formation within it. The additional cells may sometime indicate the cause of the granuloma 
formation e.g. neutrophil presence in aspiration pneumonia, eosinophils in fungal 
infections, etc. Granulomas can be present in a wide variety of disease, in either infectious 
or  non-infectious  pathology. In infections, granuloma formations can be seen in 
tuberculosis. Leprosy, histoplasmosis and catch scratch diseases. Sarcoidosis, 
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 rheumatoid arthritis, GPA and eosinophilic GPA (Churgg-Strauss syndrome) are some 
non-infectious  conditions that could portray granuloma formations in its histology. 
Granuloma can also show different characteristics morphologically. A necrotic granuloma 
for example is seen as a granuloma containing dead cells, appearing as a mass of 
formless debris with no nuclei present.  Caseous granuloma is termed for granuloma with 
a central “cheese like“(caseation) appearance, usually (although not always) seen in 
tuberculosis infection. 
 
9.1.1.8 Vasculitis 
 
 
Figure 9.8: Vasculitis 
   
Vasculitis infers inflammation and damage to blood vessel walls. The blood vessel 
involved can either be capillaries, venules, arterioles, arteries and even large veins. 
Pathologically, vasculitis is divided according to the size of the vessels involved namely, 
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 small vessel vasculitis, medium vessel vasculitis and large vessel vasculitis. In small 
vessel vasculitis, the pathology can further be associated with either a positive ANCA 
association such as in GPA and MAP or a negative ANCA association such as Henoch- 
Sconlein purpura, infective induced or drug related hypersensitivity vasculitis. Diseases 
associated with medium vessel vasculitis include PAN and Kawasaki disease although in 
GPA, vasculitis if medium size vessels have been noted. Large vessel vasculitis is seen in 
Takayasu disease and giant cell arteritis.  
There are different types of inflammation that can occur in the walls of the affected vessel. 
Neutrophilic vasculitis results in necrosis of the blood vessel wall (termed necrotising 
vasculitis) where fibrin deposition (fibrinoid necrosis) and neutrophil infiltrations are seen. 
In giant cell vasculitis affecting large vessels, histiocytic (macrophage) infiltrations are 
seen in the vessel wall with formation of multinucleated giant cells observed. 
Granulomatous vasculitis is associated with histiocytic granuloma formation adjacent to 
the damaged vessels and lymphocytic vasculitis demonstrates vessel wall infiltration with 
lymphoid cells. 
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 9.1.1.9 Fibrosis 
 
 
Figure 9.9: Fibrosis 
   
Fibrosis is the generally a formation of excess fibrous connective tissue in an organ or 
tissue. It is usually a reparative sequelae of tissue damage; either from trauma, 
inflammation or infection. The process is similar to scarring where it involves laying down 
collagen, glycosaminoglycan as well as other connective tissues. TNF Beta is mainly the 
stimulating protein for this process where it stimulates the activation and proliferation of 
fibroblast. Activated fibroblasts will in turn deposit connective tissues. Fibrosis is usually 
benign however it can cause structural damage and organ dysfunction. 
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 9.1.1.10 Necrosis 
 
 
Figure 9.10: Necrosis (arrow) 
 
Necrosis is an irreversible cell injury resulting in cell and tissue death. Factors that could 
cause tissue necrosis include ischaemia, physical agents like trauma, chemical agents like 
toxins and immunological injury during infections and inflammation. Histologically necrosis 
is the combination of morphologic changes following cell death in living tissues or organ. 
The course of necrosis involves denaturation of intracellular proteins as well as digestion 
of cells by enzymes. Changes that are seen are usually observed in both cytoplasm and 
nucleus. The cytoplasm generally becomes  homogenously  glassy  in appearance with 
vacuolation. There is also calcification of dead cells and increased eosinophils in the 
cytoplasm as well as appearance of myelin figures and generation of calcium soaps. 
Nuclear changes undergo three main changes which are karyolysis, where there is fading 
276 
 of basophilia of chromatin due to DNA activity; pyknosis, which is nuclear shrinkage and 
increased basophilia; and karyorrhexis, a process of fragmentation of pynknotic nucleus.  
There are several types of necrosis namely; coagulative necrosis, liquefactive necrosis, 
caseous necrosis, fat necrosis, gangrenous necrosis and fibrinoid necrosis. Coagulative 
necrosis can occur in any tissue except the brain and is generally due to blood loss. 
Tissue becomes firm and microscopically cells outlines are preserved but appear ghostly 
and tissues look generally red. Liquefactive necrosis is commonly associated with 
infection, and also in brain infarcts. Grossly tissues become liquefied and creamy yellow 
(pus). Microscopically neutrophils are seen to predominate among dead cellular debris. 
Caseous necrosis is usually associated with tuberculosis. Tissues turn cheese like in 
appearance and histologically granuloma formations are seen. Fat necrosis occurs in 
acute pancreatitis. The enzyme lipase contained in pancreatic cells is released during 
necrosis and splits triglycerides within fat cells. Grossly, chalky white areas resulting from 
fatty acids and calcium (saponification) combination is seen. On microscope examination, 
shadow outlines of dead fat calls, which have basophilic features can be observed. 
Fibrinoid necrosis has been associated with GPA and affects vessels. It consists of a 
complex of antigens, antibody and fibrins. Microscopically vessel walls appear thickened 
and pinkish red. Gangrenous necrosis occurs when an entire limb losses blood supply and 
dies. Skin looks discoloured and dead, and underlying tissues become decomposed. 
Histologically, coagulative necrosis occurs and in an event where infection sets in, 
liquefactive necrosis results. 
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Abstract 
Wegener's granulomatosis (newly renamed granulomatosis with polyangiitis [WG/GPA]) is a 
granulomatous autoimmune inflammatory disorder of unknown etiology that is associated with anti-
neutrophil cytoplasm antibodies. It can involve any organ system, but most commonly affects the 
respiratory and renal systems and the head and neck, including the eye. The ophthalmic 
manifestations of WG/GPA are diverse and can affect any of the ocular structures. Despite 
continuing research, the exact pathogenesis of WG/GPA remains elusive, but there is increasing 
awareness of the disease, especially as its prevalence and incidence are both on the rise. 
Unhelpfully, the diagnosis and management of WG/GPA remains a challenge, especially in its 
limited form, as blood tests, imaging and tissue biopsies are often negative or nonspecific. 
Nevertheless, the emergence of new treatment regimens for WG/GPA, particularly target-specific 
drugs such as rituximab, the anti-CD20 antibody, is bringing promise in providing patients with 
better and potentially safer treatment for the disease. 
Introduction 
Granulomatosis with polyangiitis (previously known as Wegener's granulomatosis, Wegener's 
granulomatosis/granulomatosis with polyangiitis [WG/GPA]) is a multisystem granulomatous 
inflammatory disorder with vasculitic and necrotic manifestations, and is presumed to be of 
autoimmune origin.
[1] It was initially described by Heintz Klinger, a medical student, in 1931, but the 
disease was later named after a German pathologist, Frederick Wegener, who defined the disorder 
and clearly distinguished it from other inflammatory diseases such as polyarteritis nodosa.
[2,3] 
The pathology of WG/GPA is characteristically described as a granulomatous necrotizing 
inflammation and pauci-immune vasculitis of the small- to medium-sized blood vessels (Figure 1). 
WG/GPA can affect any organ system but has a tendency to affect the upper and lower respiratory 
tract system and the kidneys. Together with Churg–Strauss syndrome, microscopic polyarteritis 
(MPA) and renal limited vasculitis, WG/GPA has been demonstrated to have a strong association 
with antineutrophil cytoplasm antibody (ANCA), although not all cases may be accompanied with a 
positive ANCA serology. This group of disorders is known collectively as the ANCA-associated 
vasculitides (AAV). In the eye, the manifestations of WG/GPA are variable, but can involve any 
ocular structure. Indeed, ocular involvement occurs in up to 60% of WG/GPA patients and not 
infrequently forms the initial presentation of the disease.
[4] 
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 Figure 1. 
  
Wegener's granulomatosis/granulomatosis with polyangiitis. (A) Vasculitis (arrowed) and 
granulomatous infiltrates are apparent. (B) High-power photograph of a vasculitic blood vessel 
demonstrates neutrophil infiltration of the vascular wall. Eosinophils and lymphocytes are also 
present. (C) Typical granulomatous infiltration is apparent. 
Epidemiology 
The overall annual incidence of WG/GPA is estimated to be approximately 4–8.8 cases per million, 
but this varies depending on location; in the UK, the annual incidence of WG/GPA is reported as 
being at the higher end of the scale at 8.4 cases per million.
[5] WG/GPA has been reported 
throughout the world,
[6–9] but is more common among Caucasians,
[10] and epidemiological studies 
have demonstrated an apparent latitude-dependent predisposition, with a decreasing north–south 
gradient in the northern hemisphere and a reciprocally increasing south–north gradient in the 
southern hemisphere, although the reasons for this remain unclear.
[11–14] 
The peak incidence of WG/GPA is seen in the sixth decade of life and there appears to be no 
gender predilection. Although WG/GPA is considered a relatively rare disease, recent studies have 
shown that its incidence 
[11,15] and prevalence 
[5,11,15] lie on an increasing trend, and it is now affecting 
patients of a younger age.
[5,11,14,16] 
General (Systemic) Versus Limited WG/GPA 
Wegener's granulomatosis/granulomatosis with polyangiitis has a broad range of clinical 
presentations and can affect any organ with variable disease severity. Generally, WG/GPA can 
present in a limited or a general (systemic) form. However, these terms are mainly widely used in 
clinical trials to classify patients for the purpose of treatment options and in medical literature, but 
are not commonly used during clinical practice. To date, there is no current consensus on the 
characteristics that clearly define these two forms. 
Limited WG/GPA was first described in 1966 by Carrington and Liebow as the identical clinical 
onset and pathologic manifestations to the classic form of the disease, except in the absence of 
renal involvement.
[17] The Wegener's Granulomatosis Etanercept Trial (WGET) research group used 
the term 'limited WG' in their clinical trial for patients fulfilling the American College of Rheumatology 
(ACR) criteria for WG/GPA, but lacking features that pose immediate threat to either a critical 
individual organ or to the patient's life.
[18] The term 'localized WG/GPA' has also been used in 
medical trails and literature, although it has not been generally accepted worldwide. In their study, 
the European League Against Rheumatism (EULAR) group defined localized WG/GPA as 
individuals with vasculitic features confined only to the upper and/or lower respiratory systems, 
including the orbit.
[19,20] In general, patients with limited WG/GPA are often considered to run a 
milder course of the disease and usually respond well to less aggressive treatment regimens.
[21,22] 
General (systemic) WG/GPA, by contrast, reflects a more severe form of the disease with a more 
widespread organ system involvement. Severe WG in the WGET encompassed patients with 
significant involvement of vital organs that is potentially life threatening.
[18,23]EULAR divided patients 
with general WG into early systemic, generalized, severe and refractory.
[19,20] 
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 Ocular and orbital structure involvement is common in patients with both limited and general forms 
of WG/GPA, and may be the presenting feature in both. A very limited form of WG/GPA, with 
localized ophthalmic features only, has also been described.
[24] There appears to be no difference 
between the spectrum of ocular manifestations and incidence of potentially sight-threatening 
complications seen in either the general and limited forms.
[25] 
Pathogenesis 
The exact pathogenesis of WG/GPA is still unknown, but an interplay of both cellular and humoral 
immunity are believed to be involved in the disease process. Pathologically, WG/GPA is described 
as a triad of granulomatous inflammation, vasculitis of small- to medium-sized vessels and necrosis. 
ANCAs have been demonstrated to have strong associations with WG/GPA as well as with the 
other AAV. These are a group of IgG antibodies directed against the cytoplasm of neutrophil 
granulocytes and monocytes and can be detected in the serum by indirect immunofluoresence. 
Based on the pattern of staining on ethanol-fixed neutrophils, ANCAs can be divided into two main 
patterns: cytoplasmic-ANCA (c-ANCA; which show a diffusely granular, cytoplasmic staining pattern 
and are strongly associated with WG/GPA) and perinuclear-ANCA (p-ANCA), which show a 
perinuclear staining pattern, mainly associated with MPA. In AAV, ANCA are shown to specifically 
target the antigens proteinase 3 (PR3), the predominant antigen in WG/GPA, or myeloperoxidase, 
the predominant antigen in MPA, and these can be detected by ELISA. The exact mechanism by 
which ANCA are generated is as yet undetermined, but molecular mimicry by viruses or bacteria, 
drugs, and genetic predisposition, such as the defective allele PI*Z on chromosome 
14q32.1 
[26] and HLA-DPB1,
[27] have all been associated with WG/GPA and may potentially be 
possible causes in the development of ANCA in AAV.
[28,29] 
The etiology and exact role of ANCA in the pathogenesis of WG/GPA is still uncertain, and studies 
in this area are ongoing. In vitro studies have shown that ANCA activate primed neutrophils, 
promoting their adherence and transmigration through TNF-stimulated endothelium, and induce 
neutrophil degranulation. The degranulation of neutrophils subsequently releases reactive oxygen 
species and lytic enzymes such as elastase, which damage endothelial cells and tissues. This 
phenomenon is suggested to be responsible for the extensive damage to vessel walls that is seen 
in WG/GPA.
[30] 
The alternative complement pathway has also been shown to be involved in this process, and C3 
complement deposition is found in more than half of tissue biopsies in patients with AAV.
[31,32] In 
vitro, activation of primed neutrophils by ANCA leads to the release of factor B as well as factor C3. 
This further causes the activation of the complement pathways that release the split product C5a, 
which functions as a strong chemotatic factor for neutrophils, but is also able to prime neutrophils 
for interaction with ANCA. This process thus forms a perpetual cycle for neutrophil recruitment and 
activation, leading to ongoing vascular inflammation and tissue damage.
[33] 
The granulomatous inflammation observed in different tissues in WG/GPA suggests a strong role 
for the T-cell response, and both Th17 cells and regulatory T (Treg) cells are now receiving 
attention as potential players in disease development.
[28,34] Other T-cell subtypes currently being 
investigated in the pathogenesis of AAV include CD8
+CD57
+ and natural killler-like CD4 cells, but 
their role has not yet been clearly defined.
[35,36] The role of B lymphocytes and memory plasma cells 
in immune regulation, antibody production and pathogenesis has now been well established in 
autoimmune disease,
[37,38] and plasma B cells have been demonstrated to have a role in the 
production of autoantibodies, including ANCA.
[39,40] Activated peripheral B cells have also been 
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 linked to disease activity and severity in WG/GPA,
[41] and treatment regimens targeting B cells have 
thus been advocated in AAV (Figure 2).
[42,43] 
 
Figure 2. 
  
Wegener's granulomatosis/granulomatosis with polyangiitis biopsies indicating the presence of 
CD20
+ B cells (stained brown). 
Staphylococcus aureus has been implicated in the pathogenesis of AAV, as low-grade chronic 
infection in the upper airway can cause release of proinflammatory cytokines that can locally prime 
neutrophils that are then further activated by ANCA.
[44] In addition, patients who are PR3-ANCA-
positive have antibodies reactive with a protein produced from PR3 antisense RNA, and have been 
shown to have an amino acid sequence that has homology with proteins from many microbes and 
viruses, implicating molecular mimicry in the pathogenesis.
[45] Recently, anti-human lysosomal 
membrane-associated protein (LAMP) 2 antibodies have been found to be present in 100% of AAV 
patients with active renal involvement, and in 93% of a cohort of 84 patients with either WG/GPA, 
MPA or renal-limited vasculitis.
[46] Interestingly, anti-LAMP2 antibodies have also been shown to 
target the adhesion elements FimH (fimbriae) on Gram-negative bacteria, thus suggesting a link 
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 between infection and vasculitis through molecular mimicry.
[47] However, there has been no general 
consensus on this finding, and further confirmatory studies are required. 
Diagnosis 
The diagnosis of WG/GPA, particularly the limited form, requires a heightened level of clinical 
suspicion based on clinical presentation and pathological criteria, particularly as the severity of 
disease in WG/GPA may range from a nonspecific inflammatory picture involving only one site or 
organ, to fulminant multiorgan vasculitis that can lead to death.
[47] 
In systemic WG/GPA, c-ANCA were found to be positive in 74% of patients, with anti-PR3 detected 
in 87%.
[48,49] One study conducted in Norway quoted a diagnostic sensitivity of 70% for c-ANCA and 
63% for PR3-ANCA, with a specificity of 97 and 99%, respectively, for the diagnosis of WG (27 out 
of 319 patients).
[50] In current clinical practice, ANCA detection is used for the diagnosis of WG/GPA 
and as an indicator of the disease activity. However, the ANCA titer is not entirely reliable in 
monitoring disease activity, and should not be solely relied upon in the management of WG/GPA 
patients.
[51] 
The ACR and The International Consensus Conference at Chapel Hill (CHCC) have proposed 
classification criteria and definitions, respectively, for the purpose of epidemiological studies for 
AAV, including WG/GPA. However, these classifications are rather limited, particularly as they did 
not include the presence of ANCA as a diagnostic criterion.
[52] In 2007, a stepwise algorithm was 
developed by consensus between a group of doctors interested in the epidemiology of vasculitis, for 
the classification of AAV and polyarteritis nodosa to address the lack of compatibility between ACR 
and CHCC.
[53] This includes a four-step algorithm incorporating both the ACR and CHCC systems 
that has been shown to be effective in classifying patients into a single category.
[54,55] Nevertheless, 
all three of the aforementioned classification criteria have been developed mainly for clinical studies 
and have their own individual limitations,
[56,57] and thus should not serve as a definitive tool for 
clinical diagnosis.
[58] 
In pediatrics, a EULAR/Pediatric Rheumatology European Society (EULAR/PReS) working group 
has recently developed classification criteria for childhood vasculitis using a Delphi 
technique.
[59] Agreement was reached to classify childhood vasculitis according to vessel size, with 
small-vessel diseases subdivided into granulomatous and nongranulomatous. The ACR criteria for 
WG/GPA were modified to include two new criteria: the presence of subglottic, tracheal or 
endobronchial stenosis; and the presence of high levels of PR3-ANCA or positive cANCA by 
indirect immunofluorescence.
[58] 
In the limited form of WG/GPA, like ocular WG/GPA, classical features of the disease are often 
lacking and may not fit any classification or definition. In addition, in the limited form of WG/GPA, 
ANCA presence and level is a poor indicator for diagnosis and disease activity, as ANCA is only 
found to be positive in 50–65% of patients.
[21,60] As a result, the diagnosis of limited WG/GPA may 
be missed or delayed and only detected once disease progresses to a more severe systemic 
form.
[10,47] 
Ophthalmic Features of WG/GPA 
Ocular involvement occurs in 50–60% of patients with WG/GPA,
[61] and it can affect any structure of 
the eye, from the eyelid and orbit to the optic nerve. Ocular WG/GPA can either manifest de novo, 
as disease spread from contiguous structures such as the sinuses, or as part of systemic WG/GPA. 
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 Ophthalmic presentations vary from an orbital mass formation (orbital granuloma), ocular vasculitic 
changes, adnexal inflammation and nasolacrimal duct changes. 
Ocular inflammation can occur with or without systemic manifestations of WG/GPA,
[62] and both 
limited and systemic forms of the disease can result in severe ocular morbidity, with visual loss 
occurring in up to 8% of patients. In 8–16% of patients, ocular manifestations may be the initial 
presentation of WG/GPA, but diagnosis is often difficult as the signs and symptoms are usually 
nonspecific and tend to overlap with those of other orbital inflammatory disorders.
[4,63] Patients with 
ocular WG/GPA have been reported to progress to the systemic form by one study,
[64] but others 
have failed to observe the same pattern.
[65,66] Only 50–65% of the limited form of WG/GPA is found 
to be ANCA positive.
[67–69] 
Scleritis & Episcleritis 
Scleritis is inflammation involving the entire thickness of the sclera. Scleritis of the necrotizing type 
is one of the common ophthalmic manifestations of WG/GPA, occurring in 50% of patients (Figure 
3).
[70,71] It may be the initial clinical presentation of WG/GPA,
[72] and typically presents with severe 
deep boring pain that may radiate to the temple and jaw, and red, tender eyes. The pain typically 
worsens at night, waking the patient up from sleep. Areas of severe vasculitis causing capillary 
closure in the deep episcleral vascular bed are characteristic of this disease and are seen as areas 
of capillary nonperfusion on ocular examination. This can lead to infarction and necrosis of the 
involved sclera, exposing the underlying uvea.
[67] Despite thinning of the sclera, ocular perforation is 
rare. During inflammation, adjacent ocular structures such as the cornea, trabecular meshwork and 
ciliary body may also be involved and can lead to complications such as keratitis, corneal 
ulceration, uveitis, ocular hypertension or glaucoma.
[68] 
 
Figure 3. 
  
Clinical appearances of necrotizing scleritis. In both (A) and (B), the necrotic area is seen as a 
white patch on examination due to capillary closure of the deep episcleral vascular beds and deep 
sclera vascular plexus that overlies the sclera. Disease is more marked in (B). 
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 Episcleritis is characterized as inflammation of the loose episcleral tissues between the conjunctiva 
and sclera.
[4] Although episcleritis is not usually associated with systemic diseases it has been 
described in patients with WG/GPA.
[69] It usually has a less-severe presentation, where patients may 
complain of red eye with mild discomfort and epiphora. The eye is seen to be either diffusely or 
locally injected on examination. Episcleritis typically runs a milder course compared with scleritis 
and is generally self-limiting with few or no ocular complications. However, in WG/GPA it has been 
reported that patients with episcleritis often require a short course of topical glucocorticoids.
[21] 
Keratitis 
Peripheral ulcerative keratitis (PUK) is also a common ocular manifestation of WG/GPA (Figure 
4),
[70] and bilateral PUK has been reported in the past.
[73] In this situation, it is often associated with 
scleritis, and ocular pain may be pronounced. Other symptoms may include tearing, photophobia 
and reduced vision. Corneal stromal infiltration and clouding, with invading vessels from the limbus, 
are typically seen. Breakdown of the overlying corneal epithelium resulting in ulceration and stromal 
thinning can occur, and if left untreated, may result in corneal perforation.
[4] In WG/GPA, corneal 
melt may occur earlier in the disease course, which can progress quickly, resulting in visual 
loss.
[67,79] 
 
Figure 4. 
  
Peripheral ulcerative keratitis evidenced by guttering of the peripheral superior cornea. 
Orbit 
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 The orbit is another common ocular structure involved in WG/GPA. The majority of patients with 
WG/GPA and orbital involvement have contiguous disease involving the nose and paranasal 
sinuses, although orbital WG/GPA may also occur de novo with orbital granuloma formation or 
orbital vasculitis. Common presentations of orbital WG/GPA include proptosis due to an orbital 
mass, diplopia, periorbital swelling, reduced vision, eye redness and pain and epiphora.
[4,21] Patients 
with orbital WG/GPA are prone to develop significant visual loss and ocular complications, with 20–
50% of patients developing severe visual loss (i.e., six out of 60 or less).
[75] 
Proptosis is the most common ocular presentation of orbital WG/GPA (Figure 5).
[21] It is an important 
sign, as together with respiratory disease or glomerulonehphritis, highly suggests the diagnosis of 
WG/GPA.
[10] Patients with proptosis and lid destruction are prone to develop exposure keratopathy, 
which can lead to corneal ulceration, ocular perforation and blindness.
[4] Orbital myositis in WG/GPA 
may occur as a result of inflammation of the extraocular muscles or vasculitis of the vasa nervorum, 
and patients mainly present with symptoms of diplopia and pain on ocular movement and signs of 
restriction of ocular motility.
[76] 
 
Figure 5. 
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Orbital Wegener's granulomatosis/granulomatosis with polyangiitis with an orbital mass (arrowed) 
and subtle right eye proptosis seen on computed tomography scan. The orbital granuloma can be 
seen to extend through the superior orbital fissure and into the cavernous sinus. 
Orbital apex infiltration of WG/GPA may involve the optic nerve resulting in painless optic 
neuropathy, optic nerve swelling and ensuing atrophy; further infiltration may cause painful 
ophthalmoplegia and blindness.
[77] Ophthalmoplegia may also be a result of vasculitis involving the 
cranial nerves supplying the extraocular muscles.
[4] Orbital contracture syndrome can occur as a 
complication of orbital WG/GPA and is described as proptosis followed by development of 
enophthalmos with radiographic evidence of fibrotic changes in the orbit. This complication is 
thought to be due to the proliferation of fibrous tissue replacing areas of acute inflammation and 
necrosis where ensuing contracture leads to restriction of motility and enophthalmos. The optic 
nerve may also be involved in this, causing further visual loss. As with other fibrosing manifestations 
of WG/GPA, socket contracture responds poorly to immunosuppressive therapy.
[78] 
Eyelid, Adnexal & Conjunctiva 
Eyelid involvement in WG/GPA is uncommon, but includes lid granulomas and ptosis. In severe 
cases, lid destruction may also occur. The 'yellow-lid sign', when associated with orbital 
inflammation, has been suggested to point to the clinical diagnosis of WG/GPA,
[79] and is described 
as resembling florid xanthelasma despite the patient having normal lipid 
metabolism.
[80] Dacroadenitis and lacrimal gland enlargements are recognized features of adnexal 
involvement in WG/GPA and may cause ocular sicca syndrome.
[81] Dacrocystitis and epiphora can 
occur as a consequence of nasolacrimal disease, and nasolacrimal blockage in WG/GPA may be a 
result of inflammatory spread from adjacent sino–nasal inflammation, or a direct consequence of 
focal WG/GPA inflammation.
[4,21] Conjunctival involvement occurs in 16% of patients with 
WG/GPA,
[82] manifesting as ulcerative and necrotic conjunctivitis, which may result in marked 
cicatricial changes of the conjunctiva.
[21] 
Uveitis, Retina & Choroid 
Uveitis is a rare manifestation in WG/GPA and is seen only to occur in 3% of patients according to 
one study.
[75] Often, uveitis in association with WG/GPA occurs concurrently with scleritis and is 
termed sclerouveitis, and probably carries a poorer ocular prognosis.
[4]Retinal and choroid 
involvement in WG/GPA is also rare, but recognized retinal manifestations of WG/GPA include 
retinitis, chorioretinitis, macular edema, exudative retinal detachment and retinal necrosis.
[4] Retinal 
vein occlusion has been reported, and is thought to occur owing to external wall compression by 
tissue granulomas.
[83] By contrast, central retinal artery occlusion, which can occur bilaterally and 
simultaneously in WG/GPA, is associated with vasculitis; prompt treatment of the inflammation may 
improve the visual prognosis in these patients.
[84–86] Other rare presentations of WG/GPA in the 
retina and choroid include sclero–choroidal granulomas mimicking uveal melanoma,
[87] vitreous 
hemorrhage from chorioretinal and ciliary body granulomas 
[88] and acute multifocal placoid pigment 
epitheliopathy.
[89] 
Systemic Clinical Features of WG/GPA 
Wegener's granulomatosis/granulomatosis with polyangiitis can affect any organ system, although 
the disease has a tendency to affect the upper and lower respiratory tract and kidneys. However, 
287 
 the clinical presentation may be nonspecific, with just symptoms of fever, malaise, anorexia, weight 
loss and arthralgia.
[90] 
In a study conducted by Lane et al. in 2005, the ear, nose and throat was shown to constitute the 
most common initial symptom (81%) in WG/GPA. Ear, nose and throat also commonly makes up 
the first hospital speciality that reviews patients with WG/GPA.
[91] The upper and lower respiratory 
tract systems are commonly affected in WG/GPA, occurring in up to 85% of patients.
[10,92] Chronic 
sinusitis that is unresponsive to treatment is the most frequent initial presentation, occurring in 
approximately 70% of patients with WG/GPA. Subglottic stenosis is a life-threatening complication 
of WG/GPA and should be suspected in a WG/GPA patient who presents with dyspnoea in the 
absence of active pulmonary disease. Pulmonary involvement occurs in approximately 67% of 
WG/GPA patients, although 85% eventually develop lung disease.
[91,92] 
Renal involvement occurs in 75–80% of patients with WG/GPA, although only 20% of patients will 
have features of active glomerulonephritis.
[16] Once the renal system is involved, the disease may 
accelerate rapidly despite the patient being asymptomatic. Prognosis is related to serum creatinine 
at presentation.
[55] Rapidly progressive glomerulonephritis is the most severe renal manifestation of 
WG/GPA and, if untreated, can lead to the need for dialysis or transplantation within weeks. The 
pulmonary renal syndrome is a combination of diffuse alveolar hemorrhage and rapidly progressive 
glomerulonephritis. It is a rare but serious complication of various systemic disorders, with the 
majority of cases related to AAV.
[56] 
Approximately two-thirds of patients with WG/GPA complain of musculoskeletal symptoms. 
WG/GPA involves the nervous system in 20–50% of patients, most frequently affecting the 
peripheral nervous system, with mononeuritis multiplex present in some 22%. Gastrointestinal 
manifestations of WG/GPA are uncommon but are now increasingly recognized as part of this 
disease. Lesions are seen when performing colonoscopy or enteroscopy, manifesting as multiple 
intestinal ulcerations that can involve both the large and small bowels,
[93,94] and can lead to multiple 
intestinal perforations.
[93,95] Vasculitis of the coronary vessels in WG/GPA may lead to myocardial 
ischemia.
[96] It has been reported in one study that WG/GPA patients seem to have an increased 
morbidity from ischemic heart disease compared with the rest of the population.
[97] There is also an 
apparent increased risk of first WG/GPA relapse after initial remission in patients with 
cardiovascular manifestations.
[98] 
Histology in Ocular WG/GPA 
The histopathology of WG/GPA, based on postmortem examination of WG/GPA patients, consists 
of a variable mixture of granulomatous lesions with fibrinoid necrosis or microabcesses, tissue 
necrosis and vasculitis of small- to medium-sized vessels. Granulomas are said to occur early in the 
disease process, with vasculitis developing in the later stages.
[99] In 2008, Ahmed et al. described 
the pathologic features of biopsies from patients with ophthalmic WG/GPA, and reported that 
WG/GPA was associated with granulomatous foci, collagen necrosis, neutrophil/nuclear dust, 
plasma cells and infiltrating eosinophils.
[100] The presence of granular degeneration of the interstitial 
collagen, mummification of the collagen with disappearance of fibroblastic nuclei, and a 
polymorphous infiltrate exhibiting plasma cells, lymphocytes, neutrophils and eosinophils within the 
epithelioid granulomas were said to be particularly suggestive of the diagnosis of WG/GPA.
[98] By 
contrast, granulomatous inflammation without vasculitis is more characteristic of other orbital 
inflammatory diseases.
[101] 
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 Following the introduction of rituximab (RTX; an anti-CD20 antibody), there has been a growing 
interest in the potential role of B cells in the pathogenesis of WG/GPA. However, B-cell infiltrates in 
WG/GPA are not found in all involved organs and T cells and macrophages predominate in tissue 
biopsies. The presence of eosinophils has also been demonstrated in biopsies.
[64] Interestingly, 
nuclear debris has been repeatedly described in pathological reports in WG/GPA,
[60,64,100] but does 
not seem to be seen in any other ocular inflammatory conditions. 
Classic histological features of WG/GPA are not always present in biopsy material. This is possibly 
more so in the case of the limited form of WG/GPA, especially ocular WG/GPA, where biopsy 
specimens are often too small to capture the whole pathologic picture, or the inflammatory process 
is too mild to mount a typical tissue cellular response.
[102] 
Orbital Imaging 
Radiographic investigations are used frequently in the investigation of orbital masses. Imaging with 
computed tomography (CT) and/or MRI is of value in the diagnosis of orbital WG/GPA to 
demonstrate orbital mass lesions and delineate involvement of adjacent structures, and radiological 
features of orbital and sinus involvement are detectable in approximately 70% of patients with 
clinical orbital involvement.
[103–105] 
CT Scan 
Computed tomography scanning is more effective at evaluating sinus opacification and bone 
invasion, which is a common finding in WG/GPA.
[106] Classically, appearances on CT are of an ill-
defined soft tissue mass that may cloak the globe, obscuring the optic nerve and extraocular 
muscles, with associated local bony destruction. On unenhanced CT images, orbital lesions appear 
homogeneous and isodense relative to the extraocular muscles. The contrast-enhanced CT 
appearance is that of a moderately heterogenous mass that was isodense or mildly hyperdense 
relative to nasal mucosa. Studies with contrast can show a wide range of enhancement 
characteristics with extreme diversity of enhancement values.
[107] There are no radiological features 
that can make a specific diagnosis of WG/GPA. 
MRI 
Magnetic resonance imaging may be helpful in characterizing orbital lesions in WG/GPA. On T1- 
and T2-weighted images, low-to-intermediate signal granulomas can be distinguished from the 
surrounding orbital fat tissues and extraocular muscles.
[108,109] However, granulomas can only be 
depicted as low-signal-intensity lesions on MRI in the later stage of granulomatous transformation 
and, in the initial inflammatory process of WG/GPA, it is not possible to differentiate between 
mucosal inflammation and granulomatous tissue on MRI. A marked decrease in T2 signal is a 
characteristic of WG/GPA, but similar findings can occasionally be seen with idiopathic orbital 
inflammation, chronic lacrimal gland sarcoidosis and in metastatic melanoma of the orbit.
[107,110] 
Following contrast, varying degrees of enhancement may be observed.
[109] After gadolinium 
injection, granulomas may show homogenous 
[104] or heterogeneous signal enhancement, or, in a 
minority of cases, no enhancement.
[108] Therefore, Wegener's granulomatosis should be included in 
the differential diagnosis of patients with low-signal-intensity lesions on T1- and T2-weighted SE 
sequences of the nasal cavity, paranasal sinuses and orbits. The unenhanced, nonfat-suppressed 
T1-weighted sequence is the preferred method for lesion detection in orbital WG/GPA.
[110] Bony 
erosion of the orbit and sinuses has also been demonstrated in WG/GPA and most often affects the 
ethmoid sinuses, nasal septum and medial walls of the orbit.
[108,109] 
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 Differential Diagnosis of Ocular WG/GPA 
The overlapping clinical presentation of orbital WG/GPA with other orbital inflammatory conditions 
poses difficulty in establishing a definitive diagnosis. The differential diagnosis of orbital 
inflammatory disorders can be broadly divided into infectious, inflammatory and neoplastic causes. 
Thyroid eye disease is the most common cause of systemic-related orbital inflammation and may 
be unilateral or bilateral.
[111] Typical features of ocular thyroid eye disease, such as lid lag and lid 
retraction, together with systemic symptoms of thyroid dysfunction, may help in making the 
diagnosis. Abnormal thyroid function tests and raised anti-thyroid antibodies may also assist in the 
diagnosis, although normal levels do not exclude it. 
Orbital cellulitis from bacterial or fungal infections must be excluded prior to commencement of 
immunosuppressive treatment, particularly when there is a history of trauma to the sinuses or dental 
infection or intervention.
[21] Patients with orbital cellulitis often present with symptoms of infection 
such as fever, tachycardia, leukocytosis and discomfort, and blood cultures may be useful in 
identifying the infective agent. 
IgG4-related disease is a systemic lymphoproliferative disorder where affected organs show hyper-
IgG4-γ-globulinemia and IgG4-producing plasma cell expansion with fibrotic or sclerotic changes. In 
the orbit it commonly affects the lacrimal gland where patients present with bilateral symmetrical 
lacrimal gland swelling and dacryoadenitis. Other ocular symptoms include eyelid or periocular 
swelling and proptosis. The diagnosis of IgG4-related disease is confirmed with serologically high 
levels of serum IgG4 (>135 mg/l) and marked IgG4-positive plasmacyte infiltration (>40% IgG4-
positive/IgG-positive cells in five high-power fields) into lacrimal biopsy tissues.
[112,113] 
Apart from WG/GPA, other inflammatory disorders with orbital presentations include sarcoidosis, 
idiopathic orbital inflammation, Churg–Strauss syndrome, Erdheim–Chester syndrome and Tolosa–
Hunt syndrome. Rheumatoid arthritis may present with scleritis, episcleritis and PUK. Neoplastic 
disorders that may present with proptosis include rhabdomyosarcoma and lymphoma. Tumor 
metastasis to the orbit from a remote primary tumor should also be considered.
[114,115] 
Treatment 
Wegener's granulomatosis/granulomatosis with polyangiitis is a fatal disease if left untreated, and 
the natural history is for only 50% of patients to survive 5 months after diagnosis and for 80% to die 
within 1 year, mainly from renal disease 
[10] and secondary infection. Treatment with corticosteroids 
(CSs) alone only moderately increased the mean survival time to 12 months, but the present 
combination of CS with other immunosuppressive drugs such as cyclophosphamide (CYC) has 
been shown to achieve disease remission in 93% of patients 
[116] and improve survival. 
The treatment of ocular involvement in WG/GPA largely depends on the clinical presentation, 
severity of the disease and whether there are extraocular organ involvements. There are very few 
clinical trials that specifically address the treatment for ocular WG/GPA. Many reports on the subject 
are mainly based on single case reports and case series. Frequently, the management of ocular 
WG/GPA requires treating the underlying systemic disease with CSs and cytotoxic agents; thus, 
treatment decisions can be guided by clinical trials for systemic WG/GPA. 
Although clinical presentation may be confined to only ocular manifestations of WG/GPA, the 
disease may progress to involve other organs over time and, once WG/GPA is suspected, 
collaboration between ophthalmologists and physicians for thorough evaluation, investigation, 
management and future monitoring is essential. Identification of eye and extraocular disease of 
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 WG/GPA will require systemic therapy. In cases where evidence of WG/GPA is strong, such as 
bilateral ocular inflammation, necrotizing scleritis, particularly with corneal infiltrates, or eye 
symptoms with corresponding sinus or upper respiratory characteristics of WG/GPA, treatment 
should be advocated even though serology testing for ANCA is negative. 
Topical treatments with NSAIDs or CSs are only used in the treatment of episcleritis or mild anterior 
uveitis, as ocular WG/GPA tends not to respond to topical agents. Keratitis in WG/GPA will require 
treating the underlying systemic condition, and in cases of impending perforation, adhesive glue 
and tectonic grafting may be necessary.
[71] In cases of isolated non-necrotizing anterior scleritis, the 
use of oral NSAIDs or oral CSs may be advocated. Local injection of CSs may be considered for 
rare cases of unilateral uveitis and refractory nonnecrotizing scleritis with no evidence of active 
systemic disease.
[117] 
Aggressive immunosuppressive treatment with CYC and CSs (1 mg/kg/day) is necessary for the 
more severe cases of ocular WG/GPA, such as necrotizing scleritis, bilateral ocular involvement, 
posterior scleritis, orbital or adnexal presentation and refractory cases. Holleet al. reported that the 
most frequent indication for CYC in localized WG/GPA is patients with orbital masses and cavitating 
pulmonary masses.
[66] Recently, the management of WG/GPA has been moving away from CYC 
owing to its well-recognized serious adverse effects and the emergence of new treatment regimens 
with biologics such as RTX, which is recently gaining popularity as the first line of treatment in the 
management of WG/GPA. 
Cyclophosphamide, when considered for treatment in WG/GPA, may be given orally or 
intravenously as pulses, initially at a 2 week interval, then three-times weekly with oral CS (1 
mg/kg/day). Intravenous pulse CYC has been shown to have a similar remission rate to continuous 
oral CYC and is advocated to reduce the toxicity of the drug (CYCLOPS study),
[118] but may have a 
higher relapse rate. With this combination, remission is seen in 70–90% of patients with systemic 
WG/GPA, with mortality rates of 9% at 18 months.
[119]However, 30–70% of patients relapse, and up 
to 42% experience severe side effects from the treatment. CYC is known to cause many serious 
adverse effects such as serious infection, bladder cancer and increased malignancy risk (two- to 
four-fold), as well as other complications, including amenorrhea, infertility, cystitis, hematuria and 
transient alopecia.
[47,120] 
Rituximab has been reported to be effective in treating various ocular manifestations of WG/GPA, 
such as PUK,
[121] relapsing necrotizing scleritis,
[43] optic nerve infiltration 
[76] and optic 
neuritis,
[122] although remission may take 7 months to occur.
[123] RTX has also been found to be 
effective in inducing remission in refractory ophthalmic WG/GPA, and is capable of inducing 
extended remission compared with other biologics and conventional treatments.
[124] RTX is a 
chimeric monoclonal anti-CD20 B cell antibody that depletes B cells. It is now being more frequently 
used as a treatment regimen for WG/GPA instead of the standard CYC induction protocol 
recommended by the European Vasculitis Study Group (EUVAS). RTX has been reported to be as 
effective in the treatment of AAV as CYC in two clinical trials.
[40,125,126] 
The RTX versus CYC for ANCA-Associated Vasculitis (RAVE) study in 2010 was a head-to-head, 
multicenter randomized double-blind noninferiority trial, comparing CS plus RTX (375 mg per 
square meter of bodysurface area per week for 4 weeks) with CS plus CYC (2 mg per kilogram of 
bodyweight per day) for remission induction in 197 patients with severe ANCA positive-associated 
vasculitis.
[125] In both arms, CSs were tapered off over a period of time in the usual regimen. The 
primary end point of the study was remission of disease without the use of prednisolone at 6 
months, and RTX was found to be noninferior to CYC in achieving this. Interestingly, in inducing 
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 remission in relapse diseases, RTX was found to be more effective than CYC. Surprisingly, there 
was no difference in the adverse event rate between the two groups. 
Similarly, the RTX versus CYC in ANCA-Associated Renal Vasculitis (RITUXVAS) trial compared a 
standard CS regimen plus either RTX with two intravenous CYC pulses or intravenous CYC for 3–6 
months followed by maintenance azathioprine (AZA).
[126] The primary end point of the study was 
remission at 12 months, and this was equal in both groups. There were no significant differences in 
severe adverse events, and renal function improved in both groups. The result shows that RTX can 
spare CYC in the treatment of AAV, thus reducing the exposure of patients to CYC. 
These two studies not only demonstrate that RTX is an effective treatment for AAV, but it also 
appears to be well tolerated by patients. However, being a relatively new treatment, length of 
disease remission, disease relapse rate and its long-term safety profile is as yet uncertain; late-
onset neutropenia in patients treated with RTX for rheumatic diseases has recently been reported, 
the highest incidence being seen in WG/GPA and systemic lupus erythematosus.
[122] 
Apart from CYC and RTX, in limited WG/GPA it has also been suggested that the combination of 
methotrexate (MTX) and CS achieves remission rates of approximately 70%.
[127] In patients with 
early systemic WG/GPA (defined by EUVAS as AAV with systemic vasculitis without organ-
threatening or life-threatening disease), the combination of MTX (20–25 mg per week) with CS (1 
mg/kg/day and gradually tapered) has been recommended by EULAR as a less-toxic alternative to 
CYC for inducing remission (NORAM study).
[106,128]However, MTX was found to be less effective in 
achieving remission in patients with extensive disease and pulmonary involvement compared with 
CYC, and had a higher relapse rate in this group. Nevertheless, MTX is widely considered to be the 
drug of choice for patients with early systemic WG/GPA. 
Adjunctive Anti-TNF-α Agents 
The anti-TNF-α agents infliximab and etanercept have been extensively studied for their potential 
role as remission-inducing therapies for vasculitic diseases, although not for ocular WG/GPA per 
se. 
Infliximab has been reported to be effective in treating cases of WG/GPA with ocular involvement in 
several isolated reports.
[129,130] In a previous study, infliximab, a chimeric monoclonal antibody 
directed against TNF-α, was shown to be effective at inducing remission in WG/GPA,
[131,132] but the 
numbers representing ocular WG/GPA were very small (three out of 12 patients). However, 
recently, a cohort study by Morgan et al. showed that the addition of infliximab to standard therapy 
was found not to influence remission rates, adverse events, damage index scores, relapse rates or 
biomarker levels; thus, infliximab appears not to have further clinical benefits for patients with active 
AAV.
[133] 
Importantly and unexpectedly, the WGET, which included 30% of patients (n = 180) with eye 
involvement, found that etanercept was ineffective for the maintenance of remission in patients with 
Wegener's granulomatosis and was associated with a high rate of treatment-related complications, 
including solid-organ tumors.
[134] A recent report of the long-term follow-up of these patients 
revealed that compared with the general population, the risk of solid malignancies in the etanercept 
group was increased.
[135] 
Maintenance Therapy 
Maintenance therapy following disease remission is recommended in AAV patients owing to the 
high tendency for disease relapse to occur. It has been suggested that remission therapy should be 
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 continued for at least 18 months, particularly in WG/GPA.
[128] In cases of ocular WG/GPA, this 
practice would also seem beneficial owing to the potential aggressive and destructive nature of this 
disease, although it is uncertain whether such a long maintenance period is necessary, and what 
treatment regime is best for remission maintenance in patients with ocular WG/GPA. MTX and AZA 
have both been shown to be equally as effective as CYC in maintaining disease remission in 
WG/GPA, and the CYCAZAREM trial showed that, in patients with generalized vasculitis, the 
withdrawal of CYC and substitution of AZA after remission did not increase the rate of relapse, and 
thus the duration of exposure to CYC may be safely reduced.
[136] 
Mycophenolate mofetil (MMF) has also been demonstrated to be effective in sustaining short- and 
medium-term remission and is a well-tolerated drug.
[137] Surprisingly, however, in the IMPROVE 
study, MMF was found to be inferior to AZA in maintaining disease remission among AAV 
patients.
[138] MTX has also been recommended by EULAR as an effective remission maintenance 
therapy.
[128] Other options include leflunomide, a pyrimidine synthesis inhibitor that targets T cells by 
inhibiting the mitochondrial enzyme dihydroorotate dehydrogenase, thus limiting pyrimidine 
synthesis. This has also been reported to be an effective alternative immunosuppressive drug for 
remission maintenance in WG/GPA,
[139,140] although it has been associated with increased frequency 
of adverse events.
[140]Unfortunately, relapse rates remain high,
[141] particularly in patients who are still 
ANCA positive at time of remission, and it is therefore recommended that treatment is maintained 
for up to 18 months post remission, and continued close follow-up of patients during this period is 
mandatory. 
Bacterial and viral respiratory tract infections have been postulated to trigger relapses in patients 
with PR3-positive vasculitis. Data have suggested that treatment with cotrimoxazole may be 
beneficial, because this antibiotic could act by eliminating the offending microbe and thereby 
stopping the initiating stimulus in these patients. Treatment with cotrimoxazole has been shown to 
reduce the incidence of relapses in patients with WG/GPA in remission in previous 
studies,
[142,143] and should be considered in cases of persistent endonasal activity of WG/GPA, 
together with S. aureus carriage.
[144] Cotrimoxazole was also recommended by both EULAR 
[128] and 
the British Society for Rheumatology (BSR) and British Health Professionals in Rheumatology 
(BPHR)guidelines 
[145] as prophylaxis againstPneumocystis jerovicii infection in patients with 
WG/GPA. 
Surgical Intervention for Orbital WG/GPA 
Surgical procedures in the management of ocular WG/GPA are largely performed for diagnostic 
purposes; that is, orbital biopsy. In cases of nasolacrimal duct obstruction, dacryocystorhinostomy is 
shown to be effective in restoring nasolacrimal duct function affected by WG/GPA. Outcomes of 
dacryocystorhinostomy are mostly best when surgery is performed during disease remission and 
low ANCA titers. As mentioned previously, in cases of severe ulcerative keratitis with impending 
ocular perforation, using adhesive glue and performing tectonic corneal grafting is necessary. 
Severe ocular proptosis secondary to WG/GPA is often unresponsive to conventional medical 
therapy. In severe cases of proptosis associated with pain and optic nerve compression that are 
refractory to medical therapy, surgical orbital decompression should be considered.
[146] Prompt 
diagnosis and surgical decompression following acute visual deterioration can lead to good visual 
outcome.
[147] However, related ocular symptoms such as diplopia may still be difficult to resolve, 
even when orbital decompression is performed. Other indications for surgery in ocular WG/GPA are 
cataract surgery and trabeculectomy for the control of glaucoma, both common complications in 
WG/GPA developed either from ocular inflammation or steroid induced. 
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 Treatment of Systemic WG/GPA 
In 2007, the EUVAS devised a system of disease subgroupings for AAVs, based on the severity of 
WG/GPA presentation, to guide therapy ( ).
[145] Current treatment for these diseases is based on 
assessing the patient's clinical severity and disease extent. 
9.1.1.11  Table 1.  Disease categorization of antineutrophil cytoplasm antibody-associated 
vasculitis (based on the European Vasculitis Study Group classification). 
Category  Definition 
Localized 
Upper and/or lower respiratory tract disease without any other 
systemic involvement or constitutional symptoms 
Early 
systemic 
Any, without organ- or life-threatening disease 
Generalized 
Renal or other organ-threatening disease, serum creatinine <500 
µmol/l (5.6 mg/dl) 
Severe 
Renal or other vital organ failure, serum creatinine >500 µmol/l 
(5.6 g/dl) 
Refractory 
Progressive disease unresponsive to glucocorticoids and 
cyclophosphamide 
Data taken from 
(19,20). 
As with ocular WG/GPA, treatment for systemic WG/GPA is focused on remission induction and 
thereafter maintenance therapy. Treatments for early systemic and generalized disease are similar 
to the treatment regime as previously described. As for severe WG/GPA, additional treatment 
regimens have also been advocated, such as CYC (intravenous or pulse) and steroid with adjuvant 
plasma exchange (plasmapheresis).
[148,149] Intravenous immunoglobulin has been shown to reduce 
disease activity in refractory AAV, although the effect was not maintained beyond 3 months.
[150] 
Other Treatment Regimens 
15-deoxyspergualin has been used with some success in refractory WG/GPA cases,
[151] and is a 
synthetic derivative of spergualin, a protein from Bacillus laterosporus that is capable of preventing 
T-cell and B-cell maturation. It may offer a safer alternative to CYC for induction therapy, but is not 
yet supported for routine clinical use. Anti-T-cell antibodies, such as anti-thymocyte globulins, are 
polyclonal antibodies targeted against T-lymphocyte antigens that cause rapid depletion of T 
lymphocytes and have been investigated for use in refractory WG/GPA.
[152] Anti-CD52 therapy 
(alemtuzumab; CAMPATH-1H) is a humanized monoclonal antibody to CD52 with anti-lymphocyte 
activity and has been shown to induce remission in AAV, although relapses and adverse events are 
common; its use in WG/GPA is considered experimental.
[153] 
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 Other treatment options for AAV on the horizon include hematopoietic stem cell transplant, 
intravenous high-dose AZA, intravenous immunoglobulins and abatacept. 
Prognosis 
Improved treatment regimens have resulted in improved survival and morbidity rates in patients with 
WG/GPA. Most studies now report a 5-year survival probability of 65–75% in these patients. The 
toxic profiles of these new drugs also appear to be more favorable and are better tolerated by 
patients compared with previous conventional standard treatment. Ocularly, significant visual 
problems are seen in up to 17% of cases, and in patients with orbital WG/GPA, significant visual 
loss occurs in 50% of patients. Visual losses in WG/GPA are largely a result of corneoscleral 
damage, macular edema, optic nerve compression from orbital mass or vascular occlusion. Prompt 
disease recognition, management and regular follow-up by an ophthalmologist is therefore 
mandatory. 
Conclusion 
Wegener's granulomatosis/granulomatosis with polyangiitis is a complex multisystem disorder with 
variable clinical presentation and disease manifestation. Despite better understanding of the 
disease process involved in WG/GPA currently, exact pathogenesis of the WG/GPA is still 
undetermined. There are no specific disease markers either in blood, histology or radiological 
investigations for WG/GPA, and this causes difficulty and delay in making the diagnosis. 
Ophthalmic involvement in WG/GPA is relatively common and diagnosis requires a heightened level 
of suspicion by ophthalmologists. As ocular signs may be the initial presentation of the disease, 
collaboration between ophthalmologists and physicians in the management of these patients is 
recommended, to optimize treatment and provide close monitoring in the hope of preventing 
progression and irreversible organ damage. Alternative drug treatment for WG/GPA with MTX and 
RTX with CS has been found to be equally effective as the conventional therapy of CYC and CS, 
and provides a potentially safer treatment option for patients. 
Expert Commentary 
The ocular manifestations of WG/GPA are relatively common, and there is increasing awareness 
among ophthalmologists of this disease. However, despite recent advances in the understanding of 
WG/GPA, it still remains a challenging disease to diagnose and manage. This is particularly more 
so for ocular WG/GPA, given its overlapping clinical presentations with other ocular inflammatory 
disorders, low percentage of ANCA positivity and the lack of classic histological findings in biopsies, 
thus making it indistinguishable from other orbital inflammatory diseases. To date, the pathogenesis 
of WG/GPA remains elusive and specific clinical signs or disease markers pathognomonic for 
WG/GPA are still absent. Successful treatment with anti-B-cell therapy in the form of RTX has 
indicated that B cells play a major role in disease development as well as T cells, but their precise 
interaction remains as yet undetermined. 
Tissue damage remains an important problem with systemic vasculitis despite effective remission-
inducing drugs. Only a fraction of patients with systemic vasculitis are unmarked by their disease. 
Unfortunately, there is no way of deciding which treatment regime would be best suited for 
individual patients. There is a healthy increase in the development of new treatment regimens for 
systemic vasculitic diseases that are targeting cell specific. However, recent studies looking into 
alternative and safer treatment options for the management of WG/GPA have shown some 
unexpected findings. One in particular was the comparison between the two purine inhibitors, MMF 
and AZA, for remission maintenance in WG/GPA. It was surprising that MMF, a newer generation 
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 drug, was shown to be inferior to the older generation drug, AZA, in maintaining remission, where 
patients were found to relapse quicker on MMF and had a higher relapse rate. 
Current studies and reports on RTX as a new treatment regime for WG/GPA have been 
encouraging. RTX currently appears to be an effective treatment for both the systemic and limited 
form of WG/GPA, and is well tolerated by patients. Although to date it appears to be a better 
treatment option when compared with CYC, recent studies have shown that the adverse events 
between the two treatment regimens were surprisingly comparable. Furthermore, as it is a new 
treatment method, the long-term safety profile of RTX is yet to be established. 
Five-Year View 
Newer biologic therapies will undoubtedly play a significant role in the management of WG/GPA in 
the future and, although the long-term safety profile of RTX remains uncertain, it holds a potential 
role as a substitute to CYC as the standard treatment for WG/GPA in the future. Further 
understanding of the immune response involved in vasculitides should result in the development of 
target-specific treatment regimens. 
Identifying tissue markers or cellular patterns in tissues biopsies that are specific for WG/GPA 
would be of great value to aid and improve diagnosis, and the discovery of a key factor that could 
predict disease remission, disease extension or relapse would also be of great benefit. This could 
lead to a risk stratification and aid in the formulation of a rational treatment approach for WG/GPA, 
especially in the early stages of disease course. 
Key Issues 
•  Granulomatosis with polyangiitis (previously known as Wegener's granulomatosis 
[WG/GPA]) is a granulomatous autoimmune inflammatory disorder of unknown etiology, 
and has a strong association with cytoplasmic-antineutrophil cytoplasm antibodies and anti-
proteinase 3. 
•  Its etiology is still unknown; however, there is growing awareness of the disease, with an 
increasing trend in prevalence and incidence observed in the general population. 
•  Both cellular and humoral immune responses appear to be involved in the pathogenesis of 
WG/GPA. 
•  WG/GPA can affect any organ system, but has a predilection for the upper and lower 
respiratory system and kidneys. 
•  Ocular manifestations can be the initial presentation of WG/GPA, occurring in 8–15% of 
patients. 
•  Proptosis and necrotizing scleritis are the most common ocular complications of WG/GPA, 
and adequate management of the systemic disease is necessary for their resolution. 
•  The emergence of new treatment regimens using biologics such as rituximab is recently 
gaining popularity as the first line of treatment in the management of WG/GPA. 
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Abstract:Background:ThelimitedformofGranulomatosiswithPolyangiitis(GPA),formerlyknownasWegener’sGranulomat
osis(WG)primarilyinvolvestheheadandneckregion,includingtheorbit,butisoftenadiagnosticchallenge,particularlyasitco
mmonlylackspositiveanti-
neutrophilcytoplasmantibody(ANCA)titresorclassicalfeaturesondiagnosticorbitalbiopsies.Thepurposeofthisstudywast
orelatebiopsyfindingswithclinicaloutcomeandtodeterminewhichhistopathologicalfeaturesarepredictiveofaclinicaldiag
nosisofGPA.Methods:Retrospec-
tivecaseseriesof234patientsidentifiedfromthedatabaseoftheUCLInstituteofOphthalmologyDepartmentofEyePatholo
gyashavinghadorbitalbiopsiesoforbitalinflammatorydisordersperformedbetween1988and2009.Clinicalrecordswere
obtainedforthepatientsandanalysedtoseewhetherpatientshadGPAornot,accordingtoastandardsetofdiagnosticcriteria
(excludinganyhistopathologicalfindings).Biopsyfeatureswerethencorrelatedwiththeclinicaldiagnosisinunivariateandm
ultivariateanalysestodeterminefactorspredictiveofGPA.Results:Ofthe234patients,36werediagnosedwithGPAand198
withotherorbitalpathologies.Themajorityofbiopsieswerefromorbitalmasses(47%).Histologyshowedarangeofacuteand
chronicinflammatorypicturesinallbiop-
sies,butthepresenceofneutrophils(P<0.001),vasculitis(P<0.001),necrosis(P<0.001),eosinophils(P<0.02)andmacrop
hages(P=0.05)weresignificantlyassociatedwithalaterclinicaldiagnosisofGPA.Inamultivariateanalysis,onlytissueneutro
phils(OR=3.6,P=0.01)andvasculitis(OR=2.6,P=0.02)wereindependentlyassociatedwithGPA,incontrasttopreviousrepo
rtsassociatingeosinophilsandnecrosiswiththediagnosis.Conclusions:Neutrophil,eosinophilandmacrophageinfiltration
oforbitaltissues,togetherwithvasculitisandnecrosis,areallassociatedwithaclinicaldiagnosisofGPA,butonlyneutrophilinf
iltrationandvasculitisareindependentlyassociatedwiththisdiagnosis.Thesefeaturesmayassistintheestablishingthedia
gnosisoflimitedGPAamongpatientswithearlyorbitaldisease,particularlyintheabsenceofpositiveserumANCAtitres. 
 
Keywords:Granulomatosiswithpolyangiitis,histopathology,eosinophils,nucleardust 
 
 
Introduction 
 
Granulomatosis  withPolyangiitis(GPA),former-
lyknownasWegener’sgranulomatosis(WG),isasyst
emicsmall-vesselvasculitisthatischar-acterised 
bynecrotisinggranulomatousinflam-
mationaffectingtherenal,pulmonary,upperairway
sandocularsystems,andisassociatedwithcirculati
nganti-neutrophilcytoplasmanti-
bodies(ANCA)[1].TheinitialsymptomsofGPAareob
servedintheheadandneckregionin 
some95%ofpatients,butmakingthediagno-
sisatthisstageisoftenextremely 
challenging.GPAremainslimitedtoENTandocularin
volve-
mentinsomepatients,butcaninvolveotherorgans,
such  asthelungs  andkidneys 
[2],withsevereconsequencesforthepatient.Impor
tantissuesinthe  managementof  GPA 
includebothpredictionofdiseaseprogressionandt
heside-
effectsofthedrugsrequiredtotreatactivedis-
ease.EarlydiagnosisoflimitedGPAisuseful,asitena
blesearlierintroductionoftheappro- 
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priateimmunosuppressivetherapy,presum-
ablyreducingtheriskoflocalprogressionofthedise
aseandofinvolvementofotherorgans,includingthe
kidney,afterwhichtheprognosisdramaticallyworse
ns[3]. 
 
Ocularinvolvementoccursin50-
60%ofpatientsandisthepresentingfeaturein8-
16%,withsevereocularmorbidityoccurringasacom
plicationofbothlocalisedandsystemicGPA[4].Orbit
alinvolvementoccursinapproxi-
matelyhalfofallpatientswithGPA,andmayleadtoor
bitalbonedestructionandlossofvisionfromcontrac
tionandfibrosisaroundtheopticnerve,despitetreat
mentandresolutionofinflammation[5].Ocularfeat
uresofGPAincludescleritis,whichcanbenecrotisin
gandbilateral,andwhichcan  pose 
amajorthreattotheintegrityoftheglobe.Neverthele
ss,thediagnosisofocularGPAisparticularlydifficult
asitsclinicalmanifestationsoftenoverlapwithothe
r  inflammatory  conditions  such  assarcoid-
osisandidiopathicinflammatoryorbitaldisor-
ders.Inaddition,inthelimitedformofGPA,anti-
neutrophilcytoplasmantibody(ANCA)titresareposi
tiveinonly50-65%ofpatients[6,7]. 
 
Althoughthehistopathologicalfindingsareoftendi
agnosticforGPAinrenaldisease[8,9],thisisnotthec
asefororbitalandupperair-
waysdisease,withclassicfindingsbeingpres-
entinlessthanathirdofpatients,andfewerthanthisi
nrecent-
onsetdisease[10,11].Indeed,thehistologicalfeatu
resofGPAcanmimicotherformsofidiopathicorbitali
nflam-
mationsuchassarcoidosis,idiopathicinflammator
yorbitaldisordersandlymphoidhyperplasia. 
 
ThehistologicalfeaturesoforbitalGPAarediversea
ndcanincludeanyofthefollowing:granulomatousfo
ci,collagendeposition,necro-
sis,nucleardust,plasmacellsandaninfiltrat-
ingeosinophilicresponse[12].Thelatterhasbeens
uggestedtopredictdiseaseprogression[13],analo
gous  tothesuggestionthat, 
inrenalbiopsiesinGPA,anincreaseCD8
+cellsmight
alsopredictandincreaseindiseaseactivity[14].The
sedescriptionsaredrawnfromrela-
tivelysmallnumbersofpatients,and,asyet,thereha
snotbeenastudywhichhassystem-
aticallyanalysedalargenumberoforbitalbiop-
sies.Wethereforeperformedsucharetrospec- 
tiveinvestigation  for 
aconsecutivecaseseriesinwhichweexaminedhist
opathologyreportsofallpatientswhohadundergon
eorbitalbiopsiesfororbitalinflammatorydisorders
overaperiodof21years,andrelatedthistotheirclinic
alout-comes. 
Toourknowledge,thisisthefirststudyofitskind. 
 
Methods 
 
ThestudywasapprovedbytheMoorfields&Whitting
tonResearchEthicCommitteeandwasaretrospecti
vestudyofallpatientswhohadundergoneorbitalora
dnexalbiopsyfororbitalinflammatorydiseaseatMo
orfieldsEyeHospitalover21years.Allpatientswhoh
adundergoneanorbitaloradnexalbiopsybetween1
988and2009wereidentifiedfromtheUCLInstitute
ofOphthalmologyDepartmentofEyePathologyDat
abase.Thebiopsyreportswerereviewed,andthecel
ltypesandtissuerespons-
esdocumentedqualitativelyaspresentorabsent.C
elltypesnotedincludedneutrophils,eosinophils,pl
asmacells,multinucleatedgiantcells,macrophage
sandmastcells;tissueresponses 
assessedincludednecrosis,sclerosis,lymphoidfoll
icles,nucleardebrisandgranulomas. 
 
Acomprehensivereviewoftheclinicalnoteswasnex
tperformedtoobtaininformationonpatientdemogr
aphicsandclinicaldatainclud-
ingthefinalclinicaldiagnosis,orbitalsignsandsymp
toms,ocularsignsandsymptoms,otherorganinvolv
ement,ANCAstatus,treatmentanddurationoffollo
wup.Patientswereclassifiedashavingclinicalfeatu
resconsistentwithadiagnosisofGPAiftheymetanyt
woofthefol-
lowingclinicalcriteria:(1)Characteristicocularfeatu
resofGPA;(2)CharacteristicENT,pulmo-
nary,renalorcardiacinvolvement;(3)Positiveimmu
nofluorescenceforANCA;(4)PositiveELISAforanti-
PR3antibodies.Crucially,histo-
logicalfindingsanddiagnosiswereexcludedfromth
elistofdiagnosticcriteriatoavoidcon-
foundingthestudyandpatientswereincludedin 
the“non-GPA”group  if  they  didnot  meet 
theabovecriteria.SystemicandlimitedGPAweredef
inedbythepresenceorabsenceofrenalorlowerairw
ayinvolvement,respectively.Patientswerealsoclas
sifiedas‘newly-
diagnosed’or‘known’GPAdependingonwhetherth
eirclini-cal diagnosis had been made prior to the 
biop-syprocedure. 
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Table1.Patientcharacteristics   
 
GPA (n=36)  NonGPA(n=198)  P 
Age  50.7 ± 3.2years  50.4 ± 1.2years  0.92 
Gender (M:F)  21:15(57%:43%)  127:71 (64%:36%)  0.57 
Biopsystructures 
-  Orbital mass  20  91  0.29a 
-  Lacrimalgland  8  79 
-  Nasolacrimal/sinonasal  12  31 
-  Extraocularmuscle  2  28 
-  Other  3  11 
aPvaluerepresents χ2testoforbitalmassvs.otherbiopsysite foreachgroup 
Table2.Comparisonofcellularprofiles 
 
Cell type 
GPA(%)
  NotGPA(%)(n=36) 
  (n 198) 
  Unadjust 
OR 
ed   
P 
Adjuste 
OR 
d    
P 
PMN  19 (53%)  30 9(15%)  5.9(2.7 – 12.6)  <0.0001*  3.9(1.4 –11.2)  0.01* 
Eosinophil  19 (53%)  62(31%)  2.5(1.2 – 5.0)  0.02*  0.7(0.24– 1.8)  0.42 
Vasculitis  19 (53%)  11 (6%)  19.0(7.8– 46.4)  <0.0001*  4.8(1.6 –14.7)  0.006* 
Necrosis  22(39%)  21(11%)  5.4(2.4 – 12.0)  <0.0001*  2.4(0.8 – 6.6)  0.10 
Lymphocyte  19 (53%)  113(57%)  0.8(0.4 – 1.7)  0.86     
Fibrosis  22(61%)  111 (56%)  1.2 (0.6 – 2.6)  0.72     
Macrophage  16 (44%)  55(28%)  2.1 (1.0 – 4.3)  0.05*  2.0(0.9 – 4.5)  0.11 
Plasmacells  18 (50%)  85(43%)  1.3 (0.7 – 2.7)  0.47     
Giantcells  2 (6%)  23(12%)  0.4(0.1– 2.0)  0.39     
Follicles  4(11%)  34(17%)  0.6(0.2 – 1.8)  0.47     
Nucleardebris  2 (6%)  6 (3%)  1.9 (0.4 – 9.7)  0.36     
Granuloma  12(33%)  45(23%)  1.7 (0.8 – 3.7)  0.21     
+ve =cellsreported presentinbiopsy; -ve =cells not reported inbiopsy;OR= oddsratio;CI= confidence interval; *=statisti-
callysignificantdifference(P<0.05);%= percentage ofpatientswith positive occurrenceofcelltypeortissue 
responsereportedinbiopsywithineach group.Adjusted odds ratiosare adjusted for allstatisticallysignificant variables (P<0.05) 
fromtheunivariateanalyses. 
 
Theunpairedstudent’sT-
testandFisher’sexacttestwereperformedtoexami
nediffer-
encesbetweenthetwogroups.Univariateanal-
ysiswasperformed,includingthecalculationof95%
confidenceintervals.Multivariateanalysiswasperf
ormedto  
lookforanyindependentassociationofacellularpro
fileortissueresponsewiththeclinicaldiagnosisofG
PA.Forthemultivariatelogisticregressionanalyses,
allstatisticallysignificantvariables(P<0.05)fromth
eunivariateanalyseswereincluded.SPSS17andGr
aphPadPrism5.01wereusedtoper-
formthestatisticalanalysis. 
Results 
 
Twohundredandthirty-fourpatientswereiden-
tifiedfromtheUCLInstituteofOphthalmologypathol
ogydatabaseashavingundergoneorbit- 
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albiopsyforanorbitalinflammatoryconditionbetw
een1988and2009,andforwhomfullclinicaldetai
lswereavailable.Ofthese,36patientsfulfilledourc
riteriaforthediagnosisofGPA.Diseasesinthenon-
GPAgroupincludedchronicidiopathicinflammatio
noftheorbit(CIIO)in74/198patients(37%),lymph
oidhyperplasiain16(8%),sarcoidosisin13(7%), 
myositisin3(2%),dacroadenitisin33(17%),andth
yroideyediseasein12(6%).Patientcharacteristic
sareincludedinTable1,andindicate  no 
significantdifferences  betweentheGPAandnon-
GPAgroups. 
ClinicalcharacteristicsoforbitalGPA 
 
Ofthe36patientsintheGPAgroup,twopatients(6
%)hadsystemicGPA(thatis,withrenalorlowerairw
ays involvement)and34 
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(94%)hadlimiteddisease.Seventeen(47%)hadbee
ndiagnosedwithGPAbeforetheirocu-
larsymptomscommencedandhadreceivedtreatm
entintheformofcorticosteroids,withorwithoutsec
ond-
lineimmunosuppression;theremaining19(53%)h
adadiagnosisofGPAbasedontheiroculardisease.T
hemostcom-
monocularpresentationsintheGPAgroupwerepro
ptosis(55%),lidswelling(44%)andscleritis(32%).Ot
herocularpresentationsincludeddiplopia,epiphor
a(nasolacrimalblock),ocularpainanddecreasedvi
sion.Interestingly,andinagreementwithrecentstu
dies,nopatientswithlimitedGPAwereobservedtop
rogresstothesystemicformofGPAduringthedurati
onofthisstudy[15,16].Thedurationoffollow-
upinthisstudywasamedian36months(range24to
190months;708patient-yearsintotal). 
 
Biopsyfeaturespredictiveofclinicalfeaturescon
sistent withadiagnosisof GPA 
 
Intheunivariateanalysis,neutrophils,eosino-
phils,vasculitis,macrophagesandnecrosiswerepr
esentsignificantly  
moreoftenintheGPAgroupthaninthenon-
GPAgroup(Table2).Amultivariateanalysis,controlli
ngforcon-
foundingfactors,showedthatneutrophilsandvasc
ulitis  areindependently  associated 
withtheclinicaldiagnosisofGPA-withoddratiosof 
3.9and4.8respectively. 
 
TwelvepatientswereANCA-positive,11wereANCA-
negativeandtheremaining13patientsdidnothave
anyANCAlevelsonrecord–
beingpatientswithanestablisheddiagnosisofGPA
priortotheirophthalmicpresentation.Therewasatr
endforeosinophils(P=0.08)andlym-
phocytes(P=0.09)tobeseenmorefrequentlyinthe
ANCA-positivegroupthanintheANCA-
negativegroup. 
 
Justoverahalf(19/36)ofthepatientswerenewlydia
gnosedwithGPAand17hadaknowndiagnosisofGP
Apriortoophthalmicpresenta-
tion,including2patientswithsystemicGPA.Allpatie
ntswithestablishedGPAhadpreviouslyreceived,or
werestillon,immunosuppressivetreatment.Presu
mablyduetoalackofpriortreatment,cellular  
infiltration    was    greater  
inpatientswithoutapriordiagnosisofGPAandthech
angesincludingthepresenceofnucleardebrisandg
iantcells,bothofwhichwereseenonlyinpatientswit
houtpriortherapy. 
Discussion 
 
ThediagnosisofophthalmicGPAisdifficult,asitsclin
icalmanifestationsoftenoverlapwithother 
inflammatorydisorders. 
Furthermore,ANCAtitresarepositiveinonly50-
65%ofsuchpatients,andclassichistologicalfeatur
esarealsofrequentlyabsentfrombiopsymaterial;t
hisbeingincontrasttodiseaseaffectingotherorgan
s,suchasthekidney[5,7,11,13].Nevertheless,thisi
nvestigationindicatesthattherearesignificantdiff
erencesinthecellularandtissueprofileinbiopsiest
akenfrompatientswhowilllaterbeassignedadiagn
osisofGPA,ascomparedtootherdiseases,thepres
enceof  infiltratingneutrophils  and  vasculi-tis 
beingindependentlyassociated  witha  clini-
caldiagnosisofGPA.BiopsiesfrompatientswithGP
Aalsoshowmanymoreinflammatorycellsascompa
redtoothertypesoflymphocyticorbitalinflammator
ydisorders,whichreflectsthetendencytoamoreful
minantdiseasewithGPA. 
 
Previousstudieshavesuggestedthateosino-
philsplayapartinthepathogenesisofGPAand,inon
estudy,thepresenceofeosinophilsinbiopsiesofpat
ientswithlimitedGPAwassaidto 
bepredictorofdiseaseprogression 
[7].Inourstudy,aunivariateanalysisdidindicatesig
nificantlymoreeosinophilsinpatientswithGPA,butt
hiswaslostwhenotherconfoundingfactors  were 
controlledfor,suggesting 
thatthenumberoftissueeosinophilsmightbeassoc
i-
atedwithdiseaseseverity,ratherthanbeingassocia
tedwithGPAinparticular. 
 
Nucleardebrisisanentitythathasrecentlybecome
asubjectofinterestinGPAandisthoughttooriginate
fromtheruptureofnucleiofneutrophilsinthetissue
ofpatientswithGPA,possiblyasaresultofANCAacti
vity[9,12].Inourstudy,nucleardebriswasseenmor
efrequentlyintheGPAgroup,butthismightbeunderr
epresentedaspathologistsmaynothavespecificall
yreportedthisphenomenoninthepast;furtherqua
ntitative  evaluation 
ofthisentityinorbitalbiopsieswouldbeinterestinga
ndbeneficial.Inaddition,the  efficacyofritux-
imabincertainpatientswithGPAimplicatesarolefor
Bcellsintheaetiologyandperpetua-tionofdisease, 
and  furthercharacterisation 
ofthesecellsatdifferentstagesofdiseasewouldbe
ofinterest [5,17,18]. 
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Interestingly,despitethelimitationthatallofthe
cellularprofilesinthisstudywerebasedonhisto
pathologicalreports,wewerestillabletodetects
ignificantdiffer-
encesincellularactivitybetweentheGPAandno
n-
GPAgroup.Developingagradingsystemforthec
ellularandtissueprofilesshouldprovideacleare
rpictureofcellularactivity  in  these  orbital 
biopsies,  and  there-
byenableamoreaccuratecomparisontobemad
ebetweenorbitalbiopsies. 
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Abstract 
Histology investigation from orbital biopsies plays an important role in the diagnosis of orbital 
granulomatosis with polyangiitis (GPA). However classical histological features of GPA in orbital tissues 
may not always be present and the histology picture regularly appear similar to other orbital 
inflammatory diseases (OID). Despite this, disease progression in orbital GPA usually runs a more severe 
course compared to OID. Subjective histopathology reports have shown that biopsies of orbital GPA 
appear to have higher cellular activity when compared to OID. In this study, we performed Haematoxylin 
and eosin (H&E) and immunohistochemistry stain to objectively count and compare the cellular activities 
and tissue changes between orbital biopsies of GPA and other OIDs. We also observed for any distinctive 
feature in the histology for orbital GPA. Our findings objectively confirmed that the inflammatory activity 
was more in orbital GPA compared to other OID. However, no distinctive feature for the diagnosis of 
orbital GPA was identified. Nevertheless, cytokines IL-17 and IL-23 and B-lymphocytes with B-cell 
activating factor receptors (BAFF-R) were seen significantly more in orbital GPA, suggesting that they may 
have a large influence in the pathogenesis of GPA and can potentially be of value in the diagnosis of this 
disease.  
Introduction 
Granulomatosis with polyangiitis (GPA), previously known as Wegener’s granulomatosis, is an idiopathic 
granulomatous inflammatory disease that forms part of the spectrum of anti-neutrophil cytoplasm 
antibody (ANCA) associated vasculitis(1). Pathologically, the disease is characterised by granulomatous 
inflammation, vasculitis involving small and medium vessels and patchy necrosis.  GPA can generally be 
divided into two forms: systemic GPA or localised GPA. Systemic GPA refers to major organ involvement, 
in particular renal disease, and can be life-threatening. In contrast, localised GPA is more confined, 
involving one or two organs, such as the eye and/or the upper respiratory system and is generally not 
life-threatening. In up to 95% of cases, patients present with head and neck disease(2).  Ocular 
involvement occurs in 50-60% of patients (3) and is the presenting feature in 8-16%; severe ocular 
morbidity may be a complication of both localised and general GPA(3).Orbital involvement is present in 
about a half of patients with GPA, which may be secondary to spread from the sinuses, occur as part of 
systemic GPA or just localised to the periocular area; simultaneous orbital and intraocular disease occurs 
only rarely. 
The diagnosis of GPA is often challenging, especially if localised (such as orbital GPA), as the clinical 
presentation maybe non-specific and often indistinguishable from other orbital inflammatory diseases 
(OIDs) such as idiopathic inflammatory orbital disease (IIOD) and orbital sarcoidosis. Serologic testing for 
serum anti-neutrophil cytoplasm antibody (ANCA), an antibody intimately associated with GPA, is usually 
advocated to aid diagnosis but with localised disease ANCA is often negative at presentation and is 
detected in fewer than two-thirds of patients with time(4)(5), as compared to 90% in those with 
generalised disease(6).Although imaging is useful in GPA to assess the extent of disease, its diagnostic 
value is limited. 
  
Histological examination plays an important role in the diagnosis of GPA and should be used where 
possible. The absence of major vessels in orbital biopsies can, however, make the diagnostic vasculitic 
changes hard to find in orbital biopsies from patients with localised GPA; in nasal and orbital biopsies, for 
example, typical histological findings are seen in less than a third of patients(7).  In most patients with 
localised GPA, the difficulty in interpretation of the tissue biopsy and the low rate of ANCA positivity not 
uncommonly leads to a significant delay to diagnosis and possibly and consequential risk of widespread 
disease. 
Orbital involvement in GPA can lead to more severe disease than other causes of orbital inflammation.A 
recent report observed more neutrophil infiltration in biopsies from patients with GPA but did not find 
any distinctive features diagnostic for orbital GPA(8).Sarcoidosis is also characterized by granulomatous 
inflammation but the disease course of orbital GPA and sarcoidosis can bedissimilar, the latter tending to 
cause chronic lacrimal gland inflammation with a lower incidence of more widespread or posterior 
disease. 
These clinical observations suggest that different inflammatory pathways occur in GPA as compared with 
other inflammatory orbitopathies, with T-cell CD134 (cluster of differentitation 134) and T-helper 17 
(Th17) markers, as well as B-cell markers, implicated in the pathogenesis of GPA(9)(10)(11)(12). CD134, 
also known as OX40, is a member of the tumour necrosis factor receptor (TNFR)family of receptors and 
plays a critical role in maintaining an immune response by preventing activated T-cell death. Th17 cells, 
producing interleukin (IL) 17, play an important role in inducing and mediating a pro-inflammatory 
response by enhancing T-cell priming and stimulating the production of other pro-inflammatory 
molecules (including IL-1, IL-6, and tumor necrosis factor (TNF)).   IL-23 is known to stimulates naive CD4-
positive T-cells to differentiate into Th17 cells and has been associated with other autoimmune diseases, 
such as Crohn’s disease (13) as well as ANCA-associated vasculitis (AAV) (14).B-cell activating factor 
(BAFF), also known as B lymphocyte stimulator (BLyS) or “tumour necrosis factor ligand superfamily 
member 13C”, belongs to the TNF ligand family and is a ligand for the BAFF receptor (BAFF-R). BAFF is a 
potent B-cell activator and plays a role in the proliferation and differentiation of B-cells during an 
immune response.  All such studies report, however, surrogate markers in the serum and the tissue 
levels of pro-inflammatory chemokines and cytokines remains unknown. 
In this study we investigate thedifferences in cellular infiltrates in orbital tissuesfrom patients with orbital 
GPA and other OID, by objectively comparing and quantifying the different T-cell types and tissue 
changes. Weused immunohistochemistry (IHC) to investigate expression of tissue cytokines, to 
determine whether IHC could have a role in early diagnosisof orbital inflammatory diseases. The main 
findings of the study arethat the tissue expression of IL-17, IL-23 and BAFF-Raresignificantly greater 
among patients presenting with orbital GPA than in patients diagnosed with sarcoidosis and IIOD, 
suggesting a possible early diagnostic role for such 'sentinel' biomarkers. 
Method and materials 
Ethical approval 
The study was approved by the Moorfields& Whittington Research Ethics Committee (REC ref. no. 
09/H0721/75, LIGS 1023). 
Patient selection 
  
All patients who, between 1988 and 2009, had undergone biopsy of periocular tissues for orbital 
inflammatory disease were identified from the Institute of Ophthalmology Eye Pathology Database and 
their case notes reviewed.  The biopsy was only included in this study if the diagnosis and management 
of their orbital disease was based on their having features from two or more of the following groups: 
clinical history, clinical manifestations, biochemical investigations or radiological features.  Biopsies from 
patients in whom the diagnosis and management of their orbital disease wasbased entirely on the 
histological appearance were excluded from this study. 
Tissue selection 
Paraffin blocks of tissue biopsies were retrieved from archive at the Department of Eye Pathology, UCL 
Institute of Ophthalmology.Paraffin blocks were anonymised by using the pathology numbers that 
matched an allocated patients’ study number. Haematoxylin and Eosin (H&E) staining was performed on 
all blocks for general cellular analysis and then, for specific immunohistochemical (IHC) staining, patients 
were further divided on the basis of their clinical diagnosis.  Paraffin blocks of 25 patients from the 
orbital GPA group and 25 patents from the IIOD group were randomly selected for IHC analysis. Due to 
insufficient tissue in one case, only 13 blocks from the 14 patients with a clinical diagnosis of orbital 
sarcoidosis were available for IHC.  
Antibodies 
Antibodies used are listed in Table 4 
Slide preparation and H&E staining 
Five μm thick tissue sections were cut using a sledge microtome and mounted on Superfrost-plus object 
glass slides. The slides were left on a hot plate at 40°C for 60 minutes and then incubated overnight at 
37°C before use.  Haematoxylin and eosin (H&E) staining was performed on all slides using a 
standardlaboratory protocol. 
Immunohistochemistry staining of fixed paraffin tissues 
Tissue sections were dewaxed in two changes of xylene (each of 5 to 10 minutes) with agitation at 
regular intervals, then twice with 100% ethanol (10 to 20 seconds), and then hydratedsequentially in 
90%, 70%, and 50% ethanol -- each for 10 to 20 seconds -- followed by two washes in water. Sections 
were incubated in the appropriate antigen retrieval solution: Tris/EDTA pH 9.0 (H-3301, Vector Labs, UK) 
for CD3, CD4, CD20 and CD68; sodium citrate pH 6.0 (H-3300, Vector Labs, UK) for CD134, IL-17 and IL-
23); and heat-induced epitope retrieval was performed using pressure cooker at 95°C. Slides were then 
cooled under running water and left immersed in Tris-buffer solution (9L distilled water + 1L DAKO Wash 
Buffer 10X (Code S3006; DAKO UK) for 5 minutes. CD3 (1:400), CD4 (1:50), CD8 (1:50), CD20 (1:200) and 
CD68 (1:100) stainings were performedby the DAKO Autostainer Plus.  
For CD134 (1:200), IL-17 (1:800), BAFF-R (1:50) and IL-23 (1:400), IHC preparation was performed 
manually: After de-waxing and antigen retrieval (v.s.), the slides were placed in a moist chamber, the 
tissues kept hydrated with Tris-buffer solution, and the tissue encircled using a hydrophobic barrier pen 
(ImmEdge Pen H-4000). Primary antibodies, diluted in blocking solution, were added and left to incubate 
overnight at 4°C. Washing with Tris-buffer was performed after each incubation step. The LSAB+, Dako 
REAL™ Detection Systems kit (K5001 HRP/DAB+, Rabbit/Mouse or K5005 AP/RED, Rabbit/Mouse; DAKO, 
UK) was used for visualization. Finally, the slides were counterstained with haematoxylin, mounted with 
DPX mounting medium and cover slips, and then allowed to dry overnight before imaging. 
  
Imaging and image analysis 
Haematoxylin &Eosin 
Images of whole slides were acquired using the Hamamatsu Nanozoomer Digital Pathology Scanner and 
the counts for cell-types and tissue changes were obtained using the ImageScope image analyser and 
ADCIS ® Stereology Toolkit. Cell counts were performed for neutrophils, eosinophils, lymphocytes, 
macrophages, plasma cells, giant cells and mast cells. Tissue changes characterized were nuclear debris, 
granulomas, vasculitis, necrosis and fibrosis. 
The ADCIS ® Stereology Toolkit frame count programme was used for cell counting: initially the border of 
the whole tissue section was defined manually and then the region of interest was identified within the 
image of the tissue section. The software was programmed to generate 20 random counting frames 
within the region of interest, each counting frame measuring 1mm x 1mm and consisting of two inclusion 
lines (right and top borders) and two exclusion lines (left and bottom borders). A total area of 20mm
2 
was therefore analysed for every slide, with cells inside the frame and not touching the exclusion lines 
being included in the count.  In all 20 frames, each cell type was identified manually and marked using 
different specific colours. The computer then assessed the total number of marked cells for each cell 
type, to generate the total counts. 
For tissue changes, the ADCIS ® Stereology Toolkit point count programme was used. The region of 
interest was identified from the slide image as previously described and the software was then 
programmed to generate 20 random points (marked with X) within the region of interest. Different 
colourcodings were assigned to different tissue changes and eachof the 20 randomly-chosen point was 
marked accordingly if that particular tissue change was present.  The computer then summates the 
number of ‘hits’ for each tissue change. 
Immunohistochemistry 
The ADCIS ® Stereology Toolkit frame count programme was used as before but, for IHC, 50 counting 
frames (instead of 20) were randomly generated by the software, giving a total analysis  of 50mm
2 for 
every slide.  The total number of marked cells was censused using the same edge-convention for 
counting. 
Data analysis 
Cell counts were entered into an Excel spreadsheet. For H&E analysis the patients were classed as 
clinically-diagnosed orbital GPA or non-GPA (other OIDs), and cell and tissue counts were compared. 
Further sub-analysis was also performed within the orbital GPA group. For IHC, quantitative comparisons 
of the individual stained cells were done between the GPA, IIOD and sarcoidosis groups. 
Statistical analysis 
The non-parametric count comparisons for general cellular and tissue analysis (H&E stains)between 
orbital GPA and non-GPA were performed using Mann-Whitney tests with SPSS17. Multivariate analysis 
was carried out with SPSS17 to look for any independent association between the cellular profile or 
tissue response and the diagnosis of GPA. 
Kruskal-Wallis test was performed using GraphPad Prism 5 for comparisons of the non-parametric IHC 
cell counts between orbital GPA, IIOD and orbital sarcoidosis, and a secondary analysis used Dunn’s 
Multiple Comparison Test to compare groups. 
  
Results 
A total of 234 patients with a clinical diagnosis of orbital inflammation were identified from the Institute 
of Ophthalmology(UCL)Eye Pathology database, and  fulfilled the inclusion criteria (see methods); 239 
tissue blocks of orbital biopsieswereretrieved.  With review of the pathology, the final diagnoses were 
GPA 39 (16%), IIOD 65 (27%), dacryoadenitis 35 (14%), lymphoid hyperplasia 23 (10%), sarcoidosis 14 
(6%), thyroid eye disease 12 (5%), orbital myositis 4 (2%); the diagnoses in the remaining 47 specimens 
included ruptured dermoid cyst, dacryocystitis, mucocoele, orbital xanthogranuloma, Churg-Strauss 
syndrome and post-surgical granulomas. Tissue IHC was performed on 63 orbital biopsies from 63 
patients, consisting of25 consecutive specimens where a clinical diagnosis of GPA was secured, 25 
specimens from patients with IIOD, and 13 with orbital sarcoidosis(1 had insufficient tissue). 
Haematoxylin&Eosin analysis 
Orbital biopsies from GPA patients appearedmore cellular thanthose from other OIDs (Figure 1), with the 
cell-counts for each cell-type and the tissue changes summarized in Table 1.  Neutrophils (p=<0.001), 
eosinophils (p=0.002), macrophages (p=<0.001), nuclear debris (p=0.011), vasculitis (p=<0.001) and 
necrosis (p=<0.001) were found to be significantly more abundant in the orbital GPA group compared to 
non-GPA group (Table 1). Multivariate analysis showed that necrosis and vasculitiswereindependently 
associated with the clinical diagnosis of GPA, with an odds ratio of 2.40 (p<0.001) and 1.33 
(p<0.001),respectively. Nevertheless,12/39 (31%) of orbital GPA biopsies did not show any necrosis andin 
5 (13%) cases there was neither vasculitis nor necrosis.  Granulomas were significantly less frequent in 
GPA as compared to non-GPA (odds ratio (OR) = 0.12, p=0.02) (Table 1). 
Immunohistochemical analysis 
Comparisons of IHC staining between three orbital pathologies are summarized in Table 2: CD3 and CD68 
expressions showed significant differences between the three diseases, but further analysis showed that 
the differences were only between GPA and IIOD (Figures 2 and 3). 
Three cytokines or receptors; namely IL-17 (p=0.002), IL-23 (p<0.001) and BAFF-R (p=0.008), showed 
distinct differences between the three pathologies: further analysis (post-hoc) with Dunn’s multiple 
comparisons revealed these three cytokines/receptors wereexpressed significantly more in GPA biopsies 
as compared to both IIOD and orbital sarcoidosis (Table 3; Figures 4-6Error! Reference source not 
found.).  A raised IL-17 count was more likely to be found in orbital GPA than in IIOD or orbital 
sarcoidosis.Likewise, high IL-23 counts are 9 times more likely in orbital GPAthan IIOD (OR=9.3; CL 1.05-
82.8), and not likely to be present in orbital sarcoidosis.Biopsies with a high BAFF-R count were 6 times 
more likely in orbital GPA, as compared to both IIOD (OR=6.6, CI=0.65-55.7) and orbital sarcoidosis 
(OR=6, CI=0.65-55.7). 
Histology and clinical correlation analysis within GPA group 
Of the GPA group, 18/39 tissue samples were from patients newly-diagnosed with GPA and the 
remaining 21 had known GPA; having been treated for other clinical manifestations before orbital 
presentation. Patients with known GPA had significantly greater eosinophil counts and a trend towards 
increased macrophage infiltration (p=0.045 and p=0.06, respectively). 
Other comparisons in the GPA group 
  
There was no difference in cell and tissue counts with regards to ANCA status (positive versus negative), 
disease extension (generalized versus localized GPA) and treatment regimen (single versus multiple 
therapies). 
Discussion 
The diagnosis of orbital GPA is challenging and tissue biopsy is anticipated to be important in confirming 
a suspected clinical diagnosis but this is not always possible. The clinical presentation  of orbital GPA can 
be similar to other forms of orbital inflammation and diagnostic tests, such as serum ANCA and orbital 
CT, lack sensitivity and specificity. 
Histopathology from GPA orbital biopsies show a significantly higher inflammatory activity as compared 
to other OIDs (8), and this study was designed to quantify and compare the cellular and tissue 
inflammatory responses in orbital GPA and other OIDs.  Based on morphology and IHC markers, the 
distribution of cell types present were compared across different forms of OID to determine which, if 
any, might be practical diagnostic biomarkers. Our study showed three biomarkers that are significantly 
elevated in GPA orbital biopsies – namely,IL-17, IL-23 and BAFF-R that are significantly higher in the 
orbital biopsies of GPA patients as compared to those with IIODor sarcoidosis. 
IL-17 is a pro-inflammatory cytokine produced by Th17 cells, a subset of T-helper cells, that are 
considered to be distinctly developed from Th1 and Th2 (15). Th17 cells have been reported in many 
autoimmune and chronic inflammatory diseases, such as rheumatoid arthritis (16), psoriasis (17)(18), 
Crohn’s disease and systemic lupus erythematosus (19). In the eye, Th17 cells have been shown to play a 
role in ocular inflammations, such as in uveitis and scleritis(20), Behcet’s uveitis (21)(22)and the uveitis 
associated with Vogt-Koyanagi-Harada disease(23). 
Th17 cells have also been reported to be instrumental in the pathogenesis of ANCA-associated vasculitis 
(AAV)(24)(14), particularly GPA. In ANCA-positive GPA patients, Th17 cells were found to be skewed upon 
stimulation of PR3 (11), and seen to be expanded in both active and quiescent GPA when compared to 
healthy individuals (10). Our IL-17 finding concurswith these reports and also affirms the possible role of 
IL-17 in the pathogenesis of GPA.  Bronchial tissue granulomas and circulating memory T-cells in 
sarcoidosis are reported to have an increased expression of IL-17A, this possibly being involved in the 
induction and maintenance of granulomas (25). Involvement of IL-17A in granuloma induction and 
maintenance was not mirrored in our orbital GPA biopsies, where higher IL-17A expression was 
accompanied by few granulomas. This suggests that IL-17 might have a different mechanism of action in 
the pathogenesis of GPA and sarcoidosis. 
The significant increase in IL-23 in GPA,as compared to both IIOD and sarcoidosis, is particularly 
interesting. IL-23 is produced by macrophages and dendritic cells and its role in inflammation is primarily 
established as a crucial factor in the development of Th17 and IL-17 cytokine production(26). 
Nevertheless, IL-23 alone has been shown to induce disease: IL-23 has been shown to inducearthritis and 
osteoclast formation in animals, with resultant bone destruction, this being independent of IL-17A (27).  
A similar mechanism might explain the sino-orbital bone destruction seen in GPA, but which does not 
occur in orbital sarcoidosis or IIOD. IL-23 has also been related to disease severity: in AAV, including 
GPA,patients with elevated levels of IL-23 had more active disease compared to those with low IL-23 
(14). 
In autoimmune diseases, IL-23 has been shown to drive pathogenic T-cells that induce autoimmune 
inflammation by expanding self-reacting IL-17, TNF and IL-6 producing T-cells (28).  Indeed, the IL-23/IL-
  
17 pathway has been shown to be involved in several autoimmune diseases, such as Crohn’s disease (13) 
and Vogt-Koyanagi-Harada disease (23).  As compared to healthy individuals, serum IL-17 and IL-23 levels 
in AAV are significantly higherand remained elevated in a proportion of convalescent patients (14). To 
our knowledge this is the first report to show the presence of raised IL-17 and IL-23 in inflammatory 
orbital tissues, and also the first to identify a significant rise in tissue IL-23 in orbital GPA as compared to 
other forms of orbital inflammatory disease. 
Rituximab, a monoclonal anti-CD20 antibody, has been found to be effective in treating refractory AAV 
(29), including refractory ophthalmic GPA (30), this implicating the role of B-cells in GPA(31).  The B-cell 
activating factor receptor (BAFF-R), expressed on B-lymphocytes, selectively binds cytokine B-cell 
activating factor (BAFF) (32), a member of the tumournecrosis factor (TNF) ligand family which, like 
APRIL(a proliferation-inducing ligand), acts as potent B-cell activator and plays an important role in their 
proliferation and differentiation. BAFF-receptor activation is crucial to the survival and maintenance of 
mature B-cells (33)(12), and BAFF is known to be elevated in the serum and inflamed musosal surfaces of 
patients with GPA (34)(35)(12).  Serum levels of BAFF are also elevated in chronic active sarcoidosis, as 
compared to healthy people or patients with inactive sarcoidosis(36).  Although CD20 counts in our study 
were similar between orbital GPA and IIOD, and between orbital GPA and sarcoidosis, orbital GPA tissues 
were found to exhibit the highest levels of BAFF-R. This suggests that, while B-cells probably have a role 
in all three diseases, prolonged B-cell survival and the ability of B-cells to remain activemight be a 
differentiating factor in the manifestations and severity of orbital GPA. 
The H&E tissue analysis of this study confirmed our previous report of increased cellular infiltrationin 
orbital GPA,as compared to other OIDs(8).  In addition, this study also showed that vasculitis and necrosis 
were features independently associated with the diagnosis of orbital GPA. This finding is consistent with 
the histology of GPA in other organs. Pulmonary necrotizing vasculitis is said to be the single most 
important feature in the histologic diagnosis of GPA (37) and, likewise, the main histological feature in 
patients with active renal GPA is segmental glomerular necrosis (38). Together with the higher tissue 
inflammatory cell infiltrate, the presence of vasculitis and necrosis in GPA orbital tissuesreflect the more 
severe and destructive nature of orbital GPA, compared to other OIDs. Nevertheless, it is important to 
acknowledge that vasculitic and necrotic changes might be absent in orbital biopsies although clinically 
the diagnosis is confirmed to be orbital GPA -- thereby highlighting the importance of biomarkers. The 
biopsies in orbital GPA often display a more varied and denselycellular appearance than other forms of 
OID, this histology being mirrored in pulmonary biopsies from GPA -- described as areas with a deeply 
basophilic, “dirty” appearance due to the presence of neutrophils and nuclear debris (39)(37). 
GPA pathology is classically described as a granulomatous inflammation with vasculitic and necrotic 
features and so, in our study, it was unexpected to find that granulomas were inversely associated with 
the diagnosis of orbital GPA. A granuloma is typically described as a distinctly organized “ball or nodule-
like” collection of macrophages, in response to infection or inflammation. GPA and sarcoidosis are both 
described as granulomatous inflammations, although this term is probably more consistent with the 
histology of sarcoidosis, in which discrete, well-formed interstitial non-necrotizing ganulomas are seen 
(37). In GPA, the term ‘granulomatous inflammation’ is ill-defined (40) and, even in lungs, the compact, 
“sarcoid-like,” non-necrotizing granulomas are said to be exceptional.  Pulmonary granulomas with GPA 
tend to be suppurative or neutrophil-filled, and have an irregular contour -- unlike the granulomas seen 
in sarcoid or infection (37). The histology of our orbital GPA biopsies showed an inflammatory picture 
with abundance of macrophages, neutrophils and nuclear debris, but distinct granuloma formation was 
rare. 
  
The role of eosinophils inGPA is unclear, although their presence in orbital GPA has been 
documented(41)(42).  We found eosinophilsto be more frequent in orbital GPA as compared to other 
OIDs, and also to be marginally more in patients with known systemic GPA.  This finding might suggest 
either that the recruitment of eosinophils is higher during recurrent GPA, or that eosinophils in orbital 
GPA persist despite treatment and are retained in affected peripheral tissues.  Thus, eosinophils might be 
associated not only with disease severity (as indicated in our previous report (8)), but also the chronicity 
or relapseof orbital GPA. 
Conclusion 
There exist clear differences in the histology and cellular infiltrates in orbital GPA when 
compared to other OIDs.  The heightened expression of IL-17, IL-23 and BAFF-R seen in the 
biopsies of orbital GPA could both serve as early diagnostic markers for disease, and also 
provide new insights into the underlying inflammatory pathways. Early identification of such 
markers in patients with orbital inflammation could prompt the clinician to consider a diagnosis of 
GPA and instigate earlier treatment of a potentially sight- and life-threatening disease.    
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Figure 1Representative tissues (H&E) showing (A&B)orbital granulomatous polyangiitis 
with a ‘darker’ stained tissue and a more densely cellular appearance; (C&D) tissues from 
patient with idiopathic orbital inflammatory disease; (E&F) orbital sarcoidosis showing 
distinct granulomas.  
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Figure 2CD-3 staining on orbital tissues from patients with (A) orbital granulomatous 
polyangiitis (“GPA”), (B) idiopathic orbital inflammatory disease (“IOID”) and (C) orbital 
sarcoidosis (“S”).    (D) Scatter plot showing the mean count of CD-3 for each of the three 
orbital diseases. 
 
 
 
 
           
 
  
   
 
 
   
Figure 3CD-68 staining on orbital tissues from patients with (A) orbital granulomatous 
polyangiitis (“GPA”), (B) idiopathic orbital inflammatory disease (“IOID”) and (C) orbital 
sarcoidosis (“S”).    (D) Scatter plot showing the mean count of CD-68 for each of the 
three orbital diseases. 
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Figure 4IL-17 staining on orbital tissues from patients with (A) orbital granulomatous 
polyangiitis (“GPA”), (B) idiopathic orbital inflammatory disease (“IOID”) and (C) orbital 
sarcoidosis (“S”).    (D) Scatter plot showing the mean count of IL-17 for each of the 
three orbital diseases. 
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Figure 5IL-23 staining on orbital tissues from patients with (A) orbital granulomatous 
polyangiitis (“GPA”), (B) idiopathic orbital inflammatory disease (“IOID”) and (C) orbital 
sarcoidosis (“S”).    (D) Scatter plot showing the mean count of IL-23 for each of the 
three orbital diseases. 
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Figure 6BAFF-R staining on orbital tissues from patients with (A) orbital granulomatous 
polyangiitis (“GPA”), (B) idiopathic orbital inflammatory disease (“IOID”) and (C) orbital 
sarcoidosis (“S”).    (D) Scatter plot showing the mean count of BAFF-R for each of the 
three orbital diseases. 
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TABLES 
Table 1: Cellular density in histological specimens from patients with GPA and non-GPA (the cell/tissue count was performed 
in 20 fields of 1mm
2 frame in each slide(total of 20mm
2 in each slide)) 
Cell & tissue 
changes 
GPA (n=39) 
Mean  ± SE 
Non-GPA (n=200) 
Mean  ± SE 
Unadjusted  Adjusted 
      p  OR  p 
Neutrophils  37.2  ± 10.4  11.1  ± 2.4  <0.001 *  0.99 (0.97 - 1.01)  0.26 
Eosinophils  50.0  ± 19.4  12.4  ± 2.4  0.002 *  1.00 (0.99 - 1.01)  0.50 
Lymphocytes  3292  ± 141  3672  ± 188  0.582     
Macrophages  290.5  ± 19.7  188.9  ± 8.8  <0.001 *  1.00 (0.99 - 1.01)  0.34 
Plasma cells  81.8  ± 16.5  66.3  ± 6.4  0.146     
Giant cells  0.26  ± 0.90  0.32  ± 0.10  0.066     
Mast cells  0.33  ± 0.20  0.12  ± 0.03  0.096     
Nuclear debris  3.7  ± 1.5  0.96  ± 0.30  0.011 *  1.08 (0.96 - 1.22)  0.19 
Granulomas  0.50  ± 0.40  0.55  ± 0.10  0.046 *  0.12 (0.21 - 0.71)  0.02* 
Vasculitis  7.1  ± 0.8  2.95  ± 0.2  <0.001 *  1.33 (1.15 - 1.54)  <0.001* 
Necrosis  3.0  ± 0.4  0.35  ± 0.75  <0.001 *  2.39 (1.73 - 3.30)  <0.001* 
Fibrosis  6.6  ± 0.5  7.6  ± 0.5  0.906     
* = p<0.05 
 
   
  
 
Table 2: Quantitative IHC cell count and comparison between orbital GPA (GPA), IIOD and orbital sarcoidosis (S) (the cell 
count was performed in 50 fields of 1mm
2 frames in each slide (total of 50mm
2 in each slide)) 
Cellular 
marker 
Orbital GPA 
 
[mean ±se (total)] 
IIOD 
 
[mean ±se (total)] 
Orbital sarcoidosis 
 
[mean ±se (total)] 
p 
 
(Kruskal-Wallis) 
p 
 
Post hoc multiple comparison 
 
 
CD3  5221 ±449 (130532)  3633 ±560 (90827)  4951 ±851 (64369)  0.03*  GPA vs IIOD  : p= 0.01* 
GPA vs S        : p= 0.5 
CD4  1157 ±145 (28914)  864 ±162 (21606)  955 ±198 (12422)  0.21   
CD8   1041 ±140 (26021)  764.5 ±15.1 (19113)  1015 ±267 (13200)  0.12   
CD68  2202 ±216 (55062)  1152 ±152 (28802)  1561 ±300 (20228)  0.013*  GPA vs IIOD   : p<0.001* 
GPA vs S         : p = 0.1 
* = p<0.05 
 
 
   
  
Table 3: Comparison of cytokine or receptors markers in tissues from patients with localised granulomatous polyangiitis 
(“orbital GPA”), idiopathic orbital inflammatory disease (“IIOD), and orbital sarcoidosis; cell counts performed in 50 fields of 
1mm
2 frames in each slide (total of 50mm
2 in each slide) 
Cell marker  Orbital GPA 
[mean ±se (total)] 
IIOD 
[mean ±se (total)] 
Orbital sarcoidosis 
[mean ±se (total)] 
p 
(Kruskal-Wallis) 
p (odds ratio) 
Post hoc multiple comparison 
 
IL-17   270 ±39 (6758)  88 ±9 (2212)  71  ±16 (924)  0.002*  GPA vs IIOD  : p <0.001 (high) 
GPA vs S        : p <0.001 (high) 
IL-23  3186 ±338 (79653)  1461 ±208 (36529)  1461 ±326 (18991)  <0.0001*  GPA vs IIOD  : p< 0.001 (9) 
GPA vs S        : p = 0.002 (high) 
BAFF-R  486+103 (12635)  203 ±34 (5080)  238 ±135 (3102)  0.008*  GPA vs IIOD  : p = 0.002 (6) 
GPA vs S        : p = 0.005 (6) 
CD20  1025 ±232 (25613)  1026 ±363 (25642)  932 ±213 (12117)  0.40   
CD134  94.6 ±18 (2365)  59 ±11 (1475)  150 ±37 (1955)  0.16   
* = p<0.05 
 
 
 
   
  
Table 4: Antibodies 
Markers  Antibody details  Information 
CD3  A0452, DAKO, Cambridgeshire, UK  A T-cell co-receptor that non-covalently associates 
with the T-cell receptor (TCR) and can be used as a 
specific T-cell marker. 
 
CD4  Clone 4B12; M7310, DAKO, 
Cambridgeshire, UK 
A surface protein expressed on mature Th cells, 
CD4-positive T-cells being considered to have a T-
helper cell function. 
 
CD8  Clone C8/144B; M7103, DAKO, 
Cambridgeshire, UK 
A co-receptor that is predominantly expressed on 
the surface of cytotoxic T-cells, and an also be 
found on natural killer cells, cortical thymocytes 
and dendritic cells. 
 
CD134  Clone ACT35; 555836, BD 
Pharmingen™,Becton, Dickinson 
and Company, Oxford, UK 
 
Also known as OX40, is a member of the TNFR-
superfamily of receptors. 
CD68  Clone PG-M1; M0876, DAKO, 
Cambridgeshire, UK 
A glycoprotein used as a marker for the various cells 
of the macrophage lineage. 
 
CD20  Clone L26; M0755, DAKO, 
Cambridgeshire, UK 
A surface protein expressed on surface of all B-cells 
thatenables optimal B-cell immune response 
specifically against T-independent antigens. 
 
BAFF-R  11C1; ab16232Abcam, Cambridge, 
UK 
A receptor expressed on B-lymphocytes which 
selectively binds cytokine B-cell activating factor 
(BAFF); a potent B-cell activator and plays a role in 
the proliferation and differentiation of B-cells. 
 
IL-17  IL-17A; AHP455G AbDSerotec, 
Kidlington, UK 
A pro-inflammatory cytokine produced by Th17 (a 
subset of T-helper cells) that has an important role 
in inducing and mediating pro-inflammatory 
responses. 
 
IL-23  H-113; sc-50303, Santa Cruz 
Biotechnology, Inc, Santa Cruz, CA, 
USA 
A cytokine produced by macrophages and dendritic 
cells and influences the development of Th17 and 
stimulates production of other pro-inflammatory 
molecules (including IL-1, IL-6, and TNF). 
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Editor, 
hthisis bulbioccurs as the end- 
stageofsevereoculardiseaseanddescribesa
softcollapsedglobecon- taining
  atrophic  and  disorganised 
intraocularstructures.Thereislittlein 
theliteraturepertainingtothedevel-opment 
ofphthisis following 
ocularinflammation(Saeedetal.2006;Setlu
r etal.2010),soweperformedacross-
sectional  study  of  4,000  
patientsattendingauveitisclinicatMoorfiel
dsEyeHospitaltoidentifypatientswithsever
evisuallossandphthisis.Severe 
visuallosswasdefinedasabest-cor- 
rectedvisualacuityof20⁄200orworse 
(Jabsetal.2005),andocularphthisis 
wasdefinedasasoftandshrunkenglobewith
evidenceofstructuraldisor- ganisation. 
Atotalof333patientswereidenti-
fiedwithseverevisualloss,indicating a 
prevalenceof 8.3%. Sixty-four of 
thesepatients (65eyes) werediagnosed 
with phthisis  (19%). 51⁄65 eyeshad 
noperceptionoflight(78%),10eyeshadperc
eptionoflight(15%),andfoureyeshadhand
movementsvision 
(6%).27⁄64patients(42%)hadvisual 
lossintheothereye,ofwhomhalfhadseverev
isualloss(SVL),rendering them  legally   
blind.The  meanageat 
onsetofphthisiswas54years(range  17–
97years)withaMale⁄Femaleratio 
of1.3:1.Thecausesofphthisisareindicatedi
nTable1.Themostcom-moncausewasnon-
infectiveuveitis,followedbytrauma,oculari
nfectionandocularsurgery.Phthisisoccurre
datmean2.9years(range0–23) 
aftertheinitiatingevent,butpatientsdevelop
ingphthisisfromuveitistooksignificantlylo
ngertodosoat6.4± 
7.2years(mean±SEM),comparedwithtr
auma(1.4±4.3years)andinfection(0.9±
1.2years)(p=0.03,Fisher’sexacttest). 
11⁄64patients(17%)werediagnosed 
withsympatheticophthalmia.Thisfol- 
lowedapenetratingeyeinjurytotheothereye
in8⁄11patients(73%),of 
whomsevenhadhadanearlyenucle-
ation;itfollowedretinaldetachmentsurgery 
in the other three patients 
(27%).4⁄11patients(36%)withsym- 
patheticophthalmiasufferedvisualloss,and 
3⁄11 (27%) had SVL; none of 
theexcitingeyesmaintainedvision.Uveitis
wasthemaincauseofphthi- 
sisinourstudy,accountingfor28%ofcases,c
loselyfollowedbytraumaandinfection.The
intervalbetweenthetimeofdiagnosisandthe
developmentofphthisiswasthelongestinthe
uve-itis  group.  Sympathetic  ophthalmia 
developedin17%ofourpatientswithphthisi
s,but7⁄8patientsinwhomit 
followedapenetratinginjuryhadhadanearly
enucleation,supportingrecent 
evidencethatprophylacticenucleation 
doesnot  preventthedevelopmentof 
sympatheticophthalmia(Kilmartinetal.2000;
Zhangetal.2009).Encourag-ingly,  most   
patients  retained  good 
functionalacuity,64%maintainingvisualac
uityof20⁄40orbetter,and 
73%maintainingvisualacuityofbet-
terthan20⁄200. 
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No. 
study 
number  Age  Gender 
known 
WG 
ANCA 
presentation 
ANCA 
later 
ANCA 
positive 
ANCA 
comments  diagnosis WG  Clinical dx comments 
1  2  38  F  N  Y  Y  Y  PR3+ve  1995  orbital WG with systemic features 
2  12  73  F  N  N  N  N 
 
1994  localised WG, max sinus granuloma 92 
3  14  64  F  N  N  N  N 
 
1998  WG, op notes only, DCR, no other info 
4  26  52  M  N  N  N  N 
 
2006  gran inflam?limited/orbital WG 
5  33  83  F  Y  U  U  N 
 
2001  known WG, no details 
6  50  28  M  Y  Y  N  Y 
 
1983  known WG nasal, orbital, for bilat DCR 
7  74  39  M  Y  N  N  N 
 
2003  WG 2003  sinus, middle ear, hearing loss mucocoele 
8  87  25  M  N  N  N  N 
 
2002  orbital and sinus wg 
9  90  53  M  N  N  N  N 
 
2005  poor vision since 1996, prev dx as neurosarcoid > bx brain, no sarcoid, be orbital mass 
10  91  86  M  N  Y  U  Y 
 
1998  orbital WG 
11  124  46  M  Y  N  N  N 
 
1989  known localised WG 89, bilat blocked NLD 
12  133  31  M  Y  Y  Y  Y 
 
1991  orbital WG, known systemic aortic, on Cyclophos 92 
13  135  57  M  Y  N  N  Y 
 
2003  WG, nasal, lung, kidney. Pp. Op notes only DCR 
14  147  14  F  N  Y  Y  Y   c-anca +ve   1999  Orbital WG 
15  192  36  M  Y  Y  Y  Y 
 
1998  orbital WG 
16  240  69  F  Y  N  U  Y 
 
2003  known WG diagnosed at another hospital, pulmonary fibrosis, ent (bleed, 2 ops), NLD obstn for DCR, ant uveitis and cmo post cat   
17  255  78  F  N  N  N  N 
 
1995  orb pseudotumour 
18  256  66  F  N  N  N  N 
 
2001  orbital WG 
19  258  26  F  Y  N  U  N 
 
1995  limited, known WG sinonasal, R NLD obsn, LS abscess 
20  272  71  F  N  Y  Y  Y 
 
1998  orbital WG 
21  291  35  F  Y  U  N  N 
 
1999  limited WG sinus orbits. TED for decomp 
22  294  35  M  N  N  U  N 
 
2009  cxr and kindney normal 
23  301  67  M  Y  N  N  Y 
 
2002  sinonasal WG 
24  303  57  F  N  Y  U  Y 
 
2006  ANCA raised in Hammesmith once 
25  305  30  M  N  Y  Y  Y 
 
2007  limited orbital WG 
26  307  35  F  Y  N  U  Y 
 
2008  known wg with nld block 
27  311  42  F  Y  Y  Y  Y  c anca  2005  limited wg, blocked nld, scleritis march 2005, dx wg oct 2005, collapse bridge 2006, epiphora 2008 > leaking left sinus 
28  317  54  M  N  N  Y   Y 
 
2008  orbital WG 
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29  338  27  F  N  N  Y   Y 
 
2007  symptom started 2005, histo syggestive but not confirmed with blood test, anca positive later in 2007,limited orbital WG left eye 
30  361  87  F  Y  N  N  N 
 
2005  limited WG - ent, orbit 
31  375  56  F  Y  U  U  N 
 
1996  known WG, blocked DCR 
32  390  65  F  Y  N  U  Y 
 
1986  known limited WG 1994 on MTX pred, R mucocoele DCR 
33  417  50  F  Y  Y  N  Y 
 
2000  WG clinically, limited, facial pain 
34  444  35  M  Y  Y  N  Y 
 
2007  known WG aorta, big vessels 
35  449  57  F  Y  Y  Y  Y 
 
1995  known systemic WG 1995 on Aza  
36  467  57  F  N  N  Y  Y  p-ANCA 160  2006  limited orbital WG 
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No. 
study 
number  Tissue  combi tissues  orbit 
LG 
presentn  Nld  Muscle/eyelid/conj  ent  lungs  heart  kidney  cns  progress 
1  2  O 
 
Y  N  N  N  Y  N  N  Y  N  N 
2  12  COMBI  O+L  Y  Y  N  N  Y  N  N  N  N  N 
3  14  O 
 
Y  N  N  N  Y  N  N  N  N  N 
4  26  O 
 
Y  N  N  N  N  N  N  N  N  N 
5  33  COMBI 
 
N  N  Y  N  Y  N  N  N  N  N 
6  50  COMBI  N+Ls  N  N  Y  N  Y  Y  N  N  N  N 
7  74  COMBI  Ls+N  N  N  Y  N  Y  N  N  N  N  N 
8  87  LG 
 
N  Y  N  N  N  N  N  N  N  N 
9  90  O 
 
Y  N  N  N  Y  N  N  N  N  N 
10  91  O 
 
Y  N  N  N  N  N  N  N  N  N 
11  124  COMBI  Ls+N  N  N  Y  N  Y  N  N  N  N  N 
12  133  COMBI  O+L+obicularis  Y  Y  N  Y  Y  Y  Y  N  N  N 
13  135  COMBI  Ls+N  N  N  Y  N  Y  Y  N  Y  N  N 
14  147  O 
 
Y  Y  N  N  Y  N  N  N  Y  N 
15  192  O 
 
Y  N  N  N  Y  N  N  N  N  N 
16  240  COMBI  Ls+O  Y  N  N  N  Y  Y  N  N  N  N 
17  255  O 
 
Y  N  N  N  Y  N  N  N  N  N 
18  256  N  nasal septum  N  N  Y  N  Y  N  N  N  N  N 
19  258  COMBI  N+Ls  N  N  Y  N  Y  N  N  N  N  N 
20  272  COMBI  enucleation  Y  N  Y  Y  Y  N  N  N  N  N 
21  291  O 
 
Y  N  N  N  Y  N  N  N  N  N 
22  294  O 
 
Y  N  N  N  Y  N  N  N  N  N 
23  301  COMBI  Ls+N  N  N  Y  N  Y  Y  N  N  N  N 
24  303  COMBI  O+L  Y  Y  N  N  Y  N  N  N  N  N 
25  305  O 
 
Y  Y  N  N  N  N  N  N  N  N 
26  307  COMBI  Ls+N  N  N  Y  N  Y  Y  N  N  N  N 
27  311  COMBI  Ls+N  N  N  Y  N  Y  N  N  N  N  N 
28  317  COMBI  L+O  Y  Y  N  N  Y  Y  N  N  N  N 
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29  338  O 
 
Y  Y  N  N  N  N  N  N  N  N 
30  361  COMBI 
 
Y  N  N  Y  Y  N  N  N  N  N 
31  375  COMBI  Ls+N+ethmiod  N  N  Y  N  Y  N  N  N  N  N 
32  390  COMBI  Ls+N  N  N  Y  N  Y  N  N  N  N  N 
33  417  LG 
 
N  Y  N  N  Y  N  N  N  N  N 
34  444  COMBI  O+Lid+skin  Y  N  N  Y  Y  Y  Y  N  N  N 
35  449  LG 
 
N  Y  N  N  Y  Y  N  N  N  N 
36  467  COMBI  LG+O  Y  Y  N  N  N  N  N  N  N  N 
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No. 
study 
number  main eye symptom  Laterality  VA R  VA L  final VA R  final VA L 
VA 
improve 
decreased 
VA 
decreased 
colour  pain  proptosis  diplopia 
1  2  proptosis diplopia  R  6/5  6/5  6/4  6/4  S  Y  N  N  Y  Y 
2  12  orbital swelling  R  6/18  6/12  NPL  6/9  N  N  N  Y  Y  Y 
3  14  blocked nld  L 
       
S  N  N  N  N  N 
4  26  lower lid swelling  L  6/9  6/9  6/9  6/9  S  N  N  N  N  N 
5  33  nld block > dcr  R  6/9  PL  6/12  PL  S  N  N  Y  N  N 
6  50  nld block > dcr  L  6/6  6/5  6/6  6/12  N  N  N  N  N  N 
7  74  nld obstruction, mucocele  R  6/6  6/6  6/5  6/6  S  N  N  N  N  N 
8  87  ul ptosis with mass  R  6/5  6/5  6/36  6/5  N  Y  N  Y  N  N 
9  90  poor vision and diplopia  B 
       
S  N  N  N  N  N 
10  91  lower lid swelling  R  6/9  NPL  6/12  NPL  N  Y  N  N  Y  N 
11  124  blocked nld  R  6/6  6/12  6/5  6/9  S  N  N  N  Y  Y 
12  133  swelling and diplopia  R  6/12  6/6  6/12  6/6  S  N  N  N  Y  Y 
13  135  nld block > dcr  B 
       
N  N  N  N  N  N 
14  147  ptosis, hypoglobus  L  6/5  6/12  NA 
 
S  Y  N  N  Y  N 
15  192  EOM limitation, previous scleritis, prev DCR RL  R  6/5  6/5  6/4  6/4  S  N  N  N  Y  Y 
16  240  epiphora/nld block/dacryocystitis  L  6/12  6/9  6/60  6/36  N  N  N  N  N  N 
17  255 
frozen orbit 1 year later despite steroids, sinusitis 
?WG  L  6/9  6/9  6/9  6/9  S  N  N  Y  Y  Y 
18  256  left ptosis and diplopia  L  6/5  6/6  6/4  6/5  Y  N  N  N  N  Y 
19  258  dacryocystitis > dcr  R  6/5  6/5  6/5  6/5  S  N  N  N  N  N 
20  272  scleritis  R  PL  6/5  A/E  6/4  N  Y  Y  Y  N  N 
21  291  epiphora/nld block/dacryocystitis  R  6/5  6/4  6/4  stable Feb 10  S  N  N  Y  Y  Y 
22  294  left proptosis and reduced vision with redness  L  6/5  HM  6/5  CF  S  Y  Y  Y  Y  Y 
23  301  nld block > dcr  L  6/5-2  6/5-2  6/6 
 
S  N  N  N  N  N 
24  303  left periorbital swelling  L  6/6  6/36  6/5  6/12, 6/6  Y  Y  N  Y  Y  Y 
25  305  left lac gland enlargement  L  6/6  6/6  6/4  6/5  S  N  N  Y  N  N 
26  307  nld block > dcr  L  6/5  6/5  6/5  good  S  N  N  N  N  N 
27  311  nld block > dcr  L  6/5  6/4  6/5  good  S  N  N  N  N  N 
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28  317  orbital swellinh  R  6/9  6/5  6/6  6/4  Y  Y  N  N  N  N 
29  338  orbital swelling, proptosis and diplopia  L  6/6  6/6 
   
S  N  N  Y  Y  Y 
30  361  diplopia and motility limitation, fibrosis, pain  R  6/12  6/12  NPL  not rx old frail, stable  N  N  N  Y  Y  Y 
31  375  nld block > dcr  R  6//9  6/6  6/9  disch  S  N  N  N  N  N 
32  390 
 
R  6/5  6/4  6/6  improved, disch  Y  N  N  N  N  N 
33  417  limitation, lid swelling, diplopia  L  6/6  6/6  6/6 
FU Hams, persistent facial 
pain  S  N  N  Y  N  Y 
34  444  painful orbital swelling and then nld block > dcr  L  6/5  6/5 
   
S  N  N  N  Y  Y 
35  449  dacryoadenitis  R  6/9  6/6  6/6  no active ds  S  N  N  Y  Y  N 
36  467  hypoglobus, scleritis, PUK 2 and 3 y later  L  6/6  6/9  6/9  6/12  S  Y  Y  Y  Y  N 
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No. 
study 
number  lid swelling  lid redness  red eye 
EOM 
limitation 
globe 
displacement  sinonasal  other signs 
Systemic 
present 
Systemic 
presentation 
Systemic 
later  Systemic details 
 
 
1  2  Y  N  N  Y  Y  Y  hypoglobus  N  N  N 
 
 
2  12  Y  Y  N  Y  Y  Y  epiphora, ptosis, frozen orbit; scleritis, LOV 2y later  N  N  N  unknown   
3  14  N  N  N  N  N  N 
 
N  N  N 
 
 
4  26  Y  N  Y  N  N  N  indurated mass L LL  N  N  N 
 
 
5  33  Y  Y  N  N  N  Y  dacryocystitis  U  U  U  known WG?system on Pred and Aza   
6  50  N  N  N  N  N  Y  epiphora 2000, sleritis 2004  N  N  N 
 
 
7  74  N  N  N  N  N  Y  R epiphora  N  N  N 
 
 
8  87  Y  Y  N  N  N  N  ocular surface  N  N  N 
 
 
9  90  N  N  N  N  N  N 
 
U  N  N 
 
 
10  91  N  N  N  Y  Y  N  lat globe displcm, optic neuropathy ?compressn  N  N  N 
 
 
11  124  N  N  N  Y  N  Y  epiphora bilat  N  N  N  sinonasal, arthritis   
12  133  Y  N  Y  Y  N  N 
R RAPD, disc swelling, sclerokeratitis, orbital oedema 
96  N  Y  Y  limited wg, tracheal, aortic inflm 91 on     
13  135  N  N  N  N  N  N 
 
Y  Y  N  lung, kidney, nasal   
14  147  N  N  N  Y  Y  N  ptosis, hypotropia  N  N  Y  DI, intracranial invovlem   
15  192  Y  Y  N  N  N  N  EOM limitation, previous scleritis, prev DCR RL  N  Y  Y  known limited WG on MMF, MTX, pred   
16  240  N  N  N  N  N  Y  epiphora  N  N  N  previous known WG ? Course ?rx   
17  255  Y  N  N  Y  N  N 
frozen orbit 1 year later despite steroids, sinusitis 
?WG  N  N  N  ESR 86   
18  256  N  N  N  N  N  N  LL retraction,conj-nasal fistula  N  N  N 
 
 
19  258  Y  Y  N  N  N  Y  R periorb cellulitis, LS abscess, epiphora  N  N  N 
 
 
20  272  N  N  Y  N  N  N  sclerokeratitis, pannus, AION  N  N  Y  deafness   
21  291  Y  N  N  N  N  Y 
 
N  N  N  previous epiphora dx WG   
22  294  Y  N  N  Y  Y  N  RAPD  N  N  U 
 
 
23  301  N  N  N  N  N  Y  epiphora, dacryocystitis  N  N  N  upper airways, nasal. Middle ear   
24  303  Y  Y  N  Y  Y  N  ON, ptosis, hypoglobus, subglottis stenosis  N  N  N 
 
 
25  305  Y  N  Y  N  N  N  LG swelling l>R, L conj congestion  N  N  N 
 
 
26  307  N  N  N  N  N  Y  epiphora  Y  Y  Y  known wg kidney and lung   
27  311  Y  Y  N  N  N  N  epiphora  N  Y  N  known wg, orbit and sinonasal   
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28  317  Y  N  N  N  N  N  R lid swelling recurrent  N  N  N 
 
 
29  338  Y  N  N  N  N  N 
 
N  N  N 
 
 
30  361  Y  Y  Y  Y  Y  Y  mucocoele, fixed globe  N  N  N 
treated conservative although has orbit        
age   
31  375  N  N  N  N  N  Y  Lepiphora  N  N  N  known WG   
32  390  N  N  N  N  N  Y  dacryocystitis sticky discharge  N  N  N  known limited WG    
33  417  Y  N  Y  Y  N  Y  nasal crusting, collapse nose bridge 07  N  N  N 
 
 
34  444  Y  Y  Y  Y  Y  Y  preseptal cellulitis, mucocoele  N  Y  Y  aorta, cerebral aneurysm   
35  449  Y  N  N  N  N  N  LG enlargem, necrotic defect R UL  Y  Y  Y  upper airways   
36  467  N  N  N  N  Y  N  hypoglobus, scleritis, PUK 2 and 3 y later  N  N  N 
 
 
 
   
435 
 
 
 
  
No. 
study 
number  immunosuppressive 
number of 
immunosuppressives  details  surgery 
number of 
recurrences 
No of 
meds for 
control  Outcome  Date 1st seen 
Date last 
seen  months 
1  2  Y  3 
MMF 2000, tacrolimus 96, aza 
97  DCR RL  ESRF GN 1975, tx 76, 2000 
 
30/10/1996  26/11/2008  145.01 
2  12  Y  1  cyclophos 
 
1  2  Telford 97  14/6/1994  2/7/1997  36.65 
3  14 
             
1/11/1995  11/3/1999  40.34 
4  26  Y  1  Aza 
 
0  2  mid Essex April07  31/5/2006  4/7/2006  24.00 
5  33  Y  1  Aza  DCR, LCS 
   
discharge  23/8/2001  2002  24.00 
6  50  Y  4  CPM,MTX,Infix, Ritux   RDCR00, LDCR01, L phaco 06  2 
 
Belfast 07  1/6/2002  31/1/2007  56.09 
7  74  Y  1  Aza  R DCR 
   
discharged Dec 06  25/5/2006  21/12/2006  24.00 
8  87  Y  2  aza +rtx  lid repair and debulking of lac gland 
 
19/6/2002  11/7/2011  108.82 
9  90  Y  1  cyc 
       
5/9/2005  14/9/2005  24.00 
10  91  Y  1  cyclophosphamide  1  2  frozen orbit  1/8/1998  2/12/1998  24.00 
11  124  Y  1  CPM, Aza  bilat DCR  1  2  ?FU  31/3/1994  23/9/1998  53.82 
12  133  Y  1  CPM started before 
   
back to Edin, refer 
Cambridge 
monoclonal Ab  4/3/1997  17/3/1997  24.00 
13  135 
             
20/4/2005  11/8/2009  51.78 
14  147  Y  3  MTX, Aza, (CPM initial) 
 
3  FU central middlesex  1998  2003  60.00 
15  192  Y  1  MTX 
 
2  2  epiphora, no proptosis  1998  2000  24.00 
16  240  N 
   
DCR 
   
recurrent AU, topical 
drops, cat extn, CMO, 
disch  15/12/2004  5/3/2009  50.70 
17  255 
       
1  1 
local FU for frozen 
orbit severe diplopia  16/3/1995  13/3/2000  60.00 
18  256  N 
       
1  DNA FU Devon  24/1/2001  2/4/2003  26.27 
19  258  Y  1  Aza, Septrin  DCR  0 
 
Disch  20/12/2001  21/2/2002  24.00 
20  272  Y  1  Aza  Enucleation  1  2 
 
22/1/1998  13/11/2002  57.76 
21  291  Y  1  MMF, Ritux. Previous Aza toxy  R orb debulk, L lat decomp  2  5/4 
 
1999  2001  24.00 
22  294  N 
         
back to Guys vasculitis  30/9/2009  18/11/2009  24.00 
23  301  Y  1  MTX  DCR bilat  2  6/9 
 
4/1/2006  21/4/2011  63.58 
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24  303  Y  1  Aza 
     
11/10/2006  11/10/2006  6/12/2006  24.00 
25  305 
       
2 
 
current FU Hams  4/7/2007  3/8/2011  49.05 
26  307  Y  1 
already on MTX, had rituximab 
for systemic WG  DCR  2  6/5  20/11/2008  10/1/1997  12/3/2009  146.14 
27  311  Y  4 
2005 pred and azt, flare up 
when pred 5, oct 2008 mtx pred 
+ cellcept, iv cyclophosphamide 
2009 2 courses, stopped due to 
vaginal bleed  dcr 
 
6/9 
 
7/5/2009  5/5/2011  23.97 
28  317  Y  1  Aza 
 
2 
 
14/3/2008  31/12/2005  10/6/2009  41.36 
29  338 
             
25/9/2006  22/6/2011  56.94 
30  361  N 
     
0  6/9  29/6/2005  29/6/2005  14/2/2008  31.59 
31  375  N 
   
DCR redo  0  6/9  10/4/2008  4/8/2008  2010  24.00 
32  390  Y  1  MTX from previous  R DCR  0  6/6  22/6/2006  3/3/1999  27/9/2007  102.93 
33  417  Y  2  Aza, MTX 
 
3  6/6  20/12/2006  16/9/2009  2011  24.00 
34  444  N 
           
2/2/2008  13/4/2011  38.37 
35  449  Y  3  Aza then MTX then RTX  Bilat DCR06  2  6/9  2/5/2008  26/3/2001  21/6/2011  122.95 
36  467  Y  2  MMF 06, CPM 09  tectonic graft for PUK 09  1 
 
3/5/2006  2/6/2009 
 
24.00 
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